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Abstract  
Heart failure (HF) disease carries a poor prognosis despite optimisation of cardiovascular (CVD) treatments.  
Non-CVD comorbid diseases are common and known to influence the HF clinical course.  These 
comorbidities change in severity over time from new onset yet, only static measures of comorbidity have been 
included in prognosis. A major gap in the management and prognosis of HF is how non-CVD comorbidity 
severity and longitudinal change influences individual risk.   
 
A systematic review (SR) and two phase observational study were conducted in the general HF population to 
test the hypothesis that increasing severity and change of non-CVD comorbidity would be associated with 
worse outcomes. The SR showed that the three most common non-CVD comorbidities included in prognosis 
were diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD) and chronic kidney disease 
(CKD). Hospital admission outcome studies were limited and there were no studies on quality of life. With the 
exception of hospital based renal studies, comorbidity severity and change evidence was scarce.  
  
The observational studies used a case-control study nested within the UK Clinical Practice Research Datalink 
database (2002- 2014), of 50,114 incident HF patients. Using risk set sampling, multiple controls were 
matched to cases on follow-up time. A framework for measuring recent comorbidity severity and change was 
devised using drug or physiological indicators for DM, COPD and CKD measured in two time-windows prior to 
the match date. Conditional logistic regression was used to estimate adjusted odds ratios for all-cause 
hospital admission and mortality.  
 
The observational study findings were that all three comorbidities were common and associated with both 
outcomes. Severe and worsening comorbid disease was also common and independently and significantly 
associated with increased risk of hospital admission and mortality. These dynamic measures of non-CVD 
comorbidity significantly improved HF prognostic models which has important implications for HF 
management and prognosis.
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Chapter 1 Introduction  
 
This chapter will introduce the broader principles that underpin the thesis which include epidemiology, disease 
and health, comorbidity and prognosis. Current conceptual thinking on the key terms will be explored before 
application to the context of heart failure disease in Chapter 2.  
 
1.1 Concepts of epidemiology  
1.1.1 Definition 
Epidemiology is based on the assumption that the occurrence of disease does not happen randomly but that 
there are factors, identifiable through systematic enquiry, which cause and prevent disease(1). Epidemiology 
is defined as ‘the study of the distribution and determinants of disease frequency(2) and the science of 
epidemiology is focused on the investigation and description of these fundamental concepts.  
 
1.1.2 Background  
The notion that the development and occurrence of disease may be related to factors that are external to the 
person, such as the environment, dates back to the beginning of medicine and can be found in the works of 
Hippocrates in 5BC(3) but it wasn’t until the 17th century that the importance of using routinely collected data 
to quantify disease was recognised.  John Graunt used the weekly ‘Bills of Mortality’ to summarize natural 
observations of births and deaths, trends in disease, categorisation of disease and population growth. The 
recognition of the value of routinely collected data by Graunt has been said to form the basis of modern 
epidemiology(1). Many years later John Snow in characterising the cholera epidemic of 1853-1854 provided 
one of the first attempts to establish cause and effect when he determined that the water supply was 
responsible for the outbreak and spread of cholera(4). The epidemiological approaches used by Snow are still 
in use today but until the early nineteenth century were almost solely applied to outbreaks of infectious 
diseases. Over the past century the patterns of mortality have changed with non-communicable diseases 
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becoming the greatest threat to public health(5). Modern epidemiological approaches have developed in 
sophistication to account for the broader and more complex epidemic of chronic diseases.  
 
1.1.3 Core concepts: frequency, distribution and determinants  
The frequency of disease occurrence is determined within specific populations. Studying and comparing 
populations allows for the identification and investigation of patterns of disease that may be characterised by 
personal attributes e.g. age, or demographic characteristics e.g. geographical areas or time periods. 
Measures of disease frequency include (i) disease prevalence; or the number of people with a particular 
disease (new and existing cases) divided by the total number in the population at a given time (point 
prevalence) or time period (period prevalence) and (ii) disease incidence; or the number of new disease cases 
over a specified time(6).  Within a population of interest the occurrence of disease will not usually be evenly 
distributed and the investigation of the uneven distribution allows for the development of hypotheses about 
possible causal and preventive factors or ‘exposures’ which can then be tested. The focus of the investigation 
here is on the person, place and time(7):  
 
 Person: who within the population is contracting the disease? 
 Place: where are the people that are contracting the disease? 
 Time: when are they contracting the disease? 
 
The enquiry into possible causal or preventive exposures is often precipitated by prior knowledge or 
experience of potential important factors generated by basic science, clinical experience or biological 
knowledge.  
 
Testing hypotheses about possible causal or preventive exposures allows for the investigation of the true 
determinants of disease.   In order to demonstrate that a true possible relationship between an exposure and 
the occurrence of disease exists, the group of individuals with the exposure are compared with an appropriate 
unexposed group(8).  
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The investigation of a determinant or cause of disease is central to epidemiological research. True cause and 
effect requires that there is a direct relationship between an exposure and an outcome that cannot be 
explained by any other factors.  This does not mean that any individual factor will be fully responsible for an 
outcome or event. Instead there are usually combinations of causal components, that commonly include 
genetic and environmental factors and that may be separated by time, which interact to bring about an 
outcome(9). The induction time to disease which refers to the time between causal action and disease onset, 
is therefore specific to each component rather than the disease itself(10). As multiple components may be 
necessary to cause the event, the strength of a component cause is more a function of the number of cases in 
which the causal component plays a role. This means that the strength of cause (or subsequent effect) is 
neither strong nor weak but depends on the role the factor plays in its interaction with the other causal 
components and may change from population to population and over time if the distribution of the multiple 
causal components changes.  
 
Rothman explains this phenomenon by way of a Causal Pie Model(2) by the use of three pies shown in Figure 
1.1. Each pie has the potential to cause a specific disease but requires all of its constituent parts to be a 
sufficient cause. It can be seen that for each sufficient cause (pie) the constituent parts are equally important 
to the individual experiencing the disease. If one part was missing the disease would not occur. However 
constituent A is part of all sufficient causes and so at a population level is responsible for a higher burden of 
the disease and would yield a higher strength of cause.  
 
Biological interaction, also referred to as causal interaction(11), occurs where some cases require the 
presence of two variables together. The first pie in Figure 1.1 requires both A and B for causation. This does 
not mean that A depends on B as A also contributes independently of B to the other two pies. Instead, for 
some cases, both A and B are required. A simple way of measuring whether there is biological interaction 
between A and B is to subtract the individual effect of A, the individual effect of B and the effect of having 
neither A nor B from the joints effects of having A and B.  
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Biological interaction = Effect AB – Effect A – Effect B – Effect neither A nor B 
 
1.1.4 Population-based versus clinical epidemiology 
A population refers to a group of individuals who share a characteristic such as a geographical area but can 
also relate to more specific characteristics such as employment, year of birth, gender or schools. Population-
based epidemiology refers to the scientific enquiry into the determinants of disease within a population which 
is often done by comparing those in the population who develop the disease with those who don’t. 
Alternatively the characteristic that a population shares may be the disease itself and here scientific enquiry 
will focus on determining how to accurately diagnose the disease, predict its natural or clinical course or the 
best intervention or treatment(12). This clinical epidemiology concept, often referred to as health services 
research or prognosis research, shares the same methodological approaches to population epidemiology(13). 
In this thesis, this clinical epidemiology approach is used to determine the importance of other co-existing 
chronic diseases for predicting the clinical course of people with an index disease.    
 
1.1.5 Importance of epidemiology for current healthcare  
The increasing number of people with non-communicable or chronic diseases in developed countries over the 
past century(5,14) requires sophisticated epidemiological investigation in order to address important questions 
relating to the cause, progression, management and prevention of disease. Primary and secondary prevention 
of chronic disease has become a public health priority demanding deeper understanding of causal factors.  
Prevention strategies in chronic disease management have focused primarily on risk factors associated with a 
specific disease for example cardiovascular aetiology or risk factors such as smoking or hypertension in heart 
failure, but important questions remain about how factors that are external to the specific disease may 
influence both the onset and progression of disease. One clear example is where people experience more 
than one chronic disease at the same time and public health policy needs to understand how different 
diseases influence each other and which combinations of diseases are most influential on health deterioration. 
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The longer latency period between a sufficient cause and the clinical presentation of a chronic disease means 
that causal associations are more difficult to infer(15). Similar challenges within chronic disease populations 
occur where the period of time between the exposure to factors that influence the progression of the disease 
and the manifestation of this progression in the outcomes of the disease can be lengthy. Many different 
exposures may confuse the relationship between a specific exposure and outcome and possible causation 
may be less obvious and difficult to detect. A further complication of the longer latency is that the exposure 
itself may change in intensity or duration from its initial inception. In order to clearly understand the 
association between the exposure and the outcome, the quality and quantity of exposure needs to be 
characterised.  
 
Whilst true mechanisms of association may be challenging to prove, carefully designed epidemiological 
approaches can provide important information for public health policy that is immediate and reliable(16). 
Unlike basic research conducted in a laboratory, epidemiology focuses on what is happening in human 
populations and can ascertain the effects of exposures in the real world context.  
 
1.1.6 Application to nursing practice 
One of the first pioneers of epidemiology after John Snow was Florence Nightingale. As an accomplished 
epidemiologist and statistician Nightingale made major contributions to public health through her nursing 
leadership. Through meticulous scrutiny of carefully collected data, Nightingale observed the uneven 
distribution of mortalities during the Crimean war, UK military and rural India and was able to identify key 
associations with sanitation, nutrition and medical interventions(9).  
 
Today, epidemiological evidence underpins public and preventative healthcare policy and legislation that 
impacts directly on nursing practice. The role of epidemiology in identifying and measuring health states and 
testing interventions to improve them also has wide ranging implications for nursing. However, despite the 
importance of epidemiology for nursing practice and the early promise from Nightingale’s work, epidemiology 
as a scientific research discipline has since predominated in medicine rather than nursing.  
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Whilst nurses may apply epidemiological approaches in their studies, explicit acknowledgement in the 
literature is lacking. It has been argued that a major barrier to epidemiology for nurses has been the close 
alignment of epidemiology with the biomedical research model(17). Alongside the move away from biomedical 
and positivist models of health in the nursing discipline, nursing research moved away from quantitative 
approaches focused on disease and towards qualitative approaches aimed at understanding health more 
broadly and from the individual perspective(18). The early alignment of epidemiology with the quantification of 
disease within populations created obvious conflicts with the interests of nursing research.  
 
However, the development of clinical epidemiology in the era of chronic disease means that the nursing 
profession is well placed to contribute to and gain from the science of epidemiology. The study of disease 
causation indicates that there is rarely a single causal agent. Social epidemiology is now adding to the 
evidence of wider determinants including social inequalities and poverty(19). The uncertainty inherent in true 
casual relations, the complex and multiple factors that interact to determine outcomes and the range of 
possible outcomes that are of interest to patients with a specific disease, means that nursing with its roots in 
holism and a humanistic perspective is well placed to embrace epidemiology. This broader perspective on the 
determinants and outcomes of disease in clinical populations favours an integrated approach where medical 
and nursing models can easily complement each other to develop epidemiological science.  
 
1.2 Concepts of disease and health 
Epidemiology has traditionally been concerned with the biological causation of disease within populations 
which resulted in the concept of health being aligned with the state of ‘non-disease’. The development of 
clinical epidemiology with its focus on the onset, progression and outcomes of people with a chronic disease 
requires a broader perspective both in the consideration of the possible determinants and selection of 
outcomes which define the health of patients. Before clinical epidemiology questions can be subjected to 
scientific scrutiny, a clear definition of health is required.  
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1.2.1 Defining disease  
The term ‘disease’ is multifaceted and challenging to define. In its simplest form disease is used to indicate 
illness or conditions that impair normal functioning and that have a specific set of signs and symptoms or 
pathology(20). What constitutes as ‘normal functioning’ is however context dependent and changes across 
cultures and time(21) and at a minimum could be argued is a product of evolution rather than a ‘natural 
state’(22).    Whilst the term disease is diverse and includes illnesses and conditions with varying duration, 
‘chronic’ diseases are defined by their long duration, slow progression and incurable nature and account for 
63% of annual deaths globally(23).  
 
1.2.2 Measuring disease  
In its simplest form chronic disease can be measured in individuals by its presence or absence or ‘diagnostic 
status’. However, the impact of diseases on populations and individuals will vary for different diseases and 
provides a notion of ‘between disease’ severity(24). Individuals with a specific disease will also vary in their 
experience of the same disease.  The progressive nature of chronic disease from new onset to more severe 
disease and to death means that ‘within disease’ the stage and severity needs careful consideration.  Severity 
then can be measured at different levels which include the population (between diseases), the disease (within 
disease) and the person (experience). 
 
Measuring disease severity within populations: The severity staging of diseases according to their population 
impact can be applied to biological systems e.g. to hypertension or ischemic heart disease within the broader 
definition of cardiovascular disease or between systems e.g. a cardiovascular disease compared to 
respiratory disease. Morbidity indexes attempt to weight diseases by severity as determined by outcomes or 
characteristics of the disease(25). The Charlson index was one of the first morbidity indexes to recognise that 
in summing up the impact of multiple coexisting diseases that both the number and severity of the diseases 
were important. Charlson weighted different diseases according to their relative risk of mortality and grouped 
them into four severity groupings(26). In the Kadam morbidity index(27), morbidities were categorised using 
broader definitions of severity characterised by general practitioners through their experience of routine 
consultations. This index demonstrated that increasing degrees of severity in relation to four morbidity 
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dimensions (chronicity, time-course, health-care-use, patient impact) were associated with worse physical 
health. Other work has demonstrated the cumulative effect of overall severity of disease combinations on 
physical health and symptoms(28,29).  This staging of diseases in populations provides useful insight into the 
overall health needs of patient groups and for planning of health care delivery. However, the caveat to this 
approach is that within disease groups there will be variation of the patient experience, health and intensity of 
interventions required.   
  
Measuring severity and change within diseases: Following the reduction in deaths caused by infections, 
accidents and childbirth, the trajectory of illnesses have changed from sudden and critical to slow and 
progressive(30) and patients’ experience of a disease will vary according to the stage or severity of the 
disease. ‘Within disease’ severity is important in determining the possible outcomes or trajectory of disease. 
Three distinct illness trajectories have been described for people with three different types of chronic diseases 
(Figure 1.2) which provide an external measure of disease severity(31). The first trajectory of slow 
progression and then a clear terminal phase (graph A) is usually associated with cancer where as in end 
organ failure disease (graph B) there is a gradual decline punctuated by acute episodes of exacerbation 
requiring intensive treatment and hospital admission. These episodes occur with increasing frequency as the 
failure progresses. Death can occur at any point and is often less predictable. The final trajectory of steady 
and progressive decline (graph C) is associated with fragility or dementia. 
 
Another external measure of disease severity is indicated by the processes of care received. Chronic 
diseases develop along different aetiological pathways and patients will usually present first in general 
practice with a trajectory of increasing symptoms leading to an initial diagnosis and on-going care(32). More 
detailed diagnostic or acute care may occur in hospital settings if the disease onset is more sudden or severe 
or where there is an exacerbation of symptoms during the disease course. Finally end of life care may be a 
combination of hospital and community care until death.  
 
The heterogeneous nature of chronic disease development with multiple potential causes and varied 
progression means that disease severity at different points in the trajectory can vary widely across individuals. 
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Whilst disease and care trajectories provide the average severity path of populations with the disease, internal 
and external measures of disease severity in individuals provides more detailed information. Internally a range 
of tests are used in the diagnosis and measurement of individual disease severity and externally, medical 
interventions such as prescribed medications are common and are likely to change with increasing symptoms 
as the disease progresses. Whilst these provide potential mechanisms for measuring severity, for the same 
intervention or physiological measure there will still be variation in the ‘patient experience’ which is itself 
influenced by a range of multidimensional factors.   
 
Measuring severity of disease by patient experience: The manifestation of disease in individuals, which 
changes and progresses from its onset, will be both determined by and influence a range of multiple and 
complex individual factors. Concepts of health are multiple and attempt to define the combination of factors by 
which disease is expressed.    
 
1.2.3 Defining health 
Biomedical model to biopsychosocial model of health: Definitions of health have evolved from simple 
reductionist definitions to multidimensional patient models, yet there is still no clear consensus. Engel argued 
that the biomedical model which reduced health and its deviation ‘disease’ to measurable somatic variables, 
reinforced mind-body dualism and rather than remain a scientific model for investigation, it became a cultural 
perspective about disease in Western society(33). This was to the detriment of the practice of medicine which 
aims to reconcile the experience of illness as expressed by patients. Here Engel refers to biochemical defects 
as being one component of the diagnostic criteria for disease but as inadequate as an explanation for the 
manifestations of disease. How illness is experienced and reported by patients, its causes and remedies, 
requires a broader perspective, one which considers psychological, social, and cultural factors.  
 
Extended definitions of health: The World Health Organisation defines health as “a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity”(34). Whilst this reflects the 
biopsychosocial model purported by Engel it also sets a qualifying standard on health that has been criticised 
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as failing to distinguish health from happiness and making the achievement of health an unattainable 
goal(35). Broader definitions still, refer to other more specific determinants of health such as Bircher’s 
definition “health is a dynamic state of wellbeing characterized by a physical, mental and social potential, 
which satisfies the demands of a life commensurate with age, culture, and personal responsibility. If the 
potential is insufficient to satisfy these demands the state is disease”(36: p.336). In the term disease he 
includes malady, illness, ill-health and sickness. Saracci takes an intermediate approach and defines health 
as “a condition of well-being free of disease or infirmity and a basic and universal human right”(35: p.1409). 
 
These definitions are framed within a concept of the human being as a person whose experience of 
disequilibrium whether physical, mental or both are presented through a multidimensional lens. This lens is a 
kaleidoscope of real life contexts including psychological, cultural, spiritual and social influences. The resulting 
image is the patient’s health. This closely reflects ‘holism’ and the philosophical and practical approach that is 
embedded within nursing practice in managing a patient’s response to health, illness, frailty, and disability(37). 
 
Definition of health for thesis: Core elements of the emerging definitions of health are biological, psychological 
and social dimensions and the notion that more than one factor impacts on a person’s experience and 
presentation of illness.  For scientific enquiry definitions need to be clear, measurable and reproducible. In the 
context of epidemiology Saracci’s definition of health as a state of well-being, free of disease or infirmity, 
recognises the holistic and subjective nature of health whilst providing a mechanism for measuring health with 
appropriate indicators such as mortality, morbidity and health related quality of life.  
 
1.2.4 Measuring health related quality of life 
Health related quality of life (HR-QoL) includes a range of multi-dimensional measures that summarise the 
patient’s perception of their health experience. These often include assessment of symptoms, ability to 
perform daily tasks, physical limitations and well as the impact of their illness on behaviours such as self-care 
and psychological well-being including resilience, illness perception or anxiety(38). General HR-QoL 
measures overall health status using generic indicators of health which is important for assessing and 
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managing patients whereas disease specific HR-QoL focuses on the health status attributed to a specific 
disease and can help to guide the clinical management of the disease.   
  
1.3 Concepts of Comorbidity 
Extending the epidemiological approaches from infections and non-communicable diseases is the most recent 
focus on the presence of multiple diseases occurring at the same time in ageing populations which has 
become a global healthcare priority(39). These diseases together will determine the overall health trajectory of 
the patient. Individually or in combination, additional diseases may also influence the progression or trajectory 
of a patient with a specific disease. 
 
1.3.1 Definition  
The terms ‘multimorbidity’ and ‘comorbidity’ have been applied interchangeably although they are distinct 
terms. Multimorbidity describes the co-occurrence of two or more chronic or acute diseases or medical 
conditions within one person at any one time(40). The illnesses are not prioritised and each may have an 
impact on the other. The importance for health and health care is on how the illnesses combine to have an 
overall impact on the patient and their healthcare management. This differs from comorbidity where the focus 
of interest is on one illness or disease and at how additional illnesses or diseases impact on the presentation, 
progression, management and experience of the patient with the ‘index’ disease. Alvan Feinstein in 1976 
defined comorbidity as “any distinct additional clinical entity that has existed or that may occur during the 
clinical course of a patient who has the index disease under study”(41: p.456-457). 
 
In multimorbidity or comorbidity the choice of health ‘entities’ included in the definition has been categorised 
by number and type. Morbidity ‘type’ has included acute and chronic diseases versus only chronic diseases, 
somatic disorders with or without psychiatric and social disorders and physician diagnosed or patient reported 
problems(42). Once ‘type’ of morbidity has been decided some studies have limited the number included to 
specific morbidities. Broader definitions may include risk factors, conditions, complications or treatments or 
the wider determinants of health including biological, psychological, social and cultural factors(40).  
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The broader definition of comorbidity reflects closely the bio-psycho-socio-cultural model of health. Fried(43) 
argues that to fully understand the interplay or interactions of different diseases or illnesses that the definition 
should be opened up further still to include multiple physiologic or pathophysiological levels such as 
impairments, biomediators or subclinical diseases and not simply focus on manifested diseases. However, 
whilst this has clear importance in understanding causal mechanisms and the pathophysiological and 
aetiological interactions between specific diseases it is important that the definition of comorbidity is clear and 
not loosely defined. To an extent the scientific definition of comorbidity will much depend on the focus of the 
enquiry. The definition may be multi-dimensional including biological, psychological, cultural and social factors 
or focused on clinical morbidities (symptoms, illnesses and diseases)(27). As with health, this thesis will bring 
a focus to the definition of comorbidity and will define comorbidity as: 
 
‘any clinical chronic disease in addition to the index disease, in this case HF’. 
 
The disease definition of comorbidity as opposed to the broader morbidity definitions provides a mechanism in 
which to measure comorbidity severity and its change over time following a structured framework that can be 
applied across diseases.   
 
1.3.2 Impact and importance of comorbidity  
The impact of comorbidity or multimorbidity can be measured at various levels from the patient to health 
services to society more generally and in various settings from the general population to specialist settings.  
 
Patient: Patients with multimorbidity receive fragmented care from different specialists(44) and polypharmacy, 
adverse drug reactions and inconsistent monitoring are common(45). Self-care is challenging for patients with 
multimorbidity due to difficulties in symptom recognition, lifestyle modifications and drug adherence(46-49). 
Multimorbidity and comorbidity have been associated with increased mortality risk, greater symptom burden, 
limited physical and psychological functioning and reduced quality of life for patients(50-52).  
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Healthcare systems and economics: People with multimorbidity have increased healthcare utilisation and 
associated costs(53) and are by far the greatest users of healthcare resources both in primary and secondary 
care. This healthcare burden increases with the number of morbidities and in the United States 65% of all 
healthcare utilisation is by people with multiple chronic conditions and two thirds of healthcare expenditure is 
on people with 5 or more conditions(54). Healthcare systems have been configured along disease specific 
pathways and policies which cause challenges for the management of people with multiple coexisting 
diseases.  Adherence to individual practice guidelines for each of several different diseases can lead to a high 
number of drugs prescribed and conflicting management plans and lifestyle advice for patients(55). This can 
leave patients with a heavy treatment burden and lead to adverse interactions between regimes(56). The 
increasing burden of multiple chronic diseases for patients then, reflects a growing need for redesign of 
healthcare service delivery and new quality indicators and interventions that focus on patients with 
comorbidity.  
 
Public health: It is estimated that 23% of the population have multimorbidity, rising to up to 80% in those over 
80 years(51). The number of co-existing morbidities also increases with age with one Swedish study finding 
an average of 17 coexisting chronic health problems in nursing home residents(57). By 2018 the Department 
of Health(58) forecasts a rise in the number of patients with multimorbidity to 2.9 million (53% increase over 
10 years) and multimorbidity is set to become an international public health priority(39).  
 
1.3.3 Classification 
Co-occurring morbidities have been categorised in a number of ways. Simple categorisations include those 
that occur at the same time regardless of the underlying reason. Cluster morbidities include those that occur 
together at a higher rate than expected purely by chance. The ratio of observed co-occurrence is higher than 
that expected by multiplying the risks of each morbidity(59). These morbidities show an association but are 
not known to have a causal relationship. Causal morbidities lie along the same pathophysiological pathway. 
These may be disease specific where one morbidity is dependent on another(40).  
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Comorbidities can also be classified by their time of occurrence. A comorbidity may be a cause or 
consequence of an index disease or may be unrelated. It may develop before the index disease and be 
prevalent at the time of diagnosis of the index disease or develop as an incident case during the life-course of 
the index disease. This temporal relationship may influence the effect of the comorbidity on the index disease 
or the outcomes of the person with the index disease.  
 
1.3.4 Measuring comorbidity  
Comorbidity can be measured in multiple ways from simple counts to index scores to more complex criteria 
which is usually determined by the purpose of investigation. Early work of Feinstein and Kaplan developed 
criteria for classifying people with diabetes comorbidity by type (vascular or non-vascular) and severity based 
on physical function specific to each comorbidity(60). Later Mary Charlson developed a comorbidity Index(26) 
which scored burden according to the sum and severity of a specified number of diseases. Severity was 
determined by mortality risk and the index enabled the control of sicker individuals in prospective clinical trials. 
This index was then adapted by Deyo et al(61) for use in clinical administrative datasets. More focused 
definitions classify comorbidity by an event such as Elixhauser’s definition which defines comorbidity as an 
additional clinical condition that exists before a hospital admission, that is not related to the primary cause of 
admission but which is likely to affect outcomes(62) or by Kadam severity criteria within different dimensions 
of common morbidity in the general population(27).  
 
Index scores of comorbidity can be useful as the number and overall severity of combined diseases is known 
to influence outcomes including the general health of the patient(25).This also provides important information 
at the population level for use by health providers for case management, health policy and resource 
allocation. However, similar to ‘between disease’ severity, this index score approach to severity of combined 
diseases does not provide individual or detailed information about the ‘within disease’ severity of the specific 
comorbid diseases. Chronic disease comorbidity will change from new onset to more severe disease which 
will alter its influence on the patient with an index disease. This more detailed information on comorbidity 
severity has the potential to guide clinical care through modification of the comorbid disease as it progresses 
using targeted strategies.  
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1.4 Concepts of prognosis 
Central to clinical epidemiology is the accurate prediction of the clinical course of disease. Given the long 
duration of chronic disease, the factors that are important in prediction and the outcomes that might indicate 
its clinical course and impact on the patient are multiple and varied.  An important consideration in this 
prognosis of chronic disease is the high prevalence of comorbidity and how this influences the outcomes of 
the patient with the index disease.   
 
1.4.1 Definition 
Prognosis is the prediction of the probable course and outcome of specific diseases in populations, groups 
and individuals. Prognosis research investigates the relationship between future outcomes (endpoints) among 
people with a given baseline health state (start point) in order to improve health(63). The most credible source 
of information for prognosis is past clinical observations on similar patients to predict what will happen. Crucial 
to this is how the clinical observations were made and how they are then interpreted(64).  
 
1.4.2 Importance of prognosis  
The prognosis concept has increased in importance in recent years as more people are living with one or 
multiple chronic diseases. Health care policy makers and providers as well as patients have a vested interest 
in the outcomes of disease and the efficacy of treatments and care aimed at improving those outcomes. The 
scope of prognosis research is broad. At a public health level, policy makers require information on the burden 
of different diseases in order to allocate resources for primary and secondary prevention. The variation in a 
specific outcome across geographical and clinical contexts for a given disease also facilitates the investigation 
of systems and quality of care(65). 
 
At a healthcare level, new health technologies for screening, assessment and management may be difficult to 
test in a randomised controlled trial and prognosis provides a method for investigating their benefit over 
standard tests or treatments. Where randomised trials are feasible, prognosis provides a useful rationale for 
testing the effectiveness of new treatments, a good indication of likely events to inform sample size 
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calculations and a baseline risk from which to translate relative risks back to an absolute scale(63).  Clinically, 
knowledge of the key factors that increase the risk of poor outcomes within disease groups is also important 
to enable clinicians to modify those factors through targeted interventions or to target groups for treatments. 
For patients, tailored prognostic information is important so that they can make informed decisions about 
treatments and care and share decision-making with clinicians as their disease progresses and 
changes(66,67).  
 
1.4.3 Prognostic research 
Four ‘PROGRESS’ themes of prognosis research have been proposed for methodological development which 
are (i) overall prognosis (ii) prognostic factor research (iii) prognostic model research and (iv) stratified 
medicine.  
 
Overall prognosis; describing risk in populations: In the broadest sense (PROGRESS theme 1) ‘overall 
prognosis’ research is descriptive and seeks to determine the average risk of outcomes for a given disease in 
relation to different diagnostic or treatment practices(63). Populations of people within a disease group may 
be described by different settings or interventions. The quality of healthcare delivery from screening, 
investigation, diagnosis, therapeutic treatments and care relies on good overall prognostic information(68). 
The risk or rate of a particular outcome may be measured in a group as a whole or in a sub population who 
share demographic or clinical characteristics. Part of the remit of overall prognosis research is to understand 
the variations in average risk between individuals or groups across clinical or geographical settings.  
 
Prognostic factor research; explaining risk in groups:   For individual patients the average risk of an outcome 
is of less importance than the variability in the average and where they fit into the range of risk observed(69). 
‘Prognostic factor’ research (theme 2) refines the overall average prognosis by identifying the risk of an 
outcome in subgroups of people that share a particular factor.  Prognostic factor research may focus on 
identifying one factor or a range of individual factors that each varies the average risk of outcomes(70). These 
factors may include biomarkers and clinical, social, environmental, psychological and behavioural factors. 
Classification of prognostic factors have been more simply defined as a triad of interacting causes (i) 
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environment e.g. socio-economic, health care organisations or climate (ii) host: e.g. demographic, 
behavioural, psychosocial, premorbid biologic and (iii) disease e.g. imaging, pathophysiologic, genomic, 
proteomic, metabolomics(66) If the prognostic factor causes or partly causes the outcome and is modifiable, it 
can provide an important target for interventions to improve the outcome.  
 
Prognostic factors have a range of uses from refining the diagnosis of diseases, informing treatment 
recommendations by prioritising those with the worst prognosis with a greater potential health gain or 
monitoring of disease progression and severity, identification of useful potential components for prognostic 
models and identification of potential differential treatment responses across groups(70).  Prognostic factor 
research usually starts with exploratory studies based on biological plausibility and once a factor is identified 
continues with replication of the associations before assessment of the predictive value of the factor.  
 
Prognostic model research; predicting risk in individuals: Prognostic model research (theme 3) combines 
multiple prognostic factors in an attempt to define risk at the individual patient level. Prognostic models, also 
referred to as prognostic indexes, rules or prediction models, combine the risk associated with a number of 
factors to provide an overall risk of a specific endpoint over a specified time(71).  This risk estimate may be 
converted to an absolute risk which takes into account the baseline risk or be left as a relative risk or a risk 
score. Whilst a large number of prognostic models have been developed(72,73) their use in clinical practice 
has been extremely limited(74). This is partly due to their complexity(75), lack of validation(74), use of novel 
factors which are not translated into routine practice and lack of inclusion of routinely collected data(71). The 
potential of a model to influence or modify care will in part rely on its ability to accurately predict an outcome 
and part on whether the factors included in the model are accessible in practice and amenable to intervention 
to reduce risk.   
 
Stratified medicine; explaining risks and benefits of interventions:  The fourth theme of prognosis research 
‘stratified medicine’ focuses on tailoring treatments to individuals or groups with the most potential clinical 
benefit or least potential harm(76). Treatment with a uniform effect across two groups may be targeted at the 
higher risk group who will have the largest absolute benefit. Treatment may also be stratified where it has a 
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non-uniform effect and a particular patient factor is associated with a change in the treatment effect. 
Prognosis is important to stratified medicine in order to improve outcomes and reduce harm, develop 
interventions based on known patient factors, evaluate efficacy in drug trials and to determine the 
effectiveness of the stratified medicine approach.  
 
1.4.3 Key prognosis concepts 
Start points: Prognosis is concerned with predicting the risk of an outcome that is associated with a number of 
exposures compared to the risk of the same outcome in those without the exposures(64). It is important that 
the overall prognosis in the unexposed group is as close to those people as possible in whom future 
predictions will be made(9). A uniform time point in the disease progression should ideally be selected to 
facilitate this, which means that the disease status in the exposed group and unexposed groups will be 
comparable. Many studies use a prevalent cohort where there will be wide variation in the ‘average’ patient 
and predictive estimates are based on the average overall prognosis.   
 
Endpoints:   A study endpoint will be determined by the outcome of interest. Prognosis often focuses on a 
clear end point such as mortality and much less on other important outcomes such as hospital admissions or 
quality of life(63). It is becoming increasingly recognised that prognosis needs to address questions that are 
important to both patients, clinicians and policy makers, which includes patient reported outcome measures 
(PROMs)(64). The inclusion of PROMs in prognosis is a key indication within international position statements 
on palliative care(77) but is currently under-investigated(63). In terms of understanding chronic disease 
progression from new onset to more severe disease, prognosis research needs to identify the factors that 
influence a range of outcomes across the life course of a disease from patient reported health to hospital 
admission and to death. Another key consideration is whether the focus is on disease specific or generic 
outcomes. Disease specific outcomes provide understanding about how factors may be causally associated 
with the index disease or its progression and guide clinical management of the disease whereas generic 
outcomes provide important information for guiding the overall clinical management of patients.  
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Time: The association between exposures and outcomes can be measured at a specified future time point 
which relies on all patients being followed up for the same time or measured as an average risk per unit of 
time where patients contribute varied time to their follow-up(78). The specified follow-up time will in part 
determine the prognosis information used. The time chosen may be short, medium or longer term and will be 
decided by the research question and life course of the index disease. Longer term prognosis approaches 
may include static exposures that accumulate risk over time such as age, gender or the presence of 
comorbidity. Short term prognostic approaches may include some of the cumulative risk factors but in addition 
will include prognostic factors that identify immediate high risk or unstable states which may include dynamic 
factors such as physiological markers, recent hospital admission or the current severity of or change in the 
index disease or the comorbid disease. 
 
Longer term prognosis approaches provide important information that can help plan long term care or public 
health interventions whereas shorter term prognosis can act as a useful trigger to clinical intervention. Current 
prognosis approaches that focus on shorter term outcomes have often been hospital based where patients 
have been admitted due to deterioration in disease and there is a risk of imminent readmission or death. 
Prognostic approaches for identifying similar instability within the general practice population need to include 
dynamic exposures that indicate current high risk or instability prior to events but here the evidence is limited.  
 
1.4.4 Prognosis and comorbidity 
The growing number of people with comorbidity and its influence on outcomes requires specific prognostic 
consideration but the present evidence on comorbidity has serious limitations. Prognosis studies are limited to 
the presence or absence of comorbid disease which ignores the severity and dynamic nature of comorbidity 
that develops and changes over time. Similar to an index disease which varies in severity from its onset, 
comorbidity also presents with varying severity and then progresses at different rates in individuals. This 
comorbidity may have developed many years before the onset of the index disease or subsequent to it. 
Current prognosis approaches have included the static measure of the presence or absence of comorbidity at 
baseline but have not yet taken account of the dynamic nature of comorbidity, its severity or change which 
may be important to individual risk stratification and for the development of comorbidity interventions(79-81). 
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The dynamic status of comorbidity also provides one mechanism for identifying patients with higher risk of 
imminent outcomes through an increase or recent change in the comorbidity severity.   
 
The relationship between comorbid disease severity and patient outcomes is further complicated in the 
context of multiple conditions where the interrelations between comorbid diseases may result in an 
unexpected combined effect. As discussed  in Section 1.1.3 in the context of biological interaction, two 
exposures may each have an independent effect on a given outcome (i.e. the two comorbid effects add 
together) or a combined synergistic (greater than expected) or antagonistic (less than expected) effect(11). 
This is an important consideration when considering the effects of different chronic disease comorbidities on 
the outcomes of an index disease.  
 
1.5 Summary  
This chapter has discussed the concepts of epidemiology, disease and health, comorbidity, prognosis and the 
importance of these to patients, healthcare systems and population-level policy. The key questions identified 
are how to bring the concepts that apply to individual chronic disease clinical epidemiology into the concept of 
comorbidity clinical epidemiology and prognosis for a given index disease. 
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Figures 
Figure 1.1 Causal Pie Model(2) 
 
 The causal mechanisms illustrated in pies 1, 2 and 3 each describe a sufficient cause for the same disease. 
 Each pie requires all of their constituent parts to be a sufficient cause.  
 Pie 1 requires components A,B,C,D and E together for the disease to occur 
 Some components, for example component B, are not always required for the same disease to occur and B 
does not appear in Pies 2 or 3. 
 However for some cases of the disease A and B are required to be present together. This is referred to as 
biological interaction between component A and B.  
 Constituent A is part of all sufficient causes and so at a population level is responsible for a higher burden of 
the disease and would yield a higher strength of cause.  
 
 
Figure 1.2 Chronic disease trajectories(31). 
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Chapter 2 Context setting  
 
This chapter applies the broader concepts explored in chapter 1 to the heart failure (HF) population and 
introduces the current literature on HF, comorbidity and prognosis. The prevalence of HF and comorbidity and 
their combined impact on public health, healthcare economics, patients and clinical care are addressed. The 
current evidence on prognosis research in HF and the inclusion of comorbidity will be introduced before 
providing a summary of the key gaps that underpin the rationale for the thesis and introducing a new 
framework for the inclusion of comorbidity in HF prognosis in Chapter 3.  
 
2.1 Heart failure 
2.1.1 Definition 
HF is a complex syndrome, caused by a structural or functional disorder that impairs the ability of the heart to 
meet the body’s physiological demand(82).  This triggers a multi-system syndrome that includes abnormal 
haemodynamic and neurohormonal function, metabolism, energetics and inflammatory activation. As heart 
function deteriorates patients present with key symptoms of shortness of breath, fluid overload and limitations 
in activity.  
 
Aetiology: The most common cause of HF is ischaemic heart disease (IHD) which accounts for 70% of 
cases(83). Coronary risk factors then (such as diabetes, smoking, hypertension) are also associated with the 
development of HF(84). Other causes cover a range of diverse aetiologies such as hypertension, thyroid 
disease, cardiomyopathy or valvular heart disease (85).  High output HF also occurs when a normal heart can 
no longer meet abnormal physiological demand(86).  
 
Mechanisms: HF has been associated with two primary mechanisms; left ventricular systolic dysfunction 
(LVSD) and diastolic dysfunction often characterised respectively as HF with reduced ejection fraction 
(HFrEF) and HF with preserved ejection fraction (HFpEF). A more recent perspective is that these are two 
extremes in a spectrum of overlapping phenotypes(87) with diastolic and systolic dysfunction commonly co-
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occurring(88). Systolic dysfunction occurs when there is reduced ability of the left ventricle to pump enough 
blood forward to meet the body’s metabolic oxygen demands. Damage to myocardial cells and subsequent 
myocardial remodelling can lead to poor contractility, eccentric ventricular dilatation and electrical instability. 
The ventricular dilatation initially compensates for the reduction in cardiac output by increasing end diastolic 
volume albeit usually with a reduced ejection fraction (the ventricle pumps a lower percentage of a larger 
volume of blood). Increased end diastolic and systolic volume causes an increase in left atrial and pulmonary 
venous pressures and post-capillary pulmonary hypertension. Right HF ensues which is associated with signs 
and symptoms of systemic venous hypertension. Progression to reduced stroke volume and cardiac output 
following reduced ejection fraction usually occurs(89).  
 
Diastolic dysfunction which has been mostly associated with HFpEF is more common in people who are older, 
female and have a higher body mass index, hypertension and atrial fibrillation (AF)(90,91). Diastolic 
dysfunction is caused by the inability of the ventricle to relax(92). Common causes of this diastolic failure are 
hypertension, coronary artery disease and cardiomyopathy. In primary diastolic dysfunction, initial 
compensatory mechanisms will maintain the cardiac output by increasing the filling pressure of the left 
ventricle (end diastolic volume). This in turn leads to increased left atrial, pulmonary and eventually right 
ventricular pressure and symptomatic HF. Most patients have an increased myocardial wall thickness 
(concentric hypertrophy) and an increased left atrial size. Eventually as compensatory mechanisms fail, the 
cardiac output will reduce whilst the left ventricular ejection fraction is maintained (the ventricle is pumping a 
high percentage of a lower volume of blood). Other mechanisms include abnormalities of the valves, 
pericardium, endocardium and cardiac conduction(93).  
 
2.1.2 Pathophysiology 
Given the complex and often multifactorial and overlapping mechanisms inherent in HF it is difficult to 
distinguish between systolic and diastolic HF clinically. Whatever the underlying mechanism, HF is 
characterised by cardiac muscle, skeletal muscle and renal dysfunction and a final common pathway that 
includes activation of the sympathetic and the renin-angiotensin-aldosterone system (RAAS). These 
neurohormonal processes that support the heart in normal physiological circumstances play a central role in 
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the development and progression of HF(84). The RAAS, triggered by hypoperfusion of the kidneys, leads to 
increased renin, angiotensin II and aldosterone. Collectively these hormones cause vasoconstriction, retention 
of sodium and water and excretion of potassium, endothelial dysfunction and myocardial fibrosis(82). 
Sympathetic stimulation causes further vasoconstriction and retention of salt and water. The catecholamines 
produced contribute to cardiac myocyte apoptosis, hypertrophy and focal myocardial necrosis(84). Reduced 
baroreceptor function and parasympathetic tone leads to abnormal autonomic modulation of the sinus node.  
 
2.1.3 Classification 
Two of the most frequent classifications of patients with HF are via the ejection fraction and symptom severity.  
 
Ejection fraction: Traditionally HF has been classified by the primary mechanisms of systolic or diastolic HF. 
As previously mentioned (Section 2.1.1) the challenge with this classification is that these impairments usually 
coexist. Also whilst systolic and diastolic failures are largely associated with reduced and preserved ejection 
fraction respectively, the relationship is not exclusive. Sensitive imaging may detect mild systolic dysfunction 
in preserved ejection fraction HF and diastolic dysfunction that coexists with systolic dysfunction is more likely 
to have reduced ejection fraction. These factors together with the existence of other mechanisms in HF has 
led to the classification moving away from systolic function to one that is based on whether the ejection 
fraction is affected i.e. HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction 
(HFpEF)(93,94). Whilst HFrEF forms the largest part of diagnosed HF, epidemiological studies demonstrate 
that HFpEF is as common as HFrEF and has similar risk of mortality(91,95). Clinically, whilst the primary HF 
mechanism is associated with the choice of evidence based pharmacological treatments, the aetiology of HF 
and the common syndrome that ensues is the critical factor in treatment choice.   
 
Symptoms: The HF syndrome is also grouped by symptoms using the New York Heart Association (NYHA) 
classification(93)(see Figure 2.1). This system, which stages HF patients according to symptom-related 
physical functional ability, applies to all HF patients and provides a classification system that can be applied to 
all patients across the disease trajectory.   
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2.1.4 Diagnosis  
Diagnosis of HF is made using a combination of symptoms (e.g. shortness of breath and fatigue), signs (e.g. 
ankle swelling, pulmonary oedema) and objective evidence of cardiac abnormality (e.g. ventricular function 
assessment using echocardiogram)(93). One of the challenges of accurate diagnosis in HF is the non-specific 
nature of the presenting symptoms and signs and this is often worse in women, the elderly and those with 
comorbidities such as obesity or chronic obstructive pulmonary disease (COPD)(96). For example 
breathlessness, oedema and fatigue are common generic symptoms which are sensitive but not specific to 
HF. Physical signs such as raised jugular pressure or a third heart sound may also not be present in less 
advanced disease and where present, difficult to determine(97). Most are related to fluid overload and may be 
absent in patients treated with diuretics(93). A critical part of diagnosis is to rule out a broad range of 
alternative explanations for the cause or exacerbation of symptoms.   
 
Diagnostic criteria will be applied in practice according to the clinician and availability of diagnostic tests. 
Whilst current guidelines recommend the use of brain or b-type natriuretic peptide (BNP), N-Terminal pro-BNP 
(NT-proBNP) and echocardiogram(93,94), together with electrocardiogram (ECG), chest x-ray and blood 
profile, the clinical diagnosis of the prevalent HF population will vary according to the clinical setting of the 
diagnosis and time the diagnosis was made.  
 
Specialist setting versus general healthcare settings: Ready access to physiological testing within specialist 
settings means that the diagnosis of HF can be aided by the use of BNP testing, echocardiogram and 
interpretation by a cardiologist. Patients often present first in general practice(98) with symptoms that develop 
gradually over time and HF diagnosis has tended towards using more broad criteria(99-101) such as signs 
and symptoms.   
 
Diagnostic timing: Since 2003, the use of echocardiogram to confirm diagnosis has been widely 
recommended in national evidence(102) and was introduced into the Quality Outcomes Framework (QoF) for 
general practitioners (GP) in the UK in 2006(103). The QoF initiated a reward system to GPs for the provision 
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of quality care and helped to standardise medical practices including the use of echocardiogram for HF 
diagnosis and registers which also record optimal drug treatment. 
 
The setting and timing of HF diagnosis then is an important consideration for epidemiological research. Whilst 
different population settings carry the stage of disease trajectory and severity, the definition of the disease 
itself may vary across settings and within settings as a function of time.  
 
2.1.5 Heart failure disease frequency 
Global figures show that there were 5.7 million new cases of HF in 2004 with 3.1 million of those cases from 
Europe(104) and in Britain the incidence rate has been reported as 1% per annum in women and 1.7% in men 
aged 85years and over with a median diagnosis age of 76 years(101). Incidence rate increases with age and 
recent UK statistics show a rise from 0.07% per year for men aged 55-64yrs to 0.3% for those aged 75yrs and 
over. For women the incidence rate increased per year from 0.03% for women aged 55-64 years to 0.2% for 
those aged 75years and over(105). In America the rate was higher with 2.2% per annum for women and 2.7% 
for men aged 80-89 years(106).  
 
The prevalence of HF also increases with age with figures below 3% in the younger age groups (age 55-64 
years) and above 12% in the 85 years and over group(100,107). Most recent UK statistics show a prevalence 
rate of 13.1% in men aged 75years or over and 11.9% women(108). Overall approximately 2% of people in 
the Western world have HF(109,110). 
 
2.1.6 Impact of heart failure 
The demographic of HF has changed over the past two decades with the average HF patient now older with 
more comorbidities and increased polypharmacy(111). The overall prognosis of HF patients can be 
determined at the population level or within sub populations that are defined by their severity. Overall HF is a 
serious, life limiting disease where 14-30% of patients die in the first six months of diagnosis and 38% within a 
year(83,101). In the ECHOES cohort, the 5-year survival rate of those with prevalent HF was only 58% 
compared to 93% in the general population(112). About half of all patients experience daily symptoms 
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including breathlessness and fatigue(113) and up to half of patients remain symptomatic despite optimisation 
of treatments during hospital admission(114). Patients suffer problems with walking, activities of daily living, 
self-care, pain and depression. These symptoms are exacerbated with increasing age(115) and consequently 
the quality of life of patients with HF is poor(116).  
 
Among older people HF is one of the most common causes of consultation in general practice(117) and 
accounts for 2% of all hospital inpatient bed days, with over 61,000 hospital admissions between 2011-2012 
in the UK(118). With an estimated 5% of UK deaths attributed to HF the annual cost to the NHS has been 
approximated to be over £625 million(119) which equates to 2% of the total NHS budget. The largest 
proportion of spending is consequent to protracted lengths of hospital stay and frequent readmissions. This 
figure is likely to rise by fifty percent over the next 25 years as a consequence of an ageing population, 
improved HF treatments and improved survival following acute coronary events(94). 
 
2.1.7 Heart failure severity and sub populations  
As with chronic disease generally, severity of HF disease can be measured at the population level between 
different diseases, within the disease or by HF related health measures.  HF falls at the end of the 
cardiovascular disease (CVD) spectrum and is associated with worse outcomes than other less severe CVDs 
such as ischemic heart disease (IHD) or hypertension(29). Between non-cardiovascular diseases, HF remains 
one of the most severe chronic diseases with a higher mortality rate than many common cancers(120). 
 
Within the HF population, individuals will have a variation in symptoms, outcomes and levels of treatments 
indicating variation in the severity of HF.   
 
As previously discussed (Section 1.1.3) the absolute effect of an exposure will be determined by its frequency 
in causal mechanisms of the outcome studied. However the relative effect of the comorbidity exposure will 
depend on the baseline risk of the outcome in the comparator ‘unexposed’ group. This in turn will be 
determined by the HF severity in population studied. Where there is no biological interaction between the 
exposure and HF severity (the absolute effect of the exposure is uniform across different HF severities) the 
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relative effect of the exposure will reduce as the risk in the baseline group increases(9). Where a relative 
exposure effect remains the same or increases as the HF baseline risk increases, biological interaction 
between the exposure and HF severity is indicated(9). This leads to the hypothesis that the relative effects of 
an exposure will differ across different HF severity groups. This is an important perspective in order to 
interpret relative measures of exposure risk and to prioritise the targeting of interventions aimed at the index 
disease or the exposure. To more clearly understand the independent effect of an exposure, the severity of 
the underlying HF in the exposed and unexposed groups being compared needs to be similar or accounted 
for in the analyses. Severity of HF disease can be measured by external factors such as settings or stage of 
disease (such as incident versus prevalent cases) or internal factors such as BNP or ejection fraction which 
have varying degrees of precision.  
 
2.2 Heart failure comorbidity 
Most HF patients have additional conditions or diseases which have been found to impact on their health, 
their risk of being admitted to hospital and earlier death. An important consideration for prognosis is 
understanding which comorbid diseases are important for which outcomes in HF, whether the effect of 
comorbid disease is influenced by HF severity, how the severity of comorbid disease and its progression 
influences outcomes in HF and how different comorbid diseases might interact to influence the progression of 
the disease and experience of the patient with the disease. This information can then be used to predict and 
furthermore prevent future poor outcomes.  
 
2.2.1 Measurement and type of comorbidities 
Current understanding on the prevalence, interrelations and consequences of comorbidity in HF is determined 
by the definition and measurements used so far in scientific enquiry. A systematic review of comorbidity 
measurement in cardiovascular disease studies identified inconsistent terminology and measurement of 
comorbidity across 27 CVD studies which remained unchanged over time (1965-2009). Each individual study 
used its own definition of the comorbidity concept. A few studies (n=5) used an index score to measure 
comorbidity burden, mostly the Charlson Comorbidity index(26). Most studies used the presence or absence 
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of comorbidities but did not provide rationale or a conceptual framework for the selection of comorbidities 
included(121).  
 
 In HF studies the focus so far has been on the underlying causative cardiovascular disease (CVD) 
comorbidities such as hypertension and IHD which tend to fall along a spectrum of CVD status(122). These 
comorbidities have direct pathophysiological links and are associated with the progression and severity of the 
HF syndrome(123,124). Within an ageing population, the prevalence of non-CVD comorbidities in HF have 
increased and now predominates over CVD comorbidities in older patients over 85 years(125).  The 
importance of non-CVD comorbidities on HF mortality outcomes is also becoming well recognised and may be 
a consequence of shared risk factors or common pathophysiology with the progression of one disease having 
a direct or indirect effect on the progression of a co-existing disease such as HF(126). Despite the growing 
recognition of the importance of non-CVD comorbidities in HF, their management and monitoring is lacking in 
routine care and they feature far less in prognosis assessment of HF than other cardiovascular comorbidities 
(see Section 2.3). This may be due, in part, to the evidence gap on how their severity and progression over 
the course of HF influences outcomes for the patient (Section 2.2.3.2) which is the focus of this thesis. 
 
2.2.2 Frequency of heart failure comorbidities 
Older age in HF increases the chances of developing a range of both cardiovascular and non-cardiovascular 
comorbidities. A range of non-cardiovascular comorbid diseases have been found in HF patients including 
chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), dementia, diabetes mellitus 
(DM), osteoarthritis and osteoporosis(126,127) and older patients have been found to have in excess of five 
non-CVD comorbidities(128,129). Prevalence of different comorbidities and patterns of their co-occurrence 
are similar for HFrEF and HFpEF with a slightly higher burden and prevalence in HFpEF(130,131). 
Prevalence does more markedly increase with the severity of HF disease(129,131) with higher levels in 
hospital settings versus community settings(132).  
 
Many studies have focused on individual cardiovascular comorbidities in HF but fewer studies have 
investigated multiple non-cardiovascular comorbidities(129-131,133). A multi-regional European study of 
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3,226 acute ‘de novo’ or chronic HF patients (outpatients, mean age 66 years)(131) showed a high 
prevalence of non-cardiac comorbidities with the highest prevalence encountered for hypertension (58%), 
CKD (41%) and DM (29%). In another large cross-sectional study of 122,630 Medicare HF patients 
(>65years)(129) similar high prevalence was found (hypertension 55%, DM 31%, COPD 26%). The 
prevalence of comorbidity in part depends on the measurement used with self-reported or clinically diagnosed 
comorbidities indicating higher levels than figures based on clinical administration data(111) (see Table 2.1).   
 
More recently there has been a focus on comorbidities that commonly co-occur in HF populations.  These 
clusters are identified when the observed prevalence of two or more HF comorbidities combined is greater 
than that expected by chance. In a study of 417,477 adult HF hospitalisations, comorbidity profile groups were 
identified including; few and diffuse comorbidities (46.6%), metabolic comorbidities (19%), endocrine and 
hematologic comorbidities (29%) and vascular comorbidities (5%)(134).  Another study of 23,435 hospital or 
outpatient HF patients identified that certain pairs of comorbidities commonly coexist at a greater rate than 
expected. DM and hypertension occurred at a rate of 25% more than expected, hypertension and 
dyslipidemia in 21% and hypertension, dyslipidemia and visual impairment in 56% more than expected(130). 
Understanding which comorbidities co-occur is important to guide clinical decision making and guidelines. 
What is less well studied is the interaction or impact of co-occurring comorbidities on prognosis outcomes in 
HF. 
 
2.2.3 Impact of heart failure comorbidities 
Comorbidity for the HF patient can lead to altered HF symptoms and delayed diagnosis, complicated and 
conflicting treatment regimens and poor tolerance or reduced prescription of evidenced based 
pharmacotherapy(135) including fewer-blockers and angiotensin converting enzyme inhibitors (ACEi)(131). 
Patients have been found to have difficulty understanding their symptoms and may attribute worsening HF to 
another co-morbid disease or simple ageing(50,136) which can delay health seeking behaviour.  
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2.2.3.1 Current HF comorbidity prognosis evidence 
Non-CVD comorbidity has been shown to influence the clinical course of HF and associated outcomes to 
vary. However, the relative impact of comorbidities on outcomes in HF will be influenced by which diseases 
are present, the severity of the underlying HF and comorbid diseases and the outcome measured. In the few 
studies that have investigated a range of non-CVD comorbidities and outcomes in HF the focus has been on 
the presence or absence of comorbidity identified by clinicians, patient self-report, or administration data yet, 
the severity of the comorbidity is rarely taken onto account.  
 
Comorbidities in HF are significantly associated with increased risk of mortality outcome. In 3,226 HF 
outpatients followed for a year in Europe(131), a significant association was found between non-CVD 
comorbidities and increased mortality risk, a finding shared with a previous cohort study of 9,442 Veterans 
followed for a two year time-period(133). In this latter study, significant associations with increased mortality in 
HF were found for CKD, COPD stroke, liver disease, diabetes, cancer, anaemia and dementia. In a combined 
hospital and outpatient setting a cross sectional study of 122,630 HF patients found respiratory disease, CKD, 
COPD, depression and DM to be significantly associated with increased risk of mortality(129). Hospital 
admission risk similarly increases in the presence of HF comorbidity with significant associations found for 
CKD and DM(129,131), respiratory disease, CKD, Alzheimer’s disease, COPD, asthma, hypertension, 
depression and stroke(129). Depression, DM and respiratory disease are also associated with reduced 
physical function and quality of life in HF patients (137).   
 
Whilst ‘within comorbidity disease’ severity is rarely taken into account in prognosis studies, the notion of 
‘severity’ has been investigated in terms of the number and type of disease. The number of comorbidities has 
been found to be important for HF outcomes including increased symptom burden(52) and when more than 
three comorbidities are compared to no comorbidities, increased risk of mortality and hospital admission(131). 
Index comorbidity scores which take the number and severity of multiple comorbidities into account have also 
shown significant associations with mortality.  Relative mortality risk significantly increased when HF patients 
with more than 4 points on the Charlson Comorbidity Index were compared to those with 1-2 points(138).  
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Influence of HF severity: As the severity of the underlying HF increases the relative effect of the comorbidity 
will reduce, unless biological interaction is present. Biological interaction between the comorbid disease and 
HF severity may counter the increased baseline risk and maintain the relative effect of the comorbidity as the 
HF progresses. In a cohort study of 18,322 Medicare beneficiaries with HF, Ahluwalia et al compared the 
more severe HF group (defined by those with a first hospital admission) to the less severe HF group (no 
hospital admission)(132). The more severe group had a higher burden of CVD and non-CVD comorbidities 
which had significant associations with mortality with CKD, COPD and dementia conveying the highest risk. 
This demonstrates the importance of comorbidity even in the most severe HF disease. However, whilst still 
significant in the more severe group, the relative risk associated with myocardial infarction, lung cancer, CKD, 
dementia, COPD, stroke and arthritis was significantly lower than in the less severe group. There was no 
difference in the comorbidity effects on mortality across HF severity groups for IHD, other cancers and DM 
indicating possible interaction between these comorbidities and the HF severity. Another study of 8,507 
hospitalised HF patients found that more severe HF, this time defined by older age (above 85 years of age), 
compared to younger age groups, were associated with lower relative comorbidity effects for CKD and 
DM(139).    
 
Influence of HF mechanisms: The question of whether comorbidity effects differ across HF groups defined by 
mechanisms has generated considerable research interest. Prevalence of different comorbidities are slightly 
higher in HFpEF than HFrEF(140) and patients with HFpEF tend to die more of non-CVD comorbidities (60%) 
than those with HFrEF (36%)(141). In a study of 98 hospitalised patients with HFpEF, diabetes and renal 
dysfunction were significantly associated with outcomes (death and/or HF admission) and yet cardiac 
parameters showed no association(142). This raises the question of whether the effects of non-CVD 
comorbidities are greater in the HFpEF group. Where this has been tested, with the exception of COPD, there 
was no significant difference in effects of a range of comorbidities on mortality across the two ejection fraction 
groups(133).  
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2.2.3.2 New evidence on HF comorbidity and prognosis 
Prior evidence on cardiovascular comorbidity in HF such as hypertension or ischemic heart disease has 
demonstrated that the severity and progression of the cardiovascular aetiology is associated with worse 
outcomes in HF. Examples include significant associations between the level of left ventricular dysfunction 
and HF admissions(143) and between cardiovascular events and mortality in HF patients(123,144). There is 
also developing evidence that the severity of the non-CVD comorbid disease and its change overtime 
increases its absolute effect on outcomes and may be an important consideration for prognosis.  
 
Comorbidity severity evidence: Two prior HF systematic reviews have demonstrated the importance of renal 
dysfunction severity for mortality. In the first review, eleven studies stratified renal dysfunction by severity as 
measured by levels of estimated glomerular rate (eGFR). Unadjusted associations showed an estimated 33% 
increase in all-cause mortality risk from ‘any’ to moderate/severe renal impairment. A linear relationship was 
also reported between increasing serum creatinine, decreasing eGFR and all-cause mortality(145). The 
second review included 57 prior studies and found, in adjusted analyses, that moderate renal impairment was 
associated with a 59% increase in mortality risk compared to those with normal renal function. This increased 
to a 117% increase in risk associated with severe impairment(146). 
  
Few other non-CVD comorbid diseases have been investigated for severity and outcomes in HF. In 348 HF 
patients, the severity stage of COPD measured by spirometry was significantly associated with mortality with 
increasing risk from lower to higher severity groups(147).  This finding was consistent with a study of 184 HF 
patients with comorbid COPD where stage 3 COPD severity compared to stage 1 was associated with a 
220% increase in mortality risk(148).  Diabetes severity staged by treatment type has been found to be an 
important prognosis factor in other cardiovascular studies with increased mortality risk for myocardial patients 
found from no medication to oral hypoglycaemic to insulin(149,150). 
 
Comorbidity severity change evidence: Current interest in ‘cardiorenal’ syndrome which focuses on the 
temporal relationship between renal and cardiac function has demonstrated a close link between worsening 
renal function and reduced survival in patients with HF(151-156). In two further renal HF systematic reviews 
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worsening renal function (WRF) was shown to be associated with a combined estimated 62%-95% increase in 
mortality risk and 30% increase in hospital admission risk(146,157).  This effect was similar in outpatients and 
hospitalised patients and the associated risk increased with the severity of the change in renal function.  
Whilst renal severity and change may act as a marker for worsening HF, the dose-response relationship 
together with the strength and consistency of the renal evidence suggests that a causal relationship may exist. 
This causal relationship has biological plausibility given the common pathophysiological pathways in cardiac 
and renal disease(158).   
 
Broader evidence that change in a comorbid disease or condition may precipitate or contribute to outcomes in 
HF is provided by studies that investigate the cause of hospital admissions and death. One study of 27,477 
admitted HF patients in Scotland found that HF was the principal diagnosis in only 42% of all hospital 
discharges or deaths(159). An estimated 11·8% of discharges and deaths were associated with COPD, 8·3% 
had either chronic or acute renal failure, 5·3% had had a stroke and 15·4% had atrial fibrillation. More recently 
a large national sample of admissions in America showed that the number of admissions with HF as the 
principal diagnosis had reduced by 10% over a decade compared to the same size increase in admissions 
with HF as a secondary diagnosis. These studies indicate that change in comorbid states (indicated by need 
for, and cause of admission) contribute to all-cause hospital admissions and mortality in HF.  
 
Other work has shown a link between acute non-CVD comorbid events and HF specific hospital admissions or 
death. In 25,090 HF patients in Quebec, acute gout episodes (defined by hospital admissions for gout within 
60 days of the event) were associated with an estimated 177% increase in risk compared to those with no 
acute gout(160). Interestingly the effect of longstanding gout (present at baseline) had less effect on HF 
outcomes (estimated 63% increase in risk). This evidence demonstrates a potential link between a change in 
comorbidity status prior to an event and change in HF status. 
 
The collective evidence on severity and change generates the hypothesis that weighting of non-CVD 
comorbidities by their severity and its change over time may provide better risk stratification for identifying 
patients with the worst prognostic outcomes. The dynamic nature of comorbidity severity and its potential for 
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prognosis is important for three main reasons. First it provides a mechanism for identifying HF patients whose 
prognosis is changing so that interventions can be triggered. Second, comorbidity is routinely monitored and 
recorded in general practice. Third, comorbidities are potentially modifiable by targeted interventions so that 
risk can be reduced. 
 
2.2.3.4 Importance for Healthcare systems and Economics    
Healthcare utilization increases for HF patients in the presence of comorbidity(129,161) and the cost of 
hospital admission increases. Out of 122,630 HF patients above 65years, patients with more than 5 
comorbidities were responsible for 81% of all preventable hospital admissions(129). As well as higher users of 
healthcare, HF patients with comorbidities have longer lengths of stay(162) and higher cost per admission. 
This has been shown to differ by common co-occurring groups of comorbidities with a study of  417,477 adult 
HF hospitalisations, showing that patients with metabolic comorbidities cost 10.2% more,  endocrine and 
hematologic comorbidities cost 16.7% more and those with vascular comorbidities cost 21.4% more than 
patients with few or diffuse comorbidities(134). 
 
2.2.3.3 Importance for Public Health  
HF policy and national guidelines have to date focused on the management of HF aetiology, pathophysiology, 
cardiovascular comorbidities and symptom management. The majority of evidence for the benefits of 
pharmacological treatments in HF is derived from large clinical trials that have selected patients on the basis 
of LVSD and HFrEF(87) and excluded patients with complex non-CVD comorbidities. These trial populations 
do not reflect the general population of HF patients with common comorbidity(163).  The application of these 
guidelines can be challenging as there is little evidence of potential risks and benefits in patients with non-
CVD comorbidities or on how to reconcile optimal treatment in the presence of co-existing chronic disease, 
the management of which may conflict with that of HF. HF is a clear example of where guidelines are focused 
on disease specific targets and quality indicators. Whilst latest guidelines have begun to recognize the co-
existence of a few common non-CVD conditions in HF(93), the growing prevalence and importance of non-
CVD comorbidity has yet to be recognized within government policy. Better understanding of which non-CVD 
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comorbidities are important and how the severity and progression of non-CVD comorbidity influences HF 
outcomes is required for health resource prioritisation, better prevention strategies and to develop and test 
interventions that target the comorbid disease at the population level.  
 
2.3 Prognostication in heart failure 
Prognostication in HF is challenging for clinicians due to its complex disease trajectory (see Figure 1.2, 
trajectory B) and this is further exacerbated by the high prevalence of comorbidity. Following initial diagnosis 
and management, patients can have a period of relative functional stability, before a gradual and chronic 
decline in health status, interrupted by acute episodic exacerbation of symptoms and frequent hospital 
admissions. Sudden death at any point is common(77). The variation in prognosis for individuals with HF is 
poorly predicted by clinicians(164) or patients(165) and this unpredictable nature has led to the reluctance of 
some health professionals to discuss prognosis with patients. Subsequently patients’ preferences in clinical 
care have been poorly represented in healthcare decisions(166-168).  
 
Prognosis is important in HF in order to equip patients and clinicians with the information required for decision 
making and to identify high risk groups for targeting interventions. The trajectory of severity in HF means that 
interventions escalate from the prescription of pharmacotherapy to implantation of devices to invasive 
monitoring and intravenous diuretics. The most severe patients will be considered for a left ventricular assist 
device (LVAD), continuous intravenous inotropes or heart transplant(169). Each intervention has an 
associated mortality benefit tempered by associated side effects, costs and limited resources. The prognosis 
of the HF patient is important not just to trigger but also to tailor interventions according to risks and benefits 
and evaluate interventions across different groups.  
 
Current HF prognostic tools to assist clinicians commonly rely on complex and invasive clinical data and 
biometrics(170,171), are often developed using selected hospital based(172-175) and clinical trial patient 
populations(80,175-179), focus mainly on mortality and do not relate to the usual general HF patient with non-
CVD comorbidity. Whilst there is a range of evidence across the 4 themes of prognosis research this 
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discussion will be restricted to prognostic factor and prognostic model evidence which are the focus of this 
thesis.  
 
2.3.1 Heart failure prognostic factors 
In HF, there are a range of different factors that have been associated with outcomes. They are indicated in E-
Appendix A1 in accordance with the previously defined triangle of interacting causes: environment, host and 
disease(66). There are a range of factors in each of the three domains and whilst the strength of evidence 
varies across different factors the most common and consistent factors are presented(180,181).  
 
A prior review of prognostic factors focusing on host and disease characteristics for predicting hospital 
readmission in HF included 112 studies and summarized 26 different factors(182). Most studies were single 
site studies that focused on one factor whilst adjusting for others. The most frequent host factors included 
were age (81%), gender (71%), ethnicity (35%), CVD comorbidities (hypertension 41%, coronary artery 
disease 34%, AF 27%) and DM (46%). Common HF disease factors were EF (56%), NYHA (35%), blood urea 
nitrogen or creatinine (45%), sodium (25%), BNP (21%) and haemoglobin (19%).  
 
2.3.2 Heart failure prognostic models 
Two systematic reviews have summarised six HF prognostic models for hospital readmission(182,183). Five 
of the models included only patient (host and disease) level characteristics and the only common factors that 
predicted readmission across the models were history of diabetes and a history of prior hospital admission. 
Only one model used a validation cohort and there was minimal agreement across all six models of the 
factors that predict readmission. Only two reported discrimination for hospital readmission risk which was 
poor.  
 
Three systematic reviews included prognostic models for mortality and readmission comparing the number, 
type and predictive power of the variables used and the models constructed. The first systematic review of 
prognostic models for mortality was restricted to ambulatory HF patients and included 20 models in 34 
studies(184). Only 5 models were validated in an independent cohort and were the focus of the review (see 
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summary table in E-Appendix A2). The models showed poor to moderate discrimination in the validation 
cohorts who were mostly younger, male and with a low ejection fraction. The most widely validated and used 
models (HF Survival Score (HFSS)(185) and Seattle HF Model (SHFM))(177) were derived from populations 
predating 1994 which may explain their lower level of discrimination in more contemporary cohorts. Both 
models focus on cardiac parameters and neither model includes non-CVD comorbidity. In the 15 non 
validated models half had focused on specific populations defined by ejection fraction. 
 
The second and third systematic reviews were similarly focused on predictive models for mortality and/or 
readmission in HF. The second review identified 117 different models in 55 papers for both mortality and/or 
hospital admission(186). Most of the models were focused on hospital settings for the outcome of mortality. 
The number of variables included in the models ranged from 1 to 65 with a total of 249 different variables 
used, the most common being age (64%), gender (44%), systolic blood pressure (42%), sodium (38%), 
diabetes (34%) and creatinine (31%). Models showed moderate to poor discrimination in specific populations 
for hospital admission outcomes, hospital admission or mortality and only slightly higher discrimination for 
mortality only. Models with higher discrimination identified through meta-regression were those produced in 
prospective cohort/registries, using medical records data and using more variables(186).  
 
The third systematic review(187) identified 64 main models with an additional 50 modifications of the main 
models. Again, these models were focused on mortality in hospital settings, over half were American and less 
than a third of the models were based on routine clinical data. The number of variables included ranged from 
3 to 314 with a median of 9. In addition to sodium; age, renal function, blood pressure, ejection fraction, sex, 
BNP, NYHA , diabetes, body mass index, gender and exercise capacity emerged as the strongest predictors. 
Model discrimination was again higher for the mortality outcome with shorter follow-up.  
 
The two most promising HF prognostic models for ambulatory patients with comorbidity are the MAGGIC 
model(188) and the 3C-HF model(189). The MAGGIC model, although based on mainly trial patients, does 
include a range of comorbidities and was well calibrated for mortality. The 3C-HF model was based on 
hospital discharge patients and whilst it includes two non-CVD comorbidities it mostly focused on HF severity 
  
39 
 
indicators and short term mortality following hospital admission. The biggest gap in these models, like most 
available prognostic models, is that they mainly include static measurement of baseline measures including 
comorbidity to predict future outcomes.  
 
Whilst dynamic measures that indicate the level or severity of exposure have been included in prognostic 
models the focus has been on cardiovascular exposures such as functional status(190), NT-proBNP(79), 
NYHA(179), ejection fraction(191,192) or risk factors for example blood pressure and body mass index(188).  
More contemporary approaches have begun to consider change in CVD exposure using multiple measures in 
prognosis which have been shown to be favourable compared to single measures. These have included time-
series measurement of cytokines which were found to significantly improve the discrimination of 1 year 
mortality in advanced HF over baseline measurements(193), change in cardiac symptoms over two weeks 
which had substantial value for predicting hospital admission(80) and change in BNP(79). In another study a 
dynamic risk score was calculated daily in HF patients with an implantable device using diagnostic parameters 
that fluctuate. The peak risk category over the month was strongly associated with 30 day hospital admissions 
although the event rate was low(81).    
 
The discrimination of HF prognostic models has been found to be better for HF-specific mortality than all-
cause mortality(187) which may be due to the inclusion of more cardiac specific exposures. Discrimination 
also improves when dynamic measures of change relating to these CVD exposures are included(79,80,193). 
Despite the growing evidence on the importance of non-CVD comorbidity severity and change, with the 
exception of renal severity, dynamic measures of comorbidity severity or change have yet to be considered in 
HF prognostic models. This is important as non-CVD comorbidity is common in the general population of HF 
patients, is routinely monitored and recorded, changes in severity as the disease progresses and may act as 
an important and modifiable prognostic factor for both HF specific and generic outcomes.  
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2.4 Summary 
In summary, HF is a serious chronic disease with poor outcomes. The risk of poor outcomes varies 
considerably between different groups and individuals. Prognosis is important to identify those at the most risk 
so that interventions can be optimized and information clearly communicated to patients. Non-CVD 
Comorbidities are extremely common in HF and whilst evidence has shown their importance for mortality 
there is an important gap in terms of how their severity that changes over time influences their association 
with the range of outcomes in HF. Current prognostic models have been developed on selected hospital 
based patients for the outcome of mortality and not for the general population of HF patients with comorbidity.  
Ambulatory models include mainly selected trial patients where comorbidity may be excluded. Where 
comorbidities are considered they are included as a static measure which ignores the reality of their change 
over time that may be important to risk assessment. Inclusion of the dynamic nature of exposure such as non-
CVD comorbidity has the potential for identifying ambulatory HF patients whose risk is changing so that timely 
interventions can be triggered to improve outcomes. 
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Tables 
 
 
Table 2.1 Comorbidity prevalence in HF 
 
 
 Europe(131) US(130) US(133) US(129) US(111) 
Out Patients (OP) 
Mean 66years, N=3226 
Hospital and OP 
≥65years, N=23435 
Ambulatory, Veterans (95% 
men) Mean 70yrs, N=9442 
Hospital and OP 
≥65years, N=122,630 
Ambulatory 
≥65years, N=534 
Comorbidities All (%) HFpEF(%) HFrEF(%) HFpEF(%) HFrEF(%) All(%) All(%) 
Mean no.  4.5 4.4 4 3.5  >5 
CKD  41   48.8 51.9  45.9 
Stroke 11 23 22.4 21 21.3 3 19.4 
Diabetes 29 19.3 19.1 44.5 40 31 38.3 
COPD 15   33.9 26.6 26 30.9 
Lung disease  32.6 28.9     
Hypertension 58 58.5 59.5 70.5 62 55 73.3 
Anaemia 29 59.8 52.1 33.2 28.4  22.2 
AF 40 28.2 22.1 35 35.4   
CHD  16.1 22.4 27.1 40.4 51  
Depression  17.7 17.2   8  
Arthritis      16 62 
Data are number patients (%). HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. CKD, chronic kidney disease; COPD, 
chronic obstructive pulmonary disease; AF, atrial fibrillation; CHD, chronic heart disease 
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Figures 
Figure 2.1   New York Heart Association (NYHA) classification(93) 
 
 
 
Class I No limitation of physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitation, dyspnoea (shortness of breath). 
Class II Slight limitation of physical activity. Comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, dyspnoea (shortness of breath). 
Class III Marked limitation of physical activity. Comfortable at rest. Less than 
ordinary activity causes fatigue, palpitation or dyspnoea. 
Class IV Unable to carry out physical activity without discomfort. Symptoms of heart 
failure at rest. If any physical activity is undertaken, discomfort increases. 
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Chapter 3 Conceptual framework and thesis overview 
 
This chapter summarises the key concepts relating to HF comorbidity and prognosis using the evidence cited 
in Chapter 1 and 2. The evidence gaps in relation to the concepts are highlighted and a new conceptual 
framework for the inclusion of comorbidity within prognosis is presented.  
 
3.1 Summary of evidence and key gaps 
The number of people with chronic disease such as HF is set to rise in an ageing population. HF is one 
chronic disease that carries a high mortality risk similar to many common cancers and yet the trajectory of 
disease for those with HF is less clear. This means that people with HF tend to live with uncertainty and 
clinicians are unable to plan timely interventions to provide optimal care for those with HF. Comorbidity also 
increases with older age, further complicating the HF disease course and is known to have an important 
influence on prognostic outcomes.   
 
HF prognostic research has so far focused on the risk of limited outcomes such as mortality using baseline 
measurement and static prognostic factors such as the presence or absence of comorbid diseases. This may 
not be the best approach for exposures that change over time where this change may alter the risk associated 
with the exposure. Exploratory prognostic factor studies that do not take this into account will result in 
estimates of risk that are based on an ‘average’ of this change leading to poor individual risk prediction. Non-
CVD comorbidity in HF predominates over CVD comorbidity but has been less well investigated or included in 
HF prognosis. Investigation of non-CVD comorbidity severity and change in HF prognosis will provide the 
potential for better risk stratification of more sensitive outcomes such as transitions across the specialist care 
interfaces and changes in health related quality of life. 
 
Key gap - comorbidity severity: Severity of HF disease has been clearly indicated as a risk factor for a 
range of outcomes and is included in prognosis models as biochemical or physiological markers or symptoms 
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classification. Evidence, mainly in hospital populations, on renal disease comorbidity and limited evidence on 
diabetes and chronic obstructive pulmonary disease comorbidity has demonstrated an increased risk of death 
in HF with increased severity of the comorbid disease (see Section 2.2.3.2). With the exception of renal status 
as measured by kidney function the evidence on non-CVD comorbidity severity has not been translated into 
prognosis and provides the potential for more sensitive risk stratification. A key question is: 
 
 What is the effect of non-CVD comorbidities on outcomes in HF stratified by their severity?    
 
Key gap - comorbidity severity change: A key epidemiological challenge is how the exposure should be 
defined. The traditional approach to prognosis is to investigate one or more factors in a model at baseline. 
These factors are then tested to predict the occurrence and level of risk of an event at a future point in time or 
overtime. However the baseline model approach does not take account of exposures that develop or change 
over time (time-dependent exposures) or exposure effects that vary over time (time-varying effects)(194,195). 
This omission is important and particularly in chronic disease populations where the disease and associated 
clinical factors develop and change overtime. Age is a classic example of a factor that changes overtime but is 
taken account of by the follow-up time included in cohort analysis. Other factors such as chronic disease 
comorbidity that may develop after baseline or change over time once developed may have important 
significance for outcomes but are not currently considered. Two unanswered and important questions are: 
 
 What are the effects of comorbidities that develop before or after index HF on hospital admissions 
and death in HF? 
 
 Does the effect of comorbidities on outcomes in HF differ by their timing of development before or 
after index HF? 
 
One approach to measure exposure that changes overtime that can be accommodated in analytical models is 
to use a cumulative approach that sums up the exposure or exposure time over the follow up period. One 
example may be the total daily dose of a drug and the number of days exposed(196). These approaches 
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require routinely recorded repeated measures of exposure and this can be challenging when using long term 
follow-up data or in quantifying change in exposure as opposed to quantity. A limitation of cumulative 
approaches is that they sacrifice information about potentially important patterns of exposure change that may 
have epidemiological importance. This issue of change over time generates the hypothesis that change in 
comorbidity severity that occurs in the recent time before an event may be an important prognostic factor in 
HF.  A key question is: 
 
 What is the effect of comorbidities on outcomes in HF stratified by recent change in their severity? 
 
Key gap - comorbidity interaction: An important consideration for the inclusion of comorbidity into 
prognostic models is where people experience several different comorbidities simultaneously. Multiple 
comorbidities may have a combined effect that is additional to their independent effects(29) but this is not well 
studied within the HF comorbidity evidence. Common comorbidities that share pathophysiological links may 
provide important combined prognostic information that further stratifies risk for individuals with multiple 
comorbidities. A key question is: 
  
 Is the effect of two comorbid diseases on outcomes in HF different from the sum of their independent 
effects?     
   
Key gap - prognosis outcomes: Available prognostic models in HF often focus on the risk of mortality. This 
means that the available tools have limited use in identifying HF patients’ change across the disease life 
course from stability to instability, to hospital admission and to death. Investigation of hospital admissions and 
death as two separate outcomes provides the natural comparison to use these HF trajectory points as 
indicators of increasing severity of HF status. It is hypothesised that the factors that predict change in HF 
status as indicated by hospital admission and death would also predict change in HF patient reported health 
related quality of life.  A key question is: 
 
 Does the effect of comorbidities differ by the outcome investigated in HF patients? 
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Key gap - prognostic models: Current prognostic models in HF are often developed in specific select 
populations such as those defined by HF phenotypes (HF with reduced or preserved ejection fraction) or 
hospital cohorts. There are limited models developed for use in the general practice population and where 
comorbidity is included, it is defined by the presence or absence of disease. A key question is; 
 
 Do comorbidity severity and change indicators improve a predefined HF prognostic model? 
 
3.2 Conceptual framework  
The preceding chapters and key gaps identified in the evidence suggests that there needs to be a clear 
framework for incorporating comorbidity into new prognostic models with the potential future application in 
clinical practice. A new conceptual framework for comorbidity and prognosis will now be proposed in response 
to the key gaps identified. The overall components within the framework for the index disease and comorbidity 
are status, timing, severity, severity change and disease interactions to influence the prognostic model based 
outcomes over the life course (Figure 3.1). 
 
Status: The simplest approach to incorporating comorbidity in prognosis is where the presence or absence of 
chronic disease at the point of measurement, usually baseline, is included. Whilst all people will have the 
index disease which is the focus of enquiry, other specific chronic diseases are included which may or may 
not be present with the index disease. The comorbid diseases selected for inclusion should be based on their 
common prevalence in the people with the index disease and importance for the outcomes of interest.  
 
Timing: A key choice in the measurement of the index disease is whether it is incident or prevalent. By 
choosing incident disease it allows the comorbidity to be measured according to the life course of the index 
disease. Of interest is whether comorbid disease that develops prior to the index disease (prevalent 
comorbidity), that may be associated with the development of the index disease or unrelated, has a different 
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prognostic effect than comorbidity that develops after the onset of the index disease (incident comorbidity). 
Incident comorbidity may be a consequence of the index disease through pathogenic links or unrelated.  
 
Comorbidity severity: Severity of both the index disease and comorbid disease can be measured by indicators 
that are external to the disease such as disease duration, pharmacological interventions or healthcare use 
such as recent hospital admission for the disease. The HF index disease duration for an incident cohort will be 
determined by the follow-up time.  Internal factors will include physiological markers of disease status such as 
blood test indicators, for example biochemical markers, or functional test indicators such as ejection fraction 
or peak exercise oxygen concentration in HF.  To an extent the measures selected will depend on the 
epidemiological design and available data. Administrative clinical databases now provide a continuous record 
of patients with chronic disease as they present in practice and as their diseases develop over time. 
Information including diseases, drugs and tests are routinely recorded by general practitioners and provide an 
appropriate mechanism for measuring comorbidity severity which can be incorporated into prognostic 
approaches.   
 
Comorbidity severity change: Change in comorbidity severity indicators over the progression of the index 
disease or at specific points in the index disease trajectory may provide important prognostic information for 
the occurrence of a future outcome. Again the indicators selected will depend on their availability. Many 
chronic diseases are subject to continuous monitoring as part of quality indicators and care(197). This means 
that whilst the frequency of severity measures may differ across different diseases and measures there are 
usually multiple records for each patient which provides the mechanism for measuring change over time. Drug 
prescriptions that can provide an indication of disease severity are one of the most consistent and frequently 
recorded measures. 
 
Interaction: Interaction, which is how two diseases combine to influence outcomes, should be considered to 
estimate risk for people with multiple comorbidities. This measure of interaction can be assessed on the 
disease status or in relation to the severity measures of different diseases. For example there may be an 
interaction between two diseases when they are at their most severe. Interaction between the comorbidity and 
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the index disease is also of importance and particularly to understand the influence of comorbidities on the 
progression of the index disease itself (as opposed to the patient outcomes). This approach requires a cohort 
of patients with and without the index disease(29). Another approach to investigating the interaction between 
an index disease and comorbidity is to investigate the influence of the comorbidity on index disease-specific 
outcomes where these are available. 
 
Life course outcomes: Typically prognostic models focus on mortality outcome. Yet, in understanding chronic 
disease progression and change, different outcomes are of interest. The trajectories outlined in Chapter 1 
suggest that disease severity changes over time (whether the index or the comorbidity) so the principles of 
life-course outcomes(198,199) need to be applied. These outcomes can range from those of importance at 
the new onset of disease e.g. patient reported quality of life, to more severe disease e.g. hospital admission 
and finally to death.   
 
Prognostic model: In addition to comorbidities, prognostic models need to include the range of 
multidimensional factors that are known to influence risk in individuals. These factors should represent the 
wider definitions of health and comorbidity and include a range of factors from the environment, host and 
disease. These factors will be guided  by prior evidence and clinical experience of the determinants of health 
and outcomes for the patients with the index disease (Figure3.1).    
 
3.3 Aims and Objectives 
The overall aim of this PhD thesis was to investigate the influence of non-CVD comorbidities on prognostic 
outcomes in HF.  It investigated the influence of other diseases on the likelihood of hospital admission and 
death and developed new comorbidity prognostic factors for inclusion in prognostic models for transitions from 
general practice to hospital care populations and to death. The Clinical Practice Research Datalink (CPRD) 
database was used as this provided HF and other chronic disease routinely collected clinical data in the 
general practice population and also linkage to the hospital admissions and mortality. 
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The specific objectives in three phases were: 
 
Phase 1: To systematically review evidence on current prognostic studies in the general HF 
population and identify measures of comorbidities that have been shown to influence HF outcomes.  
 
Phase 2: To develop measures of comorbidity severity and change using routinely collected clinical 
and healthcare data (from CPRD) that predict risk of mortality in the HF general practice population 
and investigate their contribution to prognostic models. 
 
Phase 3: To develop measures of heart failure comorbidity severity and change using routinely 
collected clinical and healthcare data (from CPRD) that predict risk of unplanned hospital admissions 
in the HF general practice population and investigate their contribution to prognostic models. 
 
3.4 Specific hypotheses 
This thesis was focused on three main aims. Firstly, understanding which comorbidity measures are 
associated with different outcomes in the general HF population; quality of life, hospital admission and death. 
Secondly, understanding how the recent severity of comorbid disease and recent change in severity of 
comorbid disease influence prognosis for two different outcomes in the general practice HF population; 
hospital admission and death. Thirdly on understanding how chronic disease comorbidities should be included 
in HF prognostic models for the general practice population.  
 
Three main hypotheses were formulated: 
 
I. Chronic disease comorbidities are significantly associated with hospital admissions and death in the 
general practice HF population. 
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II. Chronic disease comorbidity severity and recent change in comorbidity severity are significantly 
associated with hospital admissions and death in the general practice HF population. 
 
III. Chronic disease comorbidity severity and recent severity change factors will improve the fit of HF 
prognostic models for the outcomes of hospital admissions and death. 
 
3.6 Thesis overview and summary 
The chapters are based on (i) an overview of concepts and identifying key questions (chapters 1 to 4); (ii) 
systematic review (chapter 5) and analyses based on the Clinical Practice Research Datalink (CPRD) data 
(chapters 6 to 12), and the final discussions (chapter 13 to 14). 
 
Chapter 1 Introduction and key concepts; the principles of epidemiology, disease and health, comorbidity and 
prognosis that underpin the thesis are introduced. 
 
Chapter 2 Context setting; this chapter applies the broader principles outlined in the first chapter to the   
context of HF.  
 
Chapter 3 Conceptual framework and thesis overview; a new conceptual framework for the inclusion of 
comorbidity in prognosis of chronic disease is presented. The rationale for the thesis is stated and the aims, 
objectives and key hypotheses that underpin the design and analyses of the three phases of the study are 
framed. 
 
Chapter 4 Provides discussion and justification of the epidemiological approaches used to perform the 
investigations with a key focus on nested case-control design used in the CPRD analyses.  
 
Chapter 5 presents the systematic review that synthesises the key available evidence on non-CVD 
comorbidity and prognosis in a general population of HF patients. The review identifies the key non-CVD 
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comorbidity prognostic factors and models for potential outcomes; patient reported quality of life, all-cause 
hospital admissions and all-cause mortality.  
 
Chapter 6 presents the CPRD framework for measuring severity and change using routinely collected data. It 
is the first of 6 chapters relating to Phase 2 and 3 which investigate which non-CVD comorbidity measures 
(disease, severity and change) are associated with hospital admissions and death in a general practice 
population of HF and what the contribution of these measures is to a prognostic model.  
 
Chapter 7 describes the CPRD cohort of HF patients by study factors and the non-CVD comorbidity 
measures for all-cause mortality outcome. This chapter identifies the potential confounding factors to be 
considered in the investigation of the prognostic associations with mortality.  
 
Chapter 8 describes the CPRD sub-cohort of HF patients by study factors and the non-CVD comorbidity 
measures for first all-cause hospital admission outcome. This chapter identifies the potential confounding 
factors to be considered in the investigation of the prognostic associations with hospital admission. 
 
Chapter 9 uses the nested case-control design to investigate the strength of association between the non-
CVD comorbidity measures with mortality. Unadjusted associations are first presented followed by 
stratification by key potential confounders and then adjusted associations. 
 
Chapter 10 uses the nested case-control design to investigate the strength of association between the non-
CVD comorbidity measures with first hospital admission in the CPRD subset of patients that had linked 
hospital data. Unadjusted associations are first presented followed by stratification by key potential 
confounders and then adjusted associations. 
 
Chapter 11 tests the interaction between comorbidity measures for the outcomes of hospital admissions and 
mortality. Statistical and biological interactions are tested for the comorbid disease pairs.   
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Chapter 12 tests the contribution of the non-CVD comorbidity prognostic measures to pre-specified HF 
prognostic models for mortality and hospital admission.  
 
Chapter 13 presents the overall discussion relating to the CPRD studies in Chapters 7-12. 
 
Chapter 14 provides the final summary of the thesis. 
 
This chapter has summarised the key gaps in the evidence on HF comorbidity and prognosis. A new 
conceptual framework for the inclusion of comorbidity in prognosis has been presented and used to frame the 
thesis aims, objectives, hypotheses and subsequent chapter plan. The overall components within the 
framework for the index disease and comorbidity are status, timing, severity, severity change and disease 
interactions to influence the prognostic model based on outcomes over the disease life course. 
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Figures 
Figure 3.1: A comorbidity prognostic model       
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Chapter 4 Epidemiological and Statistical Methodology 
 
4.1 Theoretical underpinnings 
This chapter covers the general components of epidemiological and statistical methods from key basic 
concepts to the more advanced methods and analyses used in the subsequent chapters. The purpose is to 
illustrate the development of the thesis framework, which included a rigorous systematic review as well as 
using a national clinical database to answer key prognosis questions in the HF population.  
 
Epidemiology is an empirical science based on inductionism that relies on a sample of observations from the 
real world, in order to infer generalisable conclusions. Its converse deductionism uses a top down approach to 
draw definitive conclusions based on logical reasoning(9). Providing the premises from which the conclusion 
is drawn are true, the conclusion will be true, a philosophy that underpins mathematical reasoning(200). 
Epidemiology however deals with truths that have to be induced from observations in the real world that are 
often incomplete and fallible(201). Epidemiologists identify patterns that exist within data to generate 
hypotheses or generalisations about nature. Skeptics of inductionism criticise the assumption that past 
observations would hold true in the future and that observations are reliant on senses that are subject to 
error(9). A response to this argument can be found in refutationism which holds that induced generalisations 
can be corroborated or refuted by further observations but that a refuting observation will carry more weight 
than any supporting observation(202). This leads to the subjection of a hypothesis to rigorous testing and 
reformulation as well the acceptance that scientific knowledge is no more than a body of currently unrefuted 
hypotheses.  
 
4.1.1 Causal criteria 
In the assertion of causality a number of criteria have been proposed to examine relationships that strengthen 
inference (E-Appendix A3). Arguably there is no definitive criteria with which to prove causation and the 
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criteria in a list may be more than required or not sufficient to determine causation. The criteria do provide a 
useful approach to supporting inference made from observations but the inability to satisfy most criteria does 
not necessarily rule out causation(203). 
 
Epidemiology uses statistical methods to summarise, examine associations and test hypotheses within a 
collection of data for a study sample, in order to infer generalisable conclusions(13). The methods used will 
depend on a number of factors including the measures of association sort and the study designs used to 
obtain them.  
 
4.2 Risk and Measures of association 
There are a number of different measures of association that can be calculated to determine the ‘effect’ of an 
exposure on a given outcome. The choice of effect measure will be determined by the data available and the 
measure of outcome used in the exposed and unexposed groups, for example, a risk or a rate. The different 
effect measures each compare the risks or rates of an outcome between the exposed and unexposed groups. 
This comparison may take the form of an absolute measure e.g. the ‘difference’ in risks or rates or a relative 
measure e.g. the risk or rate in the exposed group as a ‘proportion’ of the risk or rate in the unexposed group. 
It is first necessary then to calculate the risk or rate of outcome in the two groups. 
 
4.2.1 Measuring risk  
Risk refers to the proportion of new cases of an outcome, over a time period, in an outcome free population 
(also called cumulative incidence or incidence proportion)(13).  
 
The number of new cases of an outcome in a time period
The number of people followed for the time period
 
 
However when calculated with the baseline ‘at risk’ population as the denominator this can artificially reduce 
the risk estimate of a specific outcome if participants are either lost to follow up or experience another 
competing event that prevents the outcome occurring. These lost participants cannot appear in the numerator 
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but still appear in the denominator thus reducing the risk of the outcome(9). If they had remained in follow-up 
(i.e. had not experienced competing event X or been lost to follow-up) then their risk of outcome Y would be 
greater.   
 
Incidence rate: One approach to accounting for competing events or loss to follow-up in the analysis is to 
replace the number of individuals in the denominator with the person-years of time in follow-up. This gives an 
incidence rate(204): 
  
The number of new cases of an outcome in a time period 
Total time experienced for the subjects followed [person years]
 
 
This way each person is censored at the point of loss. The risk can then be approximated as(9): 
  
Risk ≈ rate x time 
 
This approximation only holds true where the risk is not large (e.g. the risk is <20%)(9). The risk is calculated 
on the number of people in follow-up over the total follow-up time. Rates are an instantaneous measure 
calculated on units of time which mean that the population at risk changes at different time points. There will 
be decay of the number at risk, as participants experience the outcome, for each subsequent time point. 
Using a risk (approximated from a rate) to calculate the expected number of outcomes for a population, where 
the follow-up is long or the risk high, would lead to an inflated predicted number.   
 
This method of dealing with loss to follow-up and competing events by using time in follow-up deals with the 
following question ‘given that competing event X has not occurred, what is the risk of outcome Y’? In relation 
to competing risks this method is sometimes referred to as cause-specific competing risks(205).  
 
Competing risks and prognosis:   Removing participants who have a competing event in the scenario above is 
useful when trying to determine true causality as all remaining participants are at risk of the outcome 
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investigated. However, it is useful and often of interest to patients and clinicians, to know what the effect of an 
exposure (e.g. a risk factor or an intervention) is on an outcome in the real world setting where other events 
can and do occur.   Another way of dealing with competing risks (sub-distribution competing risks(206)) deals 
with an alternative question; ‘given that event X may have occurred what is the risk of outcome Y’? For this 
approach, participants lost to follow up are censored at the point of loss but participants experiencing a 
competing event X that makes Y impossible (e.g. a death by another cause) are only censored at the study 
end. Leaving individuals in the follow-up in this way gives a true risk of Y in the context that other things (X) 
may happen. As the denominator is now larger the overall risk of Y is reduced.  
 
Risk and Survival analysis: When observing risk over a time period where the incidence rate changes, then 
survival analysis can be used to analyse the time to event. Survival analysis splits the follow up period into 
time intervals over which the incidence rate is assumed to be constant(207). Survival proportions are 
calculated at each point and the numbers of events are accumulated across the time-periods. These survival 
proportions are calculated by subtracting the incidence proportion (number of new cases of the outcome / 
number at risk of the outcome) from one. This method can include the number at risk of the outcome as (i) 
everyone at baseline without the event (no loss to follow up or competing event considered) or (ii) removing 
the loss to follow up and other competing events (cause-specific competing risks) or (iii) censoring loss to 
follow-up but leaving in the participants with competing events until study end (sub distribution competing 
risks).  In this way survival analysis provides a method of calculating risk directly whilst dealing with loss to 
follow up rather than calculating incidence rates. Whilst incidence rates use time in follow-up as the 
denominator, survival analysis removes half of the loss to follow-up (over the time interval) from the at risk 
denominator to account for an even spread of loss over the time period(9). This is the method applied in 
Kaplan-Meier or Cox proportional hazard regression modelling(64) (Discussed below in Section 4.4). 
 
4.2.2 Measuring causal effects 
As well as investigating outcome occurrence, epidemiology attempts to measure the association between an 
exposure and an outcome in order to infer causation at a population level. The ideal approach to compare 
outcome risk between groups with and without the exposure under investigation would be to compare people 
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with clones of themselves at the same point in time, one exposed and one not. That way all other risk factors, 
except for the exposure investigated, are balanced.  
 
Other epidemiological approaches try to achieve groups that, apart from their exposure status, are as 
comparable as possible in their susceptibility to the outcome e.g. randomised controlled trials attempt to 
achieve comparability by random allocation of participants to an intervention in large enough samples to 
ensure all known and unknown characteristics are evenly distributed(208). Observational methods such as 
cohort or case-control design select participants using methods that ensure that the exposure distribution in 
the sample reflects the source population and is not distorted by biased procedures. The balance of other 
factors between the exposed and unexposed groups that may be associated with the outcome, can be 
achieved through the design (i.e. matching or purposive sampling) or analysis (i.e. stratification or 
adjustment)(64).  
 
Once two groups can be assumed to have the same risk of an outcome outside of their exposure status, 
comparison of the risk or rates of outcome between the exposed and unexposed groups can be made.  This 
can be done in a number of ways as follows: 
 
Difference in means: Where an outcome is continuous and the exposure is dichotomous then a difference in 
means is calculated between the exposed and unexposed groups(13). This is an absolute measure and so 
provides an indication of the magnitude of excess risk relating to the exposure. 
 
Risk difference (RD) (Attributable risk) and incidence rate difference (attributable incidence rate):   These are 
other absolute measures of effect used when the exposure and outcome are dichotomous. The risk or rate in 
the unexposed group is subtracted from the risk or rate in the exposed group. The difference is the risk or rate 
that is associated with the exposure(78).  Alternatively a population attributable risk can be calculated, which 
is the difference between the overall risk of an outcome in a population (incidence proportion) and the risk in 
the unexposed group. This measure is a function of the exposure risk and the amount of exposure in a 
population. For example, if the risk associated with smoking was the same in two countries but one country 
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had a much higher number of smokers, the smoking attributable risk would be the same but the population 
attributable risk would be greater in the country with more smokers.  
 
Risk ratio (RR) or Incidence Rate ratio (IRR): When both the exposure and the outcome are dichotomous then 
a ratio measure can also be calculated which is the risk in the exposed group (R1) as a proportion of the risk 
in the unexposed group (R0)(209). Similarly an incidence rate ratio is the incidence rate in the exposed group 
(IR1) as a proportion of the incidence rate in the unexposed group (IR0). Rather than an absolute measure of 
risk difference, this measure provides information on how much more likely the exposed group is to 
experience the outcome than the unexposed group.  
 
Risk ratio = 
R1
Ro
     Incidence rate ratio = 
IR1
IRo
 
                   
The measure does not however reflect the prevalence of the outcome in the two groups and two exposures 
with the same relative risk may have very different risk differences(9). For example, if in group A, there was a 
20% risk of an outcome in the exposed group compared to a 10% risk in the unexposed this would lead to a 
risk ratio of 2.0 but a risk difference of 10%. Conversely if in group B, there was a 2% risk of outcome in the 
exposed group compared to a 1% risk in the unexposed group, the risk ratio would still be 2.0 but the risk 
difference would be much lower at 1%.  In the same way that risks can be approximated from rates where 
risks are small, the risk ratio will be close to the rate ratio under the same circumstances.  
 
Relative effect: Unlike the risk difference measure of effect, the risk and rate ratio do not indicate the 
magnitude of risk within the exposed group that is due to the exposure (as opposed to other causal factors 
also experienced by the unexposed group). The risk attributable to the exposure (risk or rate difference) can 
be expressed as a proportion of the risk or rate in the unexposed group. This measure provides the 
percentage increase or decrease in risk that is directly related to the exposure (as opposed to the ‘exposed 
group’ in risk or rate ratios) compared to the risk or rate in the unexposed group and is obtained by either 
(using risk ratio as an example): 
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RD
Ro
    or     RR −  1 
 
This means the percentage increase in risk in the exposed group that is due to the exposure can be 
calculated e.g. a RR of 2.5 would equate to (2.5 – 1 = 1.5) a 150% increase in risk due to the exposure. A RR 
of 1.4 = 40% increase in risk and a RR of 0.8 = 20% reduction in risk(9).  
 
Attributable Fraction: The attributable risk of the exposure (RD) can also be expressed as a fraction of the 
total risk in the exposed group using(78): 
 
RD
R1
      or  
 
RR − 1 (risk proportion attributable to the exposure)
RR (risk in all exposed out of all unexposed)
 
 
Odds ratio: An alternative to the risk ratio is the odds ratio. This is the ratio of the odds of the event in the 
exposed to the unexposed group(78). The odds of the event are calculated by dividing the number of 
individuals with the event by the number of individuals without the event within a group. This is different to a 
risk calculation where the whole group is included in the denominator. However where the number of events is 
low (<20%) the odds will be similar to the risk.  This is because the small number of events means that the 
size of the denominators for the odds and risk calculations would be similar.  The odds ratio will be greater 
than the risk ratio where the numbers of events is high (9). The odds ratio can be used to calculate the ratio of 
the odds of exposure in different groups, an approach used in case control studies, discussed next. 
 
4.3 Epidemiological designs  
Observational approaches such as cohort, case-control, cross-sectional studies and case cross over studies 
deal with the observation and measurement of exposure and outcomes as they naturally occur(208). The 
method chosen is often a combination of pragmatism and possibility given the research questions asked and 
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the data available. In order to investigate the association between chronic disease comorbidity and outcomes 
in HF, a number of approaches were considered before selecting a cohort with a nested case-control 
approach, the rationale is provided in the following sections. 
 
4.3.1 Cohort design 
A cohort study is the key design for following of a group of individuals over a period of time. The group is 
subdivided into sub-groups which are usually classified by their exposure status at study entry and should be 
otherwise similar in their risk of developing the event.  Epidemiological experiments are one type of cohort 
study where the exposure is assigned(210). In other observational cohort studies the exposure is observed as 
it naturally occurs and measured. The total cohort, regardless of their exposure status, makes up the 
population at risk. This population should each be at risk of the outcome at the start of follow-up.   
 
Calculating risk in a cohort 
The numerator: This is counted as the number of events in the group of interest. For outcomes such as 
hospital admission, the event can occur more than once to each patient in follow-up and a number of options 
exist for analysis:  
(i)  the first event only is counted in the numerator which is preferable when it is difficult to 
distinguish between a new event and an exacerbation of a previous event or when 
subsequent events may have different precipitating factors(209). Where first events only are 
counted, participants are removed from the at risk population after experiencing the event,  
(ii)  each event can be counted as a separate event. This way the estimate of an exposure 
effect would apply to any of the events or  
(iii)  to investigate each event separately e.g. first event, second event, third event.   
 
The denominator: In most cohorts incidence rates are used to calculate a rate ratio (for the exposed to 
unexposed). To calculate the incidence rates for the exposed and unexposed groups, the ‘at risk’ person time 
in follow up is used for the denominator as this allows adjustment for loss to follow-up and competing risks. 
The incidence rate ratio can be used as an estimate of the risk ratio where the risk is small or the follow-up 
  
62 
 
short(9). Risk can also be calculated directly using the number of people at risk in the exposed and 
unexposed groups as the denominator where there is no loss to follow-up or by using survival analysis and 
segments of follow-up time.  
 
Classifying exposure:  The assignment of participants to the exposed or unexposed ‘at risk’ person time in 
follow-up should be done at study baseline but there are two important considerations; induction time and 
exposure status change. Following exposure, ‘sufficient causation’ for an event to occur requires a number of 
complementary causal factors to interact for example environmental and biological factors(9).  Only then will 
the person be at risk of the outcome. Based on this phenomenon, some analyses will only contribute the ‘at 
risk’ person time in the exposed group that commences after the induction time. Similar to cause-specific 
competing risks, this approach seeks to determine the true causation as a measure of effect between the 
exposure and the outcome. Similarly an adaption of this approach is to add the induction time to the ‘at risk’ 
person time in the unexposed group as any event occurring during this time will be unrelated to the exposure. 
An alternative approach is to ignore the induction time which is more aligned to prognosis where the time to 
event from a given point, in the real life context, is of interest. Each approach will give a different rate ratio and 
will be determined by the questions framed. 
 
The presence or absence of exposure status may change during the follow-up period and the ‘at risk’ person 
time may then switch and contribute to a different group i.e. from unexposed person time to exposed person 
time or vice versa. In historical cohort studies where all exposure status is known for the follow-up in advance 
of the start of the study, it is important to classify the exposure status appropriately. If an individual that 
became exposed during follow-up was classified as exposed for the total duration of the follow up this leads to 
‘immortal time’(211).  Immortal time the participant is contributing to the time ‘at risk’ in the exposed group 
where they could not have experienced the event (they were not exposed during this time and had they 
experienced the event they could not have become exposed). This results in an underestimation of effect in 
the exposed group and an overestimation of effect in the unexposed group(212). 
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In addition to the presence or absence of exposure that can change during follow-up, for some exposures 
such as chronic diseases, the quantity or ‘severity’ of the exposure may change. The new exposure ‘severity’ 
or ‘change’ that has occurred may alter the association between the exposure and the outcome.  As stated 
earlier in Chapter 3 one approach to measure exposure that changes overtime is a cumulative approach that 
sums up the exposure or exposure time over the follow up period but this approach is limited by the frequency 
of routinely recorded measures of the exposure in clinical databases. Also this approach does not easily 
capture the change in exposure as opposed to its quantity or the timing of the exposure severity and change 
that might be of epidemiological importance such as in the current time-period leading up to an event. Other 
more advanced statistical methods have been developed to accommodate exposures than change over time 
such as Cox proportional hazard regression modelling(64) but this becomes more complicated where the 
change is frequent or continuous or the number of events is high (see Section 4.4). 
 
4.3.2 Case-control design 
Case-control studies compare the exposure status of all cases within a defined population sample over a time 
period to a sample of controls in the population at risk. Case-control samples are nested within a population or 
cohort and the control sample should reflect as closely as possible the exposure distribution in the source 
population from where it was drawn(213).  
 
Cumulative case-control sampling: In a cumulative case-control design, controls are selected at the end of 
follow-up from the participants that did not experience the event. Exposure status is then measured in the 
cases and controls at the beginning of follow-up(214). Case-control studies estimate odds ratios (OR) as a 
measure of risk. In Section 4.2.2 it was reported that an OR will not approximate the risk ratio when the risk of 
an event is high. Furthermore bias might be introduced in case-control studies where controls are selected on 
the basis of their non-case status representing the number of people in follow-up who did not experience the 
event of interest. Unlike the denominator population using a cohort approach, this source population does not 
include the exposure experience of the case group. Providing that the event is rare, then this missing 
information will be minimal and the odds ratio will be a good approximation of the risk ratio. However where 
the exposure is related to the outcome and the outcome is common, the denominator that excludes this 
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information can lead to overestimation of the risk ratio(215). This issue was an important consideration for the 
investigation of comorbidity exposure in HF due to the high risk of outcomes(209) and a worked example is 
given below. 
 
If the exposure distribution of a cohort is considered, some of the baseline cohort will go on to experience the 
event and some won’t. If half of the baseline were exposed, one may hypothesise that the proportion of 
exposure, once the events have occurred, would be greater in the case group. An odds ratio of exposure is 
calculated using      
 a/b
c/d
      where: 
 
a number of exposed people in the case group  
b number of unexposed people in the case group 
c number of exposed people in the control sample  
d number of unexposed people in the control sample  
 
This can also be written as a cross product fraction     
ad
bc
 
 
The control sample  𝑐 𝑎𝑛𝑑 𝑑   should reflect the same proportion of exposure as in the source population. In 
cumulative sampling where the control group is analysed after the events have occurred, the exposure 
distribution in the control group will differ to the source population as the exposure experience of the cases 
has been removed. This means that proportionally, in a given control sample,  𝑑 (number of unexposed 
people) will be more and 𝑐 (number of exposed people) will be less than the source population. This will 
overestimate the risk ratio. 
 
Case-Cohort sampling: In case-cohort sampling the controls are sampled from the source population at 
baseline (regardless of their future event status).  Given that the exposure distribution in the control group 
using this approach does include those that go on to become cases, the ‘rare event assumption’ required in 
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cumulative sampling is not required in case-cohort sampling(216).  Here, the odds ratio provides a good 
estimation of the risk ratio(217). Controls can be used more than once and may later also become cases, 
which closely reflects survival analysis where nearly all subjects are used more than once, or cohort analysis 
where every subject contributes to the denominator time until they experience the event. The control sample 
in a case cohort design represents the exposure proportion of the source population.   
 
Both cumulative and case-cohort sampling approaches to case-control studies mirror a closed cohort study 
where the denominator is sampled from the people at the start of follow-up and both measure baseline 
exposure status. This creates a challenge for studies where there is loss to follow-up in the study or the 
exposure status changes over the duration of the follow-up. 
 
Risk set sampling:    Where the time in study may vary across individuals or where exposure status may 
change during follow-up, risk set sampling (also called density sampling) provides a mechanism where the 
rate ratio can be estimated using a case-control design(218). The aim of risk set sampling is to produce a 
control sample that mirrors the distribution of exposure time in the source population in terms of ‘at risk’ 
exposed and ‘at risk’ unexposed person time. With this method, the odds ratio will be a good estimation of the 
incidence rate ratio as opposed to the risk ratio. Consider the following(9): 
 
a number of cases in the exposed group  
b number of cases in the unexposed group 
PT1 ‘at risk’ person time in the exposed group 
PT0 ‘at risk’ person time in the unexposed group 
c Number of people exposed in the control sample (should reflect the same 
proportion of exposure time as in the source population) 
d Number of people unexposed in the control sample (should reflect the 
same proportion of unexposed time as in the source population) 
I1 Incidence rate in the exposed group 
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I0 Incidence rate in the unexposed group 
 
Incidence rate ratio is calculated by    
IR1
IRo
 
 
which can be equally written as  
a /PT1
b /PT0
 
                                                                   
or its cross product fraction                                      
a
b
 x 
PT0
PT1
 
 
If density sampling has been performed properly then   
PT0
PT1
    should be equivalent to   
d
c
 
              
And so                                                                     
IR1
IR0
 ≈  
ad
bc
 
 
The approximation will be subject to sampling error and reduced statistical precision but this can be reduced 
by increasing the ratio of controls to cases. Key to this approach is the sampling of controls that represent the 
distribution of exposure time in the source population. 
 
Because the exposure distribution in the cohort will change overtime as cases are accrued, the approach is to 
match controls at the same point of follow-up time that the case was identified. Using this approach controls 
will be selected randomly from those subjects who have not experienced the event on the match date. Similar 
to the case-cohort approach this means that controls can be used more than once and later they may become 
a case. Where risk set sampling differs is that the inclusion of a control and its exposure contribution now 
depends on their length of follow-up and exposure status on the match date(214). A control with longer follow-
up time has more chance of being selected as a control and having their exposure included. This way the 
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proportion of exposure in the control sample will reflect the length of follow-up and exposure time of the 
control sample. A control’s future potential as a case also means that the control sample mirrors the exposure 
time in the source population at the time the case event occurs producing an unbiased estimate of a rate 
ratio(219).  
 
4.4 Epidemiological and statistical methods in CPRD 
4.4.1 Epidemiological method 
The main thesis questions were answered using a case-control design that was nested within a defined 
CPRD cohort. Participants were followed up from baseline which was their first HF consultation code applied 
in their general practice clinical record over a 10 year time-period. Due to the varying time in follow-up of the 
sample and the expected change in the exposure distribution in the source population during follow-up as the 
cases were accrued, ‘risk set’ sampling of controls that were matched to cases on follow-up time, was chosen 
(Figure 6.10 for diagram). This approach means that the exposure distribution in the control group reflected 
the exposure time in the source population at the same point in follow-up as the case occurred giving an 
unbiased estimate of the rate ratio. Due to the long follow-up (of up to 12 years) controls were also matched 
on calendar time to reduce the influence of clinical management changes during the length of the study 
(detailed further in Chapter 6).   
 
The focus of the thesis investigation was on comorbidity severity and the change that occurs prior to an 
outcome event. The risk set sampling approach provided a mechanism where comorbidity change could be 
measured longitudinally over a specific time-windows prior to an event and compared to a control group that 
remained ‘at risk’, at the same point of follow-up as the cases. The comorbidity severity and change occurring 
during the course of HF disease in the source population could be captured by measurement in the control 
group at the same point in time as each case occurred. The potential for multiple selections of the same 
control does not necessarily duplicate exposure or confounder time as these factors may also change during 
the follow-up time(9).  
 
  
68 
 
This approach is analogous to Cox proportional hazards regression which accommodates time-dependent 
exposures and yields similar estimates of effect but less efficiently(220). Cox regression is a form of survival 
analysis (see Section 4.2.1) which uses the time of each event to calculate survival proportions and covariates 
are compared at each of these time points (221). This means that covariates that change over time can be 
easily accommodated. Using the counting approach to Cox regression analysis, each change in exposure 
status is included as a new observation for the length of time it remains unchanged. This results in multiple 
observations for each subject corresponding to the different exposure changes and all are included in the 
analysis. The resulting effect estimate adjusts for the level and duration of exposure(222).  The challenge with 
this approach for comorbidity measured using physiological biomarkers or drugs is that these changes are 
very frequent. Time dependent markers such as biomarkers that change continuously cannot be easily 
accommodated using this approach. Instead, their time dependency needs to be based on their current value 
measured prior to an event(221). 
 
An alternative approach referred to as the ‘programming statements approach’ to Cox regression analysis 
measures the exposure at the point of each event thus creating multiple exposure statuses corresponding to 
different time points for the same subject. All of the different exposure measures (corresponding to each event 
time point) are included in the model as separate covariates which becomes challenging when there are a lot 
of events(221).  
 
In this thesis the risk set sampling with nested case control approach was selected for three key reasons; 
 
(i) the thesis studies included a large sample with over 26,0000 events and investigated measures of 
comorbidity severity that normally change frequently over time 
(i) the approach selected closely mirrors Cox regression that includes time-dependent exposures, but is more 
efficient where there are a large number of events and accommodates exposures that experience frequent 
change 
(ii) the approach allows the measurement of exposure severity and change prior to an event to test the study 
hypotheses  
  
69 
 
(iii) the approach produces unbiased estimates of rate ratios by comparing exposures for the case and control 
at the time point in follow-up of each event.  
 
Unless the distribution of the comorbidity exposure and its change over time is known, using current 
information prior to an event in this approach means that it cannot be used directly for prognosis. The strength 
of association for the different comorbidity exposures does however yield important information and generate 
hypotheses about the potential importance of comorbidity severity and change for prognosis which can be 
further tested in a prognostic model using different approaches(see Chapter 14). 
 
The two routinely available outcomes investigated in CPRD were all-cause mortality and first all-cause 
hospital admission. For all-cause mortality there were no competing events as any events other than death 
would not prevent death occurring. However, for the hospital admissions outcome, death itself becomes a 
competing event. Where this competing event is at least as prevalent as the main outcome it can produce 
biased estimates of effect(223,224). In this study, for first hospital admission, the competing risk of death was 
less than the risk of the main event and so was not considered further.  
 
Matching on follow-up time also facilitated the comparison of cases and controls that would be of similar HF 
severity defined by disease duration. The severity of the HF disease is associated with the outcome of 
mortality and hospital admission and also with the relative effect of the comorbidity exposure. Matching on 
follow-up time provided the mechanism for comparing the exposure distribution of cases and controls that 
were of similar HF disease severity.  
 
4.4.2 Statistical methods 
Regression models combine a number of variables into an equation that i) describes the best fitting line for the 
data given the observations and ii) looks at each variable independently(225). In simple linear regression a 
straight line is fitted that best describes the relationship between one or more independent variables and a 
continuous dependent variable. Consider: 
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Then a linear equation would be: 
                                        
Y =  a +  𝛽1X1 + ⋯ +  𝛽kXk +  𝑒 
 
The intercept describes the outcome variable where all independent variables are set to zero (the baseline 
risk when all exposure variables are not present) and the β is the coefficient which estimates the absolute risk 
difference between the exposed and unexposed group for each unit of the variable X(9).  
 
4.4.2.1 Logistic regression 
Where the outcome is dichotomous such as the event of death or hospital admission it is expressed as a risk 
or a probability of the event occurring and so the range of predicted values of Y needs to fall between 0 and 1.  
As probabilities cannot lie outside of 0 and 1 and the risk of an event usually changes very little at the high 
and low extremes of any singular or combined independent variables, the relationship is usually nonlinear and 
instead takes a ‘S’ or sigmoid shape (Figure 4.2)(226). 
 
A linear equation to predict the risk of a dichotomous outcome would produce estimated values of Y that are 
outside of the range of 0 and 1. In order to derive a linear equation for a logistic curve the Y variable 
(probability of the event) must be transformed into a value that can take any value from – infinity (∞) to + ∞.  
This requires a two stage transformation(226). Firstly the risk (R) must be converted to an odds by dividing it 
by its own complement R/(1-R). This transforms the range to positive values of 0 to ∞ (when converted back 
using odds/(1+odds) the value is then below 1). Secondly the logarithm of the odds needs to be taken which 
transforms the positive odds to a value between - ∞ to + ∞ (when converted back by exponentiation this will 
Y dependent variable  
a intercept 
β coefficient 
X independent variable 
k 
e 
1,2,3,4……. 
error 
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places the predicted value on the positive scale again). The two steps together = ln [R/(1-R)] produces the 
logit. Logistic regression can now produce an equation to predict the logit (Y): 
                  
                                             logit (Y) = ln [
R
1−R
] =  a +  𝛽1X1 + ⋯ +  𝛽kXk  
or                                          Odds (Y) (
R
1−R
)  = exp (a +  𝛽1X1 + ⋯ +  𝛽kXk)    
 
 
β in a logistic regression model is the estimated increase in the logged odds of the outcome per unit increase 
in the value of the independent variable X.  When the β is exponentiated it is no longer an absolute measure 
of risk but a relative measure which is an odds ratio (OR).  
 
The risk (Y) can be back transformed by  
 
Y =    
ea+ 𝛽x+..+ 𝛽k 
1+ea+ 𝛽x+..+ 𝛽k
     =      
1
1+e−(a+ 𝛽x+..+ 𝛽k)
 
 
4.4.2.2 Conditional logistic regression 
Where cases are matched to controls on any factor (such as follow-up time), they form a matched group. 
Conditional logistic regression is very similar to logistic regression but the analysis is performed at the 
individual group level. The positive event within each group is selected (in this study each group had one case 
matched to multiple controls). The likelihood of the data is therefore dependent on conditional probabilities. 
This is the probability of the observed pattern of the case and controls within a group conditional on their 
being one case(227).  Only discordant pairs are included in the analysis. If any variables within the group are 
constant (same for the case and the controls) they are dropped from the analysis and remain not estimated. 
One constant term in each group is the intercept and so this is not estimated in a conditional logistic 
regression. Therefore the equivalent conditional logistic equation to standard logistic regression would be 
 
logit (Y) = ln [
R
1 − R
] is proportional to  𝛽1X1 + ⋯ +  𝛽kXk 
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or                 Odds(Y) are proportional to exp (𝛽1X1 + ⋯ +  𝛽kXk) 
 
Whereas the probability from a standard logistic equation uses  
 
P(Y)    =    
𝑒𝑎+ 𝛽𝑥+..+ 𝛽𝑘
1 + 𝑒𝑎+ 𝛽𝑥+..+ 𝛽𝑘
 
 
a conditional model where a group has one case and one control asks: 
 
P(1,0  ∣ one positive outcome) 
or   
   
P(1,0)
P(1,0) + P(0,1)
 
 
where P is the probability,  1 indicates the case and 0 the control. The probabilities in the above equation 
represent the possible combinations of the case and control within a group that has two subjects and only one 
case.  Transformation back to a probability then uses 
 
P(1,0  ∣  one positive outcome) 
=    
e𝛽x+..+ 𝛽k(1,0)
e𝛽x+..+ 𝛽k (1,0) + e𝛽x+..+ 𝛽k (0,1) 
 
 
This equation seeks the probability of the observed case (numerator) given the probability of the different 
scenarios (observation 1 or observation 2 being the case)(227). 
 
4.4.2.3 Model assumptions 
Logistic regression does not carry many of the underlying assumptions of linear regression models(228). 
However there are a few assumptions listed below which will be further considered in Chapter 6.  
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 No important variables are omitted (model selection, Section 6.3.4, 6.3.6, 6.4.2, 6.4.3). 
 No extraneous variables are included (model selection, Section 6.3.4, 6.3.6). 
 The independent variables are measured without error (measurement bias, Section 6.3.4, 6.3.6) 
 The logit of the dependent variable has a linear relationship with the parameters of the continuous 
independent variables (linearity, Section 6.4.2, 9.2, 10.2) . 
 The independent variables are not linear combinations of each other (collinearity Section 6.4.3, 9.3, 
10.3).  
 Variables are independent (additivity assumption, Section 6.4.2, Chapter 11). 
 
4.5 Chance, bias and confounding 
4.5.1 Chance 
As well as establishing the presence and size of an association, statistical testing also allows the investigation 
of chance through the measurement of variability in the data. Confidence intervals are used to indicate the 
precision of point estimates of unknown population values or parameters from a sample from that 
population(208). The degree of confidence is defined as the probability, which depends on the estimate’s 
(assumed) probability distribution, that the interval contains the true value of the parameter of interest(229). 
Often we wish to estimate the difference in means of two independent populations in which case the interval 
would then be approximately the difference in sample means ± two standard errors of the difference, 
assuming normality and 95% confidence. This level is purely based on statistical variability and assumes that 
all systematic error including bias and confounding are completely removed or controlled.  
 
The other common statistical test is the P value. A P value or significance level is the probability of observing 
a more extreme value than an observed estimate of a parameter when the null hypothesis is true.  A P value 
below .05 is usually chosen to indicate a departure from the null hypothesis.. This value should be interpreted 
with caution. The P value is a function of both the effect estimate size and the study sample size. This means 
that a study with a big effect size but low precision (wide confidence interval) may be found statistically non-
significant(230). A P value of 0.06 indicates that there is a 6% probability of a value at least as extreme as the 
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observed value if the null hypothesis (RR=1) was true and this, in most studies, would be too high a 
probability in order to reject the null hypothesis. However this value also indicates that the variable could be 
worthy of further investigation since it approaches significance. A larger sample size may lead to a statistically 
significant effect size. This is in contrast to a small and clinically insignificant effect that is found to be 
statistically significant through larger sample size). It would be counterintuitive to give more weight or 
importance to the second scenario in considerations of clinical importance(9).  
 
4.5.2 Bias 
Bias relates to the systematic error that is introduced in the collecting or analysis of data(64) and is an 
important consideration for the accuracy of findings. Two main biases related to observational studies are the 
selection of the study sample and measurement. Selection bias occurs when the participants entering into a 
study differ in some way to the general population of potential participants with the same inclusion 
criteria(209). This can be through the self-selection of volunteers who may be healthier than non-volunteers or 
conversely have more concerns about their health than non-volunteers. Similarly investigator-led selection 
can also introduce similar bias, for example in a case control study where control participants are not chosen 
independently of the exposure.   
 
Information collected about or from participants can result in bias due to misclassification which may be 
differential (related to other variables such as the exposure or the outcome) or non-differential (unrelated to 
other factors). One example of differential bias may be where the recall of exposure is greater in cases than 
non-cases or where the outcome is more likely to be observed or diagnosed in the exposed group due to 
better monitoring(204). In situations where misclassification is non-differential and the exposure is 
dichotomous then the exposure effect will be diluted and the resultant bias in the exposure effect estimate will 
be towards the null value. Where there are two or more exposure categories, non-differential misclassification 
leads to convergence of the effects across categories(9).  
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In this study, selection bias was minimised by using a national sample of heart failure patients with random 
sampling of controls from the risk sets of the cases. Steps taken to reduce misclassification bias will be 
detailed in Chapter 6.    
 
4.5.3 Confounding 
Confounding is caused where there is a factor, other than the exposure of interest, which is associated with 
the exposure and separately with the outcome. A confounder has a causal effect on the outcome or is a proxy 
marker for another causal factor and may be unevenly distributed across exposure groups(13). A confounder 
should not be an effect of the exposure itself (i.e. on the causal pathway between the exposure and effect)(1). 
Unless a confounding factor is taken into account it may lead to an incorrect inference on the association 
between the exposure and the outcome. Restriction of participants to one category of the confounder (e.g. 
specific age) or matching participants on a confounding factor can limit the confounding through selected 
study design(207). 
 
When matching is done on the basis of the cases in a case-control study it can adversely influence the 
exposure distribution in the control sample. A confounding variable is by definition associated with the 
exposure and the outcome. By matching on this variable the control group is forced to mirror the cases on a 
factor that is also associated with the exposure of interest i.e. increase the exposure proportion in the control 
group which will artificially reduce the effect of the exposure on the outcome. For this reason, matching in this 
study was restricted to the time in follow-up and calendar time as opposed to any potential confounding 
factor(231). Potential confounders were investigated and then adjusted within the regression models (see 
Chapter 6). 
 
4.6 Clinical data sources 
There are a range of clinical data sources which vary in nature, content and detail. The choice of data source 
for use in epidemiological research will be determined by the questions asked and the ability of the data to 
represent the source population from where it is drawn. For this reason data that has a clear denominator 
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population is an important consideration for epidemiological research. Other common considerations across 
different data sources are accuracy, consistency, completeness, timeliness, precision and access(232). There 
are four main sources of clinical care data: national records, registers, surveys and electronic databases. 
 
4.6.1 National records, disease registers and surveys  
Countries including the UK keep a national archive of all births, marriages and deaths(232) which provide 
important information on population demographics including cause of death. Whilst accurate, this data lacks 
the detail and frequency of recording necessary to study disease.  Other national data records related to 
broader determinants of health include scores of deprivation related to small geographical areas such as the 
Index of Multiple Deprivation (IMD) which was used in this study where available through linkage with the 
CPRD (see Chapter 6).  Disease registers can be an excellent source of information on people with a specific 
risk profile, disease, condition or intervention which can be linked using patient identifiers to other health 
data(233). One of the advantages of disease registers is that they are based on a concerted effort to identify 
all people within a defined denominator population who share a particular health characteristic rather than 
relying on health care contacts. However limitations of this data source are that registries are usually district or 
regionally based and there is heterogeneity across registers in terms of quality and purpose(234). Surveys, 
such as the National Census(235) and the Health Survey for England(236), collect self-reported information 
from the public and are a means of collecting socio-demographic as well as health information from a targeted 
denominator population. An advantage of surveys is that they capture a wider population than those who 
consult for ill health providing important information about the true burden of disease in populations. 
Limitations with self-reported health surveys include the smaller samples and subjectivity across patients.   
 
4.6.2 Electronic databases and the Clinical Practice Research Datalink (CPRD)  
Healthcare data is routinely recorded in clinical practice during patient contacts and can be a rich source of 
information on disease, interventions and outcomes. As the largest provider of ongoing care in the UK general 
practice captures most of the reported health problems in the population. The introduction of a GP UK 
contract in 2004 which established the Quality Outcomes Framework (QoF) has meant that the recording of 
clinical information and completeness of data has improved for specific conditions such as HF and renal 
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disease. This QoF data is collected centrally although it is not accessible directly and targets a limited set of 
conditions(197).  
  
One of the largest longitudinal captures of general practice data which was used in this thesis, is the Clinical 
Practice Research Datalink (CPRD). This database is the world’s largest electronic database of anonymised 
records for primary care(237). CPRD has, since 1987 collected data from voluntary GP practices across the 
UK to create anonymised, longitudinal medical records of registered patients’ demographic information (e.g. 
age, sex, weight), clinical events (medical diagnoses), referrals to specialists and secondary care settings, 
prescriptions issued in primary care, diagnostic testing, lifestyle information (e.g. smoking and alcohol status) 
and all other types of care administered as part of routine general practice. 
 
The main primary care database held by CPRD is known as GOLD which covers approximately 8.8% of the 
UK population, including practices in England, Northern Ireland, Scotland and Wales. As of September 2014 
there were 684 GP practices and 13.58 million research quality patients in GOLD, of which 5.69 million are 
active (still alive and registered with the GP practice)(238). The CPRD sample is therefore representative of 
the UK general population, with comparable age and sex distributions as those reported by the UK National 
Population Census.  
 
The CPRD has established linkages to a number of other datasets, including Hospital Episode Statistics 
(HES), Hospital Treatment Insights (HTI), cancer registry data, Index of Multiple Deprivation (IMD) and 
mortality data from the Office for National Statistics (ONS). Linkage of CPRD GOLD data with other patient 
level datasets is only available for English practices that have consented to participate in the linkage scheme. 
These linkages cover approximately 75% of the contributing practices in England, or roughly 58% of all 
practices in the database. 
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4.7 Summary 
This chapter has presented an overview of key epidemiological and statistical methods.  The thesis focus is 
on the investigation of comorbidity severity and change that occurs prior to an event in HF which poses 
epidemiological and statistical challenges.  Different methods were considered in order to illustrate the 
development of and rationale for the methods chosen to investigate the thesis hypotheses. The CPRD cohort 
with a nested case control design, using risk set sampling, will be further detailed in Chapter 6 with specific 
application to the thesis.   
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Figures 
Figure 4.1  Cohort with nested case control approach using risk set sampling 
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Figure 4.2 Logistic curve 
 
 
Taken from Park (2013)(228)
  
 
 
 
 
 
 
 
Phase 1: Systematic review 
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Chapter 5 Non-cardiovascular comorbidity and prognosis in HF 
populations: A systematic review and meta-analysis 
 
The association between different non-cardiovascular (CVD) chronic disease comorbidities and outcomes in 
HF has been the focus of a number of studies over recent years but these studies have mostly included 
selected HF patients and there is no systematic framework for the inclusion of comorbidities in prognosis 
studies. This chapter describes a systematic review to examine which non-CVD comorbidities have been 
included in general HF population prognosis studies and estimate the magnitude of association between non-
CVD comorbidities and different outcomes in HF(239). The influence of comorbidity severity and how this has 
been included in prognostic models for HF is also described. Inclusion of non-CVD comorbidity in prognosis 
provides the potential for developing prognostic factors that are sensitive to changing severity of an index 
disease such as HF and to predict key transitions in health and healthcare.  
 
5.1 Introduction  
The evidence focus stated in Chapter 2 has been on cardiovascular comorbidities in selected populations 
despite non-CVD comorbidities now predominating in the older general HF population. The impact of chronic 
disease comorbidity on patient outcomes depends on a number of factors which include (i) the disease, (ii) the 
severity status of the disease and (iii) the outcome investigated.  Prognostic models that aim to provide 
individual risk for HF patients currently focus on mortality outcomes(73,174,240) and whilst they have included 
one or two non-CVD chronic disease comorbidities, no systematic approach has been developed for clinical 
practice and severity status of comorbid disease is rarely studied.  
 
A systematic review and synthesis of current evidence provides the opportunity to compare the influence of 
different chronic disease comorbidities for different outcomes which lays the basis for understanding how non-
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CVD comorbidity may be used to predict key life course changes with disease progression in health, 
unplanned hospital admission and mortality outcomes over the disease course.   
 
5.2 Aims and Objectives  
Aims:  The aims of this systematic review was to examine the current evidence on the influence of clinical 
non-CVD comorbidities on outcomes in HF and on current prognostic models for HF that incorporate non-
CVD comorbidities to predict outcomes for unselected HF patients in community and hospital settings.  
 
Objectives:   The three specific objectives were; 
 
(i) To determine which clinical non-CVD comorbidities influence the HF outcomes of patient reported 
health status measures, hospital admissions or mortality.  
 
(ii) To investigate if and how non-CVD comorbidity severity and change in severity status has been 
investigated in HF prognosis studies.  
 
(iii) To determine how non-CVD comorbidities have been included in current HF prognostic models, 
by chronic disease type, severity or status change. 
 
5.2.1 Hypotheses 
In addition to identifying the current evidence and measuring the association between non-CVD comorbidity in 
HF and outcomes, three hypotheses were postulated: 
 
(i)     The risk estimates for the association between non-CVD comorbidities and outcomes in HF will       
    differ by disease and chosen outcome. 
(i)     Increased non-CVD comorbidity severity is associated with worse HF outcomes. 
 
(ii)     Increasing non-CVD comorbidity severity change is associated with poorer HF outcomes. 
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5.3 Methods 
In total medical databases of published and unpublished studies were searched and studies were included 
that focused on the HF population, the prognosis outcomes of self-reported health status, hospital admission 
or mortality and which included a chronic disease non-CVD comorbidity measure. Selection was performed 
within the review team and data extraction was undertaken using a predefined template. Quality assessment 
was performed by two reviewers and inter-rater agreement was tested using Cohen's kappa coefficient. The 
risk estimates for different chronic diseases were described for different outcomes and meta-analysis was 
performed where appropriate. Finally the inclusion of comorbidity in prognostic models for the different 
outcomes was described.   
 
It has been recognised over recent years that prognosis studies vary in terms of methodology, quality and 
reporting(241). For studies focused on a particular disease there can be much variation in clinical definitions, 
settings and selection of exposures and outcomes. Systematic reviews of prognosis studies that do not take 
these factors into consideration can lead to collective bias, misrepresentation of the effects of exposures or 
conflicting results between multiple reviews with the same objective (observed in reviews of cancer and stroke 
amongst other diseases)(242). As a number of similar prognosis studies accumulate it is important to identify 
all the available studies to provide an overall assessment of risk. However this is complex given the variation 
in the reporting of studies (identification) and variation in methods used (overall assessment of risk)(243). 
These issues were carefully considered in a protocol for the systematic review which was registered with 
PROSPERO (protocol no.CRD42013003605; www.crd.york.ac.uk/prospero/) (E-Appendix D1) and was 
reviewed by a member of the Cochrane Prognosis Methods Group (E-Appendix E1). Initial steps taken to 
improve the identification and methodological consistency of studies were the use of a validated search 
strategy for prognosis studies, quality appraisal of each study by two reviewers and careful consideration of 
the studies used in any meta-analysis.  The Meta-analysis Of Observational Studies in Epidemiology 
(MOOSE) guidelines(244) were used for the reporting of the review. 
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5.3.1 Inclusion and exclusion criteria 
The review inclusion and exclusion criteria for selecting studies (Table 5.1) were developed in relation to key 
components using the PICOS acronym (population, intervention or exposure, comparators, outcomes and 
study design)(245). The comparator component was not relevant to this review.  Given the variation possible 
within each of the components, clearly defined criteria were required to allow for the comparison of the 
comorbidity effect estimates across the studies included and meta-analysis.  
 
Population: The study samples were adults aged 18 years and over with HF. HF in younger groups is more 
likely to be associated with a rare cause such as a congenital heart defect(246) which would require specific 
consideration for prognosis.   
 
HF definition: The sample included any person with a clinical diagnosis of HF, but this varied according to the 
study settings and time of investigation. Current European diagnosis recommendations include the 
combination of symptoms (e.g. dyspnoea, limited exercise tolerance, fatigue) signs (e.g. peripheral or 
pulmonary oedema, jugular venous distension) and objective evidence of HF (e.g. impaired ejection fraction 
or ventricular dysfunction)(93). The use of echocardiogram to provide objective evidence has only been 
introduced into the Quality Outcomes Framework for general practitioners since 2006 in the UK(247). 
Inclusion in this review was on the basis that the HF population was not selected on the basis of a specific 
aetiology or manifestation of HF but instead included a contemporary mix of patients with HF reflective of the 
general population.  
 
Settings: Samples from three different broad settings were included. Firstly hospital based samples which 
included both de novo HF and chronic HF admissions (primary cause of admission or discharge). Secondly, 
community based samples which included general population, general practice and outpatient clinics. Thirdly 
randomised controlled trial populations which are often hospital based or include both hospital and community 
patients.  
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Setting exclusions: Excluded from the review were studies that selected the HF populations by causes e.g. 
cardiomyopathy or myocardial infarction, by procedure e.g. heart transplant or device or by hospital sub 
setting e.g. intensive care. Some research studies on HF have broadly selected groups such as patients with 
a preserved or reduced ejection fraction(248-251) and these were excluded to focus on the general population 
of HF patients with both preserved and reduced ejection fraction(252) and to aid the comparability and 
synthesis of effect estimates.  
 
Exposures - comorbidity definitions: The focus was on comorbidity exposure defined as any non-
cardiovascular chronic disease.  Chronic diseases were based on clinical diagnosis or patient self-report with 
inclusion of disease severity. Acceptable comorbidity indicators included in the screening process were:   
 
(i)  chronic disease type e.g. diabetes 
(ii)  chronic disease severity measure e.g. fasting glucose or glycosylated haemoglobin (HbA1c)  for 
diabetes(253). For physiological indicators of disease severity, only those used in current diagnostic 
guidelines were included. 
(iii)  chronic disease severity change measure e.g. changes to drug prescription or dose, change in blood 
test indicator (such as HbA1c) or frequency of healthcare episodes.   
 
In an initial scoping of evidence, two systematic reviews on renal function and renal function change and 
outcomes in HF were identified(145,157). This review included renal studies published after the prior reviews 
(May 2005) together with relevant studies from the prior reviews.  Whilst CKD is defined as kidney damage 
with or without reduction in estimated glomerular filtration rate (eGFR) or a reduction in eGFR for greater than 
three months(254), the latter criteria is more commonly used to describe CKD and relates to stage 3 or more 
out of five stages of CKD. Most studies that include renal comorbidity use eGFR level as a marker of 
dysfunction rather than a formal clinical diagnosis of chronic kidney disease.  
 
Exposure exclusions:  Cardiovascular comorbidities are usually associated with the aetiology or 
consequences of HF (e.g. ischemic heart disease or hypertension) and whilst important to prognosis they 
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have been well described in the literature(143,144,255-257), and hence excluded from this review. The focus 
of the review was on chronic disease comorbidity so conditions such as anaemia or depression were 
excluded as were novel biomarkers or physiological indicators that are not routinely used or not specific to a 
chronic disease status. Examples include liver function tests, cystatin-c, urea, blood glucose, blood urea 
nitrogen (BUN) and oxygen saturations. 
 
Outcomes: The primary outcomes included in the review were health related quality of life (HR-QoL), all-
cause hospital admissions or readmissions and all-cause mortality. HR-QoL outcomes included general 
measures such as the Short-form 12 or 36 or HF specific measures such as the Kansas City Cardiomyopathy 
Questionnaire (KCCQ).  All-cause mortality and hospital admissions were chosen as opposed to specific 
causes for comparability of studies and to reflect the study population with HF and comorbidity. 
 
Outcome exclusions:  Composite outcomes such as ‘hospital admission or death’ were excluded with the 
exception of ‘death or urgent heart transplant’ as this emergency procedure prevents inevitable death in HF 
and is often counted as a death event in HF studies(189,258,259).  
 
Study designs: Observational studies with more than 30 days follow up were included. These constituted 
cohort studies and secondary analyses of randomised controlled trials (RCTs). RCTs were included only 
where both trial arms were used for the prognosis study whether or not the intervention was accounted for in 
the analysis. This approach was appropriate as the controlled distribution of the intervention and the often 
negligible effect of the intervention on the effect of the exposure(225).  
 
Three types of prognosis studies were included: 
 
(i)  Prognostic factor study (chronic disease focus). These were any HF studies that focused on the 
association between a non-cardiovascular chronic disease comorbidity and an outcome. Studies that 
did not focus on a non-CVD chronic disease e.g. a pharmacological intervention study and only 
adjusted for a chronic disease comorbidity were excluded.   
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(ii)  Prognostic factor study (general). These were any studies that investigated a range of potential 
prognostic factors and included a non-CVD chronic disease comorbidity to be an independent 
prognostic factor.  
 
(iii)  Prognostic model study. These were any studies that combined a number of prognostic factors to 
provide an estimate of individual risk in HF and which included a chronic disease comorbidity 
prognostic factor. The primary study rather than validation or impact studies were included. Where 
studies included a derivation and validation cohort the derivation cohort was included. 
 
Study design exclusions: Excluded study designs included cross sectional studies and RCTs where inclusion 
criteria did not reflect the inclusion criteria in the review. Given the scope of the review it was decided to limit 
papers to those published in English language only. Whilst this may introduce some bias through authors only 
publishing in English journals when results show a significant effect, investigation of two meta-analyses has 
demonstrated that the removal of non-English studies has not affected the overall results(260). Studies that 
were only published in abstract form were excluded if a full report could not be identified.  
 
 
5.3.2 Search strategy 
A search strategy was designed that included database selection, development of search terms, search 
validation and additional searches.  
 
5.3.2.1 Literature Databases 
The main bibliographic databases used to identify the studies of interest were MEDLINE, EMBASE and 
CINAHL. MEDLINE is produced by the United States National Library of Medline and indexes over 5,200 
journals in 37 languages and EMBASE, a European database, indexes over 4,800 journals in 30 
languages(261). Both generate a similar number of relevant references and whilst there is some overlap 
depending on the topic, it has been recommended that both databases be used for a comprehensive 
search(261,262). This may be of particular importance where meta-analysis is considered as some bias in the 
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reporting of effects has been found across the two databases with EMBASE including proportionally fewer 
studies with smaller effects(263). CINAHL (Cumulative Index to Nursing and Allied Health Literature) which 
indexes journals that are orientated to nursing and allied health was searched in addition to capture any 
studies relating to HR-QoL that may be missed by the other databases. Each database has its own search 
interface and related syntax depending on the service provider. For this search the interface was determined 
by validated prognosis search strings for MEDLINE and EMBASE and were as follows; (i) MEDLINE: PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), (ii) EMBASE: OvidSP (http://ovidsp.ovid.com/), and (iii) CINAHL: 
EBSCO (http://www.ebscohost.com/).               
 
Other databases: To improve the retrieval of any prior systematic reviews in relation to the topic, DARE 
(Database of Abstract of Reviews of Effects) and CDSR (Cochrane Database of Systematic Reviews) were 
also searched. CENTRAL (The Cochrane Central Register of Controlled Trials) was searched to indicate any 
prognosis studies that were performed as a secondary analysis of a trial.  
 
5.3.2.2 Developing search terms 
Search strings were developed for three of the four components of the inclusion criteria: population, outcome 
and study type. A decision not to include the comorbidity exposure in the search strategy was made due to 
the breadth of possibilities when considering all chronic diseases and their indicators. Also for prognostic 
factor studies (general) and prognostic model studies, chronic disease terms would be unlikely to be listed in 
free text or controlled vocabulary where they were not the focus of the study.  
 
HF population search string: A validated search string for HF was identified(264) for use in MEDLINE using 
OvidSP. The HF search string used a combination of controlled vocabulary words and free text headings (E-
Appendix E2) which retrieved 98% of records validated using two different methods. Precision was quite low 
and 25% of all records retrieved using the strings in MEDLINE were not relevant to the HF population(264).  
When this population string was used in conjunction with the prognosis and outcomes string it resulted in over 
23,000 citations in EMBASE alone (E-Appendix E3). Initial random check of 500 articles demonstrated that 
only 29% (n=145) of the articles were focused on the HF population. As HF falls at the end of a spectrum of 
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cardiovascular disease it was often indexed as a controlled vocabulary term in studies where HF was an 
exposure or an outcome rather than the focus of the study. Following this initial search a HF string focused to 
the title of articles was then designed.  
 
HF title search: The controlled vocabulary terms and their subheadings from each database were reviewed to 
develop a list of possible descriptors of the population that might appear in an article title. This list was then 
reviewed and added to by two HF clinical experts (E-Appendix E4).   The search was rerun using the new 
population string focused to the title and then 1% of the initially excluded articles were checked for appropriate 
exclusion. None of the excluded studies checked were relevant to the review.  
 
Prognosis string: Validated prognosis search strings were identified for retrieval of prognosis studies in 
MEDLINE and EMBASE. Prognosis search filters have been found to be less sensitive for prognostic factor 
studies than prognostic model studies so search strings that optimized the capture of both types of study were 
selected. An updated version of the Haynes broad filter was chosen for MEDLINE (E-Appendix E5a) as this 
yielded a sensitivity of 0.84 for prognostic factor studies and 0.9 for prognostic model studies when validated 
against the included studies in four prior systematic reviews(265). Before the update low specificity was found 
for both factor and model studies (0.67) and this remained after the update reported as a high ‘number need 
to read’ (NNR). The NNR reflects the number of articles that need to be read before a good quality article is 
likely to be identified. The NNR was 1010 for factor studies and 208 for model studies. The high sensitivity but 
low specificity means that most good quality studies would be captured by the search but the efficiency of the 
search would be low leading to a high number of articles requiring screening out. 
 
For EMBASE a number of different combinations of terms had been previously tested for the retrieval of 
prognosis studies. The chosen string(266) (E-Appendix E5b) was one that again optimized sensitivity (99%) 
over specificity (51%). This search string was adapted for CINAHL using the appropriate syntax for EBSCO 
interface (E-Appendix E5c). 
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Outcomes string:  Free text words for each of the three outcomes included in the review were selected using 
common descriptors and thesaurus terms (E-Appendix E6).  
 
5.3.2.3 Validating the search 
All three search strings were combined using the Boolean operator ‘AND’.  The resulting combined unique 
citations were cross checked to make sure that they included a selection of known comorbidity prognosis 
articles.  Four of the fifteen known studies were not included in the Medline citations but were included in 
EMBASE. Free text words that were common to all of the MEDLINE non retrieved articles and which were not 
part of the prognosis string in MEDLINE were risk, HR, hazard. These terms were then added to the 
MEDLINE prognosis string as free text words. When the MEDLINE citations were reran then this included all 
known articles. Also it was noted that the outcomes ‘admission’ and ‘readmission’ were often termed 
hospitalization or rehospitalisation in American studies. These words were added to the outcomes string.  
 
The final search strategy was ran (E-Appendix A4) and two systematic reviews of prognostic factors(182) and 
prognostic models(183) for readmissions in HF were used to check the validity of the current review. The 
combined 112 prognostic factor studies and 6 prognostic model studies across the two prior reviews were 
screened against the current review inclusion criteria. Only one factor study and two model studies met the 
inclusion criteria for this review and had been identified by the current search. Most of the factor studies in the 
prior review were focused on a non-chronic disease prognostic factor or an outcome of less than 30-day 
follow-up.  
 
As the inclusion criteria for the current review was applied during the screening stage and not the search 
stage, half of the prognostic factor studies (n=56) from the prior review that did not meet the inclusion criteria 
for the current review were again cross checked against the citations identified by the current search and 51 
of the studies had been identified. Of the 5 not identified, 4 did not have a HF term in the title and none were 
focused on the HF population.  
 
  
92 
 
5.3.2.4 Additional searches 
Grey literature: To reduce publication bias, online databases were searched for unpublished studies. These 
included HMIC (Health Management Information Consortium) for unpublished studies, Index to Scientific and 
Technical proceedings, Zetoc and the Conference Papers Index for conference abstracts and ETHOS, 
ProQuest and Networked Digital Library of Theses and Dissertations for any related thesis. Studies only in 
abstract form that had not been reported in full elsewhere were excluded.  
 
Other searches: All reference lists from included studies were reviewed for any missed relevant studies and 
key authors in the field were contacted. These included Professor John McMurray (Scotland), Professor 
Martin Cowie (London) and Professor Greg Fonarow (America). Citation searching was performed on some of 
the key included articles to increase sensitivity(267) using Web of Science, an online scientific citation 
indexing service.  The Cochrane Prognostic Method’s Group website was also searched to identify any 
prognosis studies or prognosis reviews relevant to the topic. Hand searching of key journals included the 
European Journal of HF, Journal of Cardiac Failure, HF Reviews and the Journal of Comorbidity. Zetoc was 
also used to set up an email alert and RSS feed of the journal’s contents.    
 
5.3.3 Screening of articles 
This stage was performed by a total of three reviewers comprising topic and methodological expertise (CAR, 
LD, UTK). Initial screening was performed by the first reviewer (CAR) based on title and where necessary 
abstract, to exclude duplications and studies that were not suitable and these were cross checked (1% of 
articles) by a second reviewer (UTK).  This initial screen focused on two main inclusion criteria (i) a prognostic 
factor study that focused on a non-CVD chronic disease or (ii) a general prognostic factor or prognostic model 
study that reported a non-CVD chronic disease factor as independently associated with an outcome. The first 
reviewer then selected articles based on abstracts that met the inclusion criteria of the review. Two second 
reviewers (LD, UTK), who were blinded to the decision of the first reviewer, screened half of the abstracts 
each and any disagreement between the first and second reviewer was arbitrated by the remaining second 
reviewer. The final set of papers was read in full by the first reviewer (CAR) and second reviewer (UTK) 
separately and any disagreements were resolved by consensus.  
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5.3.4 Data extraction 
Methods, exposures and outcomes: A data extraction form was designed in relation to the review’s aims and 
objectives. The form needed to facilitate the collection of information relating to the key elements of the review 
for analysis and interpretation of the findings. The form included criteria in relation to the study source, 
eligibility, methods, participants, exposure, outcomes, results and analysis (E-Appendix A5). It was decided to 
collect the information needed to assess risk of bias on a separate form to simplify the process (see next 
section 5.3.5). A structured approach to data extraction was performed by two reviewers (CAR, UTK) 
separately and any discrepancies were again resolved through consensus.   
 
Extraction of the results: Where summary variables were reported by sub groups, whole group results were 
calculated. For the participant variables of age and ejection fraction the sub group means and standard 
deviations were combined using a formula to calculate the combined mean and pooled standard deviation (E-
Appendix A6a) which provides an approximation to the true standard deviation of the total group.  An 
alternative, more detailed formula that takes the difference in group means into account could have been used 
(E-Appendix A6b) however this was not deemed necessary given the small difference in the means and 
standard deviations of the subgroups within the included studies(268). Where the effect estimates were 
presented by sub groups and the whole group, the whole group effect estimates were extracted. The only sub 
group effect estimates that were extracted were those presented by age or gender.   
 
5.3.5 Quality appraisal 
Systematic reviews of prognosis studies need to appraise the methodology of the included studies to assess 
the risk of bias that is associated with the study design, conduct, analysis and interpretation(269). Failure to 
do this can lead to misinterpretation of the collective evidence. Collectively, included studies also need to be 
appraised for reporting and publication bias particularly where meta-analysis is considered (see section 5.3.6).  
Risk of bias assessment was performed in this review for each included study after the initial selection. It was 
used to include only studies with overall low or moderate risk in the meta-analyses and to perform sensitivity 
analysis on the combined effects, removing studies that had one or more individual domains at high risk. The 
overall and specific domain risk assessment was also included in the description of the included studies.  
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Quality appraisal Assessment tool:  The Quality in Prognosis Studies Tool (QUIPS) tool was identified for the 
review which is a tool constructed by a team of epidemiological, clinical and statistical experts and  
based on 163 prior reviews of prognosis studies(270). The tool has six domains relating to areas of potential 
study bias in prognosis studies (E-Appendix A7a). Each domain has a number of prompt questions to facilitate 
the reviewer making a scientific judgement of high, moderate or low risk of bias for each domain. The reviewer 
then makes an overall study judgement of risk using the six domains. 
 
The QUIPs assessment attempts to go beyond the determination of whether or not a study was clearly 
reported or conducted well, an approach used in other quality assessments(270)  as these studies may still be 
open to bias. The Cochrane review risk assessment categorises risk as low, high or unknown which allows for 
the allocation of a risk category to studies with non-reported information. Using the QUIPs tool, where 
information was missing or information was presented but the level of risk was unclear, the moderate risk 
category was used.  
 
A challenge with assessing the overall risk of a study across the six domains is that assessments are subject 
to personal interpretation of the importance or weight given to the different domains. Attempts to overcome 
this challenge for this review were made in two ways. Firstly a component approach to assessment that 
considered the specific QUIPs criteria for each domain was conducted and a focused set of objective criteria 
were selected for reporting to aid transparency of the overall risk assessment. The QUIPs tool provides 38 
different criteria for consideration across the 6 domains which can be time resource intensive to report in any 
detail (taking up to an hour per paper for experienced trained assessors)(270). Whilst these criteria were used 
in the assessment of risk, selected specific objective measures were used for reporting. These measures 
were selected from the QUIPs domain criteria as well as some additional criteria pertaining to internal and 
external validity used in other prognosis reviews(271). The main supplementary criteria related to statistical 
analysis where there was less detail given in the QUIPs tool (E-Appendix A7b). As the review included 
prognostic model studies as well as prognostic factor studies additional criteria for models were also added.  
Secondly, whilst domain and overall study risk were assessed, to reduce subjectivity, CAR and UTK 
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performed the quality assessment and inter-rater agreement in the overall study risk assessment was 
measured using Cohen's Kappa coefficient.  
 
5.3.6 Synthesis of findings 
Overview: Meta-analysis was performed on the sub-set of prognostic factor (chronic disease focus) studies 
with effect estimates that could be combined. Quantitative synthesis was limited to these studies for three 
main reasons. Firstly these studies were more likely to appropriately consider confounding and provide 
unadjusted and adjusted comorbidity effect estimates.  Secondly because the effect of comorbidity on an 
outcome was the focus of the studies, the measure of comorbidity exposure status was commonly more 
detailed which aided comparison of the studies. Lastly, whilst reporting bias can still exist in focused studies, 
this is more likely for individual exposures in general prognostic factor studies. These studies commonly group 
a large number of factors together for analysis and only those found to have statistically significant 
independent effects are usually reported by the study authors(272). For this reason the prognostic factor 
studies (general) in this review were selected on the basis that a chronic disease exposure was reported as 
independently significant in a final model. The purpose of this approach was to investigate the scope of 
studies that had found comorbidities to be important to specific outcomes whilst at the same time 
acknowledging that a number of studies that had not found a significant and independent effect of chronic 
disease would have been missed. Combining these studies would therefore not have been appropriate. 
Where heterogeneity in the observational study designs, population and analyses prevented meta-analysis, a 
descriptive approach was used for the synthesis.  
 
The studies were summarised using the following hierarchy (1) chronic disease (1.1) prognostic outcome 
(1.1a) prognostic factor studies (chronic disease focus) including meta-analysis where appropriate (1.1b) 
prognostic factor studies (general), and (1.1c) prognostic model studies.  
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5.3.6.1 Meta-analysis 
The framework for the synthesis of the prognostic factor (chronic disease focus) studies to assess the 
strength of association between a given factor and a specified outcome was as follows; 
 
 What is the direction of the effect?   
 What is the size of the effect? 
 Is the effect consistent across studies? 
 What is the strength of evidence of the effect? 
 
Meta-analysis is the statistical combining of results from two or more separate studies(273). Performed 
appropriately meta-analysis can (i) increase the power to detect a real effect if it exists (ii) improve precision 
and reduce the variation in the overall effect by including more information and (iii) allow for the investigation 
of the consistency of chronic disease exposure effects across populations and exposure definitions that may 
differ slightly across studies. However care has to be taken not to combine studies that are so diverse that the 
meta-analysis becomes meaningless or have serious publication or reporting bias which would provide an 
inappropriate summary(272). Steps taken to address these considerations will be described through the 
different steps of analysis. Inclusion criteria for the studies used in meta-analysis are summarised in Table 
5.2. 
 
 What is the direction and size of the effect?   
Meta-analysis uses effect estimates from each individual study to produce a summary pooled effect estimate 
which is a weighted average of the exposure effects estimated in the individual studies. The following formula 
was used(274): 
 
Weighted average   =     
∑ estimate X weight
∑ weight
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The effect measure chosen for meta-analysis in the review was the adjusted Hazard Ratio as this was most 
commonly reported in the included studies. In a fixed-effect meta-analysis the weight given to the effect 
estimates of individual studies uses the inverse-variance method(275). Using this approach more weight is 
given to the effect estimates with less variance (or smaller standard errors). This way, larger studies that tend 
to have small standard errors are given more weight and therefore contribute more information to the pooled 
estimate of effect(272).  Given that the chosen effect measure was a ratio measure the natural logarithm of 
the estimate was included in the analysis which makes the confidence intervals appear symmetrical around 
the study mean(268) but then displayed on the original scale.  
 
Variation: Due to variation in the exposure effects across individual studies, random-effects meta-analysis 
using the DerSimonian and Laird method(276)  was used in this study to combine maximally adjusted hazard 
ratios (HR) using Metan in Stata version 13. This method assumes that the studies are not estimating the 
same exposure effects but instead are estimating different exposure effects that are related and follow a 
distribution across studies. The conventional choice of distribution is the normal distribution with smaller and 
larger exposure effects evenly distributed around the mean although this cannot be easily validated(274). The 
pooled summary effect in a random-effects meta-analysis reflects the centre of this distribution and the 
confidence interval, the variability around this ‘centre’ point.  
 
A Tau2 estimate was calculated to give an estimate of the between study variance which was then square 
rooted to give an estimate of the standard deviation in the underlying effects. Tau X 2 above and below the 
pooled estimate gives an approximation of the range of effects across 95% of the studies(274). As the pooled 
estimate was calculated on the natural logarithm scale then the range needed to be exponentiated to give the 
interval on the original scale.  The weighting of individual study effect estimates in a random-effects meta-
analysis takes account of the variation in effects by adjusting the standard errors of the individual studies with 
Tau2.   
weight i = (
1
weighti
 +  Tau2)
−1
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The standard error of the pooled exposure effect was then used to derive a confidence interval and a P value.  
 
 Is the effect consistent across studies?  
 Heterogeneity is a term used to describe the difference in study effect estimates and where present, often 
reflects both clinical and methodological diversity of the studies(243). Testing for heterogeneity provides a 
measure of whether the variation in the effect estimates of individual studies reflects random variation (or 
chance) or true difference in the study effects. It is common in prognosis studies for the population definition 
(in this case HF) and the exposure measure (chronic disease comorbidity) to differ across studies(272). This 
is only detrimental to the review if a specific definition of these factors is of interest. However if the object of 
the review is to ascertain the ‘average’ effect of having a chronic disease on the ‘average’ HF patient then this 
is not a problem(274). This review included HF patients that were not characterised by any specific 
characteristics and chronic disease exposures that could be routinely identified in practice. This means that 
the presence of disease as defined by routine practice could be investigated for its effect on the average HF 
patient.  
 
Measuring heterogeneity: Two approaches for testing heterogeneity were used in this review: Cochran’s Q 
test and I2. The Cochran’s Q tests whether the observed variation in effects of individual studies could be due 
to chance. A low P value of the test can be interpreted as evidence of heterogeneity across studies. However 
due to the low power commonly observed in meta-analysis resulting from small sample sizes or few studies, a 
non-significant P value should not be taken as evidence of no heterogeneity. A P value level of 0.1 is often 
used for this reason(273).  
 
The Cochran’s Q test provides a method to detect heterogeneity however it is usually understood that 
heterogeneity will always exist particularly across observational studies(272). An alternative approach to 
assessing heterogeneity and the method used alongside the Cochran’s Q test in this review was to test the 
level of heterogeneity present using the I2 statistic. The I2 test was used to estimate the percentage of the 
variability in effect estimates that was due to heterogeneity as opposed to sampling error using this 
formula(278): 
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I2  =   (
Q − df
Q
)  x 100% 
 
where Q=  Cochran’s Q and df = degrees of freedom which is calculated as the number of included study 
effects – 1. 
 
Whilst there is no clear consensus on what I2 value may indicate important heterogeneity, a value of 40% or 
below is usually considered a low level of heterogeneity(274).  
 
 What is the strength of evidence of the effect?    
Supporting evidence for the effect was investigated through exploration of bias introduced by explained 
heterogeneity or reporting bias. Random-effects meta-analysis should only be used to combine studies where 
heterogeneity cannot be readily explained(279) and the study effects are randomly distributed around the 
mean. Three approaches for exploring heterogeneity were considered for this review: sub-group analysis, 
meta-regression and sensitivity analysis. Sub-group analysis stratifies the total population (either at study or 
individual patient data level) by characteristics that may modify the effect. The sub-groups’ effects are then 
compared to identify any significant difference between them(275). Random-effects meta-regression was also 
considered which allows multiple potential effect modifiers to be investigated together. This approach 
investigates the influence of the factor on the pooled effect estimate (which becomes the outcome in this 
case). Both approaches require a-priori selection of potential effect modifiers to prevent potential bias in 
selecting factors once study results are known. Sub-group analysis requires that individual studies have 
analysed data at the sub-group level which is often not consistent across studies. Meta-regression requires 
adequate numbers of studies and typically ten studies are recommended for each potential modifier 
investigated(280).  Given these limitations it was decided to perform sensitivity analysis to explore 
heterogeneity. This form of exploration repeats the initial meta-analysis of the included studies but replaces 
certain decisions in the review process with alternative decisions to investigate whether the pooled effect 
remains unchanged by those decisions(281). Demonstrating the robustness of the pooled effect in this way 
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provides credibility to the findings of the review. Sensitivity analysis was performed for three a-priori 
characteristics included in the study protocol; setting, population definition and exposure definition and a post-
hoc characteristic which was identified during the review which was risk of bias level.  
 
In addition, Galbraith plots were used to further explore studies that may contribute to heterogeneity. In this 
plot each estimate is divided by its standard error (y axis) and this is plotted against the inverse of its standard 
error (x axis). Larger studies move to the right of the plot. Two reference lines are plotted which are 2 units 
above and below the pooled effect estimate line. These mark out a region where 95% of the study effects will 
lie. Studies that fall outside of these lines have confidence intervals that do not contain the pooled effect and 
can indicate heterogeneity(282).  
 
Reporting bias: Reporting bias occurs when the dissemination of research findings are influenced by the size, 
significance or direction of the study results(267,275). Attempts to reduce reporting bias were made through 
using multiple resources for the review(Section 5.3.2). For each meta-analysis conducted where there were 
sufficient studies (>5) a funnel plot was performed to display small study effects. These plotted the standard 
error of individual studies on the y-axis against the hazard ratio on the x-axis, both on the logarithmic scale. 
The logarithmic scale meant that equal but opposing effect sizes such as 0.5 and 2 would be equidistant from 
1(283). Where no publication bias exists the funnel plot will display an inverted funnel with an even broad 
spread of small study effects at the base and larger studies congregated more towards the estimated pooled 
effect at the top.  Visual inspection was performed to explore asymmetry(284). 
 
An Egger’s test was performed which is based on the Galbraith plot. This test looks for a correlation between 
the study effect estimate and the weight given to the study (which was derived from the standard error). The 
Egger’s test regresses the effect estimate divided by its standard error on the inverse of the standard error 
and tests the null hypothesis that the intercept is equal to 0 in the population. A low P value is evidence of 
publication bias. This test also usually has low power given the low number of studies usually included and so 
0.1 is usually used as a reference point for evidence of bias(284).  
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Pooled effects from the random-effects meta-analyses were also compared to the pooled effects from fixed-
effects meta-analyses.  If the pooled effect was greater in the random-effects analysis (which gives more 
weight to the smaller studies) then this provided some evidence of small study effects. If this could not be 
rationalised by the sample size reasonably influencing the effect size (e.g. as might be the case if smaller 
studies had higher risk patients), then a decision to exclude the smaller studies had to be made. An 
alternative approach would have been to use fixed-effects meta-analysis which gives less weight to smaller 
studies, but has the disadvantage of not taking the variance in effects across studies into account(274). 
 
5.3.6.2 Descriptive synthesis 
Prognostic factor studies (general): The descriptive synthesis for the prognostic factor studies (general) used 
the following framework: 
 
 Which chronic disease comorbidity factors have been found to be significantly associated with which 
outcomes? 
 What is the size and direction of effects of the chronic disease in these studies?  
 
Questions of whether effect estimates were consistent across studies and the strength of evidence of the 
effects were not explored given the selective nature of the studies that was based on statistically significant 
effects. Some discussion on the risk of bias in the included studies was however provided. 
 
Prognostic model studies: The main question addressed for the prognostic model studies focused on 
establishing how chronic disease had been included in prognostic models and specifically whether the 
inclusion was via comorbid disease type, severity or severity change. 
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5.4 Results  
Results will be reported as numbers (n), percentages (%), mean (standard deviation; SD) or median 
[interquartile range; IQR]. Effect estimates will be reported as Hazard Ratio (HR) with a 95% confidence 
interval (95% CI).  
  
5.4.1 Identified prognosis articles on HF  
A total of 10,331 unique articles were identified from the three databases and after title screening by the lead 
reviewer (CAR), 417 were retained. 1% of all the original articles excluded were checked by the second 
reviewer (UTK) for appropriate exclusion (n=99).  Abstract screening was performed by three reviewers and 
consensus was reached for the exclusion of 327 articles. This resulted in 90 articles remaining for full article 
review. During the full article review by two reviewers (CAR, UTK), 27 articles selected in the abstract screen 
were found not to meet the inclusion/exclusion criteria and were subsequently excluded. Full consensus for 
the excluded articles was achieved by the two reviewers. This left 63 articles from the database searches to 
be included in the review. Four additional articles were identified from citation and reference searches. A 
further article was sourced from the one of the experts contacted resulting in a final set of 68 articles to be 
included in the review (Figure 5.1).      
 
5.4.2 Overall characteristics of the studies 
There were 34 prognostic factor (chronic disease focus) studies (E-Appendix A8) including 4 chronic 
diseases, 22 prognostic factor (general) studies (E-Appendix A9) including 7 chronic diseases and 12 
prognostic model studies (E-Appendix A10)  including 7 chronic diseases (summary provided in Table 5.3). 
The 68 studies were based in 16 countries covering 4 continents (North America, 35%, South America, 3%, 
Europe, 43%, Asia, 15%, multiple 4%). All studies used a cohort design; 26% (n=18) were secondary analysis 
of randomised controlled trials (RCTs), 60% (n=41) were hospital based, 12% (n=9) were hospital and 
community based and 2% (n=1) were community based.  90% of studies (n=60) had 1 or more years of 
follow-up and 35% (n=24) had 5 or more years of follow-up. Mortality outcome was investigated in 93% (n=63) 
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studies and hospital admissions in 16% (n=11) studies. There were no studies investigating HR-QoL 
outcomes.  
 
5.4.3 Quality of the overall studies   
Overall risk of bias was low in 34% (n=23) studies, moderate in 63% (n=43) studies and high in 3% (n=2) 
studies (E-Appendix A11). Agreement was good between the first (CAR) and second (UTK) reviewers with a 
Kappa Coefficient of 0.86 (E-Appendix E7 for worked example).  Out of the 43 moderate risk studies, 6 had 
one of the six risk domains assessed as high risk, 7 studies had 2 domains at high risk and one study  
had 3 domains at high risk. 29 of the studies had no domains at high risk.  The risk domains with the highest 
proportion of low risk scores were outcome measurement and study attrition (Table 5.4). In the outcome 
domain, 95% of the studies achieving a low risk score investigated mortality outcome. In the study attrition 
domain 91% of studies achieving a low risk score had less than 10% loss to follow up. Risk domains with the 
highest proportion of high risk scores were study confounding and statistical analysis and reporting. In the 
study confounding domain 63% of studies achieving a high risk score did not report what confounders were 
included in the analysis. Of the 65% of studies achieving a moderate risk score all reported confounders 
considered but only 9% provided any rationale or detail about their selection. In the statistical analysis domain 
91% of studies achieving a high risk score did not report unadjusted effects or consider interactions between 
exposures and none of the studies using proportional hazards referred to testing model assumptions.    
 
5.4.4 Characteristics of prognostic factor (chronic disease focus) studies  
 Diabetes Mellitus (DM) studies  
The 11 studies focusing on DM(285-295), had a combined sample of 138,953 HF patients from 6 countries 
(North America n=4, South America n=1, Europe n=5, Multiple=1). HF was identified by clinical records in one 
study, administration codes (admission or discharge) in 4 studies (2 were verified by clinical records) and 
clinical diagnosis in 6 studies (4 included signs, symptoms and objective evidence and 2 unspecified). The 
combined sample was from 6 RCT, 1 hospital/community and 4 hospital samples. Mean ages of the samples 
ranged from 50 (SD 11) years to 77 (12) years. The samples showed the proportion of males was 46-73%, 
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systolic HF range was 47 to 87%, mean ejection fraction (EF) 27 (14) to 47(13)% and the prevalence range 
for New York Heart Association (NYHA) Class grade 3 and 4 was 36% to 84%.  
 
Of the 138,953 combined sample of HF patients, 22,790 (16%) had DM. Prevalence of DM in individual 
studies ranged from 13-47%. Mean follow up was from 6 months to 5 years. 3 studies investigated the effect 
of DM by gender and one study by age. Two studies investigated DM severity by glycaemia (glycosylated 
haemoglobin (HbA1c), fasting glucose) and two studies stratified the sample by DM treatments. All studies 
investigated all-cause mortality and only one study investigated hospital admissions 
 
Quality of DM studies:  There were 64% (n=7) of studies that were assessed as moderate risk using the 
QUIPs tool and 36% (n=4) of studies that were low risk. No studies had any of the six QUIPs domains scored 
at high risk. All studies described the sample by key characteristics and gave some detail of the baseline 
population. Of the total 73% had <10% loss to follow-up (27% not reported), all described the chronic disease 
exposure and only one study used imputation methods for missing data, the outcome and confounders were 
described in all studies but no study provided a rationale for confounders selected in any detail. Only 36% of 
studies provided unadjusted associations, 64% examined for interactions but only 18% reported on whether 
proportional hazards assumptions had been checked.  
 
 Chronic obstructive pulmonary disease (COPD) studies  
The 5 studies focusing on COPD(181,296-299) had a combined sample of 7,121 HF patients from 5 
European countries. HF was identified by hospital discharge administration codes in 2 studies and clinical 
diagnosis in 3 studies (all using signs, symptoms and objective evidence). The combined sample was from 1 
RCT, 1 hospital or community and 3 hospital samples. Ages of the samples ranged from mean 70 (SD 12) to 
median 80 [IQR 75-87] years. In the study samples the proportion of males was 50% to 71%, systolic HF 
prevalence range was 25% to 83%, mean EF was 33(12) to 50(16)% and the prevalence range for NYHA 
Class 3 and 4 was 52 to 95%.  
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Of the 7,121 combined sample of HF patients, 1,384 (19%) had COPD. Mean follow up was from 2.9 (SD 2.1) 
years to 4.5 (range 2.9-5.5) years. Only one study investigated COPD severity (reduction in Forced Expiratory 
Volume in one second [FEV1]). All studies investigated all-cause mortality. 
 
Quality of COPD studies:  There were 60% (n=3) of studies that were assessed as moderate risk using the 
QUIPs tool and 40% (n=2) of studies that were assessed as low risk. One study had one domain scored at 
high risk and one study had two domains (study participation and prognostic factor measurement) scored at 
high risk. All studies described the sample by key characteristics and gave some detail of the baseline 
population. Of the total, 80% had <10% loss to follow-up (10% not reported), all described the chronic disease 
exposure, no studies used imputation methods for missing data, the outcome and confounders were 
described in all studies but no study provided a rationale for confounders selected in any detail. All studies 
provided unadjusted associations but only 20% examined for interactions or reported on whether proportional 
hazards assumptions had been checked.  
 
 Renal dysfunction (RD) studies  
The 17 studies focusing on RD(155,156,300-314) had a combined sample of 102,638 HF patients from 10 
countries (North America n=7, South America n=1, Asia n=4 and Europe n=5). HF was identified by 
administration codes (discharge) in 2 studies, clinical diagnosis in 14 studies (11 included signs, symptoms 
and objective evidence and 3 unspecified) and was unspecified in 1 study. The combined sample was from 5 
RCTs, 1 hospital/community and 11 hospital samples. Ages of the samples ranged from mean 62 (SD 15) to 
median 80 years. In the samples, the proportion of males was 43 to 76%, systolic HF prevalence was 36% to 
82%, mean EF was 27(12) to 44(16)% and the prevalence range for NYHA Class grade 3 and 4 was 32% to 
84%. 
 
All renal studies used blood measurements to define RD. Mean follow up was from 6 months to 6.5 years.  
Out of the 17 renal studies, 8 studies investigated ‘any’ RD and 6 of these categorised RD by eGFR severity 
level. 2 of the 8 studies also investigated increments of eGFR by mls/min.  Any RD was defined as all 
categories of renal function with eGFR of <60ml/min. Mild RD was defined as eGFR 60-89ml/min, moderate 
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RD as eGFR 30-59ml/min and severe RD as eGFR <30ml/min compared to the highest category(254). For 
prevalence of RD see Table 5.5.  
 
There were two additional studies that also investigated increments of eGFR by mls/min and the remaining 7 
studies investigated change in renal severity. Moderate change in severity was defined as an increase in 
creatinine (Cr) of ≥0.3mg/dL from hospital baseline to study defined end point (4 out of the 5 studies including 
this definition used discharge as the end point) and severe increase in severity by an increase in Cr of 
≥0.5mg/dL. This classification was based on previous studies(157,315).  Out of the 7 studies investigating 
change in renal severity, 5 studies used change in Cr as a measure, 1 study used a reduction in eGFR and 1 
study investigated improvement (increase) in eGFR. Two studies stratified samples by timing or duration of 
severity change (Table 5.6). 
 
All 17 studies investigated all-cause mortality and 4 studies investigated hospital admissions. 
 
Quality of renal studies:  There were 6% (n=1) of studies that were assessed as high risk using the QUIPs 
tool, 65% (n=11) studies were moderate risk and 29% (n=5) studies were low risk. Two studies had one 
domain (study confounding, statistical analysis and reporting) scored at high risk and two studies had three 
domains (study participation/prognostic factor measurement, study confounding, statistical analysis and 
reporting). All studies described the sample by key characteristics and 94% gave some detail of the baseline 
population. Out of the total, 47% had <10% loss to follow-up (41% not reported), all described the chronic 
disease exposure, 18% studies used imputation methods for missing data, the outcome was described in all 
studies and 88% studies described the confounders considered and 24% provided a rationale for the 
confounders selected. Of the total, 50% studies provided unadjusted associations and adjusted associations, 
53% examined for interactions and 24% reported on whether proportional hazards assumptions had been 
checked.  
 
 Other non-CVD comorbidity (Chronic Disease Focus) studies 
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 There was one study focusing on rheumatoid arthritis (RA)(316) which had a sample of 955 de novo HF 
patients from a hospital setting in North America. HF was identified clinical diagnosis using signs, symptoms 
and objective evidence. Mean age of the sample was 77 years (SD 12). The proportion of males was 45%, 
51% had systolic HF, mean EF was 44%.103 (11%) had RA. RA was identified from clinical diagnosis and 
patients were followed up for 1 year to investigate all-cause mortality. The study was of moderate risk of bias 
using the QUIPs tool with two domains out of the possible six scored at high risk (study confounding and 
statistical analysis and reporting).  
 
5.4.5 Characteristics of prognostic factor (general) studies 
From the 22 prognostic factor (general) studies(132,139,317-335), sample sizes ranged from 181 to 62,330 
HF patients from 12 countries (North America n=7, Asia n=6 and Europe n=9). HF was identified by clinical 
records in 1 study, administration codes (discharge) in 6 studies (1 was verified by clinical records) and 
clinical diagnosis in 15 studies (all included signs, symptoms and objective evidence). The samples were from 
1 RCT, 17 hospital samples, 3 hospital/community and 1 community sample. 3 samples were drawn from the 
same hospital cohort and 6 samples were de novo HF. Mean ages of the samples ranged from 66(SD12) to 
86(5) years. In samples the proportion of males was 40% to 71%, prevalence of systolic HF ranged from 36% 
to 79%, mean EF was 35(14) to 54(15)% and prevalence of NYHA Class  grade 3 and 4 was 12% to 96%.  
 
The 22 studies included 7 different non-CVD comorbidities. Prevalence of the chronic diseases in the different 
studies ranged from 1% (renal failure) to 70% (RD) (Table 5.7). Chronic diseases were identified from clinical 
diagnosis (n=1), clinical records (n=9), blood test (n=6), a combination of clinical records, prescriptions, blood 
tests or self-report (n=7), administration codes (admission or discharge) (n=2), and not specified (n=3). Mean 
follow up was from 6 months to 6 years. Only one study stratified the sample by age and one by gender and 
two studies focused specifically on women. All-cause mortality was investigated in 19 studies and 4 studies 
investigated hospital admissions. A chronic disease severity indicator was included in 4 renal studies and 1 
renal study included a severity change measure. 
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Quality of the prognostic factor (general) studies: There were 5% (n=1) studies assessed at high risk of bias, 
64% (n=14) studies were moderate risk and 32% (n=7) studies were low risk based on the QUIPS tool. Two 
studies had one domain (prognostic factor measurement, statistical analysis and reporting) scored at high 
risk, five studies had three domains (study participation/prognostic factor measurement/study confounding 
and statistical analysis and reporting) and one study had three domains (study participation, study 
confounding and statistical analysis and reporting) scored at high risk. All studies described the sample by key 
characteristics and gave some detail of the baseline population. Most of the studies (77%) had less than 10% 
loss to follow-up (but 23% of the studies did not report this figure). Of the total, 68% described the chronic 
disease exposure, 9% studies used imputation methods for missing data, the outcome was described in all 
studies and 86% studies described the predictors considered. Only 14% provided a rationale for the predictors 
selected and 27% studies provided unadjusted associations as well as adjusted associations. Some of the 
studies (23%) had examined interactions between HF and comorbid conditions and 29% of applicable studies 
reported on whether proportional hazards assumptions had been checked.  
 
5.4.6 Characteristics of prognostic model studies  
From the 12 prognostic model studies(175,179,188,189,258,259,336-341) sample sizes ranged from 152-
198,640 HF patients from 2 continents (North America n=6 and Europe n=6). HF was identified by 
administration codes (discharge) in 4 studies (1 was verified by clinical records) and clinical diagnosis in 7 
studies (all included signs, symptoms and objective evidence). One study used individual patient data from 30 
different cohort studies. The samples were from 5 RCTs, 5 hospital samples and 2 hospital/community 
samples. Mean ages of the samples ranged from 66(SD 11) to 79(6) years. In the samples, the proportion of 
males was 34% to 98%, prevalence of systolic HF was 44% to 90%, mean EF was 33(9) to 43(14)% and 
prevalence of NYHA class 3 to 4 was 25% to 55%.  
 
The 12 model studies included 7 different chronic diseases. Prevalence of the chronic diseases in the different 
studies ranged from 1% (liver cirrhosis) to 36% (DM) (see Table 5.7). Chronic diseases were identified from 
clinical diagnosis (n=1), clinical records (n=10), blood test (n=2) and a combination of clinical records and 
prescriptions (n=1). Mean follow up was from 2.4 months to 5.2 years. Most studies (n=10) had investigated 
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all-cause mortality and 2 studies all-cause hospital admissions. Only 4 studies had used a measure of chronic 
disease severity.   
 
Quality of the prognostic model studies:  There were 58% (n=7) of studies that were assessed as moderate 
risk using the QUIPs tool and 42% (n=5) of studies that were low risk. One study had one domain (study 
participation) scored at high risk. All studies described the sample by key characteristics and gave some detail 
of the baseline population. Of the total 58% studies had <10% loss to follow-up (42% not reported), 50% 
described the chronic disease exposure and 42% studies used imputation methods for missing data. The 
outcome and the predictors considered were described for all studies. Of the total, 42% studies provided a 
rationale for the predictors selected and 33% provided unadjusted associations as well as the final adjusted 
model. Most (67%) studies examined for interactions and 43% of applicable studies reported on whether 
proportional hazards assumptions had been checked. Model reduction was achieved in 42% of studies by 
backwards or forwards selection, 25% by stepwise selection, 25% by the significance level in univariate 
associations and 1 by another reduction technique. The majority of studies (83%, n=10) reported more than 
10 events per predictor included and measures of internal validity, model performance and calibration. Testing 
of external validity was only reported in 25% of the studies. All models derived were used to create a clinical 
risk score.   
 
5.4.7 Associations between non-CVD comorbidities and outcomes in HF 
The chronic disease comorbidity studies will now be summarised for each chronic disease by prognostic 
outcome structured by (i) prognostic factor studies (chronic disease focus) including meta-analysis where 
appropriate (ii) prognostic factor studies (general) and (iii) prognostic model studies. 
 
5.4.7.1 Diabetes comorbidity in heart failure 
 
All-cause mortality 
 Prognostic factor (chronic disease focus) studies: 
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Nine studies reported all-cause mortality rates associated with comorbid DM status (presence or absence) 
adjusted for socio-demographic and clinical covariates for mean follow-up ≥6 months (range 6 months to 7.5 
years). The study samples were derived from RCT and hospital settings with only one study including 
community patients(294). Out of 139,761 HF patients, 21,921 (16%) had DM (range 13-47%).  Over the follow 
up period 63% of patients without DM died compared to 62% of those with DM. This translated into a 
combined adjusted mortality risk of Hazard Ratio (HR) 1.34 (95% confidence interval [CI] 1.24-1.46) (Figure 
5.2) using random effects meta-analysis and the test of overall association was significant (p=<0.0001).   
 
Heterogeneity: The Cochran’s Q test indicated significant heterogeneity (p=0.008). The I2 value indicated that 
61% of the variability in effect estimates was due to heterogeneity as opposed to sampling error. Tau2 was 
used to provide an approximation that the range of associations across most of the studies (95%) was Hazard 
Ratios from 1.14 to 1.58 (E-Appendix C1). The included studies were similar in terms of their settings, 
population definition, exposure definition and risk of bias. One study included community patients(294) and 
one study included more chronically severe patients (NYHA stage 3-4 within past month)(287). Following 
removal of the first study(294) heterogeneity remained significant (p=0.004, I2=66%) (E-Appendix C2). 
Replacing the first study and removal of the second study(287) reduced the level of heterogeneity and it 
became non-significant (p=0.15, I2=35%). This did not alter the combined effect estimate which remained 
elevated and significant, HR 1.30 (1.21-1.39) (E-Appendix C3). A Galbraith plot also identified Gustafsson et 
al (2004) as outside of the 95% range of study effects (E-Appendix B1).  
 
 
Publication bias: The pooled effect estimate from the random effects meta-analysis was slightly larger than 
the pooled effect from the fixed effects meta-analysis (HR 1.27) which indicated small study effects (Figure 
5.2). A funnel plot revealed possible publication bias with two of the smallest studies having the biggest effect 
estimates (E-Appendix B2).  An Egger’s test was performed (p=0.119) (E-Appendix C4) which, given the low 
power of the test, provided some evidence of publication bias.  However, removal of the two smaller 
studies(285, 289) in a sensitivity analysis made little change to the pooled effect estimate which became HR 
1.31(1.22-1.41) p=<0.0001 (E-Appendix C5) and Eggers’s test (p=0.43) (E-Appendix C6) indicating no 
significant evidence of publication bias.  See E-Appendix A12 for sensitivity analysis summary. 
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Sub group analysis:  Three studies had investigated all-cause mortality risk associated with DM stratified by 
gender. Out of 64,697 women and 61,462 men 16% and 15% respectively had DM. Over the follow-up (4.8 to 
8.5 years) 74% of diabetic women versus 69% of non-diabetic women and 67% of diabetic men versus 65% 
of non-diabetic men died. This resulted in a combined HR of 1.52 (95%CI 1.22-1.89) for women and 1.27 
(1.17-1.38) for men (Figure 5.3).   Whilst there was some overlap in the confidence intervals of the combined 
effect estimates by gender each individual study found a significant sex-DM interaction with women worse off 
than men. Two studies stratified the groups by age with one finding significant sex-DM interaction to be 
present in age ≥65yrs only (p=0.005)(292) and the other also finding significant interaction in the younger 
(<65yrs) and older age groups (65-74yrs) (p=0.005). Within gender groups significant age-DM interaction was 
found with <65yrs worse off (p=0.001)(291).  
 
Diabetes comorbidity severity:  One study included a DM severity indicator by treatment type(293) and two 
studies included a measure of glycaemia to investigate the associated risk of all-cause mortality(290). In the 
first study, out of 400 HF patients from a hospital cohort, diabetics were stratified into three groups by 
diabetes treatment type and a group of undiagnosed DM. The latter group was defined as any subject with 
multiple raised fasting plasma glucose measures in their outpatient’s notes but no formal diagnosis of DM 
recorded. These groups were compared to the no DM group.  Whilst non-significant effects were found for 
oral and diet treated DM the effects increased and became significant in the undiagnosed (not treated, HR 
1.69) and insulin treated group (HR 2.11) (Figure 5.4).  
 
The second study (N=2412) had investigated the level of glycosylated haemoglobin (HbA1c) (290). In this 
study, 38% of the HF sample had DM but the measure was taken on all patients regardless of their DM status 
and the risk per 1% higher HbA1c within the RCT study sample was HR1.14 (1.06-1.23). There was a 
significant interaction between DM status and HbA1c with those with no history of DM experiencing worse 
effects per 1% rise in HbA1c (p=.008). The third study (N=456, RCT cohort) found no associated risk of DM 
(not reported) but an increased risk associated with glycaemia  ≤ 5.5mmol/L of HR 1.45 (1.09-1.69) (288). 
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 Prognostic factor (general) studies and prognostic models 
The range of effect estimates for the risk of all-cause mortality associated with DM were HR 1.16 to 3.19 in 
the prognostic factor (general) studies (E-Appendix B3) and HR 1.34 to 2.37 in the prognostic model studies 
(E-Appendix B4). DM was included in all 14 prognostic factor (general) studies by type. Only three studies 
included community patients(132,259,322). A significant interaction was found between age and DM in one 
study(139) with younger age groups worse off (p=0.014).  
 
Three of the six prognostic models included a severity indicator. The first included DM stratified by insulin 
prescription(179) (HR 1.8) and ‘other’ (HR 1.5) and the second two studies(189,259) included DM with target 
organ damage. None of the prognostic factor or model studies included an indicator of severity change. 
 
All-cause hospital admissions 
 Prognostic factor (chronic disease focus) studies: 
Only one study had investigated the effect of DM on all-cause hospital admissions within a RCT cohort and 
found an associated risk of HR 1.28 (1.19-1.38)(292). Again women (HR 1.49) were worse off than men (HR 
1.21).  
 
 Prognostic factor (general) studies and prognostic models 
The range of effect estimates for the risk of all-cause hospital admissions associated with DM were HR 1.13 
to 1.53 in the prognostic factor (general) studies and HR 1.17 in the prognostic model study (E-Appendix B5). 
Two studies had included community patients (discharged from hospital)(318,320). One study reported an 
interaction between age and DM with younger age groups worse off (p=0.014)(139). DM was included in all 5 
studies by type. 
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5.4.7.2 Chronic Obstructive Pulmonary Disease (COPD) comorbidity in heart failure 
All-cause Mortality 
 Prognostic factor (chronic disease focus) studies 
Five studies reported all-cause mortality rates adjusted for socio-demographic and clinical covariates for mean 
follow-up ≥1 year (range 1-8yrs). Out of 7,121 HF patients, 1309 (18%) had COPD (range 17-35%). Only one 
study had included community patients(73). Over the follow up period, in the 3 studies providing crude 
mortality data 38% of patients without COPD died compared to 48% of those with COPD. This translated into 
a combined adjusted all-cause mortality risk of HR 1.39 (95% CI 1.21-1.6) (Figure 5.5) using random effects 
meta-analysis. The test of overall effect was significant (p=<0.0001).   
 
Heterogeneity: The Cochran’s Q test indicated low evidence of heterogeneity (p=0.17) and I2 was 38%. Tau2 
provided an approximation that the range of effects across 95% of the studies was HR1.27 to 1.54 (E-
Appendix C7). Whilst the test for heterogeneity was non-significant, random effects meta-analysis was used 
due to the presence of some heterogeneity indicated by the I2 test. The included studies were similar in terms 
of their settings and exposure definition. One study had a lower proportion of systolic HF patients (25%) than 
the other studies and two risk of bias domains assessed as high(181). This study was removed in a sensitivity 
analysis (E-Appendix C8) and the effect estimate remained elevated and significant, HR 1.41 (1.18-1.68). A 
Galbraith plot supported the low level of heterogeneity with no studies falling outside of the 95% range of 
study effects (E-Appendix B6).  
 
Publication bias: The pooled effect from the random effects meta-analysis was similar to the pooled effect 
from the fixed effects meta-analysis (HR 1.36) which indicated no evidence of small study effects (Figure 5.5). 
The funnel plot shows that most studies (n=4) had similar sample sizes with one larger study contributing a 
smaller effect estimate (E-Appendix B7).  An Egger’s test was performed (E-Appendix C9) which provided 
only limited evidence of publication bias (p=0.118).  
 
COPD comorbidity severity:  One study (N=532) investigated the association between COPD severity and all-
cause mortality risk using forced expiratory volume over a second (FEV1)(296). Whilst the risk (unadjusted HR 
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1.26) was non-significant in the moderate severity group (FEV1 50-79%) this became significant and elevated 
(HR 1.68) in the severe group (FEV1 <49%) (Figure 5.6). Increasing FEV1 (per 10% of predicted) was 
protective, adjusted HR 0.86 (0.8-0.92). 
 
 Prognostic factor (general) studies and prognostic models 
The range of effect estimates for the risk of all-cause mortality associated with COPD were HR 1.24-1.7 in the 
prognostic factor (general) studies and HR 1.23-1.6 in the prognostic model studies (E-Appendix B8). Two of 
the studies included community patients(132,259) one of which compared community patients to hospital 
patients and found a significant difference between the associated risks(132). For the community sample the 
risk was HR 1.7(1.58-1.82) and for hospital patients HR 1.24(1.19-1.31). COPD was included in all ten 
prognostic factor (general) and prognostic model studies by type. 
 
All-cause hospital admissions 
 Prognostic factor (general) studies and prognostic models 
No studies had focused on the association between COPD and hospital admissions.   Only one prognostic 
factor (general) study and one prognostic model study included COPD to investigate hospital admissions (HR 
1.47 and OR 1.14 respectively, Figure 5.7). Both studies which included community patients included COPD 
by type. 
 
5.4.7.3 Renal dysfunction (RD) comorbidity in heart failure 
 
All-cause Mortality  
 Prognostic factor (chronic disease focus) studies 
Seven studies reported all-cause mortality rates adjusted for socio-demographic and clinical covariates for 
mean follow-up >1year (median follow up range 20 to 38months). Only one study had included community 
patients(313). Out of 69,520 HF patients, 28,596 (41%) had ‘any’ RD (range 36 to 70%).  Over the follow up 
period 42% of patients without RD died compared to 51% of those with RD. This translated into a combined 
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adjusted mortality risk of Hazard Ratio (HR) 1.52 (95% CI 1.34-1.71) using random effects meta-analysis 
(Figure 5.8). The test of overall effect was significant (p=<0.0001).   
 
Heterogeneity: The Cochran’s Q test indicated significant heterogeneity (p=<0.0001) and I2 was 88%. Tau2 
was used to provide an approximation that the range of effects across 95% of the studies was HR 1.2 to 1.6 
(E-Appendix C10). The included studies were similar in terms of their settings and exposure definition. One 
study had higher proportion of males (76%) and a lower mean EF (32%)(301) and another had an older 
population (mean age, 76 years) with a lower proportion of males (43%)(306) compared to the other studies. 
Following removal of the first study(301) heterogeneity remained significant (p=<0.0001, I2=83%) (E-Appendix 
C11). Replacing the first study and removal of the second study(306) had little effect on the heterogeneity 
(p=<0.0001, I2=81%) (E-Appendix C12). Removal of both studies removed the heterogeneity (p=0.825, 
I2=0%).  This increased the combined effect to HR 1.62 (1.59-1.66) (E-Appendix C13). A Galbraith plot 
identified three studies including the two removed in sensitivity analysis as falling outside of the 95% range of 
study effects (E-Appendix B9). See E-Appendix A13 for sensitivity analysis summary. 
 
Publication bias: The pooled effect from the random effects meta-analysis was slightly smaller than the pooled 
effect from the fixed effects meta-analysis (HR 1.58) which indicated no small study effects (Figure 5.7). A 
funnel plot (E-Appendix B10) and Egger’s test (p=0.56, E-Appendix C14) revealed no evidence of publication 
bias.  One further study found eGFR  >53ml/min compared to <35ml/min to be protective (HR 0.65)(302) . 
 
Renal dysfunction comorbidity severity: Five studies reported adjusted all-cause mortality rates stratified by 
severity groups. Out of 64,257 HF patients, 24,349 (38%) had moderate RD and 3784 (6%) had severe RD.  
Over the follow up period 42% of patients without RD died compared to 48% of those with moderate RD and 
63% of those with severe RD. Random effects meta-analysis was performed, stratified by severity group 
(Figure 5.9). This resulted in a combined adjusted mortality risk of HR 1.01 (0.84-1.22) in the mild severity 
group, HR 1.21 (1.18-1.24) in the moderate group to HR 2.01 (1.60-2.52) in the severe group using random 
effects meta-analysis.  
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Meta-regression was used to plot the upper eGFR limit for each study defined severity category (x-axis) 
against their associated hazard ratio (y-axis) and there was a dose response relationship between the effect 
estimates and reducing eGFR upper limit (Figure 5.10).  Three hospital studies(302,308,312) and one RCT 
study(304) investigated all-cause mortality risk by mls/min/m2 eGFR (Figure 5.11). Risk reduced with 
increasing eGFR (above dashed line) and increased with reducing eGFR (below dashed line).  
 
Renal dysfunction comorbidity severity change:  Five studies investigated change in renal function from 
hospital admission baseline to discharge or study defined endpoint. Random effects meta-analysis was 
performed, stratified by severity of renal function change (Figure 5.12). The combined adjusted hazard ratios 
were significant and increased from 1.53 (1.09-2.14) in the moderate change group to 2.29 (1.63-3.21) in the 
severe change group. One study found a significant interaction between baseline creatinine and worsening 
renal function with the higher than median baseline creatinine group being worse off(311). 
 
One further study investigated a monthly percentage reduction in eGFR of >=1% (measured in the 1 year 
either side of hospital admission) and found an associated adjusted mortality risk of HR 3.6 (2.2-5.7)(307). 
Another study investigated improved renal function (≥20% increase eGFR) during hospital admission and 
found an elevated adjusted mortality risk of HR1.3 (1.1,1.7)(314). 
 
 Prognostic factor (general) studies and prognostic models 
The range of effect estimates for the risk of all-cause mortality associated with RD were HR 1.35 to 2.27 in the 
prognostic factor (general) studies (E-Appendix B11) and HR 1.37 to 5.22 in the prognostic model studies (E-
Appendix B12). Only two studies included community patients(132,259). One study compared the associated 
risk of severe renal dysfunction in older and younger groups and found a significant difference between the 
risks(139). The associated mortality risk was HR 1.36 (1.13-1.63) in the older age group and HR 2.21 (2.02-
2.43) in the younger age group. Renal dysfunction was included in 4 prognostic factor (general) studies and 
one model study by a severity indicator and in one factor study by severity change.  
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All-cause hospital admissions 
 Prognostic factor (chronic disease focus) studies 
One study(301) focused on the association between different severities of RD and risk of all-cause hospital 
admission. Over the study follow-up 66% of patients without RD experienced a hospital admission compared 
to 68% of those with moderate RD and 73% of those with severe RD. Adjusted risk increased with severity 
group (Table 5.8).  Another study(302) found that an eGFR of >53ml/min compared to <35ml/min had an 
adjusted protective effect of HR 0.77 (0.56-1.06).  
 
In hospital change in renal function of Creatinine (Cr)  ≥3mg/dL was found in one study to be associated with 
increased risk of readmission(156) (HR 1.5) and insignificant in another study(155). All studies were hospital 
or RCT based. 
 
 Prognostic factor (general) studies and prognostic models 
RD was associated with increased risk of hospital admission in one prognostic factor (general) study (HR 
1.32)  and one prognostic model study (OR 1.09) (E-Appendix B13)(338). Both studies included community 
patients(318,338). 
 
5.4.7.4 Other non-CVD comorbidities and heart failure 
Twelve prognostic factor (general) and model studies included 5 additional other non-CVD comorbidities: 
arthritis, dementia, cancer, lung disease and liver disease. All chronic diseases were included by type (Table 
5.9 for the adjusted risk estimates). Only one study, including three diseases had investigated hospital 
admissions(338) 
 
5.4.7.5 Comparing comorbidity effects  
Meta-analysis of the association of the three main non-CVD diseases; DM, COPD and RD, were compared 
for the mortality outcome (Figure 5.13) and all three comorbidities had similar adjusted and significant effects 
on mortality in HF. The effect estimates were HR 1.3 for DM, 1.4 for COPD and 1.5 for RD.  
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5.4.8 Discussion 
Summary of findings: Non-CVD comorbidities are common and are strongly and independently associated 
with poorer outcomes in HF. Comorbidity prognosis studies for non-selected HF populations have to date 
focused on hospital settings and the outcome of mortality, but their importance in other HF settings and for 
hospital admissions has been demonstrated in general HF prognosis studies. The impact of comorbidities on 
mortality, where most of the evidence lies, appears similar across chronic diseases but there is some 
evidence to suggest that it differs across different HF populations. Differentiation of risk within a population for 
a specific comorbidity is evident once severity of the comorbid disease is taken into account with clear 
examples for DM, COPD and RD. Comorbidity severity change is also predictive of higher mortality and 
increased risk of hospital admission, but here the evidence is limited to RD comorbidity in hospitalised HF 
populations. Prognostic models for HF often include an indicator of HF disease severity but have yet to take 
account of comorbidity severity or of how the impact of comorbidity may in part depend on the severity of the 
index disease.       
 
The scope of comorbidity:  Comorbidities were highly prevalent within the included studies with up to at least a 
third of HF patients experiencing DM, COPD or RD. Other diseases with high prevalence such as arthritis and 
dementia featured far less and there were no studies that included other prevalent diseases such as 
osteoarthritis(129).  The estimates of disease prevalence varied across the studies and depended on the 
diagnostic criteria applied as well as the measurement tools used. Spirometry use in COPD diagnosis reveals 
higher prevalence than self-report with levels of 40% reported in studies using spirometry(342) and less than 
half of those diagnosed on spirometry, self-reporting COPD(343). DM identified by anti-diabetic drug use 
misses those controlled by diet and hospital based HF populations reported higher prevalence of DM(293). 
The most accurate identification of comorbidity is probably in renal disease where blood test indicators are 
commonly used in diagnosis. However even in renal disease the cut off value for diagnosis often differs 
across studies and accounts for some of the variation identified.  
 
Outcomes:  The outcome of mortality predominated in the current prognosis studies in 93% of studies. Only 
16% of studies had included hospital admission and 5 of these focused on a chronic disease exposure, 
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representing only two diseases; DM (n=1) and RD (n=4). This is surprising given the high number of hospital 
admissions associated with HF and the association between comorbidities and hospital admissions found in 
cross sectional studies(129). In a large incident HF population 83% of patients experienced at least one 
admission and 54% experienced three or more admissions in 5 years of follow up and non-cardiac 
comorbidities accounted for 62% of those admissions(320).   
 
Remarkably, among the 68 studies included in the review there was no study that investigated the association 
between non-CVD comorbidities in non-selected HF and HR-QoL outcomes. This was a surprising finding 
given the low HR-QoL inherent in the HF population that worsens as the disease progresses(116). HR-QoL is 
itself associated with hospital admissions and mortality(344-346) and so provides a clear indicator of disease 
progression.   In cross sectional studies(136,347) and selected HF populations comorbidity has been found to 
influence QoL and future QoL(348,349) but its impact in contemporary general populations of HF patients has 
yet to be investigated.   
 
Settings: Only one study from the 68 included was set solely within a community setting. Eight further studies 
included community patients. There is evidence that the community population of HF patients differs 
significantly from hospital based populations which represent a more severe group with poorer prognosis(350-
352) and much higher prevalence of chronic disease comorbidities(132). This has implications for the 
investigation of comorbidity exposure where there is evidence of a differential exposure effect in community 
and hospital settings with a significantly greater relative risk of exposure from comorbidities in the community 
setting(132,322). This is an important consideration for the development of prognostic models for the general 
population of HF patients particularly at earlier stages of disease and relating to quality of life and hospital 
admissions.  
 
Comorbidity as a prognostic factor:   Consistent predictors of mortality and hospital admissions in this review 
were comorbid DM, COPD and RD. The strength of effect was similar across the different diseases ranging 
from a 34% increase risk of mortality for DM to 52% increase risk for RD. The magnitude of effect associated 
with the individual comorbidities is important for four main reasons. First, it is well recognised that the latency 
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period between chronic disease comorbidity exposure and outcome is likely to be long and in HF often 
occurring many years prior to the onset of the index disease. Second, the exposure status is not static and will 
change over the progression of the index disease making precise measurement difficult. Third, the long 
latency period and imprecise and fluctuating exposure effect is likely to lead to small to moderate exposure 
effects which may be difficult to detect without careful epidemiological and statistical approaches(1). Fourth, 
HF is a severe index disease which is common in older people. These factors carry a high risk of mortality and 
hospital admission and so any significant relative exposure effect is likely to have an important impact on the 
absolute risk difference compared to non-exposed groups.  The long latency period between exposure and 
outcome and the dynamic status of comorbidity exposure leads to the hypothesis that prognosis approaches 
that capture a change in exposure status may result potentially in bigger exposure effects.     
 
The association between HF and different chronic disease comorbidities is complex with mechanisms that 
include shared risk factors, pathophysiological links, diagnostic and management conflicts or merely by 
chance as a function of age.  
 
Comorbid diabetes mellitus: In this review findings show that DM was strongly and independently associated 
with mortality (34% higher risk) and hospital admission (28% higher risk). DM shares many of the risk factors 
of cardiovascular disease which is a common comorbidity(353) and the Framingham study showed an 
increase of cardiovascular risk by up to 3 times in diabetics compared to non-diabetics(354). HF also presents 
earlier and at higher rates in type 2 diabetes(355).  
 
Hyper-glycaemia is known to activate neurohormonal and metabolic pathways which trigger a number of 
processes including vascular inflammation, endothelial dysfunction and oxidative stress in turn leading to; 
early and widespread atherosclerosis(356), apoptosis and fibrosis in the heart and kidney(357), reduced left 
ventricular function(358) and insulin resistance(359). Hypertension, diabetic nephropathy and cardiomyopathy 
are common in DM(360). Cardiovascular symptoms may be atypical or non-existent in the diabetic 
patient(361) and so diagnosis and management can be delayed leading to more advanced disease. 
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The gender difference in DM effect was significant in this review with women almost 30% more at risk of 
mortality and hospital admission than men. Women with DM tended to be older and with more severe heart 
disease than men(292)  but these factors did not influence mortality in women compared to men in the non-
diabetic group. However given the potential of this interaction in the older age groups it is likely to be, in part, 
due to the smaller DM effect in men which did not increase with age. The increased effect in older women 
may be a function of age, delayed and more extensive presentation of cardiovascular disease in diabetic 
women(362), poorer management of risk factors(363), increased insulin resistance and cardiovascular 
disease progression in post-menopausal women(364) or higher prevalence of preserved ejection fraction.     
 
Comorbid COPD:  COPD has been found, in previous studies, to be clearly associated with cardiovascular 
disease morbidity and mortality(365-367) however it has not been well explored in the context of HF and 
whilst many studies have included COPD as a factor only five studies focused on this association in this 
review.  Pooling of these similar studies reported the strong and independent association between COPD and 
mortality (39% increased risk) and hospital admission (up to 47% increase risk) in the non-selected HF 
population.  
 
It is well recognised that COPD causes chronic hypoxia and hypercapnia, neurohormonal activation and low 
grade systemic inflammation which in turn is associated with myocardial loading, deranged metabolic 
processes, atherosclerosis and cardiovascular events(368-370). Right ventricular dysfunction is common with 
or without pulmonary hypertension in COPD and is associated with increased mortality(371). COPD can mask 
the common diagnostic signs and symptoms of HF which leads to a later diagnosis and delayed 
management(372). Investigations such as echocardiogram and BNP can be unsatisfactory and HF can be 
easily missed where pulmonary vascular remodelling can hide pulmonary oedema and chest hyperinflation 
reduces the cardiothoracic ratio(96,373). The symptom of breathlessness is shared by the two diseases and 
there is no unique feature that differentiates them(374). Once HF diagnosis is made, challenges exist in the 
application of often conflicting treatment regimens with the clear example of the under-prescribing of beta-
blockers(298) which amounted to less than 10% of patients in one study(299).  
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HF can also be misdiagnosed in COPD as jugular venous distention, ankle oedema, and hepatomegaly that 
are each indicative of right ventricular failure can also be caused by lung hyperinflation with hepatic 
displacement found in COPD. This misdiagnosis of HF can often be seen in the overrepresentation of COPD 
in HF with preserved ejection fraction(375). Comorbid COPD has been found to be significantly associated 
with mortality in this review where the proportion of HFpEF was low(297), where ejection fraction was 
accounted for in the analysis(299) and where the interaction between COPD and ejection fraction was 
specifically tested(296). Where studies include a proportion of misdiagnosed HF the effect estimate is likely to 
be an underestimate of the true effect.    
 
Comorbid renal dysfunction: RD has been shown to be associated with adverse outcomes in HF previously in 
studies largely focused on selected HF populations(376-380). This review was able to combine studies 
including a more general population of HF patients encountered in the ‘real world’ of clinical practice, where 
RD was also significantly associated with mortality (52% increased risk) and hospital admissions (77% 
increased risk in severe disease).  
 
However, the temporal relationship between the two diseases is not clear.  Shared risk factors including age, 
hypertension, low high-density lipoprotein cholesterol and DM which result in atherosclerosis of renal 
disease(381) mean that RD and HF have a bi-directional relationship. However whilst this may explain some 
of the increased risk associated with RD, adjustment of these factors in analysis did not diminish the risk 
which remained significant and elevated(155,156,301,303,306,380). RD has also been considered as a 
marker of haemodynamic status and severity of the underlying cardiac disease(382). However adjustment for 
HF severity in a number of studies included in this review did not support this(156,301,310).  
 
Whilst the precise mechanism of the temporal evolution of the cardio-renal syndrome is not known, what is 
clear is that once present, both conditions serve to aggravate each other.  In chronic kidney disease, 
hypertension, arteriosclerosis and anaemia lead to myocardial pressure and volume overload in turn leading 
to hypertrophy and ventricular dilatation(383) and in HF poor cardiac output leads to reduced renal perfusion. 
Both diseases trigger neuro-hormonal mechanisms and their harmful counterparts; inflammation, endothelial 
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dysfunction and altered metabolic processes, all of which have been indicated as powerful mediators in 
cardio-renal syndrome(384). Management of HF can also be challenging in RD particularly in relation to 
diuretics(385)  and ACE inhibitors(386,387) and patients are less likely to be prescribed first line 
drugs(303,306,388).  
 
HF severity: The effect of the comorbidity exposure will be influenced by both the severity of the index disease 
and the associated comorbidity. This will depend to some extent on the mechanisms that link the diseases 
together with completely unrelated comorbidities competing with the risks of the index disease for specific 
outcomes and interrelated comorbidities that share pathophysiological processes and potentially modifying 
the risk of the index disease. Unlike cancer studies where the risk of comorbidity diminishes as the cancer 
progresses(389), in HF, comorbidity is found to have a reduced but still important effect in more advanced 
disease.  
 
The importance of the severity of the index disease for the risk of comorbidity exposure was evident for 
comorbid DM studies. The mortality risk of DM was significantly higher in the younger groups than the older 
groups(291). Follow-up in this study was 5 years, so the risk of death from the index disease becomes higher 
as the group ages, thus diminishing the relative risk exerted by the DM.  This DM-age interaction was not 
evident in the Digitalis Investigation Group trial(292), but this may be in part explained by the lack of 
adjustment for ejection fraction or HF severity in the former study. The increased effect of DM in the younger 
group was likely to be a function of less severe disease in this group which strengthens the hypothesis that 
index disease severity contributes to the relative impact of DM on mortality. Higher ejection fraction has in 
another study been associated with a greater DM impact(390) and again, this could be a function of reduced 
baseline risk in this group yielding higher DM relative risk or alternatively a function of  competing risk, with 
DM having lesser effect in the more severe patients with greater systolic dysfunction. DM has been found not 
to contribute significant risk to mortality in advanced HF with very low ejection fraction(391).  
 
Further examples of the impact of HF severity include the differential effect of comorbid COPD in different HF 
populations. The relative impact of comorbid COPD for mortality was found to be significantly worse in the 
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community setting than the hospital setting(132) which may reflect the less severe HF group.   In comorbid 
renal disease there was a significant difference in the exposure effect between younger and older groups with 
the greatest effect of renal dysfunction in the younger group(139) and also in the community and hospital 
setting with worse exposure effects in the community setting(132).  
 
Comorbidity severity: Comorbidity severity should be an important factor in prognosis studies. In this review 
the potential importance of disease severity for each of the three main comorbidities was identified. DM 
severity was included in this review in 3 focused studies. Firstly treatment type was found to differentiate DM 
risk with patients prescribed insulin having a more than 50% increase in risk of mortality than patients 
prescribed oral medication or diet control(293). Increased risk in type 1 DM was also included in a prognostic 
model for mortality in HF with 30% more risk in the insulin group than the non-insulin DM group(179). 
Although evidence on DM severity by treatment in HF is limited it has been found in other cardiovascular 
studies(149,150) and the insulin group is likely to represent those with either more severe metabolic effects or 
advanced DM disease.  
 
Mortality risk was also increased in the undiagnosed diabetes group(293) which might relate to the 
development of insulin resistance as HF progresses, which presents both a hyperglycaemic state and a proxy 
marker for HF severity(392). This evidence is important as DM is undiagnosed in 1 in 10 stable HF 
patients(393),  but effects of comorbid DM in the diet controlled group have been non-significant as a result of 
adjustment by other associated risk factors.   
 
Higher chronic glucose levels measured by each 1% rise in HbA1c was associated with increased mortality 
risk in HF and this was in all patients regardless of their DM status with stronger effects noted in the non-
diabetic group(290). This group may reflect undiagnosed DM with the associated insulin resistance and 
increased HF severity and of interest was the increased mortality risk from lower glycaemia suggesting a U 
shape relationship between glucose level and risk of mortality. Postulated mechanisms include myocardial 
energy starvation leading to a dependence on free fatty acid uptake(288) or aggressive glucose lowering drug 
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therapy which may be hazardous to the HF patient. Increased risk of cardiovascular events from intensive 
therapy to target normal glycated haemoglobin levels has been found in type 2 DM(290).   
 
These findings suggest that both DM treatment and glycaemic levels stratify the prognostic risk in HF and 
further investigation into the appropriate cut points for increased mortality risk given the U-shaped relationship 
with HbA1c is required. Three prognostic models for mortality included the severity of DM albeit two of these 
were limited to the inclusion of more severe DM by clinical complications(189,259). 
 
In comorbid COPD, risk of death increased as FEV1 decreased. Effect estimates were non-significant in the 
moderate COPD severity group but became significant and elevated in the severe group. Whilst the 
investigation of severity in COPD was limited to one HF study, this link has been found in previous selected 
populations (147,148) and in cardiovascular disease(394). This evidence suggests that inclusion of ‘any 
COPD’ in HF prognosis studies could lead to underestimation of effect in those who have severe COPD and 
overestimation in those who have less severe disease. A challenge with using FEV1 for severity assessment 
is that it is influenced by the HF status. One study showed that lung volume is reduced as a function of HF 
disease severity(395). Pulmonary oedema causes constriction of the airways and bronchial hyper 
responsiveness(396) which means that FEV1 may be partly reflective of congestion rather than 
obstruction(296). Assessment of COPD should include both FEV1 to FVC ratio which is independent of 
HF(397) and FEV1 assessment once patients are euvolaemic. COPD severity in this systematic review was 
recorded when patients did not have pulmonary congestion(296). FEV1 was more predictive than FVC or 
FEV1/FVC ratio and independent of ejection fraction. Given the prognostic importance of HF severity, FEV1 
which may represent elements of HF and COPD severity appears a useful prognostic factor and provides a 
mechanism to determine severity change over time.  
 
This systematic review identified renal severity for a combined sample of 64,257 unselected HF patients. Over 
a third of HF patients had moderate RD (eGFR 30-59ml/min) and 6% had severe disease (<30ml/min). The 
mortality risk of any RD (<60ml/min) became significantly differentiated by severity, with higher estimates for 
more severe RD. This was independent of age, gender, other comorbidities and HF severity. A linear 
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relationship was observed between eGFR and mortality risk, a finding shown in other studies(304,308,312),  
but this requires further investigation. eGFR is often categorised and becomes non-significant at different cut 
points, which in this review was at eGFR ≥60-89ml/min, but the actual level is unknown. Renal severity was 
also found to differentiate the risk of hospital admission, with the most severe group having a 60% greater risk 
of admission than the moderate severity group(301). Given the importance of comorbid RD severity it was 
surprising that only one mortality prognostic model had included it as a factor. 
 
This systematic review selected eGFR as a routinely collected measure of RD. Estimated GFR equations use 
serum creatinine to estimate true GFR, adjusting for other factors. The Modification of Diet in Renal Disease 
(MDRD) adjusts for significant non-renal influences such as age, sex, race, and body size and is preferred to 
other equations such as the Cockcroft-Gault formula(398,399). The renal studies included in this meta-
analysis all used the MDRD equation to estimate GFR. Whilst one of the most accurate formulas, it is 
important to note that this measure has several drawbacks including its tendency to underestimate GFR in the 
higher ranges (>90ml/min)(400,401). As with other creatinine based equations it also has a tendency to 
overestimate eGFR (and thus underestimate RD) in more severe disease and older age due to falling 
creatinine levels that can result from reduced muscle metabolism and increased active tubule secretion(302). 
Whilst the mean age and ejection fraction was similar across studies, NYHA (class 3 or 4) was more varied 
and it can’t be ruled out that RD may have been underestimated in those with more severe HF disease by 
symptoms. Whilst this might overestimate the risk associated with less severe renal dysfunction (due to the 
spurious inclusion of more severe dysfunction in this category) there was still a significant separation between 
the severity groups and a clear dose-response relationship between renal dysfunction and mortality risk was 
shown. 
 
Severity change: The importance of comorbidity severity change in HF was limited to comorbid RD studies, 
where it was shown to have a strong and significant effect on both mortality and hospital admission. The more 
severe the degree of renal function change the higher the associated mortality risk with a 53% increased risk 
in the moderate change group (Creatinine of ≥0.3mg/dL increase) rising to 129% in the severe change group 
(Creatinine of ≥0.5mg/dL increase). This 50% rise in prognostic risk in moderate severity RD change was also 
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found for the outcome of hospital admissions(156).These effects are larger than the exposure effect estimates 
of the respective severity groups demonstrating that both disease severity and disease progression are 
important considerations for risk assessment. Most studies use serial serum creatinine measurements as a 
marker of change but, due to the exponential relationship between serum creatinine and GFR, this can lead to 
change from lower baseline creatinine values having a more marked effect on GFR than change from higher 
baseline values. For this reason change in eGFR is recommended as a measure of renal disease 
progression(157), with a decline in eGFR of >5ml/min over a year being clinically significant. Also baseline 
renal function needs to be considered in the assessment of the change. One study found a significant 
interaction between baseline creatinine and worsening renal function with the higher than median baseline 
creatinine group being worse off (311).  The potential mechanism between baseline RD severity and severity 
change needs further investigation and within other comorbid diseases for HF populations. 
 
5.4.10 Strengths and limitations 
This is the first review to investigate the impact of non-CVD comorbidity and severity on different outcomes, in 
an unselected HF population. The study samples included a broad range of people with preserved or reduced 
ejection fraction.  All studies were conducted after the introduction of modern HF treatments and so applicable 
to current practice.  Multiple comprehensive databases were searched using validated search strategies as 
well as grey literature, reference and citation searches and expert contact to identify all good quality studies 
and the search was validated with previous systematic reviews. Clearly defined inclusion criteria were used 
and detailed data extraction and quality appraisal of each study was performed to allow for appropriate meta 
and sensitivity analysis where indicated.  
 
The population HF definition varied across studies and included the use of administration codes which may be 
subject to misclassification. Most studies did however use a clinical diagnosis of HF (up to 82% of renal 
studies) based on a combination of signs, symptoms and objective evidence and studies based on self-report 
or diuretic prescription were not included. Only non-selected HF samples were included but there was a high 
proportion of hospital-based studies so generalisability to other populations is limited.  This however does 
mean that those studies included in meta-analysis were more homogenous and it is likely from the few 
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community studies included that the effect estimates maybe even greater in community settings. Comorbid 
chronic disease exposure was also variably defined and often relied on large administrative databases or 
patient self-report where the diagnosis and severity of comorbidity cannot be well characterised. This was 
evident in some of the review studies that identified undiagnosed comorbid groups within their HF samples. 
The prevalence of DM(293) and COPD(296) increased where subjects underwent physiological testing for the 
comorbidity. Inclusion of these potentially higher risk subjects in the analyses with a misdiagnosis of no 
comorbidity is likely to diminish the comorbidity effect estimates(9).   However the risk estimates for the 
different comorbid diseases were significant and there were severity examples for each disease based on 
physiological markers for comparison. The variation in definitions of both the index HF and comorbid diseases 
reflects real life practice, where prognosis occurs. 
 
Inherent in systematic reviews of observational studies is the possibility of publication bias. Non English 
language studies were excluded, which could potentially mean that neutral or negative studies might have 
been missed(402). The prognostic factor (general) and prognostic model studies were selected on the basis 
that a non-CVD comorbidity was significantly and independently associated with an outcome.  This approach 
was chosen apriori to scope the studies where comorbidity was included in multivariable models but will mean 
that studies were excluded where the exposure was found not to be significant in adjusted models. However, 
these studies were not included in meta-analysis and publication bias was tested and accounted for in each of 
the main meta-analyses conducted.  
 
Another challenge for meta-analysis of observational studies is the heterogeneity across studies in terms of 
design, populations, exposures and outcomes. The systematic review methods clearly defined inclusion 
criteria and data extraction were used to allow comparability of studies and the appropriate selection of 
studies to combine in meta-analysis. Sensitivity analysis was performed where required. Heterogeneity was 
reduced for the three main meta-analyses by exclusion of studies and any change to the effect estimates was 
reported. Any residual unexplained heterogeneity was accounted for by random effects meta-analysis. The 
risk estimates obtained take account of the variation within and between studies and reflect the average risk 
for the unselected HF population. 
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The ability to accurately account for confounding is limited in meta-analysis of observational studies without 
access to individual patient data. For this reason only the adjusted effect estimates from the chronic disease 
focus studies were combined, which were more likely to include appropriate confounders. Only the 
confounders reported in the final adjusted model were extracted in the systematic review and so apparent 
gaps in adjustment could reflect those factors found not to be significant in individual studies. Whilst 
unmeasured confounding cannot be ruled out, the effect estimates were consistent across the studies.   
 
Risk of bias was assessed using a recommended and objective instrument(270) which has six domains in 
order to assess individual and overall risk. Overall assessment can be subjective but this was reduced by a 
high level of agreement between two reviewers. All included studies in meta-analyses were moderate or low 
risk and bias was accounted for where necessary in the analyses.   
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Table 5.1 Inclusion criteria for articles in the final systematic review 
 
Inclusion Criteria Specification 
Population Clinical diagnosis of de novo or chronic HF  
Unselected by cause  or ejection fraction 
Aged 18 years or older 
Hospital or community based 
Exposure Chronic disease comorbidity or indicator of chronic disease severity 
Renal studies to include eGFR or creatinine change (after May 2005) 
Diabetes studies to include HbA1c or fasting glucose 
COPD studies to include FEV1 
Outcome All-cause mortality 
All-cause admission (including readmissions) 
Health status measure (generic or specific) 
Study Observational studies with more than 30 days follow-up  
Prognostic factor study (chronic disease focus or general factors that include a chronic disease) 
Prognostic model study  
English language 
eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; FEV1, forced expiratory volume in 1 second;  
pp, percent predicted 
Table 5.2 Inclusion criteria for studies used in meta-analysis in the review 
 
Criteria Description 
Study type 
Chronic disease 
Outcome 
Population 
Follow-up 
Sample size 
Effect estimate 
Risk of bias 
Prognostic factor (chronic disease focus) 
Clinically defined or patient reported 
Mortality, hospital admissions 
Clinically defined HF  
> 3 months 
>100 patients 
Adjusted hazard ratios  
Moderate or low 
Table 5.3 Chronic diseases included in the systematic review  
 
Chronic disease  Prognostic factor 
(chronic disease focus) 
Prognostic factor 
(general) 
Prognostic model 
Diabetes 11 17 7 
COPD 5 6 6 
Renal dysfunction 17 11 5 
Arthritis  1 (Rheumatoid) 2  
Cancer  7 3 
Dementia  2 3 
Other lung disease  1 1 
Liver disease   3 
COPD, chronic obstructive pulmonary disease   
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Table  5.4 Proportion of risk score categories allocated for individual risk domains  
 
 
Risk domain Low Moderate High 
Study participation 
Study attrition                                    
Prognostic factor measurement 
Outcome Measurement             
Study confounding 
Statistical analysis and reporting    
35% 
69% 
21% 
81% 
23% 
29% 
59% 
28% 
74% 
19% 
65% 
55% 
6% 
3% 
6% 
 
12% 
16% 
Table 5.5 Prevalence of renal dysfunction by severity level 
 
 
Renal dysfunction (RD) 
severity level 
Studies HF sample RD number Prevalence 
Any 8 74,873 36,785 (49%) 39-79% 
Mild 1 2,680 1,137 (43%) 43% 
Moderate 6 73,968 26,441 (36%) 20-67% 
Severe 6 73,968 4,201 (6%) 2-33% 
Any RD is defined by eGFR <60ml/min; mild by eGFR 60-89ml/min; moderate by eGFR 30-59ml/min and 
severe by eGFR <30ml/min compared to the highest study defined category. 
Table 5.6  Prevalence of renal severity change 
  
 
Renal dysfunction (RD) 
severity change level 
Studies HF sample RD change number Prevalence 
Moderate 3 21,743 3823 (18%) 11-21% 
Severe 2 1,033 239 (23%) 22-25% 
Moderate severity change was defined by an increase in creatinine (Cr) of ≥0.3mg/dL from hospital baseline 
to study defined end point and severe by an increase in Cr of ≥0.5mg/dL. 
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Table 5.7 Prevalence of chronic diseases in prognostic factor (general studies) 
  
 
 Prognostic factor (general studies) Prognostic model studies 
Chronic disease exposure Studies  Prevalence range Studies Prevalence  
Diabetes 17 3* to 61% 7 14 to 36% 
COPD 6 20 to 47% 6 10 to 31% 
Renal dysfunction 11 1ƚ to 70% 5 8 to 25% 
Arthritis 2 5* to 29%   
Cancer  7 2 to12% 3 2 to 9% 
Dementia 2 10 to 23% 3 5 to 9% 
Other lung disease 1 7% 1 9% 
Liver disease   3 1 to 3% 
COPD, Chronic Obstructive Pulmonary Disease. *Studies with low prevalence used hospital admission codes to 
define chronic disease. 
ƚ 
Low prevalence defined by renal failure 
Table 5.8  Renal dysfunction stratified by severity and all-cause hospital admission  
 
 
Severity group Risk of hospital admission (adjusted HR)  
eGFR <60ml/min 1.18 (1.08-1.29) 
eGFR 30-59ml/min 1.16 (1.06-1.27)  
<30 ml/min 1.77 (1.16-2.69)  
eGFR, estimated glomerular filtration rate   
Table 5.9  Other diseases included in prognostic factor (general) and model studies 
 
 
Disease Mortality Hospital admissions 
Rheumatoid arthritis 
(Chronic disease focus) (n=1) 
 
HR 1.89 
 
 
Arthritis (n=2) 
Dementia (n=5) 
Cancer; Lung (n=1) 
Cancer; Colorectal (n=1) 
Cancer; Endometrial (n=1) 
Cancer;  metastatic (n=2) 
Cancer;  any (n=7) 
Lung Disease (n=2) 
Liver disease (n=3) 
HR 0.87-1.16 
OR 2.0, HR 1.44 to 2.02 
HR 1.86 to 3.58 
HR 1.39 
HR 2.11 
LogOR 4.36, OR1.22 
HR 1.44-2.97, OR 1.85-3.02 
HR 1.37-1.58 
HR1.98, OR 5.8 
 
OR 1.1 
 
 
 
 
OR 1.22 
 
OR 1.29 
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Figures 
Figure 5.1 Screening process 
PRISMA Flow Diagram Comorbidity and prognosis in HF populations: A systematic review 
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Figure 5.2 Combined adjusted associations between comorbid DM in HF and all-cause mortality 
Fig 5.2 * the prevalence for Ahmed et al (2007) is based on the baseline sample before matching on DM status for the analysis. There 
were 7,788 subjects in the baseline sample and 2,218 (29%) of these had diabetes. Flores-LeRoux had a baseline sample of 400 
subjects  resulting in a 37% prevalence of clinical DM. The undiagnosed DM group (n=63) were excluded from the current analysis.              
Adjusted variables: age(A), gender(G), ethnicity(E), social(S), risk factors(R), comorbidities(C), aetiology(At), HF severity(Sv), 
drugs(D), laboratory(L), physical(P), ejection fraction(Ef) 
 
 
 
Figure 5.3 Combined adjusted associations between comorbid DM in HF and all-cause mortality by 
gender  
 
* the prevalence for Ahmed et al (2007) is based on the baseline sample before matching on diabetes status for the analysis. There 
were 1,926 women and 5,862 men in the baseline sample and 650 (34%) women and 1,568 (27%) men had diabetes. 
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Figure 5.4 Comorbid DM severity stratified by treatment type in HF and all-cause mortality 
 
 
 
 
 
 
 
 
 
Figure 5.5 Combined adjusted associations between comorbid COPD in HF and all-cause mortality  
 
Fig 5.5 Adjusted variables: age(A), gender(G), ethnicity(E), social(S), risk factors(R), comorbidities(C), aetiology(At), HF 
severity(Sv), drugs(D), laboratory(L), physical(P), ejection fraction(Ef) 
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Figure 5.6 Comorbid COPD stratified by FEV1 in HF and all-cause mortality 
Figure 5.6 there were 532 subjects in the baseline sample. Only 484 had self-reported information. The reference group 
for FEV groups was FEV≥80% predicted (n=350). The reference group for the self-reported COPD was the non-self-
reported COPD group (n=377). 
 
 
Figure 5.7 Comorbid COPD in HF and all-cause hospital admission 
 
Fig 5.7 Adjusted variables: age(A), gender(G), ethnicity(E), social(S), risk factors(R),  
comorbidities(C), aetiology(At), HF severity(Sv), drugs(D), laboratory(L), physical(P), ejection fraction(Ef) 
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Figure 5.8 Combined adjusted associations between Renal Dysfunction and all-cause mortality 
 
Fig 5.8 Adjusted variables: age(A), gender(G), ethnicity(E), social(S), risk factors(R), comorbidities(C), aetiology(At), HF 
severity(Sv), drugs(D), laboratory(L), physical(P), ejection fraction(Ef) 
 
 
Figure 5.9 Combined associations between Renal Dysfunction stratified by severity and all-cause 
mortality  
  
Fig 5.9 Adjusted variables: age(A), gender(G), ethnicity(E), social(S), risk factors(R), comorbidities(C), aetiology(At), HF 
severity(Sv), drugs(D), laboratory(L), physical(P), ejection fraction(Ef) *from prior systematic review(145) **Test  of 
association between the severity subgroups and the study effect estimates was performed using random effects meta-
regression with Monte Carlo permutations to calculate the P value. The reference group for the studies was eGFR >60. 
The two studies plot that investigated mild eGFR (60-89) used eGFR≥90 as a reference group. 
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Figure 5.10 All-cause mortality in HF by study defined upper eGFR severity category limit  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 The reference group for the studies was eGFR >60. The two studies at the bottom left of the plot that 
investigated mild eGFR (60-89) used eGFR≥90 as a reference group. 
 
 
Figure 5.11 All-cause mortality risk in HF by eGFR mls/min  
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Figure 5.12 Combined associations between renal function change stratified by severity and 
all-cause mortality  
 
Fig 5.12 Adjusted variables: age(A), gender(G), ethnicity(E), social(S), risk factors(R), comorbidities(C), aetiology(At), HF 
severity(Sv), drugs(D), laboratory(L), physical(P), ejection fraction(Ef)   *From previous systematic review(157). Renal 
function change was measured as the difference between the admission creatinine and the study defined end point. 
 
 
Figure 5.13 Meta-analysis summary of the association of the three main diseases with mortality 
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Phase 2 and 3: Database studies
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Chapter 6 Time-dependent comorbidity severity and change and 
outcomes: introduction and methods 
 
This chapter will introduce the series of Clinical Practice Research Datalink (CPRD) studies used to 
investigate the main hypotheses focusing on the 3 specific common non-cardiovascular disease (CVD) 
comorbidities that were identified from the systematic review (SR): diabetes mellitus (DM), chronic obstructive 
pulmonary disease (COPD) and Chronic Kidney Disease (CKD). The study objectives and hypotheses will be 
presented followed by a detailed discussion of the methods including sample selection, the framework for 
measuring comorbidity severity and change using routinely collected data, outcome and covariate 
measurement and the statistical analysis framework.     
 
6.1 Introduction  
From the 68 heart failure (HF) prognosis studies in the systematic review (Chapter 5) that included non-CVD 
comorbidities, only one had focused on a community setting. Most studies had also investigated mortality 
rather than other outcomes that span the life course of HF disease which are important to patients and policy 
makers such as health-related quality-of-life (HR-QoL) or hospital admissions. For the outcome of hospital 
admission, the few HF comorbidity prognosis studies had only focused on the single comorbid example of RD, 
and there has been little structured investigation of comorbidity status and definitions in relation to both 
hospital admission and mortality. The CPRD provided easily accessible national population data for linking 
HF, comorbidity and mortality and hospital admission data through Hospital Episodes Statistics and mortality 
data through Office of National Statistics data. So for the purposes of the thesis, all following analyses in 
Chapters 7 to 10 focus on comorbid DM, COPD and RD in HF and their effect on the outcomes of first 
hospital admission after HF diagnosis and mortality. The outcome of HRQoL therefore lies outside the scope 
of the thesis, but initial analysis for this outcome in a separate analysis is presented as a supplementary 
published paper (E-Appendix E18).   
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6.2 Main study objectives, hypotheses and questions 
The main study which focuses on Phases 2 and 3 of the thesis is in three parts and uses the example of DM, 
COPD and CKD comorbidity in HF.  
 
Part 1: Non-CVD comorbidity measures in an incident HF general practice cohort sample by all-cause 
mortality and first hospital admission. 
 
Part 1 of the CPRD analyses forms Chapters 7 and 8 and the following objectives, hypotheses and questions 
are addressed: 
 
Chapter 7 objectives: HF patient characteristics by all-cause mortality 
(i) To describe the baseline characteristics and comorbidity status for three non-CVD comorbidities in a 
national cohort sample of incident HF patients aged 40 years and over for a 10-year time period. 
Characteristics and comorbidity measures will be described in the total sample and in those who died 
compared with those who remained alive over a maximum 12-year follow up period. 
 
(ii) To compare the time-dependent characteristics and comorbidity status, severity and change 
measures between cases and controls in a cohort sample of incident HF patients where cases were 
matched to controls on calendar and follow-up time.  
 
Chapter 8 objectives: HF patient characteristics by first hospital admission 
(i) To describe the baseline characteristics and comorbidity status for three non-CVD comorbidities of a 
sub-sample of the cohort of incident HF patients aged 40 years and over, that were linked to Hospital 
Episode Statistics (HES)  in a 10-year time period. Characteristics and comorbidity measures will be 
described in the HF sample and in those who had a first hospital admission compared with those 
who did not over a maximum 12-year follow up period. 
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(ii) To compare the time-dependent characteristics and comorbidity status, severity and change 
measures between cases and controls in a sub-sample cohort of HF patients with linked HES data, 
where cases were matched to controls on calendar and follow-up time.  
 
Questions addressed in Chapters 7 and 8 were:  
 
(i) What is the prevalence of COPD, DM and CKD in the incident HF cohort at baseline?  
 
(ii) Is the prevalence of COPD, DM and CKD at baseline significantly different in HF patients with the 
two primary outcomes of all-cause mortality and first hospital admission and those without these 
outcomes? 
 
(iii) What is the prevalence of COPD, DM and CKD defined by diagnostic status, severity and recent 
change measured before the two primary outcomes compared to those without these outcomes 
measured at the same time?  
 
Hypotheses tested in Chapters 7 and 8 were: 
 
(i) Baseline comorbid status COPD, DM and CKD are associated with increased all-cause mortality 
or increased risk of first hospital admission in HF. 
 
(ii) Time-dependent measures of recent comorbidity status, severity and change are associated 
with increased all-cause mortality or increased risk of first hospital admission in HF.  
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Part 2: Non-CVD comorbidity prognostic factors in an incident HF general practice cohort sample: 
strength of associations with all-cause mortality and first hospital admission 
 
Part 2 of the CPRD analyses in the same general practice HF population aged 40 years and over forms three 
chapters as follows:  
 strength of association with all-cause mortality (Chapter 9),  
 strength of association with first hospital admission (Chapter 10) and  
 strength of association and interactions (Chapter 11). 
 
Chapter 9, 10 and 11 objectives were: 
 
(i) To investigate the potential confounding factors for the unadjusted associations between the 
comorbidity measures and all-cause mortality and first hospital admissions identified in Part 1.   
 
(ii) To investigate whether time-dependent non-CVD comorbidity status, severity and recent change 
exposures independently and significantly increase the risk of all-cause mortality and first hospital 
admission compared to non-comorbid groups. 
 
(iii) To investigate whether the strength of associations or ‘estimate of effects’ (hereafter referred to as 
‘effects’) of non-CVD comorbidities on all-cause mortality or first hospital admission in HF are 
significantly stratified by measures of comorbidity severity or change.    
 
(iv) To investigate potential first order interactions between pairs of the 3 main comorbidities and 
between the comorbidities and other key study variables.  
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Chapter 9, 10 and 11 questions addressed were: 
 
Confounding: 
(i) What HF patient characteristics are significantly different in those with and without each of the 
comorbidities? 
(ii) Are the unadjusted effects of comorbidity on all-cause mortality and first hospital admission altered or 
modified by the adjustment by any patient characteristic? 
 
Associations: 
(iii) What is the effect of comorbidities on all-cause mortality and first hospital admission that develop 
before or after index HF? 
(iv) Does the effect of comorbidity that develops before HF differ from the effect of comorbidity that 
develops after HF on all-cause mortality and first hospital admission? 
(v) Does recent comorbidity severity and severity change significantly and independently increase the 
risk of all-cause mortality and first hospital admission in HF? 
(vi) Are the effects of comorbidities on all-cause mortality and first hospital admission in HF significantly 
stratified by measures of their severity and recent change?    
(vii) Do the effects of comorbidity prognostic factors on all-cause mortality in HF differ from their effects 
on first hospital admission? 
 
Interactions: 
(viii) Is there evidence of statistical interaction between two comorbid diseases? 
(ix) Is the effect of two comorbid diseases on outcomes in HF different than the sum of their independent 
effects?     
(x) Is the effect of comorbidity status on outcomes in HF modified by HF severity groups defined by 
age? 
(xi) Is the effect of comorbidity status on outcomes in HF modified by other key patient characteristics?  
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Chapter 9, 10 and 11 hypotheses tested were: 
 
(i) Time-dependent measures of non-CVD comorbidity status, severity and change will independently 
and significantly increase the risk of all-cause mortality and first hospital admission compared to non-
comorbid groups.  
 
(ii)  The independent effect of HF comorbidity status on all-cause mortality and first hospital admission 
compared to non-comorbid HF groups will be significantly stratified by measures of comorbidity 
severity and recent change.  
 
(iii) The effect of having two non-CVD comorbidities in HF at the same time will differ from the sum of 
their independent effects on all-cause mortality and first hospital admission. 
 
(iv) The effects of non-CVD comorbidities on all-cause mortality and first hospital admission will 
significantly differ by HF severity groups defined by age. 
 
Part 3: Non-CVD comorbidity prognostic models; comparison of multivariable models for all-cause 
mortality and hospital admission using different comorbidity measures. 
 
Part 3 focuses on Phase 3 with the following objective (Chapter 12): 
 
To investigate the contribution of non-CVD comorbidity severity and recent change measures to pre-
defined multivariable models for all-cause mortality or first hospital admission in the general HF 
population. 
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The question addressed was: 
 
Does the statistical fit of a pre-specified multivariable model that includes comorbidity diagnostic status 
measures improve when these measures are replaced by comorbidity severity and change measures? 
 
The hypothesis tested was: 
 
Replacing comorbidity diagnostic status measures with chronic disease comorbidity severity and severity 
change measures will improve the fit of pre-specified HF multivariable models for the outcomes of all-
cause mortality and first hospital admission. 
 
6.3 Methods 
This section describes in detail the study design, data, setting and sample selection, the comorbidity exposure 
measures, the outcome measures and the covariate measures used in each of the three analytic parts. 
 
Part 1 – Descriptive studies of the:  
a) baseline cohort of HF general practice population patients in the mortality sample and the hospital 
admission sub-sample, and  
b) nested case-control samples of the baseline populations to test the hypotheses that  
(i) baseline status COPD, DM and CKD are associated with all-cause mortality and first 
hospital admission and 
(ii) time-dependent measures of comorbidity status, comorbidity severity and change are 
associated with all-cause mortality and first hospital admission.  
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Part 2 – Nested case-control studies to investigate the main hypotheses that the effects of time-dependent 
measures of comorbidities on mortality and first hospital admission are significantly stratified by measures of 
their severity and change.  
 
Part 3 – Nested case-control studies to investigate the hypothesis that replacing comorbidity diagnostic status 
measures with time-dependent measures of comorbidity severity or change would improve the fit of HF 
multivariable models for mortality and first hospital admission outcomes.  
 
6.3.1 Study design and setting 
Using a nested case-control approach to analysis, a historical cohort of incident HF patients from the CPRD 
was used to investigate the effect of non-CVD comorbidity severity and severity change measures on all-
cause mortality and first hospital admission compared to non-comorbid HF groups.  The nested case control 
study design used risk set sampling of controls to estimate unbiased rate ratios for the comorbidity exposures. 
On the case index date, controls were randomly sampled from the HF cohort that had not yet experienced the 
outcome and remained at risk of the event. Controls were also matched within one month of the case HF 
index (baseline) date.  The study design is discussed in detail in Chapter 4.3.2 and shown in Figure 4.1. 
 
CPRD clinical data (GOLD) (discussed in detail in Chapter 4) was extracted from the database of all eligible 
patients who had had a first consultation code for HF between 1st January 2002 and 1st March 2012  from the 
most recent data capture available on January 1st 2014. Subjects were followed until their date of death from 
any cause or their date of first hospital admission (depending on the outcome under study), the date they 
transferred out of the practice (TOD), the date the practice stopped contributing data to the CPRD or end of 
the study period (January 1st 2014), whichever occurred first. Linked datasets were also extracted on hospital 
episode statistics (HES), mortality data from the Office for National Statistics (ONS) and Index Multiple 
Deprivation (IMD), 2007.  Access to the anonymised CPRD data was provided under Keele licence and 
following Independent Scientific Advisory Committee (ISAC) approval (see E-Appendix D2 for the CPRD 
scientific protocol). 
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6.3.2 Study sample 
Patients aged 40 years and over were eligible for inclusion if they had a first HF consultation code applied to 
their general practice clinical or referral records between 1st January 2002 and 1st March 2012. The age 
criterion was chosen as earlier presentations of HF are unusual and indicate more rare causes such as 
genetic disorders(246). Clinical data is coded within the CPRD using the Read code classification which is a 
hierarchy using three tiers; diagnostic, process and medication codes. The code set used to select the HF 
sample was based on diagnostic codes from Read chapter G58(404). An additional search was done using 
the CPRD medical code dictionary browser for any additional codes related to the clinical terms ‘ventricular’, 
‘cardiac’ or ‘heart’, in combination with ‘failure’.  All but one process code (‘HF confirmed’) was eliminated from 
this latter search as they represented ongoing care or symptoms in a prevalent cohort rather than the index 
date of HF. The code set was validated by HF specialists and against previous literature(405,406) (E-
Appendix A14 for the selection code set).  
 
Exclusion criteria were applied to the initial sample of 79,629 HF patients. First, patients were removed if their 
practice had less than 3 years of up to standard (UTS) clinical data (CPRD-defined minimum quality 
standards for data recording based on completeness, consistency and plausibility) or where the patient’s 
current registration date (CRD) was less than 3 years prior to the HF index date. Second, patients were 
removed on the basis of implausible data recording. This constituted those where their CRD, UTS, TOD or HF 
index date was greater than one month after their death date or where their CPRD and Office National 
statistics death date differed by greater than 3 months. Third, patients with unexplained gaps in their clinical 
record were excluded. These comprised those who had a CRD or UTS date after their index HF date, their 
TOD preceded their HF index date or there were recorded data gaps that were not explained by the difference 
between their first and CRD. Fourth, patients that appeared twice under different patient id numbers were 
removed. These patients move from one CPRD practice to another and are given a new patient ID number. 
They were identified through their unique hospital identifier (Figure 6.1 and E-Appendix A15 for detail of the 
exclusions). There were 50,114 HF patients in the study sample following this process for the mortality 
outcome and a sub-sample of 30,061 patients linked to HES and used for the hospital admission outcome.  
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6.3.3 Matched sampling 
In order to measure time-dependent exposures of comorbidity severity and severity change, over 12-years of 
follow-up, matched samples were created from the two baseline samples (mortality sample and HES linked 
sub-sample).  
 
Mortality: For each mortality case, 4 controls were randomly sampled from the cohort members in the risk sets 
defined by the case, after matching on HF index date (+/- 1 month) and duration of follow-up. This number of 
controls is adequate to produce similar parameter estimates to that obtained using full cohort data in a Cox 
regression model and provides 80% of the statistical efficiency of using an infinite number of controls(220). 
Added benefit from a greater number of controls is only likely where the exposure status of controls is likely to 
be low or there are very few matched sets(407). The risk sets defined by the case included all individuals still 
at risk of the outcome on the date of the case event. Controls were therefore alive, active in practice and 
event free on the match date. The match date for the controls was defined by the same duration of follow-up 
to the case. Using this approach controls are eligible to be selected multiple times as a control and later as a 
case, approximating the situation in Cox-regression where every case is compared to all controls in its risk-
set(214). This matching process resulted in 133,645 observations comprising 26,729 cases and 106,916 
controls. Over 70% of subjects were used less than 4 times in the analyses (E-Appendix E8 for the frequency 
of subject use in the matched set and E-Appendix A16 for comparison of the pre and post matched sample). 
 
Hospital admission: For each first hospital admission case, initially 8 controls were randomly selected among 
the cohort members in the risk sets defined by the case, after matching on HF index date (+/- 1 month) and 
duration of follow-up. Controls were alive, active in practice, event free and still at risk of first hospital 
admission on the date of the case event. Again, the date resulting in the same duration of follow-up for the 
cases and controls defined the match date for the controls.  Due to the high number of first hospital admission 
events within 3 and 6 months of the HF index date, controls were only retained in the match sets if they did 
not experience an event within three months of their selection as a control. This approach is analogous with 
the wash-out period in a case-crossover study(408) and provided a suitable period where cases were 
considered different from the controls on their event status, to allow for the comparison of comorbidity 
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exposures. The matching to 8 controls allowed for the removal of unsuitable controls, leaving each case 
matched to a varying number of up to 4 controls. This matching resulted in 110,789 observations comprising 
24,339 cases and 86,916 controls. Over 70% of subjects were used up to 4 times only in the analysis (E-
Appendix E8 for the frequency of subject use in the matched set and E-Appendix A17 for comparison of the 
pre and post matched sample). 
 
6.3.4 Measure of comorbidity exposures 
Three non-CVD comorbidities identified by the systematic review were selected to test the study hypotheses 
on the basis of (i) their high prevalence (COPD 18%, DM 16%, RD 41%) in the general practice population of 
HF(239) and (ii) their routine monitoring using physiological measures or their treatment with regular drug 
prescriptions in order to measure comorbidity severity or change over time.   
 
The comorbidity cohort selections were based on clinical codes or physiological measures (CKD) or a 
combination of clinical codes and drug measures (COPD and DM). For each comorbid disease, subjects were 
selected using search strategies that were validated by appropriate clinical experts and prior research 
validation where available. Differentiation was made between comorbidities that had developed before or after 
HF. The ‘before HF’ comorbidity cohorts were identified through a combination of diagnostic and process 
Read codes that indicated either a comorbidity diagnosis consultation (comorbidity index event) or an ongoing 
care consultation (comorbidity prevalence event) applied in the 3 years of UTS clinical data prior to their HF 
index date.  The after HF comorbidity cohorts were identified by a first consultation ‘index’ code that indicated 
a comorbidity diagnosis event (using diagnostic codes and a limited set of process codes that were specific to 
a comorbidity index event) applied subsequent to their HF index date. Those with a comorbidity prevalence 
event code applied after HF but no comorbidity prevalence or index event code applied in the 3 years of UTS 
prior to HF in their clinical record were excluded from the comorbidity cohorts. These were rare but meant that 
the placement of the comorbidity index date could not be verified and given the routine recording and 
monitoring of chronic diseases, including these subjects would increase the risk of misclassification bias(409). 
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The measures for each of the three comorbid diseases will now be discussed. The extraction and 
measurement of the clinical data using time-dependent windows followed a uniform approach for all three 
comorbid diseases and will be detailed for both outcomes at the end.  
 
6.3.4.1 Chronic obstructive airways disease 
Three categories of COPD measures were included; diagnostic status, severity and severity change.  
 
COPD diagnostic status: The COPD ‘before HF’ cohort was based on a combination of at least one COPD 
prevalence or index event code applied in the three year time-window before the HF index date and at least 
one COPD related drug prescription in the same time window. The ‘after HF’ cohort was based on those (i) 
without a COPD prevalence or index event code applied in the 3-year before HF, (ii) with at least one COPD 
index event code applied at any time after HF index date but before the match date, AND (iii) with at least one 
COPD related drug prescription in the same time window after HF. A COPD related drug prescription was 
defined as any COPD related drug indicated in the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines(410). 
 
There is no single diagnostic test for COPD which relies on clinical judgement (history, symptoms, frequency 
of recent exacerbations) combined with the presence of persistent airflow obstruction using spirometry(410). 
However diagnosis is complicated by non-specific symptoms such as breathlessness in COPD in the 
presence of HF and spirometry is not recorded for up to a third of patients with both diseases(411). Where 
recorded, spirometry can also be misleading in HF where restriction caused by cardiomegaly or pulmonary 
congestion can produce a false obstructive pattern. These issues combined can lead to both over and under 
diagnosis of COPD. 
 
Use of clinical codes for discriminating between those with and without COPD or for the positive prediction of 
COPD has been validated in two recent studies. The first study was based on a combination of terms (chronic 
bronchitis, emphysema, chronic obstructive asthma and chronic airway obstruction) which excluded ‘none 
specified bronchitis’ as a non-specific term.  This study found that using multiple ICD-9 codes applied in the 
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clinical record made little difference to the discriminative ability of the codes to correctly identify COPD 
however the use of a combination of ICD-9 codes with prescribed COPD related drugs improved 
discrimination(412).  
 
A more recent study to validate different approaches to identifying subjects with COPD within the CPRD found 
that the positive predictive value (PPV) of using a COPD specific code set yielded a PPV of 86.5%. When 
drugs or spirometry were added to the COPD codes, the PPV of COPD did not improve(413). However there 
was improvement in the PPV with the addition of drugs or spirometry to clinical codes for those with more mild 
COPD disease defined by forced expiration volume in one second [FEV1] level.  The validated set of codes 
used, excluded bronchitis codes and included only a narrow set of COPD specific codes which promotes 
specificity but not sensitivity. 
 
COPD was included in the Quality and Outcomes Framework (QOF) in 2004 in England and Wales which 
introduced more codes to identify COPD and promoted the recording of spirometry data.  Following the 
introduction of QOF and the NICE guideline for COPD the prevalence of recorded COPD increased by 14.4% 
from 2003 to 2005 and the presence of recorded spirometry data in people with COPD increased from 18% to 
62% over the same time-frame(411). The positive predictive value of using COPD codes to identify COPD 
also improved after 2008. However non-specific bronchitis codes and symptom codes to record COPD were 
more likely to be used before 2008 rather than after 2008 which required consideration in the present study. A 
further consideration for the present study was the reduction in diagnostic accuracy of COPD when using 
clinical codes combined with spirometry in those who also had cardiovascular disease(413).  
 
COPD search strategy: A search strategy based on broad terms was used to identify all possible relevant 
COPD codes applied in the patients clinical or referral record (E-Appendix E9a). The results of the search 
strategy were reviewed by a respiratory consultant and cross-referenced with the validated codes in the 
previous CPRD study and the codes included in QOF. None specified or acute bronchitis codes were 
excluded to reduce misclassification bias. Out of a possible 230 codes, 44 prevalence codes and 54 index 
codes were agreed, which comprised diagnostic and process codes for COPD. A total of 47 codes were 
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included in QOF and 28 had been previously validated. The remaining new codes, not previously validated or 
included in QOF were specific to COPD (E-Appendix E10). 
 
For the ‘before and after’ HF COPD cohorts it was decided to combine at least one clinical code with at least 
one COPD drug prescription in the same time period. The intention was to reduce the risk of misclassification 
bias but optimise the number of COPD subjects available for analysis. This was chosen over spirometry for 
validation of the COPD code given the relatively low recording of spirometry data in COPD patients even after 
2005(411,413). However, by not including spirometry in the definition, the ability to stage COPD according to 
GOLD stages was not possible for all patients with COPD included in the analysis. 
 
CPRD product codes for drugs prescribed were identified using the database browser.  A search identified 
any COPD related drug as defined by the GOLD guidelines(410) using appropriate British National Formulary 
(BNF)(414) codes (Table 6.1). Additional searches using truncated drug names identified those in the CPRD 
that are not linked to BNF codes, yielding the most relevant COPD drug codes available. 
 
COPD severity using physiological data:  GOLD guidelines recommend the use of FEV1 to measure the 
severity of lung function in COPD. This is used when there is evidence of obstruction defined by a FEV1/FVC 
(forced vital capacity) ratio of <70%. Four severity categories of FEV1 used to guide clinical care(410) (Table 
6.2) were included in this study. The FEV1/FVC ratio could not be used as it is not routinely recorded. FEV1 is 
measured as a percentage of the predicted value based on gender, height and age. A complication in HF is 
that a reduction in FEV1 of up to 20% predicted is frequently observed independently of COPD leading to an 
overestimation of the severity of obstruction in HF patients with concomitant COPD(342,343). Up to quarter of 
HF patients and a half of severe HF patients without COPD have an FEV1 of <80%(415). Whilst this creates 
potential difficulty in pin pointing the underlying cause of reduced FEV1, the lack of alternative measures mean 
that the GOLD classification was applied in the HF population. 
 
COPD severity using drug data: An alternative measure of COPD severity using drugs prescribed was also 
developed. Drugs are routinely and automatically recorded through electronic prescribing and so provided the 
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opportunity to stage all COPD patients based on drug measures. GOLD guidelines recommend a step up 
approach to prescribing in COPD that increases with the patient’s symptoms and risk of exacerbations(410). 
This staging ranges from short acting anticholinergics or beta2-antagonists as required to mono, dual or triple 
therapy using a combination of long acting anticholinergics, beta2-antagonists and inhaled corticosteroids. An 
additional, most severe stage was added which included oral steroids and long-term oxygen therapy. These 
latter two drugs are most commonly used following acute exacerbations or in most severe disease and do not 
form part of routine prescribing. The severity category for each COPD patient was identified by at least one 
prescription of a combination of different drugs in a specified time-window prior to the match date (Section 
6.3.4.5). To do this, all drugs included in the original drug code set were given a number according to their 
drug type and algorithms for identifying the correct drug severity category within a specified time window prior 
to the match date were developed (Table 6.3 for the COPD drug severity framework and E-Appendix A18 for 
the CPRD drug severity extraction algorithms).  Three drug-based severity classifications were defined as 
comorbidity measures (Table 6.4). 
 
COPD severity change using physiological data:  Two important questions for defining the measurement of 
severity change were how much and over how long? There appeared to be no prior studies which had 
measured COPD change by FEV1 status in HF populations but there were other definitions. In the Lung 
Health Study rapid decline in smokers was defined as a loss of >3% FEV1 over a year but this group did not 
necessarily have COPD or HF(416).  The mean rate of absolute decline in this study was 4.1% of predicted 
FEV1. In a group of patients with idiopathic pulmonary fibrosis with or without emphysema a relative decline in 
FEV1  of 5,10,15 and 20% over a year was predictive of mortality(417). As there is no clear definition of COPD 
severity change, for the thesis analyses a range of new measures were defined (Table 6.5).  
 
It was hypothesised that recent comorbidity severity change that occurred prior to a hospital admission would 
occur over a shorter time period, so change in these measures over 6 months was used for this outcome 
(Section 6.3.4.5). 
 
  
156 
 
COPD severity change using drug data: Two classifications of COPD drug severity change were considered 
(Table 6.6).  In the first classification, for simplicity, it was decided to collapse the possible number of drug 
change categories into two mutually exclusive discrete categories. This also allowed for the comparison of 
those with COPD whose medication remained stable or improved with those with worsening drug severity 
indicated by a step up in drug therapy. The second classification focused on a change in COPD drugs, prior to 
an outcome, to the most severe drug groups.   
 
6.3.4.2 Diabetes mellitus  
Three categories of DM comorbidity measures were included: diagnostic status, severity and severity change.  
 
Diabetes diagnostic status:  The DM ‘before HF cohort’ was based on at least one DM prevalence or index 
event code or at least one DM prescription applied in the three year time-window before the HF index date. 
The ‘after HF cohort’ was based on those (i) without a DM prevalence or index event code or prescription 
applied in their three years before the HF index date AND (ii) at least one DM index event code or prescription 
applied at any time after HF index date but before the match date.  A DM related prescription was defined as 
any DM related drug for blood glucose control indicated in the National Institute for Health and Care 
Excellence Guidelines(418,419). 
 
Diabetes mellitus (DM) is a progressive disease characterised by chronic hyperglycaemia and disturbances of 
carbohydrate, fat and protein metabolism caused by defects in insulin production or action or both(420). In 
Type 1 diabetes, which is normally diagnosed in younger age groups, the pancreas is no longer able to 
produce insulin and requires insulin replacement. In type 2 diabetes, which accounts for approximately 85% of 
diabetes in England, not enough insulin is produced and there may also be resistance to any insulin 
produced. This is usually diagnosed in older age groups, is less obvious to detect than type 1 diabetes and 
treatment ranges from strict diet and weight control to medicines for glucose control(421). The diagnosis of 
diabetes is made through laboratory glucose measurements. This includes a single measure in conjunction 
with classic symptoms or a repeated measure(418). The presence of a raised fasting glucose or raised 
glycated haemoglobin (HbA1c) at any time in the blood is indicative of diabetes(420). These tests provide a 
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specific and objective diagnostic measure that is not reliant on clinical judgement or heterogeneous signs and 
symptoms, thus reducing the risk of misclassification bias.  
 
Diabetes search strategy:  A search strategy was devised based on  the Read code ‘Diabetes Mellitus’ (C10) 
as well as a broad search for any diabetes related term to identify all possible relevant codes applied in the 
patients clinical or referral record (E-Appendix E9b). The results of the search strategy were reviewed by a 
general practitioner and cross referenced with other previous CPRD search strategies(422) and the codes 
included in QOF.  The current strategy was combined by a search on all product codes for diabetes related 
drugs to identify drug defined diabetes subjects.  Out of a possible 646 codes, 346 index codes and 208 
prevalence codes were agreed, these comprised of diagnostic and process codes for DM and 125 were 
included in QOF and all were used in prior studies (E-Appendix E11). 
 
CPRD product codes for DM drugs were identified using the CPRD product browser and a search was 
performed using Chapter 0601 of the British National Formulary (BNF). Using the product browser an 
additional search was performed using truncated drug names of some of the main drugs identified through the 
first search to yield the most CPRD product codes available. 
 
Diabetes severity:  There is no standard measure of severity used for DM. Studies have previously used 
diabetes related complications as a measure of severity which has indicated an increased risk of 
death(189,259). This was not used in this study given the varied and complex code set required to identify this 
group and the use of time-windows within the present study to measure severity and change meant that the 
codes that are not routinely repeated in clinical coding might be missed. So two approaches to define severity 
were a physiological measure using glycosylated haemoglobin (HbA1c) and a drug based measure. 
 
Diabetes severity using physiological data: HbA1c reflects the blood glucose levels over the preceding 2 to 3 
months and is used as an index of mean glycaemia(420)  for diagnosis, monitoring and targeting of treatment 
for diabetes.  Whilst targets should be individualised for patients, national guidelines state levels below 7.5% 
and 6.5% for adults with type 1 and type 2 diabetes respectively are appropriate targets for risk reduction, 
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whilst risk of hypoglycaemia may increase if levels reach 6.1% or lower(418,419). This measure is preferred 
over blood glucose as it does not require the patient to fast and is not as susceptible to daily fluctuations. 
Although HbA1c is more a marker of glucose stability rather than DM severity, it has been found to have 
similar associations to the development of retinopathy as glucose(420). In the general population and in 
people with DM poor glycaemic control has been associated with adverse outcomes including microvascular 
and neuropathic complications(423,424)  and new onset HF(425). In HF patients an increased risk of death 
with rising HbA1c level has been found which was worse in non-diabetic than diabetic HF subjects(290).  
 
A challenge for using HbA1c to determine risk of mortality is the U shaped relationship that has been found 
between them, with both high and low levels of HbA1c associated with increased risk. In patients with type 2 
diabetes, risk of HF development was increased at levels of HbA1c <6% as well >10%(426). In HF a U-shape 
relationship has also been identified(288) with one study of unselected HF veterans finding the highest risk of 
mortality in the outer most quintiles (<6.4% and >9%)(427). In HF some studies have found the U shape to 
shift to the right with a higher threshold for HbA1c. In a non-selected HF group of ambulatory veterans with 
diabetes the lowest risk of mortality was found in those with only modest glucose control (quintile 7.1%-
7.8%)(427). In a small sample of patients with advanced systolic HF and diabetes HbA1c >7.0 was protective 
with lowest risk of mortality risk in the third quartile (7.8-8.9%)(428). This threshold in HF has not been found 
in other studies, a group of HF patients undergoing revascularisation surgery were found to have the lowest 
risk at HbA1c levels between 5.8 and 6.2%(429). 
 
Due to the lack of consensus over the level of HbA1c associated with the lowest risk of adverse outcomes in 
HF, HbA1c levels were defined by 6 categories that included the guideline level of 6.5-7.5% (Table 6.7). Sub-
analysis was also performed using deciles of HbA1c to allow a more precise assessment of the lowest risk 
group and shape of association.  
 
Diabetes severity using drug data:  The profile of people with type 1 and type 2 diabetes differs with the latter 
group generally having more comorbidity such as obesity and a later onset. Type 2 diabetes is managed 
through a scale of treatment from good diet control to oral medications, which may be supplemented by 
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insulin for more intense glucose control. People with type 1 diabetes usually have the disease for longer and 
require intensive insulin interventions from the outset(421). Studies have shown that in the general population 
of people with type 2 diabetes(430) and in people with HF and diabetes(293) the prescription of insulin is 
associated with higher risk of adverse outcomes and may represent more severe metabolic disturbances and 
advanced disease.  
 
A simple drug severity classification was used to differentiate the sample by type of diabetes (Table 6.8). The 
two oral hypoglycaemic groups were included to differentiate between people with type 2 diabetes who may 
have more progressive disease requiring supplemental insulin therapy(430). 
 
Diabetes severity change using physiological data:  Change in HbA1c has been measured in a prior study. In 
a CPRD cohort of people with type 2 diabetes, HbA1c change of >1% increase or decrease was compared to 
<1% change over a year before death(431). Both groups were associated with increased mortality risk and 
this was most marked in the HbA1c group where levels decreased. In the thesis, the approach was taken to 
compare patients with >1% increase or decrease with patients who had a change of 1% or less over 1 year or 
6 months prior to death and hospital admission.  
 
Diabetes severity change using drug data:  For the measurement of diabetes drug severity change, an 
increase or a decrease in at least one drug category compared to no drug category change over specified 
time-windows (Section 6.3.4.5). For this change measure the two oral hypoglycaemic drug categories were 
collapsed into a single category (oral +/- insulin) to create three distinct groups. 
 
6.3.4.3 Chronic kidney disease (CKD) 
Three categories of comorbidity measures were included: diagnostic status, severity and severity change.  
 
CKD diagnostic status:  The CKD ‘before HF cohort’ was based on at least one CKD prevalence or index 
code in the three year time-window before the HF index date. The ‘after HF cohort’ was based on those (i) 
without a CKD prevalence or index code applied in their three year before HF and (ii) with at least one CKD 
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index code applied at any time after HF index date but before the match date.  A second approach used the 
physiological definition of estimated glomerular filtration rate (eGFR) of <60ml/min/m2 to indicate renal 
dysfunction. This was identified by the most recent measure before the match date but within a maximum 3-
year time window for mortality and 6-months for hospital admission. As the eGFR measure can change over 
time, renal dysfunction definition of CKD was not used to place the timing of comorbid disease in relation to 
the HF index date.  
 
CKD search strategy: CKD describes abnormal kidney function and/or structure(432) and, due to its close 
pathophysiological role in HF, is a key comorbidity for this disease group(433). CKD can develop through 
primary renal disease or as a consequence of HF and both result in similar functional changes to the kidney 
with glomerular and tubular damage; processes which are intensified when both occur together(433). The 
diagnosis of CKD is made through the identification of persistent kidney abnormalities or eGFR 
<60ml/min/1.73m2  over 3 months(434).  
 
Identification of CKD in administrative data using clinical codes can be challenging given the variety of clinical 
terms used across a number of Read code chapters to describe a wide range of presentations. The 
alternative approach using eGFR for case definition also has challenges. Not everyone has serum creatinine 
measures and whilst defining CKD by medical record likely underestimates the number of cases, using eGFR 
as a gold standard may overestimate CKD cases by misclassifying older people with normal renal function 
change or people with acute kidney injury(435). 
 
A broad search strategy for identifying CKD by medical codes was devised based on key words that might 
indicate kidney disease and specific codes used in the Quality Outcomes Framework (QoF) to indicate kidney 
disease (E-Appendix E9c). The results of the search strategy were reviewed by a renal registrar and cross 
referenced with the codes included in QoF. Out of a possible 1449 codes, 120 index codes and 56 prevalence 
codes were agreed.  Codes related to both diagnostic and process codes for CKD and 28 were included in 
QoF. Any terms that that were not definitive of CKD such as screening or investigation terms or those that 
could be acute or chronic terms such as renal failure or impairment were excluded (E-Appendix E12). 
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CKD severity using physiological data:  CKD defined by eGFR <60mL/min per 1.73m2 has been found to 
double the risk of mortality in HF(239,436). CKD is further classified by categories recommended by Kidney 
Disease: Improving Global Outcomes (KDIGO)(432,434) which were used in this study to measure severity 
(Table 6.9). The first stage in the guidelines (≥90ml/min/m2) was subdivided into two stages to identify a 
‘highest’ eGFR group which has been found to carry an increased risk of mortality in the general 
population(434) above 90ml/min/m2 (437). Various reasons put forward include the inadequacies of the eGFR 
formula at low serum creatinine levels(437) or other causes of low creatinine giving a false account of kidney 
function such as loss of muscle mass in frailty or the dilutional effects of HF(438). 
 
CKD severity change using physiological data:  The most common measure used for detecting renal change 
over time has been an increase in serum creatinine of ≥0.3mg/dL, usually measured during acute HF 
admission(146). There is some evidence that change in creatinine, in a more stable state, 6 months after 
discharge, may have a stronger influence on mortality than when measured during admission(156).  
 
Creatinine is used to calculate eGFR which in turn is used as an estimate of GFR. An alternative to using 
creatinine is to measure change in eGFR directly. As well as being a better indicator of GFR in a stable 
population, eGFR change has also been considered as less dependent on baseline renal function than 
creatinine change(439). Creatinine has an exponential relationship with eGFR. This means that for the same 
change in serum creatinine there might be a small or large change in eGFR depending on a low or high 
baseline eGFR respectively. As the rate of change of eGFR is linear across all baseline categories of 
eGFR(440), using creatinine change means that those with low baseline eGFR (in whom a smaller reduction 
in eGFR will reach the threshold of creatinine change) are more likely to experience worsening renal failure 
(WRF) defined by this measure.  
 
There has been conflicting findings as to the association between baseline renal function and the occurrence 
of WRF with studies showing that both low and high baseline renal functions are associated with subsequent 
WRF depending on the measure of change used. Whilst some studies have shown an association between 
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high baseline eGFR and occurrence of WRF measured by eGFR change(439,441,442), two reviews of 
studies using creatinine change(146) or a mixture of eGFR change and creatinine change(440) have found an 
association with low baseline function, which is likely due to a faster rate of decline in these groups. 
 
Creatinine change may not be a precise measure of eGFR change, but the importance for prognosis of a 
large change in eGFR at the higher baseline values and a small change in eGFR at low baseline values may 
be similar and has been demonstrated by the consistent effect of WRF using serum creatinine change on 
outcomes that is independent of baseline eGFR(146). This suggests that the threshold for the effect of WRF 
on mortality is lower in more severe renal disease. If this is true, relative change measures (which take some 
account of the proportion of renal function loss) may be a better approach.  
 
A change in eGFR was selected over serum creatinine due to its better estimation of GFR in a stable 
population and the potential for measuring relative change over time. Two indices of change in eGFR have 
been used previously in general population studies, the absolute difference and percentage change in eGFR, 
although guidelines have traditionally used absolute change(443).   
 
The thesis definition was an absolute measure of change and a relative measure (to better adjust for the 
baseline eGFR value) (Table 6.10). The measures included in both classifications are indicated in current 
clinical guidelines to represent accelerated change in eGFR status over 12 months(432). 
 
6.3.4.4 Extraction and measurement of physiological comorbidity data 
The extraction and cleaning of the physiological data was performed by identification of all possible values 
using the CPRD ‘Entity’ and Medcodes, conversion of differing units of measure to a standard common 
measure and removal of biologically implausible extreme data.  For detail of the steps taken for each 
comorbid disease including formula for transformations and plausible ranges see E-Appendix E13. 
 
HbA1c was converted from mmol/mol to % because, although new guidelines now advocate mmol/mol(444), 
% has been the most common unit reported and used at the time of the data recording. FEV1 was mostly 
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reported in litres and so was converted to percent predicted (pp) using a formula that included height and age. 
Whilst height data was available for most patients, missing data was imputed with the average height by age 
and gender from the Health Survey for England(445).  
 
eGFR is not reported directly in CPRD and so was converted from creatinine using the simplified 4-variable 
Modification of Diet in Renal Disease (MDRD) formula. This equation adjusts for significant non-renal 
influences such as age, sex, race, and body size, is preferred to other equations such as the Cockcroft-Gault 
formula(399) and has been validated in the HF population(398). The ethnicity component of the formula could 
not be included given the scarcity of this data in the CPRD. However the prevalence of black people within the 
UK is less than 3%(446) and given the underestimation of GFR in this group the associated risk would be 
biased towards the null value.  
 
6.3.4.5 Measurement time windows for comorbid exposure 
Measuring comorbidity severity and change using routinely collected physiological data can be restricted by 
missing data. Whilst the timing for measurement of severity and change will be guided by the research 
question, missing data will be increased where the time windows for measurement are narrow and/or the 
timings between repeated measures are short.  The key thesis focus was whether in HF, ‘recent’ comorbidity 
severity or change influences outcomes.  The hypothesis was that important comorbidity severity change that 
occurs prior to death may happen over a longer time (i.e. over one year) than that which occurs before 
hospital admission (over 6 months).  
 
Physiological measurement time-windows:  For all physiological measures of comorbidity severity the closest 
value to the match date was used but with a maximum of 3 years for mortality and 6 months for hospital 
admission. A previous measure was then taken between 6 months and 3 years before for mortality and 
between 1 month and 1 year before for hospital admission (Figure 6.2a). Change over 1 year for mortality 
outcome and over 6 months for hospital admission outcome was then calculated as follows:  
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For the absolute change measures:   
 
[most recent measure –  prior measure] X  
Outcome time interval∗ (days)
Measure interval (days)
 
 
For the relative change measures (eGFR):  
 
Absolute change
Prior measure
   X 100 
 
*Outcome time interval was 365 days for mortality and 182.5 days for hospital admission outcome 
 
Drug measurement time-windows:  Drug measures are routinely and automatically recorded in the CPRD 
through electronic prescribing systems. This means that the measurement time-windows could be more 
precise but needed to be wide enough to capture drug prescriptions that may be repeated less regularly. The 
‘recent drug severity measure’ was defined for both outcomes as at least one prescription in a 4-month time-
window before the match date. The prior 4-month time-window was placed at 12 months to 16 months before 
the match date for mortality and 6 months to 10 months for hospital admission (Figure 6.2b). 
 
6.3.5 Outcome measures 
Mortality: Mortality outcome was defined as death by any cause recorded in the patients CPRD record. There 
are a number of different entry types within the CPRD that indicate a death event and each has an associated 
date.  This means that there may be multiple records and dates for any one patient. The study date of death 
was derived using a CPRD verified algorithm which takes the earliest of the patient transfer out date (with 
reason ‘death’), first statement of death Read code or date of death/record added in the death administration 
area of the CPRD.  
 
Hospital admission:  For the subset of practices that are part of the CPRD linkage scheme, Hospital Episodes 
Statistics (HES) data were available. The data available through CPRD includes all admitted inpatient care 
episodes to English NHS practices including private patients. Discharge date and all ICD-10 codes associated 
with the patient discharge are provided free of charge. For all patients that were eligible for linkage the 
 
  
165 
 
hospital admission outcome was defined as first admission for any cause and the first date of discharge after 
(but not including) the HF index date was used.  
 
6.3.6 Covariate measures 
All covariates included were based on previous evidence on the outcomes in HF identified in the thesis 
systematic review(239) and other research (180,182,447), as well on their clinical relevance and availability in 
routinely collected clinical data. 
 
Person and socio-demographics:  The person and socio-demographic data available within CPRD includes 
year of birth, sex and index of multiple deprivation (IMD) score (2007) of the study subjects at entry to the 
CPRD practice. Age was based on current age on the match date. The IMD score combines seven weighted 
indicators which cover economic, health, social and housing domains into a single deprivation score(448). 
Within CPRD the IMD score which is based on English lower super output area is only provided for patients 
belonging to linked practices with a valid postcode which applied to approximately 60% of study patients. The 
score was ranked into quintiles ranging the lowest deprivation (quintile 1) to the highest (quintile 5).  
 
Anthropometric data and risk factors:  Information was available on body mass index (BMI), smoking, alcohol, 
cholesterol, haemoglobin and blood pressure (BP). Smoking and alcohol were categorised into three distinct 
categories (current, previous or never) and all other measures were retained as continuous variables. All 
measures were converted to a standard measure where necessary, biologically implausible values were 
removed (E-Appendix E13) and then the most recent value to the match date was extracted.  
 
Drug data: Exposure definition of HF drugs was defined as at least one prescription in a 4-month time window 
before the match date. Drug information was extracted for angiotensin converting enzyme inhibitors, 
angiotensin II receptor blockers, beta-blockers and diuretics. Again a search on key words relating to the 
drugs was also performed to optimise the inclusion of product codes that had not been categorised by a BNF 
code.  
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Imputation of data: Missing data were present for the comorbid exposure and covariate measures (E-
Appendix A19). Single imputation using chained equations was used to impute values for the covariate data 
using ICE in Stata version 13. This was the chosen approach for two main reasons. Firstly to maximise the 
number of patients retained in the analyses to aid the comparison of comorbidity prognostic models and 
secondly to reduce the risk of selection bias associated with full case analysis where the missing data varies 
for the cases and controls(225). Regression imputation was selected as the missing values were not 
completely at random and for some measures were related to the outcome (E-Appendix A20-21).  Where this 
is the case, full case analysis or use of a missing indicator can lead to bias(449). Single rather than multiple 
imputation of the main confounders was chosen so as not to over complicate the analysis by combining 
multiple data sets. For the chained equations all predictors were added to the models and logistic, 
polyotomous or linear regression was used to predict the missing values. Imputation was not performed for 
IMD for the mortality outcome due to the high level of missing data. Imputation was performed on the matched 
sample after the investigation of potential confounders and checking the model assumptions (linearity, 
collinearity) but before the regression modelling. The mean sample values of the pre and post imputed 
matched data were compared to check that they were similar (E-Appendix A22-23). 
 
6.4 Statistical analysis  
6.4.1 Part 1: Descriptive studies  
Continuous data variables are first investigated for normality using histograms. Quantile plots were also used 
to graph quantiles of the continuous variable against quantiles (Q-Q plots) of a normal distribution. Rather 
than focusing on the centre of a distribution this approach identifies whether any irregularities are in the tails of 
the distribution(450). Data are then presented as means and standard deviations (SD) for normally distributed 
continuous data, whilst skewed continuous data is presented as medians with interquartile ranges [IQR]. 
Dichotomous data are presented as counts and percent prevalence. Data tables are stratified according to the 
outcome status. Significant difference between groups was determined by parametric tests using independent 
samples t-test, non-parametric tests using the Wilcoxon rank-sum test and categorical variables between 
groups using the Chi-square test. Due to the high power to detect very small differences with large samples, 
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the P value was considered significant if ≤0.01. Following matching, due to the large number of observations 
generated and the dependence of the observations created by the inclusion of repeated controls, the groups 
were compared descriptively only and absolute differences in units were reported to indicate the magnitude of 
difference. No adjustment for multiple testing was used. 
 
Description of the samples were carried out in four steps: (i)  overall baseline patient characteristics for both 
cohorts by all-cause mortality and first hospital admission sub-sample, (ii) baseline characteristics for sub-
cohorts with  different follow-up time-periods to give a more accurate comparison of survivors and non-
survivors with varying lengths of follow-up, (iii) two calendar cohort periods that pre and post-dated the 
introduction of HF into the Quality and Outcomes framework (QOF) (April 2006), to investigate any ‘time 
effect’ caused by the introduction of new guidelines and associated clinical practices, and (iv) time-dependent 
general and comorbidity characteristics of the matched samples stratified by outcomes. 
 
6.4.2 Part 2: Hypothesis testing and strength of associations  
There were five stages to the main analyses using the matched data: investigation of confounding, testing for 
linearity, identifying correlations, regression modelling and testing for interactions.   
 
(i) Potential confounders were investigated in four steps. First, was to identify the confounders from the 
systematic review. Second, patient characteristics were compared in the comorbid versus non comorbid 
groups to identify whether the potential confounder was different across the groups. Third, for each of the 
comorbidities, the unadjusted comorbid effect on the two outcomes was investigated using conditional logistic 
regression and then observed in different strata of the potential confounder. A 10% difference in the 
comorbidity exposure effect in any strata of the confounder was deemed important. Fourth, each potential 
confounder was entered individually, into a conditional logistic model with each comorbidity exposure to 
observe a difference of 10% in the odds ratio to indicate confounding(9).  
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(ii) Testing for linearity between the continuous independent variables and the logit of outcome was performed 
by Likelihood ratio tests. The shapes of the association were also observed using fitted line plots and Eccles 
plots.  
 
Likelihood ratio tests were performed to compare predictive models with a continuous variable included in its 
most simple form to the same models with a continuous variable included together with a quadratic and cubic 
extensions or log terms. A P value of ≤0.01 was considered to be significant to reject the null hypothesis that 
the simpler model (nested model) was a better fit.  
 
Eccles plots graph the mean predicted value of the outcome against deciles of a continuous variable. The 
eclplot includes a continuous variable in the model and then plots the predicted values of the outcome over 
the same variable in categories. This means that the variable can be added in different forms to the model 
(continuous, continuous with quadratic or cubic extensions or as a log transformed variable) and fully adjusted 
for other covariates(451). Lowess lines were then overlaid on the eclpolt. Lowess provides a locally weighted 
scatterplot smoothing where a separate weighted regression is performed for every point in the data using the 
data point (most weight) and a few of the nearby data points (least weight). Lowess therefore follows the data 
more closely and can be used to observe the calibration between the predictive models (including different 
expressions of the continuous variable) and the observed data.  
 
Following these steps, for any non-linear continuous variables it was decided to use quadratic extensions 
rather than any higher order term or more complex transformations. This was to avoid overfitting and also for 
ease of clinical interpretation(225).  
 
(iii) Multi-collinearity was investigated for all variables to be added to models.  Where variables had a 
correlation coefficient of >0.5, the most clinically relevant one was selected. Where continuous variables were 
included with quadratic extensions they were centered at their mean to remove collinearity between the 
variable and its quadratic term(452).  
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(iv) Strength of associations: Conditional logistic regression (discussed in detail in Chapter 4.4.2) was 
performed for each comorbidity measure to estimate rate ratios for all-cause-mortality and first hospital 
admission. Unadjusted associations were followed by stepped adjustment of confounders according to their 
potential importance indicated by the confounder investigation. These included variables related to the person 
(age, gender), socio-demographic factors (deprivation), comorbidities (remainder of COPD, DM and CKD), 
lifestyle factors (alcohol, smoking), risk factors (blood pressure, cholesterol, BMI, haemoglobin) and HF 
medication (angiotensin converting enzyme inhibitor, angiotensin-II receptor blocker, beta-blocker, diuretic). 
The mortality models did not include deprivation given the level of missing data in the overall cohort  but a 
sensitivity analysis with the deprivation variable was performed. The hospital admission models were further 
adjusted for recent hospital admission within three months.  
 
As eGFR is routinely measured and collected on all HF patients the renal change comorbidity exposure was 
adjusted with the most recent eGFR measure and separately the prior eGFR measure used in the change 
calculation. Other comorbidity change measures are only routinely recorded in comorbidity groups so these 
measures were compared to non-comorbid reference groups and could not be adjusted for baseline comorbid 
status.  
 
Stratified associations: For each comorbidity effect on outcomes, significant stratification by categories of 
comorbidity severity and change were investigated by observing the separation of the confidence intervals 
across strata. Where confidence intervals overlapped a linear test of trend was performed on the adjusted 
associations using likelihood ratio tests.  
 
(v) Interactions: Statistical interactions between (a) pairs of the three comorbidities (DM, COPD, CKD), (b) 
comorbidities and HF severity indicated by age as a proxy measure, and (c) comorbidities and specific patient 
characteristics indicated in the investigation of confounding, were investigated. This was done by observing 
the unadjusted effects of the comorbidities on outcomes within strata of a second variable of interest. 
Separation of the confidence intervals around effects was used to indicate potential interaction (the effect of 
the comorbidity is modified by the second variable). These associations are unadjusted and the relative 
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effects are partly determined by the baseline risk in the strata groups. Where the baseline risk differs, the 
relative effect of the comorbidity will differ across strata even if the absolute effect of the comorbidity is the 
same. Using the approach, the absolute risk associated with the comorbidity across strata, cannot be directly 
compared(9).  
 
These interactions were further investigated by adding interaction terms to conditional logistic models and 
performing likelihood ratio tests between the fuller and simpler models (p≤0.01). As conditional logistic 
regression is an exponential model, a significant statistical interaction indicated a departure from multiplicity. 
This approach indicates whether a more flexible model which includes an interaction term has better fit. Again, 
even where statistical interaction exists, whether the absolute risk associated with a comorbidity differs due to 
its interaction with another variable, cannot be investigated using this approach(9).  
 
Biological interaction refers to the risk associated with an exposure on an outcome being, in part, dependent 
on the presence of two variables (Section 1.1.3). This is a theoretical concept which refers to a deviation from 
additivity of two risk factors when considered together. In biological interaction, the combined effect of two 
exposures is more or less than the sum of their separate effects. This means that these factors act together in 
a causal mechanism (11). Whilst this departure from additivity can be easily assessed in a linear model which 
is an additive model, when using a multiplicative model (e.g. logistic regression), specific analysis is required.  
 
To test biological interaction between two comorbidities in the conditional logistic regression model three 
steps were taken as recommended by Rothman(453). First step, dummy indicator variables were created for 
the presence or absence of three of the four possible disease combinations for each pair of comorbidities.  In 
the DM and COPD example this was VAR01: DM=0, COPD=1; VAR10: DM=1, COPD=0; VAR11: DM=1, 
COPD=1. The fourth possible category (DM=0, COPD=0) served as reference category (Table 6.11). Second 
step, conditional logistic regression was then performed for the dummy variables for each disease pair in turn, 
adjusted for all other confounders.  
 
Three measures of biological interaction were considered(11): 
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(1) The relative excess risk due to the interaction (RERI) is the difference between the expected risk 
associated with two diseases combined and the observed risk of the individual diseases:  
 
RERI = RR11 – RR01 – RR10 +1 
 
(2) Attributable proportion due to interaction (AP) is the proportion of risk that is due to interaction 
among persons with both diseases:  
 
AP = RERI / RR11 
 
 (3) Synergy index (SI) is the excess risk from joint exposure in the presence of interaction 
 relative to the risk from exposure without interaction:  
 
SI = 
RR11 −1 
(RR01 −1)+(RR10 – 1)
  
 
Biological interaction is indicated where RERI and/or AP ≠ 0 and/or synergy index ≠ 1. For multivariable 
models that have a number of covariates the synergy index is recommended over the other measures (as this 
remains stable across strata of covariates) and was the main approach taken. Third and final step, using a 
covariance matrix generated by the model, confidence intervals were estimated(454). 
 
6.4.3 Part 3: Model building; testing different comorbidity measures  
Pre-specified models for each outcome were developed using all non-comorbidity covariates (the core model) 
in order to compare models with the inclusion of the different comorbidity measures. A pre-specified model 
was chosen from the available measures in the CPRD on the basis that the covariate was known to influence 
outcomes through prior evidence(180,182,447) and was clinically relevant and routinely collected. This also 
avoided using an approach that relies on statistical testing such as stepwise selection which can lead to bias 
and overfitting(225,455-457). The core model included age, gender, alcohol, smoking, systolic blood pressure, 
cholesterol, BMI, haemoglobin, HF medication and quadratic extensions of the continuous variables where 
indicated. Deprivation was not available for all subjects in the mortality sample and was non-significant in the 
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multivariable models for first hospital admission and so was not included in the core model. Prior hospital 
admission was added to the core models for hospital admission outcome. All continuous variables were 
centred about their mean prior to their inclusion to remove collinearity where their quadratic terms were also 
included and for better interpretation of the final models (Chapter 12).  
 
Each set of measures for the three comorbidities were tested separately in the core model. A comorbidity was 
added to the core model first by its status (presence or absence indicator) (model 1). Then the comorbidity 
status measure was exchanged for a comorbidity severity measure (drugs; model 2a or physiological 
measure; model 2b). Finally the comorbidity severity measure was exchanged for a severity change measure 
(drugs; model 3a or physiological measure; model 3b). The remaining two comorbidities were added to the 
each core model by their status measure (DM, COPD and eGFR<60 for CKD). See Figure 6.3 for an example 
of the models for diabetes mellitus. 
 
Conditional logistic regression was performed for each model and then discrimination and tests of model fit 
were used to compare models. Models were first created using the full data followed by a restricted set of 
data. Due to varying amounts of missing data in the comorbidity measures, in the second step, models were 
restricted to the data which had complete observations for all the models to be compared. This meant that a 
set of models could then be compared using the same data with the same number of observations.  
 
A final step compared a set of models with all three comorbidities added by (i) status, (ii) exchanged for 
comorbidity severity measures and lastly (ii) exchanged for severity change measures.  
 
Calibration and discrimination:  Calibration using the Hosmer Lemeshow test could not be performed following 
conditional logistic regression due to the model intercept not being estimated. The assumption is that without 
the baseline risk the predicted risk would be less than the observed risk. Discrimination used the area under 
the receiver operating characteristic (ROC) curve also called the concordance index (C-index). This index 
investigates the probability that for a randomly selected case and control the predicted risk of the case would 
be higher. This is a less sensitive measure for prediction modelling where the magnitude of risk within groups 
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is more important than the presence of risk. ROC also performs particularly poorly at evaluating the 
contribution of predictors to a model or where the range of risk within a population is narrow(458).  For this 
reason other measures of model fit were used in addition to the ROC. 
 
Goodness of fit measures: Log-Likelihood and likelihood ratio tests (p≤0.01) were used to compare nested 
models. The null model was the comorbidity status model compared to its alternative more flexible model 
where the comorbidity was stratified into groups of severity or change. Akaike and Bayesian information 
criterion (AIC and BIC) which also take account of the complexity of the models were also used as measures 
of model quality. Both BIC and AIC penalize for the number of parameters in the model and can be used to 
compare non-nested models. Difference of more than 2 in the AIC or BIC between models indicates positive 
difference and favour of the model with the smallest AIC or BIC(459). Finally McFadden’s pseudo R2 was 
used to assess model fit. Unlike R2 in linear regression, McFadden’s pseudo R2  is not based on how well the 
models explains the variance in the data but is an index of the likelihood ratio with 0.2 to 0.4 indicating 
excellent fit(460) (for summary of measures see E-Appendix A24). 
 
6.5 Chapter summary 
This chapter has detailed the methods and analyses that were applied in the main CPRD studies described in 
the following six chapters. DM, COPD and CKD comorbidities were selected from the systematic review and 
different measures of comorbidity severity and change using routinely collected drug and physiological data 
were defined. Part 1 includes the descriptive studies of the baseline and matched HF samples for the two 
outcomes; mortality (Chapter 7) and first hospital admission (Chapter 8). Part 2 focuses on the comorbidity 
prognostic factor studies for mortality (Chapter 9), hospital admission (Chapter 10) and interactions (Chapter 
11). Part 3 focuses on the comorbidity prognostic model study (Chapter 12). Chapters 7 to 12 will present the 
main results before detailed discussion in Chapter 13.  
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Table 6.2   COPD severity stages based on GOLD criteria 
 
 
Severity Stages Description Forced expiration volume in 1 second (FEV1) 
GOLD 1 Mild FEV1 ≥80% predicted 
GOLD 2 Moderate 50% ≤ FEV1 < 80% predicted 
GOLD 3 Severe 30% ≤ FEV1< 50% predicted 
GOLD 4 Very severe FEV1 < 30% predicted 
From GOLD guidelines(410)  
 
 
 
 
 
 
 
 
Table 6.1 COPD-related drugs 
 
 
Drug class BNF section 
Beta2-antagonists: SHORT 3.1.1.1 
Beta2-antagonists: LONG 3.1.1.1 
Anti-cholinergics: SHORT 3.1.2 
Anti-cholinergics: LONG 3.1.2 
Methylxanthines 3.1.3 
Compound inhalers (SHORT x2)  3.1.4 
Inhaled steroids 3.2 
Inhaled steroids + beta2-antagonist:SHORT 3.2 
Inhaled steroids + beta2-antagonist:LONG 3.2 
Oral steroids – prednisolone 6.3.2 
Oral steroids – methylprednisolone 6.3.2 
Oxygen 3.6 
BNF; British National formulary   
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Table 6.3   COPD drug severity measure framework 
  
 
Severity Group Guideline Recommended First Choice    Severity category description  
A Short acting Short-acting anticholinergic prn  
OR 
Short-acting beta2-agonist prn 
Any short acting bronchodilators  
B Monotherapy Long-acting anticholinergic  
OR 
Long-acting beta2-agonist  
OR  
Inhaled corticosteroid 
Any one long acting bronchodilator on its own or Methylxanthines monotherapy (without 
other step up therapy) or inhaled steroid on its own   
+/- short acting inhalers 
 
C Dual therapy 
 
 
Inhaled corticosteroid AND  
[long-acting beta2-agonist OR 
long-acting anticholinergic] 
OR 
Both long-acting beta2-agonist AND long-acting 
anticholinergic AND no inhaled corticosteroid 
Any long acting bronchodilator and an inhaled steroid (separate or combined). 
Methylxanthines may replace one of the bronchodilators 
+/- short acting inhalers 
OR 
Both long acting bronchodilators without inhaled steroid 
+/- short acting inhalers 
D Triple therapy Inhaled corticosteroid AND  
long-acting beta2-agonist  
AND long-acting anticholinergic 
Both long acting bronchodilators and an inhaled steroid. Methylxanthines may replace one of 
the bronchodilators or be additional to both +/- short acting inhalers 
 
E1 Additional therapy 
E2 Additional therapy 
On oral steroids 
On prescribed oxygen therapy 
May be in addition to any of the drugs A-D 
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Table 6.4   COPD drug severity classifications 
 
Severity classification A Severity classification B Severity classification C 
1 No drugs in time window  1 No drugs in time window 1 No steroids or oxygen  
2 Short term inhalers only (A) 2 On inhalers only (A-D) 2 On oral steroids but no oxygen (E1) 
3 Monotherapy (B) 3 On oral steroids but no oxygen (E1) 3 On oxygen (E2) 
4 Dual therapy (C) 4 On oxygen (E2)  
5 Triple therapy (D)   
6 Steroid (E1)   
7 Oxygen (E2)    
Severity categories A-E devised using GOLD guidelines(410).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.5  COPD physiological severity change measures 
 
COPD FEV1% severity change classification for all-cause mortality/ hospital admission 
1 An absolute decline of 5% in FEV1 pp over a year/ 6 months 
2 An absolute decline of 10% in FEV1 pp over a year/6 months 
3 A decrease in at least one GOLD stage over a year/6 months 
FEV1, forced expiratory volume in 1 second; pp, percent predicted 
  
 
Table 6.6  COPD drug severity change classifications 
 
Severity classification A Severity classification B 
1 Drug category same or better 1 No new steroid or oxygen 
2 Drug category worse 2 New steroid but no new oxygen 
 3 New onto oxygen 
  
Table 6.7 Diabetes physiological severity stages 
 
Level HbA1c (Glycated haemoglobin) 
1 <5.5% 
2 5.5-6.4% 
3 6.5-7.5% 
4 7.6-8.5% 
5 8.6-9.5% 
6 >9.5% 
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Table 6.8 Diabetes drug severity classification 
 
 
Level Diabetes drug severity classification 
1 No drugs in time window  
2 Oral hypoglycaemic drugs only 
3 Oral hypoglycaemic drugs and insulin combined 
4 Insulin only 
Table 6.9 Chronic kidney disease physiological severity stages 
 
CKD Category eGFR (ml/min/m2) 
1+ >105 
1 90-105 
2 60-89 
3a 45-59 
3b 30-44 
4 15-29 
5 <15 
Adopted in guidelines(434,461). eGFR, estimated glomerular filtration rate  
Table 6.10  Chronic kidney disease physiological severity change measures 
 
Severity class 1 (absolute change) Severity class 2 (relative change) 
0-5 mls decrease in eGFR  0-5% decrease in eGFR  
6-15 mls decrease in eGFR 6-25% decrease in eGFR 
>15 mls decrease in eGFR >25% decrease in eGFR 
Any increase Any increase 
eGFR; estimated glomerular filtration rate (using MDRD equation) 
Table 6.11 Definition of dummy variables for different comorbidity exposure combinations 
 
 
Exposure levels VAR 01 VAR 10 VAR 11 
DM =0, COPD = 0 (reference) 0 0 0 
DM =0, COPD = 1 1 0 0 
DM =1, COPD = 0 0 1 0 
DM =1, COPD = 1 0 0 1 
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Figures 
 
Figure 6.1 Flow chart of the patient selection process  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Matched samples  
 
Cases      24,339 
Controls 86,450 
(Total patients 
included 27,976) 
  
   
Cases      26,729 
Controls 106,916 
(Total patients 
included 46,911) 
  
Total practice CPRD HF 
population  
252,584 
Total baseline cohort 
for mortality outcome 
Exclude if not CPRD 
acceptable standard 
7,307 
Exclude if HF index 
date outside of study 
recruitment window 
164,658 
Exclude for the hospital 
admission outcome 
only those patient not 
linked to HES 
20,053 
Patients with linked hospital 
episode statistics data,  
30,061 
  
Total baseline cohort 
for hospital admission 
outcome 
 
Acceptable patients  
245,277 
Index date between 1/1/2002 
and 01/03/2012 
80,619 
At least 40 years of age  
79,629 
At least 3 years up-to-standard 
records before HF index date  
64,996 
Plausible data  
62,892 
No unexplained gaps in 
longitudinal data  
50,303 
Unique patients  
50,114 
Exclude if <40 years on 
HF index date 
990 
Exclude if less than 3 
years of UTS clinical 
data before the HF 
index date 
14,633 
Exclude if clinical data 
not plausible in relation 
to date of death 
2,104 
Exclude if any 
unexplained gaps in 
clinical data during 
study period 
12,589 
Exclude if patient 
appears twice in the 
study sample 
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Exclusions 
 
Data extraction 
criteria 
 
Data cleaning 
inclusion criteria 
Mortality cohort 
50,114 
Admission cohort 
30,061 
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Figure 6.2a Time-windows for comorbidity severity change using physiological measures 
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Figure 6.2b Time-windows for comorbidity severity change using drug measures 
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Figure 6.3 Models for diabetes mellitus 
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Chapter 7 Non-CVD comorbidity prognostic factors in an incident HF 
general practice cohort sample by all-cause mortality  
 
This chapter presents the results of the main incident HF CPRD cohort aged 40 years and over, with a first HF 
consultation between 1st January 2002 and 1st March 2012 followed up until January 2014. The chapter 
describes the HF population as a whole and investigates the unadjusted associations between non-CVD 
comorbidities at baseline and as they develop over time and all-cause mortality, but also the other patient, 
social, lifestyle, risk and medication factors that may influence this outcome. Baseline characteristics are 
described in the sample using the available data including missing values. Unless stated all baseline 
associations were significant at a level of p<0.01.  For the matched sample, the patient numbers reported for 
the cases and controls refers to the number of observations generated by the matching process. Following 
imputation, differences in time-dependent characteristics between the cases and controls are described. 
Results are presented as number (%), mean (SD) or median [Interquartile range; IQR].  
 
7.1 Study sample: baseline characteristics of total sample by mortality outcome 
CPRD sample and follow-up: There were 50,114 subjects with a first HF consultation code between 1st 
January 2002 and 1st March 2012. Follow-up ranged from 0 to 12 years (median 2.57 [IQR 0.81-4.96] years 
and mean 3.25 (SD 2.86) years). The risk of death expressed as a percentage of the total cohort at baseline 
decreased exponentially with each year of follow-up time, shown in Figure 7.1 (dark purple), with most events 
occurring in the shorter follow-up time. There were 26,729 (53.3%) deaths from any cause over the follow-up, 
with the risk of death in the first 3-months (13.3%), first year (23.3%) and within 5 years (46.4%). Figure 7.1 
also shows the cumulative risk of death per year of follow-up (light purple).  Following the initial year, the risk 
of death in the remaining survivors per year (with the number of deaths expressed as a percentage of the 
remaining survivors in each year of follow-up) remained stable at 8-11% per year shown in Figure 7.2. 
 
  
183 
 
7.1.1 Patient characteristics at baseline in the HF population sample by mortality outcome 
Baseline age at HF diagnosis was negatively skewed within the sample with a higher number of older 
participants; mean 76.9 (SD 10.9) years and median 78 [IQR 71-85] years (E-Appendix E14 for all continuous 
variable histograms and Q-Q plots). Over the total follow-up time, compared to the survivors, non-survivors 
were more likely to be older, female and more deprived (Table 7.1).  Age was significantly higher in those that 
died (81 [74-87] years) than those who remained alive (75 [66-82] years). The sample was 47.1% female with 
an increase in the proportion of women in the non-survivors compared to survivors (48.5% versus 45.4%). In 
the non-survivors there were more current smokers (15% v. 13.3%) but fewer alcohol drinkers (68.9% v. 
73%).  
 
Body mass index (BMI) was positively skewed with more participants with lower BMI. Cholesterol and 
estimated glomerular filtration rate (eGFR) showed slight positive skewness in the histograms but mean and 
median values were similar and the Q-Q plots showed that the central parts of their distributions were normal. 
Haemoglobin and blood pressure were approximately normally distributed. At baseline the non-survivors, 
compared to the survivors, had lower diastolic blood pressure (mean 75.8 (SD11.9) v. 77.7 (2) mmHg), BMI 
(median 26.2 [IQR 23.1-30] v. 27.9 [24.7-32] Kg/m2), cholesterol (4.6 (1.2) v. 4.7 (1.2) mmol/L) and 
haemoglobin (12.7 (1.9) v. 13.4 (1.8) g/dL).  
 
Of the total HF sample, 32.7% were prescribed beta-blockers at baseline, 55.3% were prescribed an 
angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) and 64% were 
prescribed diuretics. Non-survivors compared to survivors, were significantly less likely to be prescribed beta- 
blockers (29.7% v. 36.1%), ACEi or ARB (50.9% v. 60.2) and more likely to be prescribed diuretics (72.2% v. 
54.5%). 
 
7.1.2 Comorbidity exposures at baseline in the HF population sample by mortality  
At HF index date, 5,848 (11.7%) of the sample had chronic obstructive pulmonary disease (COPD), 10,533 
(21%) had diabetes mellitus (DM) and 7,621 (15.2%) had chronic kidney disease (CKD). When CKD was 
defined by an eGFR <60 ml/min/m2, prevalence at baseline increased to 20,084 (49.8%). Prevalence of all the 
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comorbidities were significantly higher in the non-survivors compared to survivors; COPD (13.6% v. 9.4%), 
DM (22% v. 19.9%) and CKD (diagnostic: 16% v. 14.7%, eGFR: 57% v. 41%) (E-Appendix B14). Non-
survivors were also more likely to have ≥2 co-existing comorbidities (21.6% v. 14.3%). The most prevalent 
disease combination was DM and CKD (eGFR defined) (10.3%) and this predominated in the non-survivors 
(12% v. 8.4%) (E-Appendix B15). 
 
In the comorbid DM sample the median glycated haemoglobin (HbA1c) at baseline was 7.1 [IQR 6.4-8.1] % 
which was not associated with mortality (P=0.89). In the COPD sample, the median forced expiration volume 
in 1 second (FEV1) was 53.3 [39-69.6] percent predicted (pp) which was significantly lower in the non-
survivors than survivors (52.8 [38.2-69.2] v. 59 [46-72] pp). eGFR was measured in 80.5% of the baseline HF 
sample and was mean 61.0 (20.3) ml/min/m2. This level was significantly lower in non-survivors than survivors 
(57.4 (20.7) v. 64.9 (19.3) ml/min/m2). 
 
7.2 Study sample: baseline characteristics by mortality outcome of HF sub-
samples with (i) different follow up periods and (ii) different calendar time-
periods 
The total HF sample will now be reported (i) in 3 subgroups defined by their follow-up time and (ii) in two sub-
groups according to whether their diagnosis date was before or after April 2006 when HF was introduced into 
the Quality Outcomes Framework (QOF) in the UK. This was done firstly to investigate whether the 
unadjusted associations between baseline factors and mortality in the total sample were confounded by 
variations in the exposure time between the non-survivors and survivors with different follow-up times within 
the sample. Secondly, it was to investigate whether changes to HF clinical practice as a consequence of new 
guidelines or practices during the total follow-up time influences this association.  
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7.2.1 HF sub-samples with different follow-up periods: patient characteristics at baseline by mortality 
outcome 
The cohort was sub-grouped into three overlapping HF samples with different follow-up periods: (i) at least up 
to 1 year (whole sample), (ii) between 1 and 5 years and (iii) ≥5 years. Non-survivors and survivors at the end 
of each time-period were compared (Table 7.2). The unadjusted associations between the baseline 
characteristics and mortality were estimated for the total follow-up time and by three different lengths of follow-
up (see E-Appendix A25). As the three lengths of follow-up had different HF sample sizes it was important to 
observe the magnitude of exposure difference as well as the significance. The smaller sample in the longer 
follow-up period would reduce the power to detect significant difference between the groups.   Both the 
significance and magnitude of the difference in exposure status between non-survivors and survivors differed 
across the three follow-up periods for some exposures.  
 
Older age remained consistently associated with mortality across all 3 follow-up periods but the median 
baseline age of the non-survivors reduced from 83 years to 78 years from the shorter to the longer follow-up. 
Proportion of the most deprived groups and smokers remained higher in the non-survivors than survivors 
across the 3 follow-up periods but significance was lost in the longest follow-up groups for deprivation and in 
the longest 2 follow-up periods for smoking. The magnitude of difference in the proportion of women between 
survivors and non-survivors decreased over time (4.7% to 2.4%) and whilst remaining higher in the non-
survivors in all three follow-up periods, became non-significant in the longest follow-up period. Lower  diastolic 
blood pressure, BMI, cholesterol and haemoglobin were significantly associated with mortality in each of the 3 
follow-up periods (with the exception of cholesterol which became non-significant in the longest follow-up 
period), but the magnitude of exposure difference between survivors and non-survivors reduced over time for 
each risk factor. Lower systolic blood pressure (SBP) was associated with mortality in the shortest follow-up 
period but the association was between higher SBP and mortality in the two longer follow up periods. 
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7.2.2 HF sub-samples with different follow-up periods: comorbidity exposures at baseline by mortality 
outcome 
All three baseline comorbidities were associated with increased mortality. The magnitude of difference in 
comorbidity prevalence between non-survivors and survivors remained consistent and significant across all 3 
follow-up periods for COPD and CKD (eGFR<60ml/min/m2) with higher prevalence in non-survivors. 
Diagnostic CKD prevalence in the group with the longest follow-up period was much lower compared to the 
total cohort (8% v. 15.2%) and its association with mortality reversed in the longest follow-up period with 
higher prevalence in survivors. The magnitude of difference in prevalence of DM between non-survivors and 
survivors was small in the shortest follow-up period (0.1%) but became larger in the longer 2 follow-up periods 
(3.5-3.6%). In the DM group, there was minimal difference in median HbA1c across survivors and non 
survivors (0.1%) and whilst significant in the larger shortest follow-up group, this lost significance in the two 
longer follow-up periods. The magnitude of difference in FEV1 (in the COPD group) and eGFR between the 
survivors and non-survivors was consistent across all 3-follow-up periods but FEV1 lost its significance in the 
longest follow-up group.  
 
7.2.3 HF sub-samples with different temporal periods: patient characteristics at baseline by mortality 
outcome 
There were 22,331 (44.6%) participants who had a first diagnosis of HF before April 2006 (approximately 
halfway through the cohort time) and 27,763 (55.4%) after (E-Appendix A25). With the exception of baseline 
age and deprivation, all patient, lifestyle, risk and medication factors were significantly different across the two 
time-periods. After April 2006, there were a smaller proportion of women with HF, fewer smokers and 
drinkers; systolic and diastolic blood pressure (DBP), cholesterol and haemoglobin were significantly lower 
and BMI was significantly higher. Less people were prescribed diuretics and more people were prescribed 
beta-blockers, ACEi and ARB. 
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7.2.4 HF sub-samples with different temporal periods: comorbidity exposures at baseline by mortality 
outcome  
Prevalence of COPD and DM comorbidities in HF significantly increased after April 2006 by 2.9% and 4.3% 
respectively. Diagnostic CKD increased from 2.9% in the period before April 2006 to 25.1% after April 2006, 
an increase of 22%. CKD defined by eGFR <60ml/min/m2 decreased from 55% to 46.5% over the same time- 
period.   
7.3 Study sample: Time-dependent characteristics of the matched HF sample by 
mortality outcome 
From the total HF population sample, all 26,729 all-cause mortality cases were matched to four controls. 
Controls were live, active in practice and remained at risk of death on the case index date. Controls were 
matched to cases within 1-month of their HF diagnosis study-in date and on duration of follow-up. This 
resulted in 133,645 observations including 106,916 controls. The match date for the controls was the date that 
corresponded with the same amount of follow-up time as the case. Person, socio-demographic factors, 
lifestyle factors and risk factors were measured as the most proximal to the match date during follow-up. Drug 
and comorbidity exposures were measured in specific study time-windows as outlined in chapter 6 (Section 
6.3.4.5). 
 
7.3.1 Patient characteristics in the matched HF population sample by mortality 
Median current age on the match date for the mortality cases was 81 [IQR 74-87] years which was higher 
than controls (76 [68-82] years). Cases were also more likely to be female and more deprived (Table 7.4). The 
matched sample was 46.2% female with an increase in the proportion of women in the cases compared to 
controls (48.5% versus 45.6%). The prevalence of current smokers between cases and controls was similar 
(11.7% versus 11.3%) but there were more current alcohol drinkers in controls (68.9% v. 73%).  
 
Cases compared to controls, had lower most recent systolic blood pressure (mean 126.9 (SD 22.3) v. 132.5 
(19.9) mmHg), diastolic blood pressure (71.1 (12) v. 73.9 (11.1) mmHg), BMI (median 25.4 [22.1-29.3] v. 27.3 
[24-31.3] Kg/m2), cholesterol (4.4 (1.2) v. 4.5 (1.2) mmol/L) and haemoglobin (12.3 (2) v. 13.1 (1.8) g/dL).  
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Of the total sample, 55.5% were prescribed beta-blockers on the match date, 70.7% were prescribed an ACEi 
or an ARB and 77.3% were prescribed diuretics. Cases compared to controls, were less likely to be 
prescribed beta-blockers (45.5% v. 58%), ACEi or ARB (56.4% v. 74.3%) and more likely to be prescribed 
diuretics (80.7% v. 76.4%).  
 
7.3.2 Comorbidity exposures in the matched HF population sample by mortality  
Comorbid COPD group characteristics: COPD was present in 18,478 (13.8%) HF patients before the match 
date.  Prevalence was higher in cases (17.3%) than controls (13%). Compared to HF patients without COPD, 
those with HF-COPD were more likely to be younger and deprived but less likely to be female. The COPD 
group had lower blood pressure and cholesterol, but higher BMI and haemoglobin than the non-COPD HF 
group. In the HF-COPD group, 20.7% were current smokers compared to only 9.7% in the non-COPD HF 
group. Compared to the non-COPD HF group, the HF-COPD group were less likely to be prescribed beta-
blockers (36.7% v. 58.6%) or ACEi/ARB (68.9% v. 71.1%) but more likely to be prescribed diuretics (80.9% v. 
76.7%). Prevalence of concomitant diabetes and CKD were less likely in the HF-COPD group who had a 
higher mean eGFR (61.0 (SD 22.4) v. 57.3 (20.9) ml/min/m2) (E-Appendix A27).  
 
COPD status: Of the 18,478 HF patients comorbid with COPD, 3,995 (21.6%) had developed the comorbidity 
after HF diagnosis. COPD that developed before or after HF was  associated with mortality but the magnitude 
of difference between cases and controls was greater for the pre-HF than the post-HF COPD group (3.5% v. 
0.9%) (Table 7.4 and Figure 7.3).  
 
COPD severity: There were 8,515 (53.9%) HF-COPD patients who had had at least one recent FEV1 
recorded within the 3-year measurement window before the match date (median 295 [IQR 137-524] days). In 
the comorbid group FEV1 was  lower in the cases than controls (median 51.9 [IQR 38-69] v. 55.2 [41-71] pp) 
and most were in GOLD severity stage 2 (43.7%) and 41.3% were in stages 3-4 (see Figure 7.4). HF-COPD 
cases were more likely than controls to be in the most severe GOLD severity groups (stage 3 or 4; 46.3% v. 
38.7% respectively).  
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Of the comorbid group, 12.8% were not on any COPD-related drugs at the time of matching which was similar 
for cases and controls. Prescribing of at least one inhaler therapy was  lower in the case group compared to 
controls (49.4% v. 59.4% respectively). Cases were  less likely to be on mono, dual or triple inhaler therapy 
than controls but  more likely to be prescribed steroids (30.6% v. 24% respectively) or oxygen therapy (8% v. 
3.6%).  
 
COPD severity change: In the HF-COPD group, 4,882 (25.3%) had had a second FEV1 (pp) recorded prior to 
the most recent measure (median 462 [IQR 360-663] days). Over a year, before the match date, 19.1% had 
experienced a worsening of at least one GOLD stage which was a higher in cases (21.8%) than controls 
(17.5%). Mortality cases were also more likely than controls to experience a 5% or 10% decrease in FEV1 
(pp) over the same time period. In the HF-COPD group, 1,425 (30%) of those with two FEV1 measures 
experienced a 5% decrease in FEV1 and 710 (15%) experienced a 10% decrease in FEV1. These decreases 
predominated in mortality cases over controls (10% FEV1 loss; 16.9% v. 14.3%; 5% FEV1 loss; 33.3% v. 
28.8%).  
 
Of the HF-COPD group, 3,399 (18.4%) were newly prescribed oral steroids or oxygen therapy compared to 
the year before. New prescription of these drugs was  more prevalent in cases than controls (steroids; 19.2% 
v. 14.4%; oxygen; 5% v. 2% respectively).  
 
Comorbid DM group characteristics: DM was present in 31,962 (23.9%) of HF patients before to the match 
date. Prevalence was  higher in mortality cases (25.1%) than controls (23.6%). Comorbid HF-DM patients 
were more likely to be younger and deprived but less likely to be female than the non-DM group. The DM 
group had lower cholesterol and haemoglobin but higher BMI than the non-DM group (median 29.2 [IQR 25.5-
33.7] v. 26.3 [23.1-30] kg/m2). There were fewer current smokers and alcohol drinkers in the comorbid HF-DM 
group compared to the non-DM group. The HF-DM group were more likely than the non-DM group to be 
prescribed beta-blockers (61.5% v. 53.7%), ACEi/ARB (77.9% v. 68.5%) and diuretics (82.5% v. 75.7%). 
Prevalence of concomitant COPD was less likely in the HF-DM group but concomitant CKD was more likely 
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with a mean eGFR of 55.6 (SD 22.4) compared to 58.6 (20.7) ml/min/m2 in the non-DM HF group (E-Appendix 
A28).  
 
DM status: Of the 31,962 HF patients with DM, 4,787 (15.0%) developed DM after HF diagnosis. DM that 
developed before HF was higher in the case group (22% in cases v. 19.9% in controls). These figures were 
opposite for DM that developed after HF, with prevalence higher in controls than cases (3.7% v. 3.1%) (Table 
7.5 and Figure 7.5).  
 
DM severity: Of the comorbid group, 28,865 (90.3%) had had at least one recent HbA1c recorded before the 
match date (median 114 [IQR 52-206] days). Around 36% of the HF-DM patients had had a recent HbA1c 
level between 6.5-7.5%. Median HbA1c was significantly lower in the cases than controls (7 [IQR 6.3-8] v. 7.1 
[6.4-8.1] %), and lower HbA1c categories (<6.5%) but not higher HbA1c categories (≥6.5%) were more 
prevalent in cases than controls.  
 
Of the case group, 26.4% were not on any DM-related drugs at the time of matching and these patients were  
more prevalent in the mortality cases (30.4%) than the controls (25.4%). Most HF-DM patients were on oral 
medication (57%) +/- insulin, which was less prevalent in the case group compared to controls (50.3% v. 
58.8%). Of the comorbid group, 5,061 (16.6%) were prescribed insulin only which was associated with 
mortality in 19.3% of the cases and 15.8% of controls.  
 
DM severity change: There were 26,174 (81.9%) HF-DM patients who had had a second HbA1c recorded 
before the most recent measure (median 298 [IQR 230-379] days). Over a year prior to the match date, 
16.8% of HF-DM with two HbA1c measures experienced an absolute increase of >1% HbA1c and 19.3% 
experienced an absolute decrease of >1% HbA1c.  A greater than1% decrease in HbA1c was more prevalent 
in cases (22%) than controls (18.6%). Within the HF-DM group, 14% of patients experienced a change in drug 
category in the year before their match date. Of the cases 83% had stable drug regimens compared to 86.7% 
of the controls but a decrease in drug category was more prevalent  in the cases (7.3%) than controls (3.3%). 
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Most (81%) of patients who had a decrease of at least one drug category were on no DM drugs at the time of 
matching. 
 
Comorbid CKD group characteristics: Due to the low prevalence of CKD defined by diagnostic codes in 
patients entering the cohort before April 2006, CKD was defined by eGFR <60ml/min/m2 which was recorded 
in 119,615 (89.5%) of the total HF cohort before the match date (median 101 [IQR 37-223] days). CKD was 
present in 66,301 (55.4%) of HF patients. Prevalence was higher in cases (66.2%) than controls (52.7%). 
Compared to HF patients without CKD, those with HF-CKD were more likely to be older (74 v. 80 years) and 
female (53% v. 38%) and less deprived. The comorbid group had  lower haemoglobin, SBP and BMI than the 
non-comorbid group. There were fewer current smokers and alcohol drinkers in the HF-CKD group compared 
to the non-CKD group. Compared to the non-comorbid group, the comorbid group were less likely to be 
prescribed ACEi/ARB (74.7% v. 70.9%), more likely to be prescribed diuretics (84.9% v. 70.3%) and equally 
likely to be prescribed beta-blockers. Prevalence of concomitant COPD was less likely in the HF-CKD group 
than the non-CKD group, but concomitant DM was more likely (P<0.001) (see E-Appendix A29).  
 
CKD severity: CKD severity categories based on eGFR level in the HF-cohort (Figure 7.6) showed different 
associations with mortality. The lowest three eGFR severity categories (<45ml/min/m2) were more prevalent 
in the cases than controls (40.7% v. 24.1%), whereas the highest three eGFR categories (45-105ml/min/m2), 
were more prevalent in controls (73.8%) than cases (57%) (Table 7.6). eGFR >105 ml/min/m2 was slightly 
more prevalent in cases than controls (2.3% v. 2.1%). 
 
CKD severity change: Of the HF cohort, 104,884 (78.5%) had had a second eGFR measure before the most 
recent measure (median 315 [IQR 232-420] days). Of the cohort, 12.6% had experienced >15mls decrease in 
eGFR and 13.5% experienced >25% decrease in eGFR, over a year before their match date. An increase in 
eGFR was experienced in approximately 41% of patients over the same time frame. Decrease in eGFR but 
not an increase was associated with mortality. Mortality cases had 6.9% higher prevalence of decreasing 
eGFR (mls) and 10.5% higher prevalence with >25% decrease in eGFR than controls. 
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7.4 Chapter summary  
The characteristics of people with HF in the general practice population have changed over the last decade 
and despite more prescribed medications and improved risk profiles in the more recent years, a quarter of 
people with HF still die in the first year following diagnosis and about 10% per year after that. The unadjusted 
associations between some the patient characteristics and comorbidity exposures measured at baseline and 
death differed according to the length of follow-up time. The indications are that the effects of exposure 
change over time (time-varying effects) or the exposures themselves change (time-varying exposures). DM, 
COPD and CKD were associated with death in each of the different follow-up periods but there was less 
difference in prevalence between the cases and controls for comorbidities that developed after HF incident, 
than before HF (for COPD, DM). All measures of comorbidity severity and longitudinal change that were 
recorded in the recent time-windows to death differed between cases and controls. These findings will be 
discussed in detail in Chapter 13. 
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Tables 
Table 7.1 Baseline characteristics of the HF sample by mortality outcome over maximum 12 year 
follow-up 
 
 
Factors and exposures All (n=50,144) Dead (n=26,729) Alive (n=23,385) P 
Person and socio-demographic factors     
Age, years 78[71-85] 81[74-87] 75[66-82] <0.001 
Women 23,595 (47.1) 12,974(48.5) 10,621(45.4) <0.001 
IMD quintile  
1 
 
5,846 (19.5) 
 
3,064(18.7) 
 
2,782(20.5) 
<0.001 
 
2 6,952 (23.2) 3,708(22.6) 3,244(23.9)  
3 6,340 (21.1) 3,570(21.8) 2,770(20.4)  
4 6,235 (20.8) 3,427(20.9) 2,808(20.6)  
5 4,613 (15.4) 2,613(16) 2,000(14.7)  
Anthropometric and clinical factors     
BMI (Kg./m2) 27[23.8-31] 26.2[23.1-30] 27.9[24.7-32] <0.001 
Cholesterol (mmol/L) 4.7 ±1.2 4.6±1.2 4.7±1.2 <0.001 
Hb (g/dL) 13.1 ±1.9 12.7±1.9 13.4±1.8 <0.001 
Systolic BP (mmHg) 137.3 ±21.5 137.2`±22.1 137.2±20.8 0.48 
Diastolic BP (mmHg) 76.7 ±12 75.8±11.9 `77.7±12 <0.001 
Lifestyle factors     
Smoking status     <0.001 
yes       6,841 (14.2) 3,798(15) 3,043(13.3)  
No 22,618 (46.9) 11,898(46.8) 10,720(47)  
Ex 18,757 (38.9) 9,703(38.2) 9,054(40)  
Alcohol status     <0.001 
Yes 31,228 (70.9) 15,822(68.9) 15,406(73)  
No 11,093 (25.2) 6,229(27.1) 4,864.0(23)  
Ex 1,746 (4.0) 915(4) 831(3.9)  
Drug factors      
Diuretics 32,071(64.0) 19,311(72.2) 12,760(54.5) <0.001 
Beta blocker 16,382 (32.7) 7,933(29.7) 8,449(36.1) <0.001 
ACEi 22,582 (45.1) 11,229(42) 11,353(48.6) <0.001 
ARB 6,118 (12.2) 2,849(10.7) 3,269(14) <0.001 
Comorbidity exposures     
Diabetes Mellitus (DM) 10,533 (21.0) 5,883(22.0) 4,650(19.9) <0.001 
HbA1c (%)  7.1[6.4-8.1] 7.1[6.4-8.1] 7.1[6.4-8] 0.89 
COPD  5,848 (11.7) 3,640(13.6) 2,208(9.4) <0.001 
FEV1 (pp)  53.3[39-69.6] 52.8[38.2-69.2] 59[46-72] <0.001 
Renal disease (medical code) 7,621 (15.2) 4,194(16) 3,427(14.7) <0.001 
Renal disease (eGFR<60)  20,084 (49.8) 12,132(57) 7,952(41) <0.001 
eGFR (ml/min/1.73m2) 61.0 ±20.3 57.4±20.7 64.9±19.3 <0.001 
Number of listed comorbidities    <0.001 
0 13565 (33.6) 5,623(26.7) 7,942(41.3)  
1 19471 (48.3) 10,916(51.7) 8,555(44)  
2 6,795 (16.8) 4,224(20) 2,571(13.4)  
3 515 (1.3) 339(1.6) 176(0.9)  
Data are number patients (%) or mean± standard deviation or median[IQR].  IMD, index multiple deprivation 
(1=least deprived, 5= most deprived); BMI, body mass index; Hb, haemoglobin; BP, blood pressure; ACEi, 
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HbA1c, glycated haemoglobin; COPD, 
chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; pp, percent predicted; eGFR, 
estimated glomerular filtration rate. Number of comorbidities is based on those listed (COPD, DM, CKD defined by 
eGFR). HbA1c and FEV1 were measured in the respective DM and COPD groups only. eGFR was measured in all 
HF patients. 
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Table 7.2  Death events per year of follow-up 
Follow-up year  Number entering follow-up year Died during follow-up year n(%) Censored during follow-up year n(%) Alive at end of follow-up year  
1 50114 11678(23.2) 2298(4.6) 36138 
2 36138 4269(11.8) 2494(6.9) 29375 
3 29375 3247(11.1) 3851(13.1) 22277 
4 22277 2370(10.6) 3183(14.3) 16724 
5 16724 1710(10.2) 2687(16.1) 12327 
6 12327 1231(10) 2192(17.8) 8904 
7 8904 848(9.5) 1771(19.9) 6285 
8 6285 633(10.1) 1493(23.8) 1459 
9 4159 384(9.2) 1147(27.6) 2628 
10 2628 221(8.4) 1029(39.2) 1378 
11 1378 116(8.4) 754(54.7) 508 
12 508 22(4.3) 486(95.7) 486 
Censored data included subjects who (i) belonged to a practice that stopped contributing data to the CPRD during the follow-up year (ii) were transferred out of the 
practice (iii) reached the study end.  
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Table 7.3 Time-matched general characteristics of the matched sample by mortality outcome over 
maximum 12 years follow-up  
 
 
 
Patient characteristics 
All 
(n=133,645) 
Cases 
(n=26,729) 
Controls 
(n=106,916) 
 
Missing n(%) 
Person and socio-demographic factors 
Age, years 77[IQR 69-83] 81[74-87] 76[68-82] - 
Women 61,732(46.2) 12,974(48.5) 48,758(45.6) - 
IMD quintile     54262(40.6) 
1 15,908(20.0) 3,064(18.7) 12,844(20.4)  
2 18,089(22.8) 3,708(22.6) 14,381(22.8)  
3 16,666(21) 3,570(21.8) 13,096(20.8)  
4 16,451(20.7) 3,427(20.9) 13,024(20.7)  
5 12,269(15.5) 2,613(16.0) 9,656(15.3)  
Anthropometric and clinical factors 
BMI (Kg/m2) 26.9[23.5-31] 25.4[22.1-29.3] 27.3[24-31.3] - 
Cholesterol (mmol/L)  4.5±1.2 4.4±1.2 4.5±1.2 - 
Hb (g/dL) 13.0±1.9 12.3±2.0 13.1±1.8 - 
Systolic BP (mmHg)  131.4±20.5 126.9±22.3 132.5±19.9 - 
Diastolic BP (mmHg)  73.3±11.4 71.1±12 73.9±11.1 - 
Lifestyle factors 
Smoking status     - 
yes       15,002(11.2) 3,127 (11.7) 11,875 (11.1) - 
No 61,936(46.3) 12,573 (47.0) 49,363 (46.2) - 
Ex 56,707(42.4) 11,029(41.3) 45,678(42.7) - 
Alcohol status     - 
Yes 92,438(69.2) 17,740(66.4) 74,698(69.9) - 
No 34,755(26.0) 7,611(28.5) 27,144(25.4) - 
Ex 6,452(4.8) 1,378(5.2) 5,074(4.8) - 
Drug factors 
Diuretics 103,283(77.3) 21,574(80.7) 81,709(76.4) - 
Beta blocker 74,221(55.5) 12,171(45.5) 62,050(58) - 
ACEi 74,373(55.7) 12,207(45.7) 62,166(58.1) - 
ARB 22,753(17.0) 3,170(11.9) 19,583(18.3) - 
ACEi or ARB 94,547(70.7) 15,079(56.4) 79,468(74.3) - 
Beta blocker AND (ACEi or ARB) 58,632(43.9) 7,981(29.9) 50,651(47.4) - 
Comorbidity exposures 
Diabetes  31,962(23.9) 6714(25.1) 25,248(23.6) - 
COPD 18,478(13.8) 4,630(17.3) 13,848(13.0) - 
Renal disease (eGFR <60)  66301(55.4) 15827(66.2) 50474(52.7) 14030(10.5) 
Number of comorbidities     14030(10.5) 
0 34607(28.9) 4766(19.9) 29841(31.2)  
1 58711(49.1) 12512(52.3) 46199(48.3)  
2 24025(20.1 5964(24.9) 18061(18.9)  
3 2272(1.9) 673(2.8) 1599(1.7)  
Data are number patients (%) or mean±standard deviation or median[IQR]. IMD, index multiple deprivation (1=least 
deprived, 5=most deprived); BMI, body mass index; Hb, haemoglobin; BP, blood pressure; ACEi, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; 
eGFR, estimated glomerular filtration rate. Number of comorbidities is based on those listed (COPD, DM, CKD 
defined by eGFR.  
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Table 7.4 Time-dependent COPD comorbidity measures of the matched sample by mortality outcome 
 
Comorbidity measures HF All (n=133,645) HF cases (n=26,729) HF Controls (n=106,916) Missing n(%) 
COPD diagnostic code (n=18,478) 18,478(13.8) 4,630(17.3) 13,848(13.0)  
Diagnosis before HF (78.4%) 14,483(10.8) 3,640(13.6) 10843(10.1) - 
Diagnosis after HF (21.6%) 3,995(3.0) 990(3.7) 3005(2.8) - 
COPD severity in COPD group only  All COPD (n=18,478) Cases (n= 4,630) Controls (n=13,848)  
FEV1(percent predicted)  54.1[IQR 39.7-70.0] 51.9 [37.7-68.5] 55.2 [40.6-70.6] 9,963(53.9) 
COPD GOLD severity stage    9,963(53.9) 
   1: FEV1 ≥80% normal 1284(15.1) 396(13.9) 888(15.7)  
   2: FEV1 50-79% normal 3721(43.7) 1140(39.9) 2581(45.6)  
   3: FEV1 30-49% normal 2679(31.5) 989(34.6) 1690(29.9)  
   4: FEV1 <30% normal 831(9.8) 334(11.7) 497(8.8)  
COPD Drug severity    - 
No drugs 2,359(12.77) 561 (12.12) 1,798(12.98)  
Short term inhalers only 1624(8.79) 380 (8.21) 1244(8.89)  
Monotherapy 2417(13.08) 542 (11.71) 1875(13.54)  
Dual therapy 3329(18.02) 664 (14.34) 2665(19.24)  
Triple therapy 3140(16.99) 699 (15.0) 2441(17.63)  
Any inhalers only 10,510(56.9%) 2,285(49.4) 8,225(59.39)  
No steroids or oxygen  12,869(69.6) 2846(61.5) 10,023(72.4)  
Oral steroids but no oxygen 4,744(25.7) 1415(30.6) 3329(24.0)  
On  oxygen 865(4.7) 369(8.0) 496(3.6)  
COPD severity change in COPD group only     
   Gold stage same or better  3790 (81) 1,326(78.2) 2,464(82.5) 13796(74.7) 
   Gold stage worse (at least one stage) 892(19.1) 369(21.8) 523(17.5)  
10% change     
   <10% change  3,341(71.4) 1191(70.3) 2150(72.0) 13796(74.7) 
   ≥10% increase (better) 631(13.5) 218(12.9) 413(13.8)  
   ≥10% decrease (worse) 710(15.2) 286(16.9) 423(14.2)  
5% change     
   <5% change  2,091(44.7) 739(43.6) 1,352(45.2)  
   ≥5% increase (better) 1,166(24.9) 392(23.1) 774(25.9)  
   ≥5% decrease (worse) 1,425(30.4) 564(33.3) 861(28.8)  
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COPD severity change (Drugs)     
Drug category same or better 10,908 (59.0) 2,703 (58.4) 8,205 (59.3)  
Drug category worse 7, 570 (41.0) 1,927 (41.6) 5,643 (40.8)  
No new steroids or oxygen  15,079(81.6) 3508(75.8) 11571(83.6))  
New on steroids but no new oxygen 2,885(15.6) 889(19.2) 1996(14.4) - 
New on oxygen 514(2.8) 233(5.0) 281(2.0) - 
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; pp, percent predicted. Most recently recorded FEV1 (pp) 
before the match date was used to measure COPD severity within a maximum of a 3-yr time window. % change for FEV1 was calculated as the absolute 
change in pp over one year using the most recent measure and an earlier FEV1 measure recorded up to a maximum of 3-years before the most recent 
measure. The FEV1 change was adjusted for the time interval. Mono, dual or triple therapy; one, two or three of respectively: long acting beta2-
antagonist, long acting cholinergic, methylxanthines, inhaled steroid either individually or in combination inhalers.  
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Table 7.5 Time-dependent DM comorbidity exposures of the matched sample by mortality outcome 
 
 
Comorbidity measures HF All (n=133,645) HF cases (n=26,729) HF Controls (n=106,916)  
Missing n(%) 
Diabetes (DM) diagnostic code (n=31,962) 31, 962 (23.9) 6714(25.1) 25,248(23.6) - 
Diagnosis before HF (85%) 27,175(20.3) 5,883(22) 21,292(19.9) - 
Diagnosis after HF (15%) 4,787(3.6) 831(3.1) 3,956(3.7) - 
Diabetes severity (HbA1c) in DM group only All Diabetes (n=31,962) DM Cases (n= 6,714) DM Controls (n=25,248)  
HbA1c (%)  7.1[IQR 6.4-8.1] 7 [6.3-8] 7.1[6.4-8.1] 3097(9.7) 
<5.5% 1275(4.4) 357(6.0) 918(4.0)  
5.5-6.4% 6621(22.9) 1476(24.7) 5145(22.5)  
6.5-7.5%  10379(36.0) 2056(34.4) 8323(36.4)  
7.6-8.5% 5122(17.7) 1010 (16.9) 4112(18.0)  
8.6-9.5% 2581(8.9) 520(8.7) 2061(9)  
>9.5% 2887(10) 554(9.3) 2333(10.2)  
Diabetes drug severity      
1: None  8,452(26.4) 2 041(30.4) 6,411(25.4) - 
2: Oral only 14,700 (46.0) 2,835 (42.2) 11,865 (47.0)  
2: Oral (+Insulin) 3,518(11.0) 545(8.1) 2,973(11.8) - 
3: Insulin only 5,292(16.6) 1 293(19.3) 3,999(15.8) - 
Diabetes severity change (HbA1c) in DM group only   
   <1% change  16,706(63.8) 3380(61.8) 13326(64.4) 5788(18.1) 
   >1% increase 4,407(16.8) 889(16.2) 3518(17)  
   >1% decrease 5,061(19.3) 1205(22.0) 3856(18.6)  
Diabetes severity change (Drugs)    - 
No drug category change 27,466(85.9) 5575(83.0) 21891(86.7) - 
Increase in drug category  3,177(9.9) 647(9.6) 2530(10.0) - 
Decrease in drug category 1,319(4.1) 492(7.3) 827(3.3) - 
HbA1c, glycated haemoglobin; Most recently recorded Hba1c (%) prior to the match date was used to measure DM severity within a maximum of a 3-yr time window. % change for 
HbA1c was calculated as the absolute change in % over one year using the most recent measure and an earlier HbA1c measure recorded up to a maximum of 3-years prior to the 
most recent measure. The HbA1c change was adjusted for the time interval.  
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Table 7.6 Time dependent CKD comorbidity measures of the matched sample by mortality outcome 
 
CKD measures HF all 
(n=133,645) 
Cases  
(n= 26,729) 
Controls 
(n=106,91) 
Missing  
n(%) 
Renal disease diagnosis      
eGFR <60   66301(55.4) 15827(66.2) 50474(52.7) 14030(10.5) 
Renal severity (eGFR)     
eGFR mL/min/1.73m2 57.8±21.2 52±22.9 59.3±20.5 14030(10.5) 
Renal severity by eGFR stage*    14030(10.5) 
   1:    >105 2,591(2.2) 558(2.3) 2033(2.1)  
   1:    90-105 6,505(5.4) 1028(4.3) 5477(5.7)  
   2:    60-89 44,218(37.0) 6502(27.2) 37716(39.4)  
   3A:  45-59 33,510(28.0) 6091(25.5) 27419(28.7)  
   3B:  30-44 23,130(19.3) 5890(24.6) 17240(18.0)  
   4:    15-29 8,252(6.9) 3159(13.2) 5093(5.3)  
   5:    <15 1,409(1.2) 687(2.9) 722(0.8)  
eGFR severity change     28761(21.5) 
Classification 1 (Absolute change)   
0mls-5mls decrease (reference group) 26,056(24.8) 4522(21.3)   
>15mls decrease 13,238(12.6) 3848(18.1) 21534(25.8)  
6mls to 15mls decrease 22,817(21.8) 4690(22.0) 9390(11.2)  
any increase 42,733(40.8) 8218(38.6) 18127(21.7)  
Classification 2 (Percentage change)  34555(41.3) 
0-5% decrease (reference group) 15,244(14.5) 2262(10.6)   
>25% decrease 14,119(13.5) 4639(21.8)   
6-25% decrease 31,729(30.3) 5954(28.0) 12982(15.5)  
Any % increase 43,792(41.8) 8423(39.6) 9480(11.3)  
eGFR, estimated glomerular filtration rate. * National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) 
guidelines. >105 group added to stage one due to the prior evidence of increased risk in high eGFR 
% change was calculated as the absolute change in eGFR over one year and the relative change (difference in eGFR over a 
year as a proportion of the first eGFR measure).  
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Figures 
Figure 7.1 All-cause mortality as a percentage of the total HF survivors in each year of follow-up  
 
Figure 7.1: The dark purple bars show the percentage of the baseline cohort who died in each year of follow up. The 
denominator in this figure is the 50,114 subjects in the baseline cohort. The light purple bars show the cumulative 
percentage of the baseline cohort who died over the 12 years of follow-up. 
 
Figure 7.2 All-cause mortality as a percentage of remaining HF survivors per follow-up year 
 
Figure 7.2: The purple bars show the percentage of deaths in the remaining survivors who entered each year of follow 
up. In year 12 most subjects were censored due to the practice not contributing data to the final CPRD data capture (see 
Table 7.2). 
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Figure 7.3 Comorbid COPD diagnosed pre and post HF by mortality outcome 
 
 
Figure 7.4 Comorbid COPD GOLD severity stages by mortality 
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Figure 7.5 Comorbid DM diagnosed pre and post HF by mortality outcome 
 
 
Figure 7.6 Comorbid renal stages based on eGFR in the total HF-cohort 
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Chapter 8 Non-CVD comorbidity prognostic factors in an incident HF 
general practice cohort sample by first hospital admission  
 
This chapter presents the results of a sub-sample of the main incident HF CPRD cohort linked to hospital 
episodes statistics (HES) data. The HF sample linked to hospital admissions (HF-HA) was taken from the 
main sample of HF patients aged 40 years and over, with a first HF consultation between 1st January 2002 
and 1st March 2012 followed up until January 2014. This chapter describes the HF-HA sample and 
investigates the unadjusted associations between non-cardiovascular comorbidities at baseline and as they 
develop over time and first hospital admission, but also the other patient, social, lifestyle, risk and medication 
factors that may influence this outcome. Baseline characteristics are described in the sample using the 
available data including missing values. Unless stated all baseline associations were significant at a level of 
p<0.01.  For the matched sample, the patient numbers reported for the cases and controls refers to the 
number of observations generated by the matching process. Following imputation, differences in time-
dependent characteristics between the cases and controls are described. Results are presented as number 
(%), mean (SD) or median [Interquartile range; IQR]. 
 
8.1 Study sample: baseline characteristics of total HF-HA sample by first 
hospital admission outcome 
Sample and follow-up: There were 30,061 participants with a first HF consultation code between 1st January 
2002 and 1st March 2012 who had linked HES data. Follow-up ranged from 0 to 12 years (median 82 [IQR 12-
435] days). The risk of first hospital admission following HF diagnosis expressed as a percentage of the total 
cohort at baseline decreased rapidly with each month of follow-up time, shown in Figure 8.1 (dark purple), 
with most events occurring in the shorter follow-up time. There were 24,538 (81.6%) first hospital admissions 
from any cause over the 12-year follow-up, with the risk of admission in the first 1-month (33%), first 3 months 
(46%) and within 1 year (64.6%). Figure 8.1 also shows the cumulative risk of first admission per month of 
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follow-up (light purple). The risk of first admission in the remaining HF patients not admitted in each month of 
follow-up also decreased steeply with time shown in Figure 8.2. 
 
8.1.1 Patient characteristics at baseline in the HF-HA population sample by first hospital admission  
Baseline age at HF diagnosis was negatively skewed with a higher number of older participants; mean 77.3 
(SD 10.9) years and median 79 [IQR 71-85] years (E-Appendix E15 for all continuous variable histograms and 
Q-Q plots). Over the total follow-up time, compared to those not-admitted, people admitted were similar in age 
and gender but significantly more deprived (see Table 8.1).  The sample was 47.1% female with a decreased 
proportion of women in those admitted compared to those not-admitted (46.8% v. 48.5%) although this 
difference was non-significant. Of those admitted, 39.9% had experienced a previous admission within 3-
months of their HF index date, compared to 35% of those not admitted and there were more current smokers 
(13.5% versus 12.6%).  
 
Body mass index (BMI) was positively skewed with more participants with lower BMI. Haemoglobin, 
cholesterol and blood pressure were approximately normally distributed (E-Appendix E15). At baseline those 
admitted, compared to those not admitted, had higher systolic blood pressure (137.6 (21.5) v. 136.4(21) 
mmHg) and lower haemoglobin (13.0 (1.9) v. 13.2 (1.8) g/dL). All other associations were non-significant. 
Median BMI in the HF-HA sample was 26.9 [IQR 23.7-30.8] Kg/m2 and mean cholesterol 4.7 (1.2) mmol/ml. 
 
Of the total sample, 32.2% were prescribed beta-blockers at baseline, 55.7% were prescribed an Angiotensin-
converting-enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB) and 64.4% were prescribed 
diuretics. HF patients admitted compared to those not admitted, were significantly more likely to be prescribed 
diuretics (65.6% v. 59.2%). Other baseline medications were similar in those who had been admitted and not 
admitted. 
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8.1.2 Comorbidity exposures at baseline in the HF-HA sample by first hospital admission  
At HF index date, 3,504 (11.7%) of the sample had chronic obstructive pulmonary disease (COPD), 6,298 
(21%) had diabetes mellitus (DM) and 4,510 (15.0%) had chronic kidney disease (CKD). When CKD was 
defined by an estimated glomerular filtration rate (eGFR) <60 ml/min/m2, prevalence at baseline increased to 
12,687 (50.1%). With the exception of diagnostic CKD, prevalence of all comorbidities was significantly higher 
in the patients experiencing first hospital admission compared to those not admitted; COPD (12.1% v. 9.7%), 
DM (21.8% v. 17.3%) and CKD (eGFR: 51.4% v. 44.5%) (E-Appendix B16). Diagnostic CKD was non-
significant (14.9% v. 15.4%). HF patients admitted were also more likely to have ≥2 coexisting comorbidities 
(18.8% v. 13.3%). The most prevalent disease combination was DM and CKD (eGFR defined) (12.7%) and 
this predominated in those who were admitted (13.3% v. 9.7%) (E-Appendix B17). 
 
In the comorbid DM sample the median glycated haemoglobin (HbA1c) at baseline was 7.1 [IQR 6.4-8.1] % 
which was higher in those with an admission (7.1 [6.4-8.1] v. 6.9 [6.3-7.8] %). In the comorbid COPD, sample 
the median forced expiration volume in 1 second (FEV1) was 53.5 [38.8-70.7] percent predicted (pp) which 
was significantly lower in those admitted than not (53.3 [38.6-70.6] v. 54.8 [41-72] pp). eGFR was measured 
in 84.3% of the baseline HF sub-sample and was mean 60.8 (20.3) ml/min/m2. This level was significantly 
lower in those admitted than not (60.2 (20.1) v. 64.5 (20.6) ml/min/m2). 
 
8.2 Study sample: baseline characteristics by first hospital admission outcome 
of HF sub-samples with different follow up periods  
The total sample will now be reported in 3 overlapping subgroups defined by their follow-up time. As for the 
mortality outcome, this was done to investigate whether the unadjusted associations between baseline factors 
and first hospital admission in the total sample were confounded by variations in the exposure time between 
those admitted and those not admitted (resulting from different follow-up times within the sample). Given the 
significant associations between the baseline factors with the timing of the HF index date for mortality (before 
or after April 2006) it was not necessary to repeat this investigation for the hospital admission sub-sample.  
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8.2.1 HF sub-samples with different follow-up periods: patient characteristics at baseline by hospital 
admission outcome 
The cohort was grouped into three overlapping HF-HA sub-samples with different follow-up periods (i) at least 
up to 1 month (whole sample), (ii) between 1 month and 1 year and (iii) ≥1 year. HF patients with their first 
admission and those without were compared at the end of each follow-up period (see Table 8.2). The 
unadjusted associations between the baseline characteristics and first hospital admission outcome were 
observed over the total follow-up time and by three follow-up time-periods (see E-Appendix A30). Both the 
significance and magnitude of the difference in exposure status between those admitted and not admitted 
differed across the three follow-up periods for some exposures.  
 
Age and prescription of beta-blockers had a significant association with hospital admission in the first and 
longest follow-up periods but there was a lack of association with medium term follow-up.  Females and 
higher deprivation were only significantly associated with hospital admission in the medium term follow-up (1 
month to 1 year).  Other baseline factors varied in the nature of their associations with first hospital admission. 
Lower mean baseline SBP and cholesterol were associated with admission in the medium term follow-up 
period but this reverted to higher mean baseline SBP and cholesterol levels in the longer follow-up period. 
There was no association between these factors and admission in 1-month follow-up period. Prescription of 
diuretics was significantly associated with lower likelihood of admission in the 1-month follow-up period but 
with higher admission in the two longer follow-up periods.  The magnitude of the difference in exposure status 
between those admitted and not admitted became less over time for prior hospital admission within three 
months and for haemoglobin, BMI, alcohol drinkers and prescription of ACEi. These factors had significant 
associations with first hospital admission in the 1-month follow-up period but most lost significance over longer 
follow-up time.  
 
8.2.2 HF sub-samples with different follow-up periods: comorbidity exposures at baseline by hospital 
admission outcome 
All three baseline comorbidities were significantly associated with increased first hospital admission. The 
magnitude of difference in comorbidity exposure for COPD and DM between those admitted and not admitted 
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reduced with longer follow-up and became non-significant.in the longest follow-up period. Diagnostic CKD 
was associated with admission in the follow-up periods up to 1 year, but switched to non-admission for the 
longest follow-up period. CKD defined by eGFR was consistently associated with admission and the 
magnitude of difference in CKD prevalence between those admitted and not admitted more than doubled in 
the longer follow-up period from 4% to 10% difference (49.6% admitted v. 39.6% non-admitted in follow-up > 
1 year). 
 
In the comorbid DM group, HbA1c level was similar in those admitted and not admitted within the first month 
of follow-up, but higher HbA1c level became significantly associated with admission in the 12-month follow-up 
period (median 7.2 [IQR 6.5-8.2] % in those admitted v. 6.9 [6.3-7.7] % in those not-admitted). FEV1 in the 
comorbid COPD group (54.1 [39.6-71] pp) was similar in those with and without admission. eGFR was 
consistently and significantly lower in those admitted than those not admitted across all three follow-up 
periods.  
 
8.3 Study sample: Time-dependent characteristics of the matched HF-HA 
sample by first hospital admission outcome 
From the total HF-HA population sample, 24,339 all-cause first hospital admission cases over the total follow-
up period were matched to up to four controls. Controls were live, active in practice, remained at risk of first 
hospital admission on the case index date and were not themselves admitted for the next 3-months. Controls 
were matched to cases within 1-month of their HF diagnosis study-in date and on duration of follow-up. This 
resulted in 110,789 observations including 86,450 controls. The match date for the controls was the date that 
corresponded with the same amount of follow-up time as the case. Person, socio-demographic factors, 
lifestyle factors and risk factors were measured as the most proximal to the match date during follow-up. Drug 
and comorbidity exposures were measured in specific study time-windows as outlined in chapter 6 (Section 
6.3.4.5). 
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8.3.1 Patient characteristics in the matched HF population sample by first hospital admission 
Median current age on the match date for the hospital admission cases was 79  [IQR 72-85] years which was  
higher than in the controls (78 [70-84] years). Cases were less likely to be female and more deprived (Table 
8.3). The matched sample was 48.6% female with a decrease in the proportion of women in the cases 
compared to controls (46.8% versus 49.1%). The differences in prevalence of current smokers and alcohol 
drinkers between cases and controls were significant. The proportion of smokers in the case group was 
12.4% compared to 10.4% in the controls. Current alcohol drinkers were less prevalent in the cases than 
controls (71.9% v. 74.2% respectively). Cases were five times more likely to have had a prior hospital 
admission in the previous 3 months than controls (20.9% v. 4.1% respectively).   
 
Cases compared to controls, had  lower recent systolic blood pressure (mean 134.1 (21.5) v. 136 (19.8) 
mmHg), diastolic blood pressure (74.7 (12) v. 75.9 (11) mmHg), BMI (median 26.7 [IQR 23.5-30.6] v. 27.2 
[23.9-31.2] Kg/m2), cholesterol (4.66 (1.2) v. 4.73 (1.2) mmol/L) and haemoglobin (12.9  (1.9) v. 13.4 (1.6) 
g/dL).  
 
Of the total sample, 40.1% were prescribed beta-blockers on the match date, 72.6% were prescribed an ACEi 
or an ARB and 72.1% were prescribed diuretics. Cases compared to controls, were  less likely to be 
prescribed beta-blockers (36.5% v. 41.2%), ACEi or ARB (64.3% v. 74.9%) or diuretics (69.9% v. 72.7% 
respectively).  
 
8.3.2 Comorbidity factors in the matched HF-HA population sample by hospital admission 
Comorbid COPD group characteristics: COPD was present in 11,903 (10.7%) HF patients before the match 
date, and prevalence was higher in cases (13.3%) than controls (10.3%). Compared to HF patients without 
COPD, those with HF-COPD were more likely to be younger and more deprived but less likely to be female. 
The HF-COPD group had lower blood pressure, BMI and higher haemoglobin than the non-COPD HF group. 
In the HF-COPD group, 21.3% were current smokers compared to only 9.6% in the non-COPD HF group. 
Compared to the non-COPD HF group, the HF-COPD group were less likely to be prescribed beta-blockers 
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(20.1% v. 42.6%) but more likely to be prescribed diuretics (75.8% v. 71.6%). Prevalence of concomitant 
diabetes and CKD were less likely in the HF-COPD group who had a higher mean eGFR (62.0 (SD 20) v. 
59.2 (19.3) ml/min/m2) (E-Appendix A31).  
 
COPD status: Of the 11,903 HF patients with COPD, 1,060 (8.9%) developed COPD after HF diagnosis. 
COPD that developed before or after HF was more prevalent in the hospital admission group but the 
magnitude of difference between cases and controls was greater for the pre-HF than the post-HF COPD 
group (3.0% v. 0.3%) (Table 8.4 and Figure 8.3).  
 
COPD severity: Only a small proportion of HF-COPD patients had a FEV1 recorded within 6 months of 
admission (1,872; 15.7%). Within the HF-COPD group, median FEV1 was 50pp [38-69] which was similar in 
the cases and controls. HF-COPD categorised into GOLD severity stages was not associated with hospital 
admission. Of the HF-COPD patients, 23.7% had been prescribed oral steroids before admission which was 
higher in the cases (28.6%) than controls (21.8%). Cases were also more likely than controls to be prescribed 
oxygen therapy prior to admission (5.1%% v. 2.1% respectively) (Figure 8.4).  
 
COPD severity change:  There were only 653 (5.5%) HF-COPD patients who had a second FEV1 (pp) 
recorded in the severity measurement time-windows. Whilst there were a higher proportion of cases than 
controls experiencing a worsening of GOLD stage (21.8% v. 16.7%) over the 6-months prior to the match date 
this difference was non-significant. There were 1,171 (9.8%) HF-COPD patients with newly prescribed oral 
steroids or oxygen therapy in the 4-months before hospital admission. New prescription of these drugs were 
lower in cases than controls for steroids (8.8% v. 9.5%) and higher for oxygen (0.8% v. 0.5%), but these 
associations were non-significant.  
 
Comorbid DM group characteristics: Diabetes mellitus was present in 21,291 (19.2%) of HF patients prior to 
the match date which was  higher in cases (22.9%) than controls (18.2%). Compared to HF patients without 
DM, comorbid patients were more likely to be younger and more deprived but less likely to be female. The 
comorbid group had  lower cholesterol and haemoglobin, but higher BMI than the HF group without DM. 
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There were fewer current smokers and alcohol drinkers in the HF-DM group compared to the non-comorbid 
group. Compared to the non-comorbid group, the HF-DM group were more likely to be prescribed beta- 
blockers (45.9% v. 38.8%), ACEi/ARB (82.1% v. 70.3%) and diuretics (76.5% v. 71%). Prevalence of 
concomitant COPD was lower in the HF-DM group but concomitant CKD was more likely with a mean eGFR 
of 58.6 (SD 20.7) compared to 59.7 (19) ml/min/m2 in the non-DM HF group (E-Appendix A32).  
 
DM status: Of the 21,291 HF-DM group, 1,498 (7%) developed DM after HF index diagnosis. DM that 
developed before HF was more prevalent in the hospital admission group with 21.8% in the cases v. 16.8% in 
the controls. DM that developed after HF however was more prevalent in controls (1.4% v. 1.1%) (Table 8.5).  
 
DM severity: Of the comorbid group, 14,578 (68.5%) had had at least one recent HbA1c recorded (median 73  
[IQR 34-118] days). Around 38% of the HF-DM patients had had a most recent HbA1c between 6.5-7.5%. 
Median HbA1c was similar in the cases and controls (7.2 [6.4-8.2] v. 7.1 [6.4-8.1] %) but the lowest HbA1c 
category (<5.5%) and highest  category (≥9.5%) were more prevalent in cases than controls.   
Of the HF-DM group, 27.2% were not on any DM drugs at the time of matching and these patients were  less 
prevalent in the admitted cases (24.9%) than the controls (28.1%). Most HF-DM patients were on oral 
medication (60%) +/- insulin, which was similar in the cases and controls (60.3% v. 59.9%). Of the comorbid 
group, 2,713 (12.7%) were prescribed insulin only which was a first hospital admission in 14.8% of the cases 
and 12.0% of controls.  
 
DM severity change: There were 12,242 (57.5%) HF-DM patients who had had a second HbA1c recorded 
before the most recent measure (161 [IQR 101-212] days). Over 6-months prior to the match date, 12.7% of 
HF-DM with two HbA1c measures experienced an absolute increase of >1% HbA1c and 17.2% experienced 
an absolute decrease of >1% HbA1c. Both categories of HbA1c change were more prevalent in the cases 
than controls (P<0.05). Within the HF-DM group, 7.9% of patients experienced a change in drug category in 
the 6-months prior to their match date. Stable drug regimens were high in both cases and controls (90.6% v. 
92.6% respectively), but more cases had an increase in drug category (6.4% v. 5.8%) or a decrease in drug 
category (3% v. 1.6%). 
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Comorbid CKD group characteristics: Due to the low prevalence of CKD defined by diagnostic codes in 
patients entering the cohort before April 2006, CKD was defined by eGFR <60ml/min/m2 which was recorded 
in 72,399 (65.3%) of the total HF-HA cohort before the match date (median 47 [IQR 18-94] days). CKD was 
present in 37,784 (52.2%) of HF patients. Prevalence was higher in cases (57.9%) than controls (56%).  
Compared to HF patients without CKD, those with HF-CKD were more likely to be older (75 v. 81 years) and 
female (39.1% v. 55.7%).  The comorbid group had  lower haemoglobin and BMI and higher SBP than the 
non-comorbid group. There were fewer current smokers and alcohol drinkers in the HF-CKD group compared 
to the non-CKD HF group. Compared to the non-comorbid group, the comorbid group was less likely to be 
prescribed ACEi/ARB (77.7% v. 75.9%), more likely to be prescribed diuretics (67.8% v. 81.4%) and equally 
likely to be prescribed beta-blockers. Prevalence of concomitant COPD lower in the HF-CKD group than the 
non-CKD HF group, but concomitant DM was more likely (E-Appendix A33).  
 
CKD severity: CKD severity categories based on eGFR level in the HF-cohort (Figure 8.6) showed different 
associations with first hospital admission outcome. The lowest three eGFR severity categories 
(<45ml/min/m2) were more prevalent in the cases (29.1%) than controls (20.7%), whereas the higher three 
eGFR categories (45-105ml/min/m2), were more prevalent in controls (77.8%) than cases (69.2%). eGFR 
>105 ml/min/m2 was slightly more prevalent in cases than controls (1.8% v. 1.7%). 
 
CKD severity change: Two eGFR measures were available for 54,772 (49.4%) of the HF-HA sub-sample. The 
earlier of two measures was recorded 110 days [IQR 59-199] before the most recent measure. Of the cohort, 
12.6% had experienced >15mls decrease in eGFR and 16.4% a >25% decrease in eGFR over the 6 months 
before their match date. An increase in eGFR was experienced in approximately 41.5% of patients over the 
same time frame. Decrease in eGFR but not increase was associated with first hospital admission. Cases had 
4.6% higher prevalence of decreasing eGFR (>15mls) and 5.8% higher prevalence of >25% decrease in 
eGFR than controls. 
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8.4 Chapter summary  
A third of people with HF in the general practice population are admitted to hospital in the first month following 
diagnosis and two thirds within a year. The unadjusted associations between baseline patient characteristics 
and comorbidity exposures and first hospital admission after HF differed by the follow-up time periods. Over 
the total follow-up time these unadjusted associations differed according to whether they were measured at 
baseline or before the event. The unadjusted associations in the shorter follow-up periods were most similar 
to the time-dependent associations measured closest to the event. There was a bigger difference in the 
prevalence of a previous hospital admission within 3 months between  the cases and the controls when 
measured prior to match date rather than at baseline. Other patient characteristics measured before the 
match date showed associations with first hospital admission that were similar to mortality. All three selected 
comorbidities in HF were more prevalent in the hospital admission group than the controls but there was less 
difference for comorbidities that developed after HF than before HF. Comorbidity severity defined by 
physiological and drug measures differed between cases and controls and  measures of  recent severity 
change differed across the two groups for  comorbid diabetes and CKD. These findings will be discussed in 
detail in Chapter 13.
  
213 
 
Tables 
Table 8.1 Baseline characteristics of the sample by first hospital admission outcome over total follow-up 
 
Factors and exposures All  (n=30,061) First hospital admission (n=24,538) Not admitted (n=5,523) P 
Person and socio-demographic factors 
Age, years 79[IQR 71-85] 79[71-85] 79[70-86] 0.292 
Women 14,163 (47.1) 11,485(46.8) 2,678(48.5) 0.024 
IMD quintile  
1 
 
5,844 (19.5) 
 
4,698(19.2) 
 
1,146(20.8) 
<0.01 
 
2 6,946 (23.2) 5,640(23.0) 1,306(23.7)  
3 6,340 (21.2) 5,181(21.1) 1,159(21.0)  
4 6,232 (20.8) 5,090(20.7) 1,142(20.7)  
5 4,612 (15.4) 3,859(15.7) 753(13.63)  
Anthropometric and clinical factors 
BMI (Kg./m2) 26.9[IQR 23.7-30.8] 26.9[23.7-30.8] 27.0[23.8-31] 0.298 
Cholesterol (mmol/L) 4.7 ±1.2 4.7±1.2 4.7±1.2 0.881 
Hb (g/dL) 13.1 ±1.9 13.0±1.9 13.2±1.8 <0.001 
Systolic BP (mmHg) 137.4 ±21.4 137.6`±21.5 136.4 ±21.0 <0.001 
Diastolic BP (mmHg) 76.8 ±12 76.7±12.1 `76.9±11.6 0.503 
Prior Hospital admission     <0.001 
<3 months 11,719 (39) 9,779 (39.9) 1,940 (35.1)  
3-6 months 2,471 (8.2) 2,064 (8.4) 407 (7.4)  
>6months - 1 year 2,711 (9.0) 2,257 (9.2) 454 (8.2)  
Lifestyle factors     
Smoking status     <0.001 
Yes       3,866 (13.3) 3,198(13.5) 668(12.6)  
No 13,614 (47.0) 10,963(46.3) 2,651(49.9)  
Ex 11,504 (39.7) 9,511(40.2) 1,993(37.5)  
Alcohol status     0.927 
Yes 19,296 (72.8) 15,790(72.8) 3,506(72.9)  
No 6,152 (23.2) 5,043(23.2) 1,109(23.1)  
Ex 1,060 (4.0) 864(4) 196(4.1)  
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Drug factors     
Diuretics 19,359(64.4) 16,089(65.6) 3,270(59.2) <0.001 
Beta blocker 9,683 (32.2) 7,877(32.1) 1,806(32.7) 0.390 
ACEi 13,589 (45.2) 11,044(45.0) 2,545(46.1) 0.148 
ARB 3,779 (12.6) 3,091(12.6) 688(12.5) 0.777 
Comorbidity exposures    
Diabetes 6,298 (21.0) 5,345(21.8) 953 (17.26) <0.001 
HbA1c (%) (in diabetes only) 7.1[IQR 6.4-8.1] 7.1[IQR 6.4-8.1] 6.9[IQR 6.3-7.8] <0.01 
COPD  3,504 (11.7) 2,968(12.1) 536(9.7) <0.001 
FEV1 (pp) (in COPD only) 53.5[IQR 38.8-70.7] 53.3[38.6-70.6] 54.8[IQR 41-72] 0.464 
CKD (medical code) 4,510 (15.0) 3,662(14.9) 848(15.4) 0.419 
CKD (eGFR<60)  12,687 (50.1) 10,616(51.4) 2,070(44.5) <0.001 
eGFR (ml/min/1.73m2) 60.8 ±20.3 60.2±20.1 64.5±20.6 <0.001 
Number of comorbidities   <0.001 
0 8,518 (33.6) 6,629(32.1) 1,889(40.6)  
1 12,290 (48.5) 10,161(49.2) 2,129(45.7)  
2 4,202 (16.6) 3,601(17.4) 601(12.9)  
3 322 (1.3) 283(1.4) 176(0.9)  
Data are number patients (%) or mean± standard deviation or median[IQR].  IMD, index multiple deprivation (1=least deprived, 5=most deprived); BMI, body mass 
index; Hb, haemoglobin; BP, blood pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HbA1c, glycated haemoglobin; 
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; pp, percent predicted; eGFR, estimated glomerular filtration rate. 
Number of comorbidities is based on those listed (COPD, DM, CKD defined by eGFR). HbA1c and FEV1 were measured in the respective DM and COPD groups 
only. eGFR was measured in all HF patients 
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Table 8.2 First hospital admission by short, medium and long follow-up time periods 
Follow-up month Number entering follow-up month (n) Admitted during follow-up month (%) Censored during follow-up month (%) Not admitted at end of follow-up month (n) 
1 30061 9801(32.6) 1395(4.6) 18865 
2 18865 2471(13.1) 170(0.9) 16224 
3 16224 1573(9.7) 140(0.9) 14511 
4 14511 1147(7.9) 119(0.8) 12245 
5 13245 819(6.2) 91(0.7) 12335 
6 12335 771(6.3) 80(0.6) 11484 
7 11484 600(5.2) 69(0.6) 10815 
8 10815 563(5.2) 68(0.6) 10184 
9 10184 480(4.7) 82(0.8) 9622 
10 9622 443(4.6) 58(0.6) 9121 
11 9121 417(4.6) 64(0.7) 8704 
12 8704 349(4.0) 50(0.6) 8223 
13 8223 301(3.7) 52(0.6) 7870 
14 7870 275(3.5) 51(0.6) 7544 
15 7544 241(3.2) 60(0.8) 7243 
16 7243 221(3.1) 50(0.7) 6972 
17 6972 245(3.5) 53(0.8) 6674 
18 6674 202(3.0) 40(0.6) 6432 
≥19 6432 3619(56.3) 2831(44) 6190 
Censored data included subjects who (i) belonged to a practice that stopped contributing data to the CPRD during the follow-up month (ii) were transferred out of the practice (iii) died or (iv) 
reached the study end. 
  
216 
 
 
Table 8.3 Time-matched characteristics of the matched sample by first hospital admission outcome over maximum 12 years follow-up 
 
 
 
Factors and exposures 
 
All (n=110,789) 
 
Cases (n= 24,339) 
 
Controls (n=86,450) 
 
Missing n(%) 
Person and socio-demographic factors 
Current age, years 78[IQR 70-84] 79[72-85] 78[70-84] - 
Women 53,804(48.6) 11,388(46.8) 42,416(49.1) - 
IMD quintile     - 
1 22,567(20.4) 4,676(19.2) 17,891(20.7)  
2 26,602(24.0) 5,612(23.1) 20,990(24.3)  
3 23,003(20.8) 5,155(21.2) 17,848(20.6)  
4 22,579(20.4) 5,060(20.8) 17,519(20.3)  
5 16,038(14.5) 3,836(15.8) 12,202(14.1)  
Anthropometric and clinical factors 
BMI (Kg/m2)  27.2[23.9-31.2] 26.7[23.5-30.6] 27.3[24.1-31.3] - 
Cholesterol (mmol/L)  4.7±1.2 4.66±1.2 4.73±1.2 - 
Hb (g/dL) 13.3±1.7 12.9±1.9 13.4±1.6 - 
Systolic BP (mmHg)  135.6±20.2 134.1±21.5 136.0±19.8 - 
Diastolic BP (mmHg)  75.7±11.2 74.7±12.0 75.9±11.0 - 
Prior Hospital admission     - 
<3 months 8,663 (7.8) 5,085(20.9) 3,578(4.1)  
3-6 months 8,387 (7.6) 2,509(10.3) 5,878(6.8)  
>6months to 1 year 12,930 (11.7) 2,918(12.0) 10,012(11.6)  
Lifestyle factors 
Smoking status     - 
yes       12,028(10.9) 3,025 (12.4) 9,003 (10.4)  
No 53,310(48.1) 11,240(46.2) 42,070 (48.7)  
Ex 45,451(41.0) 10,074(41.4) 35,377(40.9)  
Alcohol status     - 
Yes 81,676(73.7) 17,500(71.9) 64,176(74.2)  
No 24,783(22.4) 5,779(23.7) 19,004(22.0)  
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Ex 4,330(3.9) 1,060(4.4) 3,270(3.8)  
Drug factors 
Diuretics 79,860(72.1) 17,023(69.9) 62,837(72.7) - 
Beta blocker 44,467(40.1) 8,893(36.5) 35,574(41.2) - 
ACEi 63,907(57.7) 12,477(51.3) 51,430(59.5) - 
ARB 19,324(17.4) 3,722(15.3) 15,602(18.1) - 
ACEi or ARB 80,420(72.6) 15,645(64.3) 64,755(74.9) - 
Comorbidity exposures 
Diabetes  21,291(19.2) 5,577(22.9) 15,714(18.2) - 
COPD 11,903(10.7) 3,230(13.3) 8,673(10.3) - 
Renal disease (eGFR <60)  37,784(52.2) 9,199(57.9) 28,585(50.6) 38,390(34.7) 
Number of comorbidities     38,390(34.7) 
0 23,607(32.6) 4,240(26.7) 19,367(34.3)  
1 36,190(50.0) 8,011(50.4) 28,179(49.9)  
2 11,687(16.1) 3,350(21.1) 8,337(14.8)  
3 915(1.3) 291(1.8) 624(1.1)  
Data are number patients (%) or mean± standard deviation or median[IQR].  IMD, index multiple deprivation (1=least deprived, 5=most deprived); BMI, 
body mass index; Hb, haemoglobin; BP, blood pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HbA1c, 
glycated haemoglobin; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate. Number of comorbidities is based on 
those listed (COPD, DM, CKD defined by eGFR), 
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Table 8.4 Time-dependent COPD comorbidity exposures of the matched sample by first hospital admission outcome 
Comorbidity measures All HF-HA (n=110,789) Cases (n= 24,339) Controls (n=86,450) Missing n(%) 
COPD diagnostic code (n=11,903) 11,903(10.7) 3,230(13.3) 8,673(10.3)  
Diagnosis before HF (91.1%) 10,843(9.8) 2,946(12.1) 7,897(9.1) - 
Diagnosis after HF (8.9%) 1,060(1.0) 284(1.2) 776(0.9) - 
COPD FEV1 severity (COPD group only)  All HF-COPD (n=11,903) Cases HF-COPD (n= 3,230) Controls HF-COPD (n=8,673)  
FEV1(percent predicted)  50[36.6-65.0] 51.6[37.0-66.0] 49.7[36.5-64.6] 10,031(84.3) 
COPD GOLD severity stage    10,031(84.3) 
   1: FEV1 ≥80% normal 187(10.0) 53(9.7) 134(10.1)  
   2: FEV1 50-79% normal 758(40.5) 232(42.4) 526(39.7)  
   3: FEV1 30-49% normal 666(35.6) 190(34.7) 476(35.9)  
   4: FEV1 <30% normal 261(13.9) 72(13.2) 189(14.3)  
COPD Drug severity    - 
No steroids or oxygen (ref) 8,743(73.5) 2,143(66.4) 6,600(76.1) - 
Oral steroids but no oxygen 2,817(23.7) 923(28.6) 1,894(21.8) - 
On  oxygen 343(2.9) 164(5.1) 179(2.1) - 
COPD FEV1  severity change (COPD group only)    
   Gold stage same or better (ref) 534 (81.8) 151(78.2) 383(83.3) 11,250(94.5) 
   Gold stage worse (at least one stage) 119(18.2) 42(21.8) 77(16.7)  
10% change     
   <10% change (ref) 379(58.0) 116(60.1) 263(57.2) 11,250(94.5) 
   ≥10% increase (better) 126(19.3) 31(16.1) 95(20.7)  
   ≥10% decrease (worse) 148(22.7) 46(23.8) 102(22.2)  
5% change    11,250(94.5) 
   <5% change (ref) 253(38.7) 78(40.4) 175(38.0)  
   ≥5% increase (better) 175(26.8) 52(26.9) 123(26.7)  
   ≥5% decrease (worse) 225(34.5) 63(32.6) 162(35.2)  
COPD severity change (Drugs)    - 
No new steroids or oxygen (ref) 10,732(90.2) 2,920(90.4) 7,812(90.1)  
New on steroids but no new oxygen 1,107(9.3) 285(8.8) 822(9.5) - 
New on oxygen 64(0.5) 25(0.8) 39(0.5) - 
Data are number patients (%) or mean± standard deviation or median[IQR].  First hospital admission is the first all-cause admission following the incident HF date. COPD, chronic 
obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; pp, percent predicted; ref, reference group. Most recently recorded FEV1 (pp) before the match date 
was used to measure COPD severity within a maximum of a 6-month time window. % change for FEV1 was calculated as the absolute change in pp over 6-months using the 
most recent measure and an earlier FEV1 measure recorded up to a maximum of 1-year before the most recent measure. The FEV1 change was adjusted for the time interval. 
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Table 8.5 Time-dependent DM comorbidity measures of the matched sample by first hospital admission outcome 
  
 
Comorbidity exposure measures All HF-HA (n=110,789) Cases HF-HA (n= 24,339) Controls HF-HA (n=86,450) Missing n(%) 
Diabetes status (n=21,291) 21,291(19.2) 5,577(22.9) 15,714(18.2)  
Diagnosis before HF (93%) 19,793(17.9) 5,300(21.8) 14,493(16.8) - 
Diagnosis after HF (7%) 1,498(1.4) 277(1.1) 1,221(1.4) - 
Diabetes HbA1c severity (DM group only) All HF-DM (n=21,291) HF-DM Cases (n= 5,577) HF-DM Controls (n=15,714)  
HbA1c (%)  7.1[IQR 6.4-8.1] 7.2 [6.4-8.2] 7.1[6.4-8.1] 6,713(31.5) 
<5.5% 424(2.9) 137(3.8) 287(2.6)  
5.5-6.4% 3,307(22.7) 803(22.2) 2,504(22.9)  
6.5-7.5%  5,461(37.5) 1,282(35.4) 4,179(38.1)  
7.6-8.5% 2,771(19.0) 673(18.6) 2,098(19.2)  
8.6-9.5% 1,302(8.9) 328(9.1) 974(8.9)  
>9.5% 1,313(9.0) 398(11.0) 915(8.4)  
Diabetes drug severity      
   1: None  5,799(27.2) 1,390(24.9) 4,409(28.1) - 
   2: Any oral (+/-Insulin) 12,779(60.0) 3,364(60.3) 9,415(59.9) - 
   3: Insulin only 2,713(12.7) 823(14.8) 1,890(12.0) - 
Diabetes HbA1c severity change (DM group only)    9,049(42.5) 
   <1% change (ref) 8,592(70.2) 2,056(67.7) 6,536(71.0)  
   >1% increase 1,551(12.7) 409(13.5) 1,142(12.4)  
   >1% decrease 2,099(17.2) 570(18.8) 1,529(16.6)  
Diabetes drugs severity change     - 
No drug category change 19,607(92.1) 5,052(90.6) 14,555(92.6) - 
Increase in drug category  1,261(5.9) 356(6.4) 905(5.8) - 
Decrease in drug category 423(2.0) 169(3.0) 254(1.6)  - 
Data are number patients (%) or mean± standard deviation or median[IQR].  First hospital admission is the first all-cause admission following the incident HF date. HbA1c, glycated 
haemoglobin; ref, reference group. Most recently recorded HbA1c (%) prior to the match date was used to measure diabetes severity within a maximum of a 6-month time window. 
HbA1c change was calculated as the absolute change in HbA1c over 6-months using the most recent measure and an earlier HbA1c measure recorded up to a maximum of 1-year 
before the most recent measure. HbA1c change was adjusted for the time interval.  
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Table 8.6 Time-dependent CKD comorbidity exposures of the matched sample by first hospital admission outcome 
 
Comorbidity measures All (n=110,789) Cases (n= 24,339) Controls (n=86,450) Missing n(%) 
Renal disease diagnosis      
eGFR <60 37,784(52.2) 9,199(57.9) 28,585(50.6) 38,390(34.7) 
Renal severity (eGFR)     
eGFR mL/min/1.73m2 59.5±19.4 56.5±20.9 60.3±18.9 38,390(34.7)) 
Renal severity by eGFR stage*    38,390(34.7) 
   1: >105 1,248(1.7) 281(1.8) 967(1.7)  
   1:    90-105 3,633(5.0) 778(4.9) 2,855(5.1)  
   2:    60-89 29,734(41.1) 5,634(35.5) 24,100(42.7)  
   3A:  45-59 21,497(29.7) 4574(28.8) 16,923(30.0)  
   3B:  30-44 12,616(17.4) 3,182(20.0) 9,434(16.7)  
   4:    15-29 3,372(4.7) 1,243(7.8) 2,129(3.8)  
   5:    <15 299(0.4) 200(1.3) 99(0.2)  
eGFR severity change     56,017(50.6) 
Absolute change     
   0mls to 5mls decrease (ref) 13,020(23.8) 2,691(21.9) 10,329(24.3)  
   >15mls decrease 8,856(16.2) 2,431(19.7) 6,425(15.1)  
   6mls to 15mls decrease 10,161(18.6) 2,307(18.7) 7,854(18.5)  
   any increase 22,735(41.5) 4,888(39.7) 17,847(42.0)  
Percentage change     
   0-5% decrease (ref) 8,148(14.9) 1,540(12.5) 6,608(15.6)  
   >25% decrease 8,972 (16.4) 2,578(20.9) 6,394(15.1)  
   6-25% decrease 14,548(26.6) 3,233(26.3) 11,315(26.7)  
   Any % increase 23,104(42.2) 4,966(40.3) 18,138(42.7)  
Data are number patients (%) or mean± standard deviation. First hospital admission is the first all-cause admission following the 
incident HF date. eGFR, estimated glomerular filtration rate; ref, reference group; ref, reference group. * National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines. >105 group added to stage one due to the prior evidence of increased 
risk in high eGFR. % change was calculated as the absolute change in eGFR over 6-months and the relative change (difference in 
eGFR over 6-months as a proportion of the first eGFR measure)  
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Figures 
Figure 8.1 First hospital admissions as a percentage of the total HF-HA sample at baseline in each month of follow-up
 
Figure 8.1: The dark purple bars show the percentage of the baseline cohort who were admitted in each month of follow up. The denominator in this figure is the 30,061 subjects in the baseline 
cohort. The light purple bars show the cumulative percentage of the baseline cohort who were admitted over the 12 years of follow-up. 
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Figure 8.2 First hospital admissions as a percentage of the remaining HF patients not admitted, per follow-up month 
 
      Figure 8.2: The purple bars show the percentage of remaining subjects who were admitted who entered each month of follow up. 
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Figure 8.3   Comorbid COPD diagnosed pre and post HF by first hospital admission outcome 
 
 
Figure 8.4 Comorbid COPD group drug severity stages 
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Figure 8.5 Comorbid DM diagnosed pre and post HF by first hospital admission outcome 
 
Figure 8.6 Comorbid renal stages based on eGFR in the HF-HA cohort 
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Chapter 9 Non-CVD comorbidity prognostic factors in an incident HF 
general practice population: strength of associations with all-cause 
mortality.  
 
This chapter follows on from the descriptive findings (Chapter 7) of the main incident HF CPRD cohort and the 
outcome of all-cause mortality. This chapter presents the results of the investigation of the strength of 
associations between the selected non-CVD comorbidities (COPD, DM and CKD) in HF and all-cause 
mortality. The effects of time-dependent exposures of the three comorbidities on all-cause mortality are firstly 
presented by their status ‘present or not’ followed by their stratification by categories of severity and change. 
All effect estimates will be presented as odds ratios (OR) with 95% confidence intervals (CI). 
 
This chapter presents the findings of the five stages to analysis: 
(i) Confounding investigation 
(ii) Test of model assumptions: linearity  
(iii) Test of model assumptions: collinearity 
(iv) Adjusted associations of the comorbidities with mortality 
(v) Comorbidity effects stratified by categories of severity and change  
 
9.1 Confounding investigations 
There were four steps to the investigation of confounding. The potential confounders for each of DM, COPD 
and CKD that were identified in all four steps are summarised in Table 9.1. The first step was to list all 
confounders that were identified for each of the comorbidities from previous HF evidence included in the 
systematic review (step 1, Table key; SR). The second step was to identify from the available CPRD data, the 
potential confounders which differed between the comorbid and the non-comorbid groups in Chapter 7 (step 
2, Table key *). In step 3, each comorbid DM, COPD, CKD effect in HF was now compared in strata of these 
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potential confounders to investigate whether their strength of association with mortality differed across strata 
(step 3, Table key #). Finally, the three comorbidity effects are then adjusted for each available potential 
confounder in turn, to further investigate confounding (step 4, Table key ƚ). A 10% difference in the 
comorbidity effect in steps 3 and 4 was used to indicate confounding(9). 
 
Comorbidity effects within strata of the potential confounders (step 3): The unadjusted associations between 
the potential confounders in HF and all-cause mortality are reported in Table 9.2. The potential confounders 
that had the strongest unadjusted associations with mortality were age, body mass index (BMI), cholesterol, 
haemoglobin and cardiovascular medications. When the unadjusted associations between the three 
comorbidities and mortality were observed within strata of potential confounders, it was these factors (with the 
exception of cholesterol) that resulted in a >10% change to the odds ratio of the comorbidity (E-Appendix 
A34). The relative effects all three comorbidities were strengthened in the youngest age groups and in the 
groups prescribed beta-blockers for HF-DM and HF-CKD. The relative effects were reduced in the groups with 
lower BMI or not prescribed ACEi or ARB for HF-COPD and HF-CKD. The effect of HF-CKD was reduced in 
the group with lower haemoglobin level or with combined HF-COPD.  
 
Comorbidity associations with all-cause mortality adjusted by each potential confounder (step 4): Age was a 
consistent confounder across all three comorbidities (COPD, DM, CKD) (E-Appendix A35). In the HF-DM and 
HF-COPD groups (which were younger than their non-DM or non-COPD HF counterparts), adjustment for age 
strengthened the comorbidity associations with mortality. This was the reverse in the older HF-CKD group 
where its association with mortality was reduced by the adjustment of age (OR 1.77 reduced to 1.34).  
 
Absence of beta-blockers was strongly associated with mortality (OR 1.75; 95% CI 1.70-1.80) and was 
observed more in the HF-COPD group (Chapter 7). Adjustment of HF-COPD by prescription of beta-blockers 
reduced its effect on mortality. BMI which also had a strong association with mortality (OR 0.94 per increase 
Kg/m2; 0.94-0.95). BMI was higher in the HF-DM group than the non-DM HF group (median 29.2 [IQR 25.5-
33.7] v. 26.3 [23.1-30] kg/m2). Adjustment of the HF-DM effect by BMI strengthened its association with 
mortality (OR 1.09 increased to 1.32). 
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Haemoglobin had one of the strongest unadjusted effects on mortality (OR 0.78 per increase g/dL; 0.77-0.78). 
The effect estimates on mortality of HF-DM and HF-CKD (which both had a lower mean haemoglobin than the 
non-DM and non-CKD groups respectively), were reduced following adjustment by haemoglobin (DM, OR 
1.09 reduced to 0.98; CKD, OR 1.77 reduced to 1.42).   
 
Summary of the confounders for each of the three comorbidities: All of the available covariates from CPRD 
were identified as potential confounders for each of the three comorbidities through the four steps of 
confounding investigation. The covariates were used to adjust each comorbidity exposure in order of their 
potential importance as follows (summarised Table 9.3): 
 
a. Factors identified in step 3 (10% change of the comorbidity effect in any strata of the 
potential confounder) and/or step 4 (10% change in the comorbidity effect when adjusted by 
the potential confounder), 
 
b. Previous evidence of confounding identified in the systematic review studies (step 1) AND a 
difference in the prevalence of the potential confounder between the comorbid disease 
compared to the non-comorbid group in the CPRD analyses (step 2), 
 
c. One of step 1 OR step 2, 
 
d. Sub-analysis adjusted for deprivation. 
 
9.2 Test of model assumptions: linearity  
There were 7 continuous covariates to include in the adjusted models, which were age, BMI, cholesterol, 
haemoglobin, systolic and diastolic blood pressure and estimated glomerular filtration rate (eGFR). The fit of 
the covariate as a linear term was investigated by using likelihood ratio tests. The fit of different expressions of 
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the covariate was also observed using fitted line plots and Eccles plots.  For each continuous variable, fully 
adjusted models using the covariates in Table 9.2 were derived and then quadratic and cubic terms for the 
continuous variable incrementally added. The models were compared using likelihood ratio tests. Fitted line 
plots were then used to compare a Lowess line, which closely follows the observed data, with linear and 
quadratic extension fitted lines of the association between the continuous variable and predicted probabilities 
of mortality. Finally Eccles plots were used to graph deciles of each covariate against predicted probabilities 
using fully adjusted models with the continuous covariate included and with the additional quadratic and cubic 
extensions. These plots included Lowess lines to compare the predicted models with the observed data. All 
linearity tests for the 7 continuous covariates are shown in E-Appendix E16 and summarised in E-Appendix 
A36 with two examples detailed below. 
 
 Age 
Likelihood ratio tests showed that addition of a quadratic extension to age significantly improved the model fit 
with a small increase in log-likelihood of 53.26, (Table 9.4). Further addition of a cubic term made no 
significant difference. The fitted line plots showed a straight line for the largest distribution of age covering the 
inter-quartile range (71-85 years) (Figure 9.1). Eccles plots showed good fit of the adjusted models with (i) 
current age and with (ii) current age plus the quadratic term (age2) (Figure 9.2).  Given that there was minimal 
improvement in model fit by addition of a quadratic extension and the largest distribution of age range had a 
linear association with mortality, the final modelling decision was to include age in its simple form assuming 
linearity.  
 
 eGFR 
Likelihood ratio tests showed that addition of a quadratic extension to eGFR significantly improved the model 
fit with a substantial increase in log-likelihood of 385.06 (Table 9.5). Further addition of a cubic term also 
made a significant difference but with only a small change to log-likelihood of 9.53. The fitted line plot showed 
a curvilinear association between eGFR and mortality risk with an upward slope starting at approximately 
eGFR 100ml/min/m2. The fitted line using a quadratic extension followed the observed line closely (Figure 
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9.3).  Eccles plots showed good fit of the adjusted models with eGFR plus the quadratic term (eGFR2) (Figure 
9.4). 
 
Given that there was a substantial improvement in model fit by adding a quadratic extension and only a slight 
improvement by adding a cubic extension, the final modelling decision was to include eGFR with a quadratic 
extension (eGFR2) in the adjusted models.  
 
9.3 Test of model assumptions: collinearity 
Most covariate pairs had a correlation coefficient of r<0.25 The strongest correlations were systolic and 
diastolic blood pressures (r=0.55) and CKD and eGFR (r=0.8) (correlation matrix E-Appendix C15). Systolic 
blood pressure and not diastolic blood pressure was selected as a covariate based on previous evidence as a 
predictor of outcomes in cardiovascular disease(462)  and  eGFR as a continuous measure for adjusting in 
the DM and COPD models. All continuous variables were centred at their means (Age 77 years; cholesterol 5 
mmol/ml; Hb 13 g/dL; BMI 28 Kg./m2; systolic BP 131 mmHg; eGFR 59 ml/min/m2) which removed the 
collinearity between the variable with a respective quadratic term (E-Appendix C16).  
 
9.4 Adjusted associations between DM, COPD, CKD comorbidity in HF and 
mortality 
 
9.4.1 Diabetes Mellitus  
In the incident HF population, the unadjusted association between comorbid DM and all-cause mortality was 
OR 1.09 (95% CI 1.06-1.12). This estimate was most influenced by adjustment for the first set of confounders: 
age, eGFR, BMI, Hb and no beta-blocker (OR 1.26; 1.21-1.30) (Table 9.6). Adjustment of the remaining 
confounders (OR 1.28; 1.23-1.33) or deprivation did not diminish these estimates (OR 1.26; 1.19-1.33).  
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9.4.1.1 Timing of DM comorbidity 
When DM was stratified by prevalent DM at the time of HF diagnosis (pre-HF DM) or incident DM developing 
after HF diagnosis (post-HF DM), there was a difference in the associations with mortality. The adjusted 
association for pre-HF DM was OR 1.31 (1.26-1.37) which was not influenced by deprivation. The adjusted 
association for post-HF DM was 1.13 (1.03-1.23) (Figure 9.5). This association became non-significant when 
adjusted for deprivation in the sub-analysis (1.08; 0.95-1.23).  
 
9.4.1.2 Comorbid Diabetes Mellitus severity 
 Physiological severity measure   
The HF group with comorbid DM was stratified into groups by glycated haemoglobin (HbA1c) levels. This 
categorisation used the closest available measure preceding the match date (median 114 [IQR 52-206] days) 
comparing the HF group with and without diabetes. 
 
Shape of association:  There was a curvilinear relationship between categories of HbA1c in the HF-DM group 
and their respective predicted probabilities of mortality observed (Figure 9.6) using a margins plot. A margins 
plot graphs categories of a continuous variable against predicted risk whilst fixing other covariate effects at 
zero. The DM category associated with the lowest risk was HbA1c 6.5%-7.5%. When HbA1c was categorised 
into deciles, the curved U shape curve remained with the lowest risk decile being HbA1c 5.9%-6.2% (Figure 
9.7). 
 
Strength of associations: Fully adjusted associations between categories of HbA1c in the HF-DM group and 
mortality, compared to the no DM HF group are shown in Table 9.6. The association between HbA1c category 
6.5%-7.5% and mortality was OR 1.19 (95% CI 1.12-1.26). From this lowest risk level, mortality increased with 
both decreasing and increasing HbA1c categories. The estimate for the lowest HbA1c category (<5.5%) was 
OR 1.34 (1.16-1.54) and for the highest HbA1c category (>9.5%) was 1.45 (1.30-1.62) (Figure 9.8. In the fully 
adjusted model, the linear tests for trend in the reducing categories from ‘6.5%-7.5%’ was non-significant but 
was significant in the increasing categories from 6.5%-7.5%.  
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The highest mortality risk categories were HbA1c 8.6%-9.5% (adjusted OR 1.49 (1.34-1.67)) and HbA1c 
>9.5% (adjusted 1.45; (1.30-1.62)). The association was also significant for the lowest risk category of HbA1c 
6.5%-7.5% (1.19; 1.12-1.26), but notably the confidence intervals did not over-lap with higher HbA1c levels 
indicating significant stratified DM effects by severity (Figure 9.8).  
 
 Drug severity measure   
The HF-DM group were stratified into groups based on DM-related prescribed medications in a four month 
time-window before the match date. The groups were: (i) DM but no related medications, (ii) DM and oral 
hypoglycaemics, (iii) DM and oral hypogycaemics plus insulin, (iv) DM and insulin only. These groups were 
compared to the HF sample without diabetes. 
 
Strength of associations: When adjusted for all confounders (Table 9.6), all HF-DM drug groups had a 
significant association with mortality with the largest effects in the ‘no medications group’ (OR 1.37; 1.29-1.46) 
and the ‘insulin only group’ (OR 1.56; 1.44-1.68). Sub-analysis with adjustment for deprivation made little 
difference to the effect estimates. 
 
The HF-DM group with prescribed ‘oral hypoglycaemic drugs’ had similar adjusted associations with mortality 
to the HF-DM group with ‘oral hypoglycaemic drugs plus insulin’ (OR 1.16 (95% CI 1.10-1.22) and 1.18 (1.07-
1.32) respectively). The largest effects estimates for ‘no medications’ and ‘insulin only’ shown above had 
confidence intervals that did not overlap with the estimate for the DM with ‘oral hypoglycaemic drugs +/- 
insulin’ (OR 1.17; 1.11, 1.22) indicating stratified effects of comorbid DM as measured by drugs prescribed 
(Figure 9.9). 
 
9.4.1.3 DM severity change 
 Physiological severity change measure 
The HF-DM group were stratified into three groups according to change in their glycated haemoglobin 
(HbA1c) level over 12-months before the match date. Change definition was based on the closest available 
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HbA1c measure preceding the match date and a previous measure before the most recent measure (median 
298 [IQR 230-379] days). Change over one-year was calculated and compared to the HF sample without DM. 
 
Strengths of associations: All three categories of HbA1c change in HF were significantly associated with 
mortality in the adjusted models (Table 9.6). Those with less than 1% change or a >1% increase in HbA1c 
had similar adjusted associations with OR 1.22 (1.16-1.28) and 1.28 (1.17-1.40) respectively. The association 
for a >1% reduction in HbA1c had the strongest association with mortality with OR 1.49 (1.37-1.61). When the 
first two groups with a similar estimate of effects were combined (<1% change or >1% increase), the 
confidence interval of the effect estimate of the group with a >1% decrease in HbA1c did not overlap with the 
combined group (OR 1.23; 1.18-1.29) (Figure 9.10). 
 
Drug severity change measure:  The DM group were stratified into three groups based on change in their 
prescribed DM-related drugs over a year before the match date. This measure used the DM drugs prescribed 
in a 4-month time-window before death compared to a 4-month time-window a year before death. The two 
oral hypoglycaemic drug categories were combined for this measurement resulting in three drug categories; 
‘no drugs’, ‘oral hypoglycaemic +/- insulin’ and ‘insulin only’. Change in drug category over one year was 
categorised into ‘no change’, an ‘increase in at least one drug category’ and a ‘decrease in at least one drug 
category’. These groups were compared to the HF sample without diabetes. 
 
Strength of associations: Fully adjusted associations between drug category change and mortality showed the 
highest risk was in the ‘decreased at least one drug category’ group with OR 2.30 (2.01-2.63). The adjusted 
associations for ‘no change’ and ‘increased at least one drug category’ were similar with OR 1.23 (1.19-1.29) 
and 1.33 (1.20-1.48) respectively.      
 
9.4.2 Chronic obstructive pulmonary disease  
The adjusted association between HF-COPD and all-cause mortality compared to non-comorbid group was 
OR 1.47 (95% CI 1.41-1.54). Adjustment was by age, no beta-blocker, BMI, eGFR, no ACEi/ARB and Hb 
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(Table 9.7) and the estimate reduced to OR 1.35 (1.29, 1.41) in the fully adjusted model (Table 9.7). Sub-
analysis adjusting for deprivation made little difference.  
 
9.4.2.1 Timing of COPD comorbidity 
When COPD was stratified by  prevalent COPD at the time of HF diagnosis (pre-HF COPD) or incident COPD 
developing after HF diagnosis (post-HF COPD), there was a difference in the associations with mortality. The 
association between pre-HF COPD and mortality was 1.32 (1.25-1.38) in the fully adjusted model. The 
adjusted association between post-HF COPD and mortality was increased following the same adjustment, 
with an OR 1.46 (1.34-1.60). This association was not further influenced by deprivation (Figure 9.5). 
 
9.4.2.2 Comorbid COPD severity  
 COPD Physiological severity measure 
The HF-COPD group was stratified into four groups according to their forced expiration volume in 1 second 
(FEV1) levels defined by GOLD guidelines(410). This measure used the closest available measure preceding 
the match date (median 295 [IQR 137-524] days) comparing the HF group with and without COPD. 
 
Shape of association: The shape of the adjusted associations between the GOLD stages and their respective 
predicted probabilities of mortality appeared linear for the last three stages (Figure 9.11) using a margins plot.  
 
Strength of associations: Fully adjusted associations between the GOLD stages and mortality, compared to 
no COPD HF are shown in Table 9.7. All GOLD stages showed higher risk estimates for mortality than the 
total HF-COPD group which included patients with and without recorded FEV1. The lowest risk category was 
FEV1 ≥80% with an estimate of OR 1.73 (1.50-1.99). Mortality risk increased with GOLD stages from stage 1 
(FEV1 ≥80%) to stage 4 (<30%) which had a relative risk of OR 3.14 (2.65-3.73) shown in Figure 9.12. Sub-
analysis with adjustment for deprivation made little difference to the risk estimates. 
 
The linear test for trend showed a significant adjusted association between the GOLD stages in HF and 
mortality. The highest risk categories were FEV1 30-49% (adjusted OR 2.31; 2.09-2.54) and FEV1 <30% 
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normal (OR 3.14; 2.65-3.73). Both risk estimates had confidence intervals that did not overlap with the 
confidence interval of the lower two risk categories of FEV1 ≥80% (OR 1.73; 1.50-1.99) and FEV1 50-79% 
(1.76; 1.61-1.91) (Figure 9.12). There was more than doubling of the risk of mortality in the higher risk HF-
COPD groups compared the lower risk COPD groups.  
 
 COPD drug severity measure    
The HF-COPD group was stratified into seven groups according to their prescribed COPD-related 
medications in a 4-month time-window before the match date. The 7 groups were: (i) COPD and no 
medications, (ii) COPD and short terms inhalers only, (iii) COPD and monotherapy, (iv) COPD and dual 
therapy, (v) COPD and triple therapy, (vi) COPD and prescribed oral steroids and no prescribed oxygen, and 
(vii) COPD and prescribed oxygen. Mono, dual or triple therapy related to the prescription of one, two or three 
of long acting beta2-antagonist, long acting cholinergic, methylxanthines and inhaled steroids, either 
individually or in combination inhalers. These groups were compared to the HF sample without COPD. 
 
Strength of associations: Fully adjusted associations between the COPD drug severity groups compared to 
non-comorbid groups and mortality are shown in Table 9.7. With the exception of ‘COPD and triple therapy’, 
the associations between COPD inhaler therapies and mortality were non-significant. In the second drug 
severity classification, combining the inhaler therapies into one group (‘any inhalers’) showed a relative 
mortality risk of OR 1.09 (1.03-1.16). The COPD drug groups with the largest effect estimates were ‘no drugs’ 
(OR 1.28; 1.14-1.43), ‘COPD and oral steroids but no prescribed oxygen’ (1.83; 1.69-1.97) and ‘prescribed 
oxygen’ (2.94; 2.47-3.50). In the third classification, when the lowest risk groups (‘no drugs’ and ‘any inhalers’) 
were combined into a ‘no prescribed steroids or oxygen’ group, the effect estimate shown was OR 1.13 (1.07-
1.19). The confidence intervals of the highest drug severity groups did not overlap with each other or the 
confidence intervals of either of the lower severity groups indicating significant stratification of comorbid 
COPD effects by drugs prescribed (Figure 9.13). 
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9.4.2.3 COPD severity change 
 Physiological severity change measure 
The HF-COPD group were stratified firstly into two groups according to (i) improvement in GOLD stage or 
stable GOLD stage and (ii) worsening of GOLD stage over the one year before the match date. Secondly the 
comorbid group were stratified into three groups according to whether they had a (i) <10% change in FEV1,  (ii)   
≥10% increase in FEV1 (better)  or (iii) ≥10% decrease FEV1 (worse) over the one year before the match date.    
Finally the COPD group was stratified into the same groups but using a 5% change measure.  These 
measures used the closest available FEV1 measure before the match date and a previous measure (median 
462 [IQR 360-663] days). Change over one year was calculated and these groups were compared to the HF 
sample without COPD. 
 
Strength of associations: The fully adjusted associations of all HF-COPD physiological change measures 
compared to no COPD HF are shown in Table 9.7. The group that had a stable or improved GOLD stage had 
an adjusted association with mortality of OR 2.15 (1.97- 2.34). There was an increase in risk of 55% for the 
COPD group with worsening of GOLD stage with an OR 2.70 (2.30-3.17) Figure 9.14). Using the 10% change 
severity classification, the adjusted risk in the HF-COPD group with <10% change was OR 2.18 (1.99-2.38) 
which was similar to the group with ≥10% improvement in FEV1 with OR 2.22 (1.82-2.70). The highest 
mortality risk was in the comorbid COPD group with ≥10% worsening of FEV1 with  OR 2.60 (2.17, 3.11). The 
linear test of trend in the fully adjusted models was not significant. Further adjustment with deprivation 
strengthened the associations of the different severity change measures weakly. 
 
 Drug severity change measure 
The HF-COPD group were stratified into three groups based on change in their prescribed COPD drugs over 
12 months before the match date. This measure used the COPD drugs prescribed in a 4 month time-window 
before death compared to a 4 month time-window, a year prior to death. Change in drug category over one 
year was categorised into (i) ‘drug category same or better’ or (ii) ‘drug category worse’. A second 
classification used three categories of (i) no new steroids or oxygen, (ii) new on steroids but no new oxygen 
and (iii) new on oxygen. These groups were compared to the HF sample without COPD. 
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Strength of associations: Using the first classification of drug severity change, the fully adjusted association 
between ‘drug category same or better’ (OR 1.34; 1.27-1.42) was similar to ‘drug category worse’ (OR 1.36; 
1.27-1.45) (Table 9.7). The second drug classification showed increasing risk from the first to third category. 
‘No new steroids or oxygen’ resulted in an adjusted effect estimate of OR 1.22 (1.16-1.28) which increased to 
OR 1.84 (1.67-1.28) for the ‘new on steroids but no new oxygen’ group and 3.41 (2.71- 4.29) for the ‘new on 
oxygen’ group (Figure 9.15). These groups were non-significant for a linear trend in the adjusted model but 
the confidence intervals of the three groups did not overlap indicating that the effect of COPD on mortality was 
stratified by drug severity change.  
 
9.4.3 Chronic kidney disease 
The unadjusted association between HF-CKD and all-cause mortality compared to no CKD HF was OR 1.77 
(95% CI 1.72-1.82), which reduced when adjusted for age, gender, COPD and Hb to 1.21 (1.17-1.26). This 
estimate was not influenced by further adjustment for the remaining confounders (1.22; 1.18-1.26) or by 
adjustment for deprivation in the sub-analysis (Table 9.8). 
 
9.4.3.1 CKD severity 
 Physiological severity measure 
The HF sample was stratified into groups based on the eGFR level. This categorisation used the closest 
available measure before the match date (median 101 [IQR 37-223] days) and these groups were compared 
to the baseline eGFR group 60-89 ml/min/m2. 
 
Shape of association: The shape of the adjusted associations between categories of eGFR and their 
respective predicted probabilities of mortality was curved, shown in Figure 9.16 using a margins plot. The 
lowest risk eGFR category was 60-89 ml/min/m2. When eGFR was categorised into deciles the curved U 
shape remained and the lowest risk deciles were 7 and 8 corresponding to eGFR of 62-74.9 ml/min/m2 
(Figure 9.17).   
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Strength of associations: Mortality risk was associated with all eGFR categories above and below the 
reference group. The lowest risk category was eGFR 90-105 with an unadjusted OR 1.09 (1.01-1.17) and this 
increased to 1.59 (1.44-1.76) in the next higher group (eGFR >105). Risk also increased with each category 
below eGFR 90-105 to a maximum of an unadjusted OR 5.53 (4.94- 6.18) in the lowest eGFR group (<15 
ml/min/m2). The same trend was observed in the fully adjusted associations (Table 9). Risk was lowest 
compared to the reference group in the eGFR 45-59 group (1.04; 1.00-1.09) and increased above this to 1.64 
(1.47-1.83) in the highest eGFR >105 group and to 3.26 (2.87-3.69) in the lowest eGFR <15 group. Further 
adjustment for deprivation made little difference to these estimates. 
 
In the fully adjusted model, the tests for linear trend in the reducing and increasing eGFR categories from 
eGFR 45-59 were non-significant.  The increasing and decreasing eGFR categories from the lowest risk 
group (eGFR 45-59) had confidence intervals that did not overlap with one another, which indicated stratified 
effects of CKD defined by recent eGFR severity levels on mortality outcome (Figure 9.17). 
 
9.4.3.2 CKD severity change 
 Physiological severity change measure 
The HF sample was stratified into three groups based on change in their eGFR level over one year before the 
match date. This change definition used the closest available eGFR before the match date and a previous 
eGFR before the most recent measure (315 days [IQR 232-420] days). Absolute change was defined as: (a) 
0-5mls decrease – reference group, minor decline, (b) any increase, (c) 6-15mls decrease – moderate 
decline, and (d) >15mls decrease – severe decline. Percentage change was defined as: (a) 0-5% decrease – 
reference group, minor decline, (b) any increase, (c) 6-25% decrease – moderate decline, and (d) >25% 
decrease – severe decline. Change over one year was calculated.  
 
Strengths of associations: All categories of absolute and percentage change in eGFR were associated with 
mortality when compared to the reference group of minimal decline in the adjusted models. HF patients with 
any increase or moderate decline in eGFR had similar associations compared to the minimal decline 
reference group (Table 9.8).  The highest risk was observed in the most severe change groups with eGFR 
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>15mls group (OR 1.83; 1.73-1.94) and >25% decrease (2.14; 2.00-2.28).  Adjusting for deprivation had 
minimal influence on these associations. The confidence intervals of these estimates did not overlap, 
indicating the stratified effects of comorbid CKD  by CKD change on mortality outcome in HF (Figure 9.20).  
 
Adjustment for eGFR: Firstly, the influence of the start and end eGFR used in the calculation of change, on 
the estimates of ORs of the eGFR change was investigated by observing the associations within sub-groups 
according to their starting eGFR (<60 and ≥60 ml/min/m2). Starting eGFR was the first and earliest measure 
in the change definition. The change estimates were also observed within same strata of the end eGFR 
measure. This was to investigate whether the estimates of change were :(i) influenced by the starting eGFR 
and whether this influence was less for the percentage change measure which already took an account of the 
starting point and (ii) depended on the end eGFR which might influence a greater effect estimate in the 
<60mls sub-group.  Secondly, the estimates for the change measures in the adjusted model were further 
adjusted, separately for the start and end eGFR in order to investigate the independent associations of 
change in eGFR (Table 9.8).  
 
Change stratified by baseline start and end eGFR: The effect estimates for eGFR moderate and severe 
deterioration were larger in those with a starting eGFR of <60ml/min/m2, for both the absolute and percentage 
change measures. The biggest difference between the groups with eGFR starting point <60 and ≥60 was 
observed in the absolute change group where the confidence intervals for the adjusted severe change effect 
estimates did not overlap between the ≥60 group (adjusted OR 1.80; 1.61- 2.01) and the <60 group (2.27; 
2.05-2.52). Increase in eGFR had a stronger effect in the higher baseline group than the lower baseline group 
for the absolute but not the percentage change measure (Table 9.9). Using the end eGFR measure, the 
mortality effect estimates for all eGFR decline measures were greater in the <60 group than the ≥60 group. 
For both the absolute and percentage measures of the severest change category, the difference in risk 
between the ≥60 and <60 end eGFR group was 57% and 70% respectively and the confidence intervals did 
not overlap, which indicated the stratified comorbid effects of CKD severity change by the end eGFR level. 
The effect estimate associated with an increase in eGFR was again more influenced by end eGFR for the 
absolute change measure having smaller effects in the <60 eGFR group. 
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Change adjusted by baseline start and end eGFR: In the adjusted model without the baseline eGFR 
adjustment, the most severe category of change using the absolute (OR 1.83; 1.73-1.94) and percentage 
change (2.14; 2.00-2.28) measures differed in strength and confidence intervals that did not overlap (Table 
9.8). Following adjustment for the starting eGFR these estimates became similar in strength with absolute 
change OR 2.08 (1.96-2.21) and percentage change 2.10 (1.96-2.24) (Table 9.10). Adjustment for the end 
eGFR, also resulted in similar effect estimates with absolute change OR 1.78 (1.67-1.88) and percentage 
change 1.77 (1.66-1.90).  
 
9.5 Chapter summary  
The three comorbidities DM, COPD and CKD were significantly and independently associated with all-cause 
mortality in the non-selected general practice population of HF. These associations were not explained by 
confounders based on routinely collected clinical data. Whilst the comorbidities had similar strength of 
associations with mortality, there were differences according to whether their onset was before or after the HF 
index date. When each of the comorbidities was stratified by categories of recent severity and severity change 
during the course of their HF, there were significant adjusted associations with increased mortality. The 
associations between increasing severity categories of HbA1c or eGFR and mortality were curvi-linear. The 
strongest risk estimates were in the higher HbA1c and lower eGFR categories levels.  The HF-COPD group 
with FEV1 measures had a higher risk of mortality than the total comorbid COPD group and this risk increased 
with decreasing categories of FEV1.  A recent decrease in HbA1c, eGFR or FEV1 over one year were all 
significantly associated with mortality. Adjustment for CKD severity change using the start or end eGFR 
measure diminished the associations but they remained significant and independent demonstrating the 
additional prognostic importance of comorbidity severity change to comorbidity severity alone. As eGFR is the 
only severity measure routinely collected in all HF patients this adjustment was not possible for HbA1c or 
FEV1 change. Comorbidity severity and change measures using prescribed drugs also provided stratified 
comorbidity effects for both DM and COPD on mortality outcomes. These findings will be discussed in detail in 
Chapter 13. 
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Tables 
 
 
 
 
Table 9.1 Summary of confounders indicated in the four steps 
 
Potential confounder Diabetes COPD CKD  
Person and socio-demographic factors    
Age SR*# ƚ SR*# ƚ SR*# ƚ 
Gender SR* * SR*# 
White SR  SR 
Deprivation * * * 
HF factors    
Left ventricular ejection fraction SR H SR 
Ischaemic aetiology SR  SR 
Other aetiology   SR 
Left ventricular systolic dysfunction SR   
Brain Naturetic Peptide   SR 
New York Heart Association class SR  SR 
Cardiovascular Drugs    
Beta-blocker SR*# SR *ƚ SR 
ACEi SR* *# SR * 
ARB SR* * SR * 
Statin SR  SR 
Diuretics SR* H SR 
Digoxin SR   
Spironolactone SR H SR 
Comorbidities    
Renal disease SR* *ƚ - 
Diabetes - SR* SR* 
COPD SR* - *# 
Vascular disease   SR 
Cerebrovascular accident SR  SR 
Hypertension SR  SR 
Charlson index SR   
Atrial fibrillation SR  SR 
Anthropometric and Clinical observations   
Systolic blood pressure SR * SR* 
Diastolic blood pressure * * * 
Heart rate SR SR SR 
Oedema SR   
Dyspnoea SR   
Elevated jugular venous pressure SR   
Sinus rhythm  SR  
Body mass index SR*ƚ SR*ƚ SR* 
Cholesterol SR* * SR* 
Glucose level SR   
Blood Urea Nitrogen (mg/dL) SR  SR 
Potassium   SR 
Haemoglobin  *ƚ *ƚ SR*ƚ 
Creatinine  SR SR SR 
Estimated glomerular filtration rate *ƚ *ƚ SR* 
Lifestyle factors    
Smoking SR* SR* SR* 
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Alcohol status * * * 
Red text, available factors extracted from CPRD. Additional factors were those indicated by the 
systematic review. SR, Systematic review (step 1),* difference identified between comorbid and non-
comorbid group (step 2), # ≥10% change in comorbidity effect observed in at least one strata of the 
potential confounder (step 3) ƚ association identified by ≥10% change in OR of comorbid exposure by 
adjustment of potential confounder (step 4).  
Table 9.2  Unadjusted estimates of association between the potential confounders and 
all-cause mortality 
  
All-cause mortality OR (95% CI) 
Person and socio-demographic factors 
Age per year  1.06 (1.05-1.06) 
Women  1.12 (1.10-1.16) 
IMD quintile*   
1 1.0 
2 1.08 (1.02-1.14) 
3 1.15 (1.08-1.22) 
4 1.10 (1.04-1.17) 
5 1.15 (1.07-1.22) 
Anthropometric and clinical factors 
BMI (per Kg/m2) 0.94 (0.94-0.95) 
Normal 1.0 
Underweight 1.81 (1.70-1.92) 
Overweight 0.66 (0.64-0.68) 
Obese 0.51 (0.49-0.53) 
Cholesterol (per mmol/L)  0.93 (0.92-0.94) 
Haemoglobin (per g/dL) 0.78 (0.77-0.78) 
Systolic BP (per mmHg)  0.99 (0.99-0.99) 
Diastolic BP (per mmHg)  0.98 (0.98-0.98) 
Lifestyle factors 
Smoking status   
No       1.0 
Ex 0.95 (0.92-0.98) 
Yes 1.03 (0.99,1.08)
ƚ
 
Alcohol status   
No 1.0 
Ex 0.97 (0.91-1.03)
ƚ
 
Yes 0.85 (0.82-0.87) 
Drug factors 
Not on beta-blocker 1.75 (1.70-1.80) 
Not on ACEi 1.66 (1.62-1.71) 
Not on ARB 1.68 (1.61-1.75) 
Diuretic 1.30 (1.25-1.34) 
Comorbidity exposures 
Diabetes  1.09 (1.05-1.12) 
COPD  1.41 (1.36-1.46) 
eGFR <60ml/min) 1.77 (1.71-1.82) 
eGFR (per ml/min/m2) 0.98 (0.98-0.98) 
*IMD in 79,383 patients only. IMD, index multiple deprivation (1=least deprived, 
5=most deprived); BMI, body mass index; BP, blood pressure; ACEi, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic 
obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.  
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Table 9.3 Summary of the steps of adjustment for each comorbidity  
 
 
Comorbidity Step 1 +   Step 2 +   Step 3 +   Step 4 
COPD Age, beta-blocker, BMI, 
eGFR or renal disease, 
ACEi/ARB, Hb 
DM, smoking 
 
Gender, diuretics, 
blood pressure, 
cholesterol, alcohol 
Deprivation 
DM Age, eGFR, BMI, Hb, 
beta-blocker 
Gender, ACEi/ARB, diuretics, 
COPD, cholesterol, smoking 
Alcohol, blood 
pressure 
Deprivation 
CKD Age, Hb, gender, COPD 
 
DM, ACEi/ARB, 
systolic/diastolic, BMI, 
smoking, eGFR, cholesterol 
beta-blocker, diuretics, 
alcohol 
Deprivation 
BMI, body mass index; Hb, haemoglobin; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; HbA1c, glycated haemoglobin; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; COPD, 
chronic obstructive pulmonary disease 
Table 9.4 Liklihood ratio tests for current age 
 
Multivariable model Log likelihood LR test  
a Age -30016.98  
b Age+Age2 -29963.72 <0.001  a nested in b 
c Age+Age2+Age3 -29974.32   0.370    b nested in c 
 
 
Table 9.5 Likelihood ratio tests for eGFR 
 
Multivariable Log likelihood LR test  
a eGFR -29917.303  
b eGFR+eGFR2 -29532.247   <0.0001 a nested in b 
c eGFR+eGFR2+eGFR3 -29522.713 <0.0001 b nested in c 
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Table 9.6  Associations between diabetes exposures and all-cause mortality in HF 
 
 
Diabetes exposures measures  
OR (95% CI) 
Unadjusted 
OR (95% CI) 
Adjusted1 
OR (95% CI) 
Adjusted2 
OR (95% CI) 
Adjusted3 
OR (95% CI) 
Sub-analysis4 
Diabetes status  *110,505 observations    
No diabetes (ref) 1.0 1.0 1.0 1.0 1.0 
Diabetes anytime 1.09 (1.06-1.12) 1.26 (1.21-1.30) 1.24 (1.19-1.29) 1.28 (1.23-1.33) 1.26 (1.19-1.33) 
No diabetes (ref) 1 1 1 1 1 
Diagnosis before HF 1.14 (1.10-1.18) 1.28 (1.23-1.33) 1.26 (1.21-1.31) 1.31 (1.26-1.37) 1.29 (1.22-1.37) 
Diagnosis after HF 0.85 (0.79-0.93) 1.15 (1.05,-1.25) 1.12 (1.03-1.22) 1.13 (1.03-1.23) 1.08 (0.95-1.23) 
Diabetes defined by HbA1c severity  *106,790 observations 
No diabetes (ref) 1.0 1.0 1.0 1.0 1.0 
<5.5% 1.55 (1.37-1.76) 1.34 (1.16-1.53) 1.25 (1.09-1.45) 1.34 (1.16-1.54) 1.30 (1.05-1.60) 
5.5-6.4% 1.18 (1.11-1.26) 1.24 (1.16-1.33) 1.22 (1.14-1.30) 1.24 (1.16-1.33) 1.26 (1.14-1.39) 
6.5-7.5% 1.01 (0.96-1.06) 1.16 (1.10-1.23) 1.14 (1.08-1.21) 1.19 (1.12-1.26) 1.21 (1.12-1.31) 
7.6-8.5% 1.01 (0.94-1.09) 1.23 (1.13-1.33) 1.22 (1.12-1.31) 1.27 (1.17-1.37) 1.18 (1.05-1.33) 
8.6-9.5% 1.06 (0.96-1.17) 1.44 (1.29-1.60) 1.42 (1.27-1.59) 1.49 (1.34-1.67) 1.44 (1.23-1.69) 
>9.5% 0.97 (0.88-1.07) 1.42 (1.28-1.58) 1.39 (1.25-1.55) 1.45 (1.30-1.62) 1.31 (1.12-1.54) 
Diabetes defined by drugs severity *110,505 observations    
No diabetes (ref) 1.0 1.0 1.0 1.0 1.0 
1: None 1.32 (1.25-1.40) 1.37 (1.29-1.46) 1.34 (1.26-1.43) 1.37 (1.29-1.46) 1.34 (1.23-1.47) 
2: Oral only  0.96 (0.93-1.01) 1.13 (1.08-1.19) 1.12 (1.07-1.18) 1.16 (1.10-1.22) 1.15 (1.07-1.24) 
3: Oral + Insulin 0.76 (0.69-0.84) 1.14 (1.03-1.27) 1.12 (1.01-1.25) 1.18 (1.07-1.32) 1.13 (0.97-1.32) 
2/3 combined: (Oral +/- insulin) 0.93 (0.89-0.97) 1.13 (1.08-1.19) 1.12 (1.07-1.18) 1.17 (1.11-1.22) 1.15 (1.07-1.23) 
3: Insulin only 1.35 (1.26-1.44) 1.50 (1.39-1.62) 1.48 (1.37-1.59) 1.56 (1.44-1.68) 1.52 (1.36-1.70) 
Diabetes defined by  HbA1c severity change *102,990 observations    
No diabetes (ref) 1.0 1.0 1.0 1.0 1.0 
<1% change  1.04 (1.00-1.08) 
ƚ
 1.19 (1.13-1.24 1.17 (1.11-1.23) 1.22 (1.16-1.28) 1.21 (1.13-1.29) 
>1% increase 1.03 (0.95-1.11) 
ƚ
 1.26 (1.16-1.38) 1.24 (1.13-1.35) 1.28 (1.17-1.40) 1.21 (1.07-1.38) 
>1% decrease 1.30 (1.21-1.39) 1.48 (1.37-1.60) 1.44 (1.33-1.55) 1.49 (1.37-1.61) 1.50 (1.34-1.69) 
Diabetes defined by drugs severity change *110,505 observations     
No diabetes (ref) 1.0 1.0 1.0 1.0 1.0 
No drug category change 1.04 (1.01-1.08) 1.20 (1.15-1.25) 1.19 (1.14-1.24) 1.23 (1.19-1.29) 1.23 (1.16-1.30) 
Increase in drug category 1.06 (0.96-1.16) 
ƚ
 1.37 (1.24-1.52) 1.32 (1.19-1.46) 1.33 (1.20-1.48) 1.20 (1.04-1.40) 
  
244 
 
Decrease in drug category 2.55 (2.27-2.87) 2.43 (2.14-2.77) 2.26 (1.98-2.58) 2.30 (2.01-2.63) 2.18 (1.79-2.66) 
Ref, reference group.* each unadjusted and adjusted measure was based on the same number of observations. There was complete data for comorbidity status and all 
confounders with the exception of eGFR. All associations excluded those without eGFR. For the comorbidity severity exposures, associations excluded the comorbid groups 
without the severity exposure or that had eGFR missing. Ref, reference group. 
1Adjusted for age, eGFR, eGFR2, BMI, BMI2, Hb, Hb2, beta-blocker 
2Adjusted further for gender, ACEi or ARB, Diuretic, COPD, cholesterol and smoking 
3 Adjusted further for alcohol, systolic, systolic2 
4 Adjusted further for deprivation (44% missing data) 
  
245 
 
Table 9.7 Associations between comorbid COPD in HF and all-cause mortality 
 
COPD exposures  Unadjusted OR (95% CI)  Adjusted1 OR (95% CI)  Adjusted2 OR (95% CI)  Adjusted3 OR (95% CI)  Sub-analysis4 OR (95% CI)   
COPD status      
No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
COPD anytime 1.41 (1.36-1.47) 1.47 (1.41-1.54) 1.40 (1.34-1.46) 1.35 (1.29-1.41) 1.32 (1.23-1.40) 
No COPD (ref) 1 1 1 1 1 
COPD diagnosis before HF 1.43 (1.37-1.49) 1.45 (1.38-1.52) 1.37 (1.30-1.44) 1.32 (1.25-1.38) 1.31 (1.22-1.41) 
COPD diagnosis after HF 1.38 (1.28-1.50) 1.58 (1.45-1.71) 1.50 (1.38-1.63) 1.46 (1.34-1.60) 1.34 (1.18-1.52) 
COPD FEV1 severity       
No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
1: FEV1 ≥80% normal 1.91 (1.69-2.17) 1.91 (1.66-2.19) 1.81 (1.57-2.07) 1.73 (1.50-1.99) 1.71 (1.40-2.08) 
2: FEV1 50-79% normal 1.87 (1.73-2.01) 1.97 (1.81-2.13) 1.86 (1.71-2.02) 1.76 (1.61-1.91) 1.76 (1.73-2.01) 
3: FEV1 30-49% normal 2.53 (2.32-2.75) 2.55 (2.32-2.80) 2.43 (2.21-2.68) 2.31 (2.09-2.54) 2.48 (2.32-2.75) 
4: FEV1 <30% normal 2.94 (2.52-3.42) 3.51 (2.97,4.15) 3.35 (2.83-3.96) 3.14 (2.65-3.73) 3.21 (2.52-3.42) 
COPD drugs severity      
Classification 1      
No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
No drugs 1.33 (1.20-1.47) 1.37 (1.23-1.53) 1.29 (1.15-1.44) 1.28 (1.14-1.43) 1.23 (1.05-1.45) 
Short term inhalers only 1.29 (1.13-1.46) 1.24 (1.08-1.42) 1.15 (1.00-1.31) 1.12 (0.97-1.29) 1.12 (0.92-1.37) 
Monotherapy 1.20 (1.08-1.33) 1.20 (1.07-1.34) 1.12 (1.00-1.26) 1.07 (0.95,1. 20) 0.99 (0.84-1.17) 
Dual therapy 1.05 (0.96-1.16) 1.10 (1.00-1.21) 1.05 (0.95-1.16) 1.02 (0.92-1.12) 1.01 (0.88-1.16) 
Triple therapy 1.21 (1.11-1.32) 1.31 (1.19-1.44) 1.24 (1.13-1.37) 1.18 (1.07-1.31) 1.26 (1.09-1.45) 
Oral steroids but no oxygen 1.85 (1.73-1.98) 1.97 (1.83-2.12) 1.89 (1.75-2.03) 1.83 (1.69-1.97) 1.78 (1.59-1.99) 
On  oxygen 3.20 (2.74-3.74) 3.31 (2.79-3.93) 3.22 (2.72-3.82) 2.94 (2.47-3.50) 2.18 (2.07-3.82) 
Classification 2      
No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
No drugs  1.33 (1.20-1.47) 1.37 (1.23-1.53) 1.29 (1.14-1.89) 1.28 (1.14-1.43) 1.23 (1.04-1.45) 
Inhalers only  1.17 (1.11-1.23) 1.20 (1.14-1.27) 1.14 (1.07-1.21) 1.09 (1.03-1.16) 1.09 (1.00-1.19) 
Oral steroids but no oxygen 1.85 (1.73-1.98) 1.97 (1.83-2.12) 1.88 (1.75-2.03) 1.83 (1.69-1.97) 1.78 (1.59-1.99) 
On  oxygen 3.20 (2.74-3.74) 3.31 (2.79-3.93) 3.22 (2.72-3.83) 2.94 (2.47-3.50) 2.18 (2.07-3.82) 
Classification 3      
No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
No steroids or oxygen  1.19 (1.14-1.25) 1.23 (1.17-1.30) 1.17 (1.11-1.23) 1.13 (1.07-1.19) 1.11 (1.03-1.20) 
Oral steroids but no oxygen 1.79 (1.68-1.91) 1.97 (1.83-2.12) 1.88 (1.75-2.03) 1.83 (1.69-1.97) 1.78 (1.59-1.99) 
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On  oxygen 3.14 (2.74-3.60) 3.31 (2.79-3.93) 3.23 (2.72-3.83) 2.94 (2.47-3.51) 2.81 (2.07-3.82) 
COPD FEV1 severity change    
Classification 1: GOLD stage      
 No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
   Gold stage same or better  2.33 (2.17-2.51) 2.41 (2.22-2.62) 2.29 (2.11-2.49) 2.15 (1.97-2.34) 2.14 (1.89-2.42) 
   Gold stage worse (at least one stage) 3.07 (2.66-3.55) 3.05 (2.61-3.57) 2.87 (2.45-3.37) 2.70 (2.30-3.17) 3.07 (2.39-3.94) 
Classification 2: 10% change      
 No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
   <10% change  2.41 (2.23-2.61) 2.46 (2.26-2.68) 2.33 (2.14-2.54) 2.18 (1.99-2.38) 2.20 (1.93-2.51) 
   ≥10% increase (better) 2.36 (1.98-2.82) 2.44 (2.02-2.96) 2.34 (1.93-2.83) 2.22 (1.82-2.70) 2.29 (1.70-3.08) 
   ≥10% decrease (worse) 2.81 (2.39-3.30) 2.92 (2.46-3.48) 2.74 (2.30-3.26) 2.60 (2.17-3.11) 2.73 (2.09-3.57) 
Classification 3: 5% change    
 No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
   <5% change  2.36 (2.14-2.60) 2.46 (2.21-2.74) 2.32 (2.09-2.59) 2.20 (1.97-2.45) 2.22 (1.89-2.62) 
   ≥5% increase (better) 2.27 (1.99-2.59) 2.35 (2.03-2.71) 2.24 (1.94-2.59) 2.10 (1.82-2.44) 2.24 (1.80-2.79) 
   ≥5% decrease (worse) 2.80 (2.49-3.14) 2.78 (2.45-3.15) 2.63 (2.32-2.98) 2.44 (2.14-2.78) 2.43 (2.00-2.95) 
COPD drugs severity change     
Classification 1      
No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
Drug category same or better 1.41 (1.34-1.48) 1.45 (1.38-1.53) 1.39 (1.31-1.46) 1.34 (1.27-1.42) 1.35 (1.24-1.46) 
Drug category worse 1.43 (1.35-1.51) 1.51 (1.41-1.60) 1.42 (1.33-1.51) 1.36 (1.27-1.45) 1.27 (1.16-1.40) 
Classification 2      
No COPD (ref) 1.0 1.0 1.0 1.0 1.0 
No new steroids or oxygen  1.29 (1.23-1.34) 1.33 (1.27-1.40) 1.27 (1.21-1.33) 1.22 (1.16-1.28) 1.22 (1.13-1.31) 
New on steroids but no new oxygen 1.92 (1.76-2.09) 2.00 (1.82-2.19) 1.90 (1.73-2.09) 1.84 (1.67-2.03) 1.75 (1.52-2.02) 
New on oxygen 3.63 (2.96-4.47) 3.94 (3.15-4.92) 3.83 (3.06-4.80) 3.41 (2.71-4.29) 2.88 (1.94-4.27) 
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; pp, percent predicted; ref, reference group. Most recently recorded FEV1 (pp) prior to the match 
date was used to measure COPD severity within a maximum of a 3-yr time window. % change for FEV1 was calculated as the absolute change in pp over one year using the most recent 
measure (<3yrs) and an earlier FEV1 measure (<3 years prior to the most recent measure). The FEV1 change was adjusted for the time interval. Mono, dual or triple therapy; one, two or 
three of respectively: long acting beta2-antagonist, long acting cholinergic, methylxanthines, inhaled steroid either individually or in combination inhalers *each unadjusted and adjusted 
measure based on the same number of observations (excluding those with the comorbidity exposure or eGFR confounder missing) 
1Adjusted for age, no beta-blocker, BMI BMI2, eGFR eGFR2 no ACEi  or ARB,  Hb Hb2 
2Adjusted further for diabetes, smoking 
3Adjusted further for gender, diuretics, systolic, systolic2, cholesterol, alcohol 
4 Adjusted further for deprivation (44% missing data) 
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Table 9.8 Associations between CKD exposures in HF and all-cause mortality 
 
CKD exposures measures Unadjusted OR (95% CI)  Adjusted1 OR (95% CI)  Adjusted2 OR (95% CI)  Adjusted3 OR (95% CI)  Sub-analysis4 OR (95% CI)  
Renal disease diagnosis (eGFR <60)     
eGFR ≥60 (ref) 1.0 1.0 1.0 1.0 1.0 
eGFR <60   1.77 (1.72-1.82) 1.21 (1.17-1.26) 1.21 (1.17-1.25) 1.22 (1.18-1.26) 1.20 (1.14-1.26) 
Renal severity (eGFR)      
eGFR mL/min/1.73m2      
60-89 (ref) 1.0 1.0 1.0 1.0 1.0 
>105 1.59 (1.44-1.76) 1.95 (1.76-2.17) 1.68 (1.50-1.87) 1.64 (1.47-1.83) 1.78 (1.52-2.09) 
90-105 1.09 (1.01-1.17) 1.31 (1.21-1.41) 1.22 (1.13-1.32) 1.20 (1.11-1.30) 1.18 (1.06-1.33) 
45-59 1.30 (1.25-1.35) 1.03 (0.99-1.08) 1.04 (1.00-1.09) 1.04 (1.00-1.09) 1.01 (0.95-1.07) 
30-44 1.99 (1.91-2.07) 1.33 (1.27-1.39) 1.30 (1.24-1.36) 1.30 (1.25-1.37) 1.31 (1.23-1.40) 
15-29 3.60 (3.41-3.80) 2.16 (2.04-2.29) 2.02 (1.91-2.15) 2.05 (1.93-2.18) 2.07 (1.90-2.27) 
<15 5.53 (4.94-6.18) 3.70 (3.28-4.17) 3.15 (2.78-3.56) 3.26 (2.87-3.69) 3.29 (2.72-3.97) 
eGFR severity change       
Classification 1      
Absolute change      
0-5mls decrease (ref) 1.0 1.0 1.0 1.0 1.0 
Any increase 1.13 (1.09-1.18) 1.19 (1.05-1.06) 1.14 (1.09-1.20) 1.14 (1.09-1.20) 1.13 (1.06-1.21) 
6mls to 15mls decrease 1.24 (1.18-1.30) 1.22 (1.16-1.28) 1.19 (1.13-1.25) 1.18 (1.12-1.25) 1.17 (1.09-1.26) 
>15mls decrease 1.98 (1.88-2.09) 1.97 (1.87-2.09) 1.85 (1.75-1.96) 1.83 (1.73-1.94) 1.93 (1.77-2.10) 
Classification 2      
Percentage change      
0-5% decrease (ref) 1.0 1.0 1.0 1.0 1.0 
Any % increase 1.37 (1.30-1.44) 1.31 (1.24-1.39) 1.25 (1.18-1.32) 1.25 (1.18-1.32) 1.23 (1.13-1.33) 
6-25% decrease 1.33 (1.26-1.40) 1.23 (1.16-1.30) 1.20 (1.13-1.27) 1.19 (1.12-1.26) 1.17 (1.08-1.27) 
>25% decrease 2.87 (2.70-3.04) 2.34 (2.20-2.50) 2.14 (2.01-2.29) 2.14 (2.00-2.28) 2.22 (2.02-2.45) 
* each unadjusted and adjusted measure based on the same number of observations (excluding those with the comorbidity exposure or eGFR confounder missing). eGFR, estimated glomerular 
filtration rate; ref, reference group. 
1Adjusted for Age, Hb, Hb2, gender, COPD 
2Adjusted further for Diabetes, no ACEi or ARB, systolic, systolic2, BMI BMI2, smoking, cholesterol  
3Adjusted further for no beta-blocker, diuretics, alcohol  
4 Adjusted further for deprivation (44% missing data) 
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Ref, reference group. All associations were fully adjusted by all remaining covariates. eGFR, estimated glomerular 
filtration rate (ml/min/m2). Change was calculated over a year before the match date using the most recent value up to a 
maximum of 3 years and a prior value between 6 months and 3 years. 
 
eGFR, estimated glomerular filtration rate (ml/min/m2); ref, reference group. All associations were fully adjusted by all 
remaining covariates and the start or end eGFR. Due to the non-linear association between eGFR and mortality eGFR2 
was also used in the models. Change was calculated over a year before the match date using the most recent value up 
to a maximum of 3 years and an earlier value between 6 months and 3 years before. 
Table 9.9 Change in eGFR effect estimates with mortality stratified by start baseline and end levels 
 
 Start  eGFR End eGFR 
eGFR severity change  ≥60 <60 ≥60 <60 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Absolute change     
0mls to 5mls decrease (ref) 1.0 1.0 1.0 1.0 
Any increase 1.21 (1.09, 1.34) 1.07 (1.01-1.14) 1.32 (1.19-1.47) 1.05 (0.98-1.12) 
6mls to 15mls decrease 1.13 (1.02-1.27) 1.30 (1.21-1.41) 1.10 (0.96-1.26) 1.19 (1.11-1.27) 
>15mls decrease 1.80 (1.61-2.01) 2.27 (2.05-2.52) 1.40 (1.20-1.64) 1.97 (1.82-2.13) 
Percentage change     
0-5% decrease (ref) 1.0 1.0 1.0 1.0 
Any % increase 1.21 (1.08-1.35) 1.24 (1.13-1.35) 1.29 (1.15-1.45) 1.19 (1.09-1.29) 
6-25% decrease 1.13 (1.01-1.27) 1.30 (1.18-1.42) 1.06 (0.93-1.21) 1.21 (1.12-1.32) 
>25% decrease 2.01 (1.76-2.28) 2.34 (2.11-2.59) 1.48 (1.20-1.81) 2.18 (1.99-2.38) 
Table 9.10 Change effect estimates with mortality adjusted for most recent and prior eGFR 
 
eGFR severity change  Adjusted3 Adjusted for start 
eGFR and eGFR2 
Adjusted for end 
eGFR and eGFR2 
 OR (95% CI) OR (95% CI) OR (95% CI) 
Absolute change    
0mls to 5mls decrease (ref) 1.0 1.0 1.0 
Any increase 1.14 (1.09-1.20) 1.16 (1.11-1.21) 1.24 (1.18-1.30) 
6mls to 15mls decrease 1.18 (1.12-1.25) 1.25 (1.19-1.32) 1.18 (1.12-1.24) 
>15mls decrease 1.83 (1.73-1.94) 2.08 (1.96-2.21) 1.78 (1.67-1.88) 
Percentage change    
0-5% decrease (ref) 1.0 1.0 1.0 
Any % increase 1.25 (1.18-1.32) 1.21 (1.14-1.28) 1.24 (1.17-1.31) 
6-25% decrease 1.19 (1.12-1.26) 1.19 (1.12-1.26) 1.14 (1.08-1.22) 
>25% decrease 2.14 (2.00-2.28) 2.10 (1.96-2.24) 1.77 (1.66-1.90) 
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Figures 
 
Figure 9.1 Calibration plots of observed versus predicted fitted effects for current age and mortality 
 
 
Figure 9.2 Eccles plots of current age and mortality 
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Figure 9.3 Calibration plots of observed versus predicted fitted effects for eGFR 
 
 
Figure 9.4 Eccles plots of eGFR and mortality 
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Figure 9.5 Adjusted associations of comorbidities with all-cause mortality 
 
 
Figure 9.6 Margins plot of HbA1c categories and mortality  
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Figure 9.7 Margins plot of HbA1c deciles and mortality  
 
 
Figure 9.8 Adjusted associations of HbA1c categories and mortality 
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Figure 9.9 Adjusted associations of DM drug severity categories and mortality 
 
Figure 9.10 Adjusted associations of categories of DM and HbA1c change and mortality 
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Figure 9.11 Margins plot of COPD GOLD stages and mortality 
 
 
Figure 9.12 Adjusted associations of COPD GOLD stages and mortality 
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Figure 9.13 Adjusted associations of COPD drug severity categories and mortality 
 
 
Figure 9.14 Adjusted associations of categories of COPD and FEV1 change and mortality 
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Figure 9.15 Adjusted associations of categories of COPD drug severity change and mortality 
 
 
Figure 9.16 Margins plot of eGFR severity categories and mortality  
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Figure 9.17 Margins plot of eGFR deciles and mortality  
 
 
Figure 9.19 Adjusted associations of eGFR categories and mortality 
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Figure 9.20 Adjusted associations of categories of eGFR change and mortality 
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Chapter 10 Non-CVD comorbidity prognostic factors in an incident HF 
general practice population: strength of associations with first 
hospital admission  
 
This chapter follows on from the descriptive findings (Chapter 8) of the main incident HF CPRD cohort linked 
to hospital admissions data (HF-HA) and the outcome of first hospital admission. This chapter investigates the 
comorbidity measures that were found to have the strongest associations with mortality, for their association 
with first hospital admission. The chapter presents the results of the investigation of the strength of 
associations between the selected non-CVD comorbidities (COPD, DM and CKD) in HF and first hospital 
admission. The effects of time-dependent exposures of the three comorbidities on first hospital admission are 
firstly presented by their status ‘present or not’ followed by their stratification by categories of severity and 
change. All effect estimates will be presented as odds ratios (OR) with 95% confidence intervals (CI). 
 
This chapter presents the findings of the five stages to analysis: 
(vi) Confounding investigation 
(vii) Test of model assumptions: linearity  
(viii) Test of model assumptions: collinearity 
(ix) Adjusted associations of the comorbidities with first hospital admission 
(x) Comorbidity effects stratified by categories of severity and change  
 
10.1 Confounding investigations 
The four steps used to investigate confounding in the associations between the three selected comorbidities 
and mortality in HF were also applied for the outcome of first hospital admission and summarised in Table 
10.1. Given that only 2 studies in the systematic review had focused on the association between the three 
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comorbidities and hospital admission outcome the evidence for mortality was used to indicate potential 
confounders for hospital admission (step 1; Table key, SR). Also shown in the table are the potential 
confounders available from the CPRD data extracted, which differed between the comorbid group and the 
non-comorbid groups in Chapter 8 (step 2; Table key, *).  In step 3, each comorbid DM, COPD, CKD effect in 
HF was now compared in strata of these potential confounders to investigate whether their strength of 
association with first hospital admission differed across strata (step 3, Table key #). Finally, the three 
comorbidity effects were then adjusted for each available potential confounder in turn, to further investigate 
confounding (step 4, Table key ƚ). A 10% difference in the comorbidity effect in steps 3 and 4 was used to 
indicate confounding(9). 
 
Comorbidity effects within strata of the potential confounders (step 3): The unadjusted associations between 
the potential confounders and first hospital admission can be seen in Table 10.2. The potential confounders 
that had the strongest unadjusted associations with first hospital admission were deprivation, prior hospital 
admission, cholesterol, haemoglobin, smoking and cardiovascular medications. When the unadjusted 
associations between the three comorbidities and first hospital admission were observed within strata of 
potential confounders, it was these factors (with the exception of cholesterol, ACEi and beta-blocker) together 
with age and BMI that resulted in a >10% change to the odds ratio (E-Appendix A37).  The relative effect of 
the comorbidities were strengthened across most age strata for DM and COPD and reduced in all age strata 
for CKD, with the exception of the youngest age group. The comorbidity effects varied across strata of 
deprivation and prior hospital admission for all three comorbidities. The effect of DM was stronger in the lower 
haemoglobin group than the higher haemoglobin group and the effect of CKD was reduced when observed in 
both strata of haemoglobin. The comorbidity effect was mainly increased in strata of BMI for DM and reduced 
for CKD and increased in one strata of diuretics for DM and CKD. DM and CKD effects were reduced in the 
non-smoking strata.  
 
Comorbidity associations with first hospital admission adjusted by each potential confounder (step 4): Prior 
admission, which had the strongest unadjusted association with first hospital admission after HF diagnosis, 
was a consistent confounder across all three comorbidities (COPD, DM, CKD) (E-Appendix A38). Each 
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comorbidity effect was reduced with the adjustment of prior admission across most severity categories with 
the most marked reduction in the most severe category of the comorbidities.   
 
Haemoglobin also had one of the strongest unadjusted effects on first hospital admission (OR 0.84 per 
increase g/dL; 95% CI 0.84-0.86). The effect estimates on hospital admission of DM and CKD (which both 
had a lower mean haemoglobin than the non-DM and non-CKD groups respectively), were reduced following 
adjustment by haemoglobin (DM, OR 1.33 reduced to 1.26; CKD, OR 1.34 reduced to 1.15. The effect 
estimates on first admission of the comorbid COPD group with a higher mean haemoglobin than the non-
COPD group, were increased following adjustment by haemoglobin (OR 1.36 increased to 1.43 and OR 1.28 
increased to 1.49 in the most severe COPD group).   
 
Adjustment of COPD and DM by CKD status had opposing results. The effect of HF-DM, a group with a 
higher prevalence of CKD than the non DM HF group (Chapter 8) was reduced following adjustment of CKD. 
The significant effect of HF-COPD, a group with a lower prevalence of CKD than the non COPD HF group 
was increased following adjustment of CKD. 
 
Summary of the confounders for each of the three comorbidities: All of the available covariates from CPRD 
were identified as potential confounders for each of the three comorbidities through the four steps of 
confounding investigation. The same stages of adjustment  in Chapter 9 were applied to the comorbidity and 
hospital admission analyses as follows (Table 10.3): 
 
a) Those identified in step 3 (10% change of the comorbidity effect in any strata of the potential 
confounder) OR step 4 (10% change in the comorbidity effect when adjusted by the potential 
confounder, 
 
b) Previous evidence of confounding identified in the systematic review studies (step 1) AND a 
difference in the prevalence of the potential confounder in the comorbid disease group compared to 
the non-comorbid group in the CPRD analyses (step 2), 
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c) One of step 1 OR step 2, 
10.2 Test of model assumptions: linearity  
The 6 continuous covariates used to adjust the comorbidity measures for the mortality outcome (Chapter 9) 
were investigated for their linear association with first hospital admission using likelihood ratio tests. The fit of 
models using different functions of the covariate was also studied using fitted line plots and Eccles plots. The 
covariates were age, BMI, cholesterol, haemoglobin, systolic blood pressure and eGFR.  
 
For each continuous variable, fully adjusted models with all covariates were derived (Table 10.2) and then 
quadratic and cubic terms for the continuous variable incrementally added. The models were compared using 
likelihood ratio tests. Fitted line plots were then used to compare a Lowess line, which closely follows the 
observed data, with linear and quadratic extension fitted lines of the association between the continuous 
variable and predicted probabilities of hospital admission. Finally Eccles plots were used to graph deciles of 
each covariate against predicted probabilities using fully adjusted models with the continuous covariate 
included and with the additional quadratic and cubic extensions. These plots included Lowess lines to 
compare the predicted models with the observed data. All linearity tests for the continuous covariates are 
shown in E-Appendix E17 and summarised in E-Appendix A39 with two examples detailed below. 
 
 Body Mass Index (BMI) 
 
Likelihood ratio tests showed that addition of a quadratic extension to BMI significantly improved the model fit 
with a small increase in log-likelihood of 8.48 (Table 10.4). Further addition of a cubic term made no 
significant difference. The fitted line plots showed BMI and risk of hospital admission appeared to show a 
linear association which increased quite steeply from the line at the highest BMI values approximately >40 
kg/m2 (Figure 10.1). However, there were only few observations of a BMI ≥40 (0.04%) and ≥50 kg/m2 
(0.005%). The interquartile range for BMI is also shown in the figure (23.9 to 31.2 kg/m2).  Eccles plots 
showed good fit of the adjusted models with (i) BMI and with (ii) BMI plus the quadratic extension (BMI2) 
(Figure 10.2). Given that there was minimal improvement in model fit by adding a quadratic extension and the 
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largest proportion of BMI followed a linear association with the probability of hospital admission, the final 
modelling decision was to include BMI in its simple linear form.  
 
 Haemoglobin 
 
Likelihood ratio tests showed that addition of a quadratic term of Hb significantly improved the model fit with 
an increase in log-likelihood of 122.32 (Table 10.5). Further addition of a cubic term made no significant 
difference. The fitted lines showed that the line with the quadratic extension followed the observed line (Figure 
10.3).  Eccles plots showed good fit of the adjusted models with Hb plus the quadratic term (Hb2) (Figure 
10.4). Given that there was improvement in model fit by adding a quadratic extension to Hb (Hb2), the final 
modelling decision was to include the quadratic terms in the adjusted models.  
 
10.3 Test of model assumptions: collinearity 
Most covariates were weakly correlated (r<0.35). The strongest correlations again were CKD and eGFR 
(r=0.79) (E-Appendix C17). eGFR continuous was selected for adjustment of DM and COPD measures over 
CKD, which used a dichotomised eGFR definition. All continuous variables were centered at their means (Age 
77 years; cholesterol 5 mmol/ml; Hb 13 g/dL; BMI 28 Kg./m2; systolic BP 136 mmHg; eGFR 59 ml/min/m2) 
which removed the collinearity between the variables with a respective squared term (E-Appendix C18).  
 
10.4 Adjusted associations between DM, COPD, CKD comorbidity in HF and first 
hospital admission 
The comorbidity measures were investigated in detail for the outcome of mortality in Chapter 9. For the 
current investigation of the sub-sample of the HF cohort that were linked to hospital data, the main 
comorbidity severity and change exposures that were found to have the strongest associations with mortality, 
are now investigated for the outcome of first hospital admission. 
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10.4.1 Diabetes Mellitus  
In the incident HF-HA population, the unadjusted association between DM and first hospital admission, 
compared to no diabetes was OR 1.30 (95% CI 1.25-1.36). This estimate was most influenced by adjustment 
for the first set of confounders: age, diuretic, prior admission, BMI, Hb and eGFR (adjusted OR 1.23; 1.17-
1.30) (Table 10.9). Adjustment of the remaining confounders made little difference to this estimate (OR 1.24; 
1.18-1.31) (Table 10.6) which was similar to the association between DM-HF and mortality (OR 1.28; 1.23-
1.33).   
 
10.4.1.1 Timing of DM comorbidity 
When DM was stratified by prevalent DM at the time of HF diagnosis (pre-HF DM) or incident DM developing 
after HF diagnosis (post-HF DM), there was a difference in the associations with first hospital admission. The 
adjusted association for pre-HF DM was OR 1.27 (95% CI 1.20-1.34). The association for post-HF DM was 
non-significant following full adjustment (OR 0.93; 0.78, 1.10). This pattern of association between pre-HF 
DM, post HF DM and admission (Figure 10.5) was similar to that found with mortality.  
 
10.4.1.2 Comorbid Diabetes Mellitus severity 
 Physiological severity measure 
HF group with comorbid DM was stratified into groups by glycated haemoglobin (HbA1c) levels. This 
categorisation used the closest available measure preceding the match date (median 73 [IQR 34-118] days) 
comparing the HF group with and without diabetes. 
 
Shape of association: The shape of the adjusted associations between categories of HbA1c in the HF-DM 
group and their respective predicted probabilities of first hospital admission was slightly curved, which is 
shown in Figure 10.6 using a margins plot which fixes other covariate effects at zero. The lowest risk HF-DM 
category was HbA1c 5.5%-6.4%. To observe the shape of association more closely, HbA1c was categorised 
into deciles. There was a trend of increasing risk with higher HbA1c deciles with the highest risk in the 10th 
decile. There was a distinct group with lower risk of admission in decile 6 (7.1%-7.4%) with the next lowest 
risk group being decile 2 (5.9%-6.3%) (Figure 10.7). 
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Strength of associations: Fully adjusted associations between categories of HbA1c in the HF-DM group and 
first hospital admission, compared to the no DM HF group are shown in Table 10.6. The lowest risk category 
was HbA1c 5.5%-6.4% (OR 1.12; 1.01-1.25). From this lowest risk category, risk of hospital admission 
increased with increasing HbA1c level categories. Risk increased in the highest HbA1c category (>9.5%) with 
an OR 1.64 (1.40-1.93) (Figure 10.8). This was a higher risk than for admission (OR 1.45; 1.30-1.62). The 
lowest category of HbA1c was non-significant for hospital admission (OR 1.19; 0.90-1.59).     
 
The adjusted associations showed a significant trend for increasing risk of admission from the second HbA1c 
group (5.5-6.4%) to the highest Hba1c group (>9.5%). The highest risk category of HbA1c (>9.5%) confidence 
intervals did not overlap with those of the lowest risk categories (Figure 10.8). This translated to an increase in 
the risk of admission of 64% in this group compared to the non-comorbid group. Increased risk in the HF-DM 
group with guideline normal HbA1c range (6.5-7.5%), compared to the non-comorbid group was 15%.  
 
 Drug severity measure 
 
The HF-DM group were stratified into groups based on DM-related prescribed medications in a four month 
time-window before the match date. The groups were: (i) DM and no medications, (ii) DM and oral 
hypoglycaemics plus or minus insulin, (iii) DM and insulin only. These groups were compared to the HF 
sample without diabetes. 
 
Strength of associations: The adjusted associations (Table 10.6) with the largest effects were the ‘oral 
hyoglycaemics +/- insulin OR 1.33 (95% CI 1.25-1.42) and ‘insulin only group’ (1.41; 1.25-1.59) (Figure 10.9). 
The confidence intervals did not overlap with the ‘no medications group’ (OR 1.00; 0.91-1.09) indicating the 
stratified comorbid effects of DM drug severity on increased first hospital admission. 
 
10.4.1.3 DM severity change 
 Physiological severity change measure 
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The HF-DM group were stratified into three groups according to change in their glycated haemoglobin 
(HbA1c) level over 6-months before the match date. Change definition was based on the closest available 
HbA1c measure preceding the match date and a previous measure before the most recent measure (median 
161 [IQR 101-212] days). Change over 6 months was calculated and compared to the HF sample without DM. 
 
Strengths of associations: All three categories of HbA1c change in HF were significantly associated with first 
admission in the adjusted models (Table 10.6) with increasing risk from the <1% change group (OR 1.17; 
1.08-1.26) to the >1% decrease group (1.34; 1.18-1.53). There was a significant trend for increasing risk in 
the adjusted models, but the confidence intervals of all three groups overlapped (Figure 10.10). 
 
Drug severity change measure:  The DM group were stratified into three groups based on change in their 
prescribed DM drug over six months before the match date. This measure used the DM drugs prescribed in a 
4-month time-window before first hospital admission compared to a 4-month time-window six months before 
first admission. Change in drug category over 6 months was categorised into ‘no change’, an ‘increase in at 
least one drug category’ and a ‘decrease in at least one drug category’. These groups were compared to the 
HF sample without diabetes. 
 
Strength of associations: Fully adjusted associations between drug category change and first hospital 
admission showed the highest risk was in the ‘decreased at least one drug category’ group with OR 1.60 
(1.18-2.17). The adjusted associations for ‘no change’ were OR 1.22 (1.16-1.29) which strengthened to 1.40 
(1.19-1.66) in the ‘increased at least one drug category’ group. There was a significant linear trend of 
increasing adjusted risk from the no change to the increase drug category group to the decrease drug 
category group.      
 
10.4.2 Chronic obstructive pulmonary disease  
The adjusted association between HF-COPD and first hospital admission compared to non-comorbid group 
was OR 1.32 (1.23-1.41) (Table 10.7) which was similar to the association between HF-COPD and mortality 
(OR 1.35; 1.29-1.41).  
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10.4.2.1 Timing of COPD comorbidity 
When COPD was stratified by prevalent COPD at the time of HF diagnosis (pre-HF COPD) or incident COPD 
developing after HF diagnosis (post-HF COPD), there was a difference in the associations with first hospital 
admission. The adjusted association with pre-HF COPD was OR 1.31 (1.22-1.41) which was similar to the 
association with mortality (OR 1.32; 1.25-1.38). The adjusted association between post-HF COPD and first 
hospital admission was OR 1.40 (1.13-1.73) (Figure 10.5), which was also similar to the association with 
mortality (OR 1.46; 1.34, 1.60). 
 
10.4.2.2 Comorbid COPD severity  
Due to the low numbers of recently recorded FEV1 measures in the HF-HA cohort, comorbid COPD severity 
was restricted to drug based measures 
 COPD drug severity measure 
The HF-COPD group was stratified into three groups according to their prescribed COPD medications in a 4-
month time-window before the match date. The groups were: (i) COPD and no oral steroids or prescribed 
oxygen, (ii) COPD and oral steroids but no prescribed oxygen, and (iii) COPD and prescribed oxygen. These 
groups were compared to the HF sample without COPD. 
 
Strength of associations:  Fully adjusted associations between the HF-COPD drug groups compared to no 
COPD-HF and hospital admission are shown in Table 10.7. Risk of hospital admission increased from the first 
category of ‘no oral steroids or prescribed oxygen’ (OR 1.17; 1.09-1.27) to the ‘oral steroids but no prescribed 
oxygen’ group (1.73; 1.53-1.96) to the highest risk in the ‘prescribed oxygen group’ (2.42; 1.66-3.52). There 
was a significant trend of increasing risk from the first to the third drug category in the in the fully adjusted 
models. The confidence intervals of the two higher risk groups did not overlap with the confidence intervals of 
the lowest risk group indicating significant stratification of comorbid COPD effects by drugs prescribed (Figure 
10.11). 
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10.4.2.3 COPD severity change 
 Drug severity change measure 
The HF-COPD group were stratified into three groups based on change in their prescribed COPD drugs over 
6 months before the match date. This measure used the COPD drugs prescribed in a 4 month time-window 
before first hospital admission compared to a 4 month time-window, six months before admission. Change in 
drug category over 6 months was categorised into (i) no new steroids or oxygen, (ii) new on steroids but no 
new oxygen and (iii) new on oxygen. These groups were compared to the HF sample without COPD. 
 
Strength of associations: The risks associated with the first two drug change categories were similar (OR 
1.31; 1.22-1.41) and OR 1.35 (1.11-1.64) respectively) (Figure 10.12), but the risk estimate for the ‘new on 
prescribed oxygen’ group was strongest but non-significant (OR 2.02; 0.93, 4.39).  
 
10.4.3 Chronic kidney disease 
The unadjusted association between HF-CKD and first hospital admission compared to no CKD HF was OR 
1.34 (95% CI 1.29-1.40), which diminished considerably when adjusted for age, gender, diuretics, diabetes, 
prior admission, BMI, smoking, and Hb to 1.15 (1.10-1.21). This estimate was not influenced by further 
adjustment for the remaining confounders (Table 10.8). This association was weaker than HF-CKD and 
mortality (OR 1.22; 1.18, 1.26). 
 
10.4.3.1 CKD severity 
 Physiological severity measure 
The HF sample was stratified into groups based on the eGFR level. This categorisation used the closest 
available measure preceding the match date (47 [IQR 18-94 days]) and these groups were compared to the 
baseline eGFR group 60-89 ml/min/m2. 
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Shape of association: The shape of the adjusted associations between eGFR categories and their respective 
predicted probabilities of first hospital admission was curved, with the risk of admission falling steeply from the 
lowest eGFR group (<15 ml/min/m2). This is shown in Figure 10.13 using a margins plot. The lowest risk 
group was eGFR 60-89. Whilst the risk of admission begins to increase in the higher eGFR groups, this curve 
is only slight and did not show the same U shape as for the mortality outcome. When eGFR was categorised 
into deciles the curve was similar to the eGFR categories but with a steeper increase in risk from the 9th to 10th 
decile (Figure 10.14). The lowest risk deciles were 7-9 corresponding to eGFR of 63.3 to 84.9 ml/min/m2 . 
 
Strength of associations:  Unadjusted associations between categories of eGFR and hospital admission 
compared to the reference group of eGFR 60-89 are shown in Table 10.8. Risk was associated with all 
categories above and below the reference group. The lowest risk category was eGFR 90-105 (OR 1.15; 1.05-
1.26) and this OR increased only slightly to the next and highest group (eGFR >105). Risk also increased with 
each category below eGFR 90-105 to a maximum of OR 9.17 (6.78-12.4) in the lowest eGFR group (<15). 
The same trend was observed in the fully adjusted associations (Table 10.8). Risk was lowest compared to 
the reference group in the eGFR 90-105 group (1.09; 0.99-1.21) which was non-significant. Risk of admission 
increased from the 45-59 eGFR group (1.12; 1.05-1.17) to the lowest <15 eGFR group (4.45; 3.19-6.21).  
 
In the fully adjusted model, the linear test for trend was non-significant (Figure 10.15). The risk associations of 
the two lowest eGFR groups had confidence intervals that did not overlap with the confidence intervals of the 
other eGFR categories, which indicated stratified effects of CKD defined by eGFR severity levels on hospital 
admission outcome.  
 
10.4.3.2 CKD severity change 
 Physiological severity change measure 
The HF sample was stratified into three groups based on change in their eGFR level over 6 months before the 
match date. This measure used the closest available eGFR measure before the match date and a previous 
eGFR before the most recent measure (median 110 [IQR 59-199] days). Absolute change was defined as: (a) 
0-5mls decrease – reference group, minor decline, (b) any increase, (c) 6-15mls decrease – moderate 
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decline, and (d) >15mls decrease – severe decline. Percentage change was defined as: (a) 0-5% decrease – 
reference group, minor decline, (b) any increase, (c) 6-25% decrease – moderate decline, and (d) >25% 
decrease – severe decline. Change over 6 months was calculated.  
 
Strengths of associations: All categories of absolute and percentage change in eGFR were associated with 
first hospital admission when compared to the reference group of minimal decline in the adjusted models. HF 
patients with any increase or moderate decline in eGFR had similar associations compared to the minimal 
decline reference groups in the adjusted models (Table 10.8). These associations were non-significant using 
the absolute change measure.  The highest risk was observed in the most severe change groups in both 
classifications; >15mls group (OR 1.37; 1.26-1.49) and >25% decrease (OR 1.49; 1.36-1.63).  The confidence 
intervals of these groups did not overlap with the confidence intervals of the other categories of change, 
indicating the stratified effects of comorbid CKD by CKD change in HF on hospital admission outcome (Figure 
10.16).  
 
Adjustment for eGFR: Firstly, the influence of the start or end eGFR on the risk estimates of the different 
change measures was investigated by observing the associations within sub-groups according to the starting 
eGFR (<60 and ≥60 ml/min/m2). Starting eGFR was the first and earliest measure in the change definition. 
The change estimates were also observed within the same strata of the end eGFR measure. This was to 
investigate whether the effect estimates of eGFR change were: (i) influenced by the starting eGFR and 
whether this influence was less for the percentage change measure that already takes some account of the 
starting point and (ii) depended on the end eGFR point meaning that the influence of decline might be greater 
in the <60mls sub-group.  Secondly, the estimates for the change measures were further adjusted, for the 
starting and separately for the end eGFR in order to investigate the independent association of change in 
eGFR (Table 10.8).  
 
eGFR change stratified by baseline start and end eGFR: The effect estimates for eGFR increase and decline 
were similar in those with a starting eGFR of <60ml and ≥60 ml/min/m2 for both the absolute and percentage 
change measure (Table 10.9). Using the end eGFR measure, the effect estimates for all change measures 
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were similar between the <60ml and ≥60 ml/min/m2 groups for the absolute measure. For the percentage 
change measure, decline in eGFR had a greater risk estimate in the <60 group than the ≥60 group 
 
eGFR change adjusted by baseline start and end eGFR: Adjustment of the absolute and percentage eGFR 
change measures with the start eGFR made little difference to the effect estimates for hospital admission 
(Table 10.10). Adjustment of the same measure with the end eGFR made little difference to the absolute 
change measure but reduced the most severe percentage change measure marginally..   
 
10.4 Chapter summary  
The three comorbidities DM, COPD and CKD were significantly and independently associated with first 
hospital admission in the non-selected general practice population of HF. The strengths of association were 
similar to the estimates for mortality and were not explained by confounders based on routinely collected 
clinical data. When each of the comorbidities were stratified by categories of recent severity, there were 
significant associations with first hospital admission. The associations between categories of HbA1c or eGFR 
and hospital admission were less curved than when observed for mortality and there was a trend of increasing 
risk with higher HbA1c and lower eGFR level.  Comorbidity severity measures using prescribed drugs also 
provided significant stratified comorbidity effects for both DM and COPD. The associations between 
comorbidity severity change and hospital admission were varied. There were significant associations between 
HbA1c change and increased hospital admission and between the drug severity change measures for DM 
and COPD and increased hospital admission, but the categories of change for each of the comorbidities were 
not significantly different to each other. Accelerated or severe eGFR decline over 6 months was associated 
with increased risk of hospital admission compared to minimal decline. Adjustment for baseline eGFR 
measures made little difference to these associations. These findings will be discussed in detail in Chapter 13. 
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Table 10.1 Summary of confounders indicated in the four steps 
 
Potential confounder Diabetes COPD CKD (eGFR <60) 
Age SR *# SR *# SR *# 
Gender SR * * SR *# 
White ethnicity SR  SR 
Deprivation *# *# *# 
HF factors   
Left ventricular ejection fraction SR SR SR 
Ischaemic aetiology SR  SR 
Other aetiology   SR 
Left ventricular systolic dysfunction SR   
Brain Naturetic Peptide   SR 
New York Heart Association class SR  SR 
Cardiovascular Drugs    
Beta-blocker SR * SR *# SR 
ACEi SR * # SR * 
ARB SR * # ƚ SR * 
Statin SR  SR 
Diuretics SR *# SR * SR *# 
Digoxin SR   
Spirolactone SR SR SR 
Comorbidities   
Renal disease SR * ƚ *ƚ - 
Diabetes - SR *# SR *# 
COPD SR * - * 
Vascular disease   SR 
Cerebrovascular accident SR  SR 
Hypertension SR  SR 
Charlson index SR   
Atrial fibrillation SR  SR 
Anthropometric and Clinical observations 
Prior admission *#ƚ *#ƚ SR *#ƚ 
Systolic blood pressure SR * * SR* 
Diastolic blood pressure * * * 
Heart rate SR SR  
Edema SR   
Dyspnoea SR   
Elevated jugular venous pressure SR   
Sinus rhythm  SR SR 
Body mass index SR *# SR * SR *# 
Cholesterol * SR SR* 
Glucose level SR  SR 
Blood Urea Nitrogen (mg/dL) SR  SR 
Potassium   SR 
Haemoglobin  *# *ƚ SR *#ƚ 
Creatinine  SR SR SR 
Estimated glomerular filtration rate *ƚ *ƚ SR * 
Lifestyle factors    
Smoking * SR * SR *# 
Alcohol status * * * 
Red text; available factors extracted from CPRD. SR; Systematic review evidence (step 1),* difference 
identified between comorbid and non-comorbid group (step 2), # ≥10% change in comorbidity effect 
observed in at least one strata of the potential confounder (step 3) ƚassociation identified by ≥10% change 
in OR of comorbid exposure by adjustment of potential confounder (step 4).  
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Table 10.2 Unadjusted associations between confounders and first hospital admission 
 
Factors OR (95% CI) 
Person and socio-demographic factors 
Age per year  1.01 (1.01, 1.01) 
Women  0.91 (0.89-0.94) 
IMD quintile*   
1 1.0 
2 1.02 (0.97-1.06) 
3 1.10 (1.05-1.15) 
4 1.10 (1.05-1.15) 
5 1.19 (1.14-1.25) 
Anthropometric and clinical factors 
Prior Hospital admission   
3 months 7.84 (7.43-8.29) 
6 months 2.39 (2.26-2.53) 
1 year 1.52 (1.45-1.59) 
BMI (per Kg/m2) 0.98 (0.98-0.99) 
Cholesterol (per mmol/L)  0.95 (0.93-0.96) 
Haemoglobin (per g/dL) 0.84 (0.84-0.86) 
Systolic BP (per mmHg)  0.99 (0.99-1.00) 
Diastolic BP (per mmHg)  0.99 (0.99-0.99) 
Lifestyle factors 
Smoking status   
No       1.0 
Ex 1.06 (1.03-1.10) 
Yes 1.28 (1.20,1.32) 
Alcohol status   
No 1.0 
Ex 1.06 (0.91-1.03) 
Yes 0.90 (0.87-0.93) 
Drug factors 
Not on beta-blocker 1.21 (1.17-1.24) 
Not on ACEi 1.36 (1.33-1.41) 
Not on ARB 1.20 (1.15-1.25) 
Diuretic 0.90 (0.87-0.93) 
Comorbidity exposures 
Diabetes  1.33 (1.28-1.37) 
COPD  1.36 (1.31-1.43) 
eGFR <60ml/min) 1.34 (1.29-1.40) 
eGFR (per ml/min/m2) 0.99 (0.99-0.99) 
First hospital admission is the first all-cause admission following the 
incident HF date. *IMD in 79,383 patients only. IMD, index multiple 
deprivation (1=least deprived, 5=most deprived); BMI, body mass index; 
BP, blood pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; COPD, chronic obstructive pulmonary 
disease; eGFR, estimated glomerular filtration rate 
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Table 10.4 Likelihood ratio tests for current BMI 
 
 
 
 
 
 
 
 
 
Table 10.5 Likelihood ratio tests for current Hb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.3 Steps of adjustment for each comorbidity with first hospital admission  
 
 
Comorbidity Step 1 +   Step 2 +   Step 3 
DM Age, diuretics, prior admission, BMI, 
Hb, eGFR, deprivation 
Gender, beta-blocker, ACEi, 
ARB, COPD, systolic BP 
 
Cholesterol, smoking, alcohol 
 
COPD Age, beta-blocker, ACEi, ARB, 
diabetes, prior admission, Hb, eGFR,   
deprivation 
Diuretics, BMI, smoking 
 
 
Gender, systolic BP, alcohol, 
cholesterol 
 
CKD Age, gender, diuretics, diabetes, prior 
admission, BMI, smoking, Hb, 
deprivation 
ACEi, ARB, systolic,  
cholesterol, eGFR 
 
Beta-blocker, COPD, alcohol 
 
BMI, body mass index; BP, blood pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; CKD, chronic kidney disease; eGFR, 
estimated glomerular filtration rate 
Multivariable Log likelihood LR test  
a BMI -17245.36  
b BMI+BMI2 -17236.88 <0.001 a nested in b  
c BMI+BMI2+BMI3 -17236.79 0.67     b nested in c 
 
Multivariable Log likelihood LR test  
a HB -17245.36  
b HB+HB2 -17123.04 <0.001 a nested in b 
c HB+HB2+HB3 -17122.13 0.179   b nested in c 
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Table 10.6  Association between comorbid diabetes exposures and first hospital admission in HF 
 
Diabetes exposures   Unadjusted OR (95% CI)  Adjusted1 OR (95% CI)  Adjusted2 OR (95% CI)  Adjusted3 OR (95% CI)  
Diabetes status  *53,159 observations   
No diabetes (ref) 1.0 1.0 1.0 1.0 
Diabetes anytime 1.30 (1.25-1.36) 1.23 (1.17-1.30) 1.25 (1.19-1.32) 1.24 (1.18-1.31) 
No diabetes (ref) 1 1 1 1 
Diagnosis before HF 1.34 (1.28-1.40) 1.26 (1.19-1.32) 1.28 (1.22-1.35) 1.27 (1.20-1.34) 
Diagnosis after HF 0.90 (0.76-1.06) 0.97 (0.81-1.15) 0.94 (0.79-1.12) 0.93 (0.78-1.10) 
Diabetes HbA1c severity   *48,427 observations 
No diabetes (ref) 1.0 1.0 1.0 1.0 
1.18 (0.89-1.57) <5.5% 1.89 (1.48-2.43) 1.20 (0.90-1.59) 1.19 (0.90-1.59) 
5.5-6.4% 1.18 (1.07-1.29) 1.10 (0.99-1.22) 1.12 (1.01-1.25) 1.10 (0.99-1.22) 
6.5-7.5% 1.18 (1.09-1.27) 1.15 (1.05-1.25) 1.17 (1.07-1.27) 1.15 (1.06-1.26) 
7.6-8.5% 1.21 (1.10-1.35) 1.20 (1.08-1.35) 1.23 (1.10-1.38) 1.23 (1.09-1.38) 
8.6-9.5% 1.27 (1.09-1.47) 1.31 (1.12-1.54) 1.30 (1.10-1.53) 1.28 (1.08-1.50) 
>9.5% 1.67 (1.44-1.92) 1.62 (1.39-1.90) 1.64 (1.40-1.93) 1.64 (1.39-1.92) 
Diabetes drugs severity *53,159 observations   
No diabetes (ref) 1.0 1.0 1.0 1.0 
1: None 1.07 (0.98-1.16) 1.00 (0.92-1.10) 1.00 (0.92-1.10) 1.00 (0.91-1.09) 
2: Oral (+/- Insulin) 1.36 (1.28-1.43) 1.32 (1.24-1.40) 1.34 (1.26-1.43) 1.33 (1.25-1.42) 
3: Insulin only 1.60 (1.44-1.77) 1.37 (1.21-1.54) 1.42 (1.25-1.60) 1.41 (1.25-1.59) 
Diabetes  HbA1c severity change *45,678 observations   
No diabetes (ref) 1.0 1.0 1.0 1.0 
<1% change  1.18 (1.11-1.26) 1.16 (1.08-1.25) 1.18 (1.10-1.27) 1.17 (1.08-1.26) 
>1% increase 1.33 (1.17-1.52) 1.24 (1.07-1.44) 1.27 (1.09-1.48) 1.26 (1.09-1.47) 
>1% decrease 1.46 (1.30-1.64) 1.36 (1.19-1.56) 1.37 (1.20-1.56) 1.34 (1.18-1.53) 
Diabetes drugs severity change *53,159 observations    
No diabetes (ref) 1.0 1.0 1.0 1.0 
No drug category change 1.27 (1.22-1.33) 1.22 (1.16-1.28) 1.24 (1.17-1.30) 1.22 (1.16-1.29) 
Increase in drug category 1.52 (1.31-1.76) 1.38 (1.17-1.63) 1.42 (1.20-1.69) 1.40 (1.19-1.66) 
Decrease in drug category 2.14 (1.70-2.89) 1.58 (1.17-2.13) 1.62 (1.19-2.19) 1.60 (1.18-2.17) 
First hospital admission is the first all-cause admission following the incident HF date. Ref, reference group. * each unadjusted and adjusted measure was based on the same number 
of observations. There was complete data for comorbidity status and all confounders with the exception of eGFR. All associations excluded those without eGFR. For the comorbidity 
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severity exposures, associations excluded the comorbid groups without the severity exposure or that had eGFR missing.  
1Adjusted for age, diuretics, prior admission, BMI, Hb Hb2,  eGFR eGFR2 
2Adjusted further for  gender, beta-blocker, ACEi or ARB,  COPD,  systolic bp, systolic bp2 
3 Adjusted further for cholesterol, smoking, deprivation, alcohol 
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Table 10.7 Association between comorbid COPD exposures in HF and first hospital admission 
 
 
COPD exposures 
 
Unadjusted OR (95% CI)  
 
Adjusted1 OR (95% CI)  
 
Adjusted2 OR (95% CI)  
 
Adjusted3 OR (95% CI)  
COPD defined by Diagnostic code *53,159 observations   
No COPD (ref) 1.0 1.0 1.0 1.0 
COPD anytime 1.36 (1.29-1.45) 1.36 (1.28-1.46) 1.34 (1.26-1.44) 1.32 (1.22-1.41) 
No COPD (ref) 1.0 1.0 1.0 1.0 
COPD diagnosis before HF 1.36 (1.28-1.44) 1.36 (1.27-1.45) 1.33 (1.24-1.43) 1.31 (1.22-1.41) 
COPD diagnosis after HF 1.44 (1.18-1.76) 1.44 (1.17-1.78) 1.44 (1.17-1.78) 1.40 (1.13-1.73) 
COPD defined by severity (drugs) *53,159 observations    
 No COPD (ref) 1.0 1.0 1.0 1.0 
 No steroids or oxygen  1.20 (1.12-1.28) 1.22 (1.13-1.31) 1.20 (1.11-1.29) 1.17 (1.09-1.27) 
 Oral steroids but no oxygen 1.81 (1.62-2.01) 1.77 (1.57-2.00) 1.76 (1.55-1.98) 1.73 (1.53-1.96) 
 On  oxygen 3.01 (2.16-4.18) 2.59 (1.78-3.77) 2.50 (1.71-3.64) 2.42 (1.66-3.52) 
COPD defined by severity change *53,159 observations   
 No COPD (ref) 1.0 1.0 1.0 1.0 
 No new steroids or oxygen  1.36 (1.28-1.44) 1.36 (1.27-1.45) 1.33 (1.24-1.43) 1.31 (1.22-1.41) 
 New on steroids but no new oxygen 1.39 (1.17-1.66) 1.39 (1.15-1.69) 1.38 (1.13-1.67) 1.35 (1.11-1.64) 
 New on oxygen 2.46 (1.18-5.12) 2.36 (1.09-5.11) 2.34 (1.08-5.10) 2.02 (0.93-4.39) 
First hospital admission is the first all-cause admission following the incident HF date. Ref, reference group. * each unadjusted and adjusted measure 
was based on the same number of observations. There was complete data for comorbidity status and all confounders with the exception of eGFR. All 
associations excluded those without eGFR. For the comorbidity severity exposures, associations excluded the comorbid groups without the severity 
exposure or that had eGFR missing.  
1Adjusted for  Age, beta-blocker, ACEi or ARB, diabetes, prior admission, Hb Hb2, eGFR eGFR2 
2Adjusted further for  diuretic, BMI, smoking 
3 Adjusted further for  gender, systolic bp, systolic bp2, deprivation, alcohol, cholesterol   
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Table 10.8 Associations between CKD exposures in HF and first hospital admission 
 
 
CKD exposures Unadjusted OR (95% CI)  Adjusted1 OR (95% CI)  Adjusted2 OR (95% CI)  Adjusted3 OR (95% CI)  
CKD status       
eGFR ≥60 (ref) 1.0 1.0 1.0 1.0 
eGFR <60   1.34 (1.29, 1.40) 1.15 (1.10-1.21) 1.14 (1.10-1.20) 1.15 (1.10-1.21) 
CKD severity      
eGFR mL/min/1.73m2     
60-89 (ref) 1.0 1.0 1.0 1.0 
>105 1.19 (1.03-1.38) 1.22 (1.04-1.43) 1.19 (1.02-1.40) 1.17 (0.99-1.37) 
90-105 1.15 (1.05-1.26) 1.11 (1.01-1.23) 1.10 (1.00-1.21) 1.09 (0.99-1.21) 
45-59 1.16 (1.12-1.22) 1.10 (1.05-1.16) 1.10 (1.04-1.16) 1.12 (1.05-1.17) 
30-44 1.41 (1.33-1.49) 1.15 (1.08-1.23) 1.14 (1.07-1.21) 1.15 (1.08-1.22) 
15-29 2.50 (2.30-2.73) 1.66 (1.51-1.83) 1.59 (1.44-1.75) 1.61 (1.46-1.77) 
<15 9.17 (6.78-12.4) 4.81 (3.46-6.68) 4.43 (3.17-6.17) 4.45 (3.19-6.21) 
CKD severity change      
Absolute change     
0mls to 5mls decrease (ref) 1.0 1.0 1.0 1.0 
Any increase 1.07 (1.01-1.14) 1.05 (0.98-1.13) 1.05 (0.98-1.12) 1.04 (0.98-1.12) 
6mls to 15mls decrease 1.12 (1.04-1.20) 1.07 (0.99-1.16) 1.06 (0.98-1.15) 1.06 (0.97-1.14) 
>15mls decrease 1.49 (1.38-1.60) 1.38 (1.27-1.50) 1.38 (1.27-1.50) 1.37 (1.26-1.49) 
Percentage change     
0-5% decrease (ref) 1.0 1.0 1.0 1.0 
Any % increase 1.21 (1.13-1.30) 1.13 (1.05-1.23) 1.12 (1.03-1.21) 1.11 (1.03-1.21) 
6-25% decrease 1.25 (1.15-1.34) 1.17 (1.07-1.27) 1.15 (1.05-1.25) 1.14 (1.05-1.25) 
>25% decrease 1.79 (1.65-1.95) 1.51 (1.38-1.66) 1.49 (1.36-1.64) 1.49 (1.36-1.63) 
First hospital admission is the first all-cause admission following the incident HF date. Ref, reference group. *each unadjusted and adjusted measure based on the 
same number of observations (excluding those with the comorbidity exposure or eGFR confounder missing) 
1Adjusted for  age, gender, diuretic, diabetes, prior admission, BMI, smoking, Hb Hb2 
2Adjusted further for ACEi or ARB, systolic bp, systolic bp2, cholesterol  
3Adjusted further for Beta-blocker, COPD, deprivation, alcohol 
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Table 10.9 Change estimates with first hospital admission stratified by start baseline and end eGFR 
 
 Start eGFR End eGFR 
eGFR severity change  ≥60 <60 ≥60 <60 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Absolute change     
0mls to 5mls decrease (ref) 1.0 1.0 1.0 1.0 
Any increase 1.02 (0.89-1.18) 1.02 (0.91-1.14) 1.08 (0.94-1.24) 1.01 (0.90-1.13) 
6mls to 15mls decrease 1.01 (0.86-1.18) 1.11 (0.97-1.27) 0.97 (0.81-1.16) 1.05 (0.93-1.19) 
>15mls decrease 1.45 (1.24-1.69) 1.32 (1.13-1.53) 1.30 (1.08-1.56) 1.35 (1.19-1.54) 
Percentage change     
0-5% decrease (ref) 1.0 1.0 1.0 1.0 
Any % increase 1.07 (0.92-1.24) 1.18 (1.02-1.36) 1.10 (0.95-1.28) 1.16 (1.01-1.33) 
6-25% decrease 1.13 (0.96-1.32) 1.31 (1.12-1.53) 1.07 (0.90-1.28) 1.25 (1.09-1.44) 
>25% decrease 1.55 (1.31-1.84) 1.53 (1.30-1.81) 1.33 (1.08-1.65) 1.55 (1.33-1.80) 
All associations were fully adjusted by all remaining covariates. eGFR-estimated glomerular filtration rate (ml/min/m2); 
ref, reference group. Change was calculated over 6-months before the match date using the most recent value up to a 
maximum of 6-months and a prior value between 1 month and 1 year. 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.10   eGFR change effect estimates with first hospital admission adjusted for the start 
and end eGFR 
 
eGFR severity change  Adjusted3 Adjusted for start 
eGFR and eGFR2 
Adjusted for end 
 eGFR and eGFR2 
Absolute change    
0mls to 5mls decrease (ref) 1 1 1 
Any increase 1.04 (0.98-1.12) 1.04 (0.97-1.11) 1.07 (1.00-1.14) 
6mls to 15mls decrease 1.06 (0.97-1.14) 1.07 (0.99-1.16) 1.05 (0.97-1.14) 
>15mls decrease 1.37 (1.26-1.49) 1.40 (1.29-1.53) 1.36 (1.25-1.47) 
Percentage change    
0-5% decrease (ref) 1 1 1 
Any % increase 1.11 (1.03-1.21) 1.10 (1.01-1.19) 1.11 (1.02-1.20) 
6-25% decrease 1.14 (1.05-1.25) 1.14 (1.05-1.24) 1.13 (1.03-1.23) 
>25% decrease 1.49 (1.36-1.63) 1.47 (1.34-1.61) 1.39 (1.27-1.53) 
eGFR, estimated glomerular filtration rate (ml/min/m2); ref, reference group. All associations were fully adjusted 
by all remaining covariates and the start or end eGFR. Due to the non-linear association between eGFR and 
hospital admission eGFR2 was also used in the models. Change was calculated over 6-months before the 
match date using the most recent value up to a maximum of 6-months and an earlier value between 1 month 
and 1 year before. 
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Figures 
 
Figure 10.1 Calibration plots of observed versus predicted fitted effects for BMI 
 
 
 
 
Figure 10.2 Eccles plots of BMI 
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Figure 10.3 Calibration plots of observed versus predicted fitted effects for Haemoglobin 
 
 
Figure 10.4 Eccles plots of Haemoglobin  
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Figure 10.5 Adjusted associations of comorbidities in HF with first hospital admission 
 
 
Figure 10.6 Margins plot of HbA1c categories and hospital admission  
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Figure 10.7 Margins plot of HbA1c deciles and first hospital admission 
 
 
Figure 10.8 Adjusted associations of HbA1c categories and first hospital admission 
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Figure 10.9 Adjusted associations of DM drug severity categories and first hospital admission 
 
 
Figure 10.10   Adjusted associations of categories of DM and HbA1c change and hospital admission 
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Figure 10.11 Adjusted associations of COPD drug severity categories and hospital admission 
 
  
 
Figure 10.12 Adjusted associations of COPD drug severity change and hospital admission 
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Figure 10.13 Margins plot of eGFR severity categories and first hospital admission 
 
 
Figure 10.14 Margins plot of eGFR deciles and first hospital admission 
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Figure 10.15 Adjusted associations of eGFR categories and first hospital admission 
 
 
Figure 10.16 Adjusted associations of categories of eGFR change and first hospital admission 
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Chapter 11  Comorbidity interactions  
This chapter investigates first order interactions for the DM, COPD and CKD comorbidities in HF for both 
mortality and first hospital admission. Interactions were investigated between (i) pairs of the three 
comorbidities, (ii) each comorbidity and HF severity as defined by age groups and (iii) each comorbidity and 
any additional patient factors. The patient factors included those that were identified as potential effect 
modifiers during the investigation of confounding in Chapters 9 and 10. First, the comorbidity effect estimates 
that differed across strata during the confounding investigations are summarised. Second, likelihood ratio 
tests are used to compare fully adjusted models with and without interaction terms to identify significant 
statistical interaction, which was defined as departure from multiplicatively. Third, biological interaction was 
investigated to investigate departure from additivity.  
  
11.1 Summary of potential interactions  
11.1.1 Comorbidity pairs 
When the estimate of effect of a comorbidity on both outcomes was observed in groups defined by the 
presence or absence of an additional comorbidity (i.e. pairs), there was only one disease pair that indicated 
possible effect modification. The unadjusted association of CKD with mortality was much higher in the group 
without COPD (OR 1.91; 95% CI 1.85-1.98) than the group with COPD (1.29; 1.13-1.47) (Table 11.1). This 
indicated that the observed risk of COPD and CKD combined might be lower than expected. 
 
11.1.2 Comorbidity and HF severity 
When the effects of each of the comorbidities were observed in quartiles of age, effect estimates were higher 
in the lower age groups than the higher age groups for mortality and for CKD and first hospital admission. This 
could indicate (i) that the effect of comorbidity is modified by age (effect modification) which may be due, in 
part, to competing risks for mortality in older age or (ii) that the absolute effect of the comorbidities is constant 
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but due to the lower baseline risk in the younger groups, the relative effect of comorbidity in relation to the 
baseline risk is higher in the younger groups (effect measure modification).  
 
11.1.3 Comorbidity in HF and patient factors 
The effect of CKD was higher in men than in women for both outcomes. This gender difference was also 
found for DM for hospital admission with greater effect estimates of DM for women than men. The effects of 
COPD and CKD were greater in the high compared to the low haemoglobin groups for mortality and for DM in 
the high haemoglobin group for hospital admission. Comorbidity effects were higher in the lower risk 
cardiovascular drug groups (on beta-blocker, on ACEi or ARB, not on diuretics) than the higher risk drug 
groups for mortality and hospital admission.  
 
11.2 Test of statistical interactions  
11.2.1 Comorbidity pairs 
There was significant statistical interaction between COPD and CKD for mortality (see Table 11.2) which was 
less than multiplicative. When an interaction term for having COPD and CKD was included in the model, the 
likelihood ratio test of the interaction term was significant (p<0.001). The effect of having COPD (without CKD) 
increased to OR 1.52 (1.43, 1.63), of having CKD (without COPD) increased to 1.27 (1.22-1.31) and the 
added contribution of having both comorbidities was protective OR 0.81 (0.74-0.87). No other comorbidity 
pairs for either outcome had a significant statistical interaction. 
 
11.2.2 Comorbidity and severity 
There was a significant statistical interaction between all three comorbidities and age for mortality which were 
less than multiplicative. The effect estimates for each of the comorbidities were increased in lower age with a 
reduction in the comorbidity risk estimate per year of older age (Table 11.2). The biggest influence of age 
appeared to be for COPD which increased to OR 4.30 (2.90-6.37) following the inclusion of an interaction 
term with an estimate of 0.98 (0.98-0.99) for each year of older age in those with COPD.  
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Figure 11.1a shows the observed effect of COPD over age and Figure 11.2b shows the predicted effect of 
COPD over age. In Figure 11.1a, the observed relative effect of COPD reduces as age increases, which 
appears to widen out again at the highest values of age. Given the low proportion of observations with Age 
≥90 years (7.6%), the second graph based on predicted probabilities does not show this anomaly.  
 
The same reduction in comorbidity effect with age can be seen on Figure 11.2a for CKD and mortality. The 
observed effect of CKD crosses the line of the no CKD group at older age. The reducing effect of CKD at 
older age is far more subtle for the predicted effects also shown in Figure 11.2b. 
 
11.2.3 Comorbidity and patient factors 
There were significant statistical interactions between gender and COPD for mortality and between gender 
and CKD for hospital admission (p<0.001). The effect estimate of COPD for mortality was decreased in males 
over females (11% lower). This was the opposite for CKD and hospital admission where the effect estimate of 
CKD was increased for males (14% higher, Table 11.2). There was also some evidence that that the effect 
estimate of DM for hospital admission was decreased in males (10% lower, p<0.05).  
 
The effect estimates for DM and CKD for mortality were reduced significantly in the groups that were not 
prescribed beta-blockers (p<0.01). There was also some evidence of statistical interaction between 
haemoglobin and CKD for mortality and haemoglobin and DM for hospital admission. The effect of having 
both low Hb and CKD was a reduction in risk of mortality of 7% compared to the risk estimates for low Hb and 
CKD combined (OR for interaction term: 0.93; 0.87-0.99). The effect of having both low Hb and DM was an 
increase in risk of admission of 12% above the individual risk estimates for both Hb and DM combined (OR for 
interaction term: 1.12; 1.00-1.22) (p<0.05). 
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11.3 Test of biological interactions  
Biological interaction was investigated between the comorbidity pairs to identify whether the observed effect of 
having two comorbidities together would differ from the sum of their separate effects. The indication of 
biological interaction is that where present, the risk of an event will depend at least in part, on the presence of 
both comorbidities.  
 
Biological interaction was also investigated between each comorbidity and age. Whilst statistical interaction 
existed between all three comorbidities and age for mortality, this may be due to the difference in baseline risk 
in different age groups, leading to variation in the relative risks of comorbidity with age. This can be the case 
where there is no actual difference in the absolute risk associated with comorbidity for different ages. 
Biological interaction was investigated here to explore this association. Lastly biological interaction was also 
explored between each comorbidity and gender. 
   
Biological interaction, which tests departure from additivity of two factors, cannot be tested directly within 
logistic or other multiplicative models and requires specific analysis described in detail in Chapter 6 (Section 
6.4.2). The Relative Excess Risk due to Interaction (RERI) and synergy index (S) are used to indicate the 
presence of biological interaction. These refer to the excess risk from joint exposure above the sum of the 
individual exposures (RERI) and the excess risk from joint exposure in the presence of interaction, relative to 
the risk from exposure without interaction (S). If there is no excess risk from interaction then the RERI = 0 and 
the S index = 1. 
 
11.3.1 Comorbidity pairs 
The biological interaction measures for each disease pair for both outcomes are summarised in Table 11.3. 
Worked examples are provided for the disease combinations where interaction was present which were 
between DM and CKD and between COPD and CKD for mortality. 
 
 
  
292 
 
 Diabetes and CKD 
DM and CKD were categorised into four mutually exclusive groups of disease combinations as follows; 
DM+CKD-, DM-CKD+ , DM+CKD+ and DM-CKD- (reference group). The expected risk associated with 
DM+CKD+ was calculated by using the equation:  
 
OR VAR11(expected) = OR VAR10 + OR VAR01 – 1 
 
where OR is the odds ratio, VAR10 is DM+CKD-, VAR01 is DM-CKD+, VAR11 is DM+CKD+ and VAR00 is DM-
CKD- (reference group). 
 
OR 1 occurs where there is no risk associated with a group, relative to the reference group (VAR00) and this 
equates to the background risk. The -1 in the equation is to account for adding in the background risk (VAR00) 
twice due to both comorbidity groups in the equation.  This resulted in an expected risk of 1.277 + 1.201 – 1 = 
1.478. 
 
This was below that observed for DM & CKD which was OR 1.615 (Table 11.3). The relative excess risk due 
to interaction was calculated as  
 
RERI = OR VAR11 – OR VAR10 – OR VAR01 +1 
 
For DM & CKD this was 1.615 – 1.277 – 1.201 + 1 = 0.137 which had a 95% CI 0.04-0.24.  
 
An increase in absolute risk of 14% above the risk associated with the individual diseases due to interaction 
between DM and CKD.   
 
The synergy index was calculated as; 
OR VAR11 − 1
(OR VAR10 − 1)  +  (OR VAR01 –  1)
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For DM & CKD this was              
1.615−1
(1.277−1)+(1.201−1)
 = 1.285 which had a 95% CI 1.05-1.57 
This equates to 29% more risk through the presence of interaction relative to if there was no interaction.  
 
Figure 11.3 shows the excess risk associated with the presence of interaction of DM and CKD for mortality. 
This was not found for these diseases for hospital admission (see Figure 11.4) where the RERI and S were 
non-significant.  
 
 COPD and CKD 
COPD and CKD were categorised into four mutually exclusive groups of disease combinations as follows; 
COPD+CKD- , COPD-CKD+, COPD+CKD+  and COPD-CKD- (reference group). The expected risk associated 
with COPD+CKD+ was calculated by using the equation:  
 
OR VAR11(expected) = OR VAR10 + OR VAR01 – 1 
 
where OR is the odds ratio, VAR10 is COPD+CKD-, VAR01 is COPD-CKD+, VAR11 is COPD+CKD+ and VAR00 
is COPD-CKD- (reference group). 
 
This resulted in an expected risk of 1.263 +  1.525 – 1 = 1.79. This was higher that observed for COPD&CKD 
which was OR 1.546 (Table 11.3). 
 
The relative excess risk due to interaction was calculated as:  
 
RERI = OR VAR11 – OR VAR10 – OR VAR01 +1 
 
For COPD & CKD this was 1.546 – 1.263 – 1.525 + 1 = -0.24 which had a 95% CI -0.37 to -0.11. A reduction 
in absolute risk of 24% below the risk associated with the individual diseases, due to interaction between 
COPD and CKD.  The synergy index was calculated as: 
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OR VAR11 − 1
(OR VAR10 − 1)  +  (OR VAR01 –  1)
 
 
For COPD & CKD this was        
1.546−1
(1.263−1)+(1.525−1)
   = 0.694 which had a 95% CI 0.57- 0.84 
This equates to 30% less risk through the presence of interaction relative to if there was no interaction. Figure 
11.5 shows the reduced risk associated with the presence of interaction of COPD and CKD for mortality. This 
was not found for these diseases for hospital admission (Figure 11.6) where there was a slight increased risk 
associated with this combination but the interaction measures (RERI and S) were insignificant.  
 
11.3.2 Comorbidity and severity 
There was no significant statistical interaction between comorbidities and age for hospital admission and this 
was also the case when tested for biological interaction. None of the measures of biological interaction were 
significant (Figure 11.7). There was significant sub-additive biological interaction between COPD and age for 
mortality (S 0.85; 95% CI 0.76-0.95). The effect of COPD was less in older age groups. This was the same 
direction of effect that was found in the multiplicative model where there was significant statistical interaction 
between COPD and older age which was less than multiplicative.  
 
DM and older age, which had significant statistical interaction for mortality, did not have significant biological 
interaction. There was a significant super-additive biological interaction between CKD and older age (S 1.17; 
1.05-1.30) which went in the opposite direction than the statistical interaction test between CKD and older age 
(which was protective). CKD was associated with higher risk in the older age groups.  
 
11.3.3 Comorbidity and patient factors 
In the statistical interaction tests, there were 3 significant findings (i) COPD and male gender for mortality was 
less than multiplicative (ii) CKD and male gender for hospital admission was more than multiplicative and (iii) 
DM and male gender for hospital admission was protective (10% lower relatives to females). The test of 
biological interactions between COPD or DM and gender for mortality were insignificant but there was 
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significant biological interaction between CKD and gender for mortality with males with CKD having a 13% 
increase in the risk of death relative to females.  
 
The biological interactions between COPD or DM and gender for hospital admission were non-significant. 
There was a significant biological interaction between CKD and male gender for hospital admission. This 
association was super-additive with males with CKD having a 18% higher risk for admission than females with 
CKD (Figure 11.8).  
 
11.4 Chapter summary  
There were interactions between CKD and both COPD and DM. For COPD and CKD there was significant 
statistical and biological interaction that reduced their combined association with mortality when experienced 
together.  Biological but not statistical interaction was present between DM and CKD for mortality with a more 
than additive effect when these diseases were experienced together.  
 
Statistical interaction but not biological interaction was present for all three comorbidities and age for mortality, 
reducing the relative effect estimates in the older age groups. Biological interaction was present for two of the 
comorbidities with age. COPD and older age had a sub-additive effect when both were experienced together 
whilst CKD and older age had a super-additive effect. This latter interaction was in the opposite direction to 
the statistical interaction and showed an increase in risk in older people with CKD than would be expected.  
 
COPD was associated with a significant statistical interaction with male gender for mortality and DM and 
gender for hospital admission. The relative effect of both diseases in males was lower than in females. These 
interactions were not significant when tested for biological interaction. CKD was associated with a significant 
statistical interaction with male gender for hospital admission. The relative effect of CKD for hospital 
admission was increased in males. This combined exposure group was also significant when tested for 
biological interaction in the same direction but for both outcomes. These results will be discussed in detail in 
Chapter 13. 
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Tables 
Table 11.1 Stratification of comorbidity effects 
 
 
Potential confounders Mortality Hospital admission 
 Diabetes COPD CKD Diabetes COPD CKD 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Unadjusted 1.09 (1.05-1.12) 1.41 (1.36-1.46) 1.77 (1.72-1.82) 1.33 (1.28-1.37) 1.36 (1.31-1.43) 1.34 (1.29-1.40) 
Person and socio-demographic factors   
Age quartile        
1 1.54 (1.38-1.71) 2.03 (1.78-2.30) 2.22 (1.98-2.50) 1.31 (1.19-1.45) 1.40 (1.23-1.59) 1.69 (1.46-1.96) 
2 1.32 (1.21-1.44) 1.70 (1.53-1.88) 1.41 (1.29-1.54) 1.36 (1.23-1.50) 1.55 (1.37-1.76) 1.21 (1.08-1.37) 
3 1.21 (1.11-1.33) 1.65 (1.49-1.84) 1.36 (1.24-1.50) 1.54 (1.38-1.72) 1.60 (1.40-1.83) 1.18 (1.04-1.34) 
4 1.16 (1.06-1.13) 1.17 (1.05-1.31) 1.21 (1.12-1.31) 1.52 (1.35-1.72) 1.41 (1.21-1.64) 1.16 (1.02-1.32) 
Male 1.10 (1.05-1.16) 1.47 (1.39-1.55) 1.94 (1.85-2.03) 1.24 (1.18-1.31) 1.36 (1.28-1.46) 1.53 (1.44-1.64) 
Female 1.13 (1.07-1.19) 1.36 (1.27-1.46) 1.55 (1.47-1.63) 1.44 (1.35-1.53) 1.38 (1.27-1.50) 1.17 (1.09-1.26) 
Anthropometric and clinical factors   
BMI quartile  
1 
 
1.36 (1.24-1.50) 
 
1.24 (1.13-1.36) 
 
1.45 (1.34-1.57) 
 
1.45 (1.28-1.65) 
 
1.45 (1.28-1.64) 
 
1.20 (1.06-1.35) 
2 1.34 (1.22-1.47) 1.45 (1.30-1.62) 1.72 (1.57-1.88) 1.50 (1.34-1.69) 1.28 (1.12-1.47) 1.29(1.13-1.46) 
3 1.29 (1.17-1.41) 1.37-1.22-1.54) 2.02 (1.83-2.23) 1.20 (1.08-1.33) 1.33 (1.15-1.53) 1.31 (1.15-1.50) 
4 1.25 (1.14-1.37) 1.52 (1.35-1.72) 2.19 (1.98-2.43) 1.38 (1.26-1.52) 1.36 (1.19-1.56) 1.41 (1.25-1.60) 
Cholesterol high  1.09 (1.03-1.16) 1.39 (1.31-1.48) 1.71 (1.62-1.80) 1.29 (1.20-1.38) 1.40 (1.30-1.51) 1.25 (1.17-1.35) 
Cholesterol low 1.04 (0.99-1.09) 1.39 (1.31-1.47) 1.84 (1.75-1.93) 1.33 (1.26-1.40) 1.40 (1.30-1.50) 1.20 (1.13-1.28) 
Haemoglobin high 1.10 (1.03-1.17) 1.59 (1.49-1.70) 1.74 (1.65-1.84) 1.14 (1.07-1.21) 1.39 (1.29-1.49) 1.22 (1.13-1.31) 
Haemoglobin  low 0.96 (0.91-1.00) 1.36 (1.28-1.44) 1.38 (1.31-1.44) 1.14 (1.07-1.21) 1.39 (1.29-1.49) 1.22 (1.13-1.31) 
Systolic BP high 1.07 (1.02-1.12) 1.45 (1.36-1.54) 1.67 (1.59-1.76) 1.39 (1.31-1.48) 1.33 (1.23-1.43) 1.31 (1.22-1.41) 
Systolic BP low 1.08 (1.03-1.14) 1.34 (1.26-1.42) 1.84 (1.75-1.94) 1.28 (1.21-1.35) 1.37 (1.28-1.47) 1.40(1.32-1.49) 
Lifestyle factors   
Smoking yes 1.05 (0.87-1.26) 1.43 (1.20-1.70) 1.83 (1.51-2.22) 1.09 (0.87-1.38) 1.33 (1.08-1.65) 1.04 (0.77-1.41) 
Smoking no 1.08 (1.05-1.12) 1.39 (1.33-1.45) 1.78 (1.72-1.84) 1.34 (1.29-1.40) 1.36 (1.29-1.42) 1.34 (1.28-1.39) 
Alcohol yes 1.09 (1.05-1.14) 1.43 (1.36-1.50) 1.79 (1.72-1.87) 1.34 (1.28-1.40) 1.37 (1.30-1.45) 1.34 (1.28-1.41) 
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Alcohol no 1.03 (0.97-1.11) 1.33 (1.22-1.45) 1.66 (1.55-1.78) 1.26 (1.15-1.37) 1.33 (1.18-1.51) 1.30 (1.15-1.46) 
Drug factors   
Beta-blocker yes 1.21 (1.15-1.26) 1.37 (1.28-1.47) 2.10 (2.00-2.21) 1.37 (1.28-1.47) 1.37 (1.28-1.47) 1.40 (1.30-1.52) 
Beta-blocker no 1.01 (0.96-1.07) 1.15 (1.09-1.22) 1.56 (1.48-1.64) 1.38 (1.31-1.45) 1.15 (1.09-1.22) 1.31 (1.23-1.39) 
ACEi or ARB yes 1.18 (1.13-1.23) 1.51 (1.43-1.58) 1.90 (1.82-1.98) 1.40 (1.34-1.46) 1.51 (1.43-1.58) 1.34 (1.28-1.41) 
ACEi or ARB no 1.11 (1.03-1.20) 1.14 (1.05-1.23) 1.51 (1.40-1.61) 1.45 (1.31-1.61) 1.14 (1.05-1.23) 1.37 (1.22-1.54) 
Diuretic yes 1.02 (0.99-1.06) 1.39 (1.33-1.45) 1.66 (1.60-1.72) 1.31 (1.25-1.36) 1.39 (1.33-1.45) 1.33 (1.27-1.40) 
Diuretic no 1.23 (1.10-1.38) 1.31 (1.14-1.49) 1.81 (1.63-2.02) 1.48 (1.34-1.63) 1.31 (1.14-1.49) 1.49 (1.31-1.69) 
Comorbidity exposures   
Diabetes - 1.51 (1.35-1.69) 1.95 (1.78-2.13) - 1.54 (1.30-1.82) 1.50 (1.31-1.70) 
No diabetes - 1.42 (1.36-1.48) 1.76 (1.69-1.82) - 1.38 (1.32-1.46) 1.29 (1.22-1.35) 
COPD 1.06 (0.92-1.21) - 1.29 (1.13-1.47) 1.28 (1.03-1.60) - 1.38 (1.06-1.79) 
No COPD 1.10 (1.06-1.13) - 1.91 (1.85-1.98) 1.34 (1.29-1.39) - 1.35 (1.29-1.41) 
CKD 1.08 (1.03-1.13) 1.29 (1.22-1.37) - 1.24 (1.14-1.35) 1.43 (1.29-1.58) - 
No CKD 1.05 (0.98-1.13) 1.79 (1.66-1.93) - 1.32 (1.23-1.42) 1.37 (1.24-1.53) - 
Framed estimates are those that differed across strata with no overlap of confidence intervals. BMI, body mass index; BP, blood pressure; ACEi, angiotensin-converting enzyme 
inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease 
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Table 11.2 Statistical interaction tests 
 
 
 
 Unadjusted 
log likelihood 
Interaction 
P  
Adjusted 
log likelihood 
Interaction 
P 
 
Independent effects  
adjusted for interaction 
OR (95% CI) 
Interaction effects 
Comorbidity pairs: mortality       
DM and COPD -42840.51  -29511.79    
DM*COPD -42840.48 0.811 -29511.29 0.318   
DM and CKD -35600.98  -29511.79    
DM*CKD -35600.00 0.162 -29510.92 0.187   
COPD and CKD  -35425.10  -29511.79  COPD 1.52 (1.43-1.63) COPD*CKD 0.81 (0.74-0.87) 
COPD*CKD -35392.85 <0.001 -29499.30 <0.001 CKD 1.27 (1.22-1.31)  
Comorbidity pairs: hospital admission       
DM and COPD -36125.46  -15316.33   
 
 
 DM*COPD -36125.45 0.93 -15315.58 0.22 
DM and CKD -18214.91  -15380.32   
 
 
 DM*CKD -18212.47 0.03 -15380.26 0.73 
COPD and CKD  -18218.95  -15380.32    
COPD*CKD -18218.83 0.025 -15380.21 0.64 
Comorbidity and Age: mortality       
DM and Age -40027.62  -29081.90  DM 2.73 (1.99-3.75) DM*Age 0.99 (0.99-0.99) 
DM*Age -40011.62 <0.001 -29070.95 <0.001 Age 1.05 (1.05-1.05)   
COPD and Age -39885.05  -29081.90  COPD 4.30 (2.90-6.37) COPD*Age 0.98 (0.98-0.99) 
COPD*Age -39848.33 <0.001 -29065.31 <0.001 Age 1.05 (1.05-1.05)  
CKD and Age -33604.71  -29511.79  CKD 2.40 (1.80-3.21) CKD*Age 0.99 (0.99-0.99) 
CKD*Age -33582.40 <0.001 -29500.91 <0.001 Age 1.05 (1.05-1.05)  
Comorbidity and Age: HA       
DM and Age -36078.07  -15316.33    
DM*Age -36077.01 0.145 -15316.08 0.48   
COPD and Age -36123.03  -15316.32    
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COPD*Age -36122.58 0.345 -16948.77 0.84   
CKD and Age -18259.59  -15380.32    
CKD*Age -18257.07 0.025 -15379.01 0.11   
Comorbidity and patient factors: mortality      
COPD and gender -42808.57 0.30 -29081.90 <0.01 COPD 1.44 (1.35-1.55) COPD*Male 0.89 (0.82-0.97) 
COPD*gender -42808.03  -29078.48  Male 1.17 (1.12-1.21)  
CKD and gender -35602.94  -29511.79    
CKD*gender -35579.55 <0.001 -29511.79 0.96   
DM and gender  -42966.02 0.82 -29081.90    
DM*gender -42965.99  -29081.78 0.63   
DM and beta-blocker  -42245.92  -29511.79  DM 1.34 (1.27-1.41)  
DM*beta-blocker -42233.74 <0.001 -29508.40 <0.01 no BB 1.41(1.36-1.47) DM*No BB 0.91 (0.85-0.98) 
COPD and beta-blocker  -42207.21  -29511.79    
COPD*beta-blocker and interaction -42196.47 <0.001 -29511.58 0.516   
CKD and beta-blocker  -34949.16  -29511.79  CKD 1.31 (1.27-1.37) CKD*No BB 0.87 (0.81-0.93 
CKD*beta-blocker -34911.92 <0.001 -29502.82 <0.001                   No BB 1.48 (1.40-1.57)  
CKD and Hb (binary; ≤13,>13)       
CKD and Hb  -34565.28  -29994.77    
CKD*Hb -34540.37 <0.001 -29992.68 0.04 Hb cat(<13)1.72(1.63-1.81) 
CKD1.31 (1.24-1.38) 
Hb binary*CKD 0.93 (0.87-0.99) 
Comorbidities and patient factors: HA      
COPD and gender -36236.43 0.828 -15316.32 0.97   
COPD*gender -36236.41  -15316.32    
CKD and gender -18256.667  -15380.32  CKD 1.07 (1.00-1.14) CKD*Male 1.14 (1.05-1.25) 
CKD*gender -18246.395 <0.001 -15375.77 <0.01 Male 1.13 (1.06-1.21)  
DM and gender  -36209.7 <0.001 -15316.32  DM 1.32 (1.22-1.42) DM*Male 0.90 (0.81-0.99) 
DM*gender -36202.469  -15314.12 0.04 Male 1.26 (1.19-1.33)  
COPD and beta-blocker  -36200.13  -15316.33    
COPD*beta-blocker -36199.84 0.450 -15315.86 0.34   
COPD and ACE/ARB  -35809.72  -15316.33    
COPD*ACE/ARB -35809.68 <0.001 -15316.07 0.47   
Other:       
CKD and Ch  -18255.14  -15383.04    
CKD*Ch -18251.32 <0.01 -15381.51 0.08   
DM and Hb  -35876.48 <0.001 -15545.89  HB (<13.4)  1.32 (1.25,1.39) HB binary*DM 1.12 (1.00-1.22) 
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DM*Hb -35870.04  -15543.85 0.04 DM 1.20 (1.11-1.30)  
*interaction; each adjusted model included age, gender, COPD, eGFR, DM, no beta-blocker, no ACEi or ARB, diuretics, BP, BMI, cholesterol, haemoglobin, smoking and alcohol status;  Cat, 
categories. BMI, body mass index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; CKD, 
chronic kidney disease 
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Table 11.3 Biological interaction measures for the comorbidity pair combinations 
 
Mortality Hospital admission 
   
Exposure RR Lower CI Upper CI Exposure RR Lower CI Upper CI 
Diabetes 1.277 1.199 1.361 Diabetes 1.241 1.150 1.339 
CKD 1.201 1.154 1.250 CKD 1.147 1.088 1.208 
Diabetes*CKD 1.615 1.535 1.699 Diabetes*CKD 1.448 1.349 1.554 
Measure Estimate Lower CI Upper CI Measure Estimate Lower CI Upper CI 
RERI 0.137 0.037 0.236 RERI 0.060 -0.065 0.186 
S 1.285 1.053 1.569 S 1.156 0.847 1.579 
 
Exposure RR Lower CI Upper CI Exposure RR Lower CI Upper CI 
Diabetes 1.292 1.239 1.347 Diabetes 1.254 1.187 1.325 
COPD 1.362 1.293 1.435 COPD 1.351 1.251 1.459 
Diabetes*COPD 1.692 1.558 1.838 Diabetes*COPD 1.542 1.352 1.759 
Measure Estimate Lower CI Upper CI Measure Estimate Lower CI Upper CI 
RERI 0.038 -0.115 0.191 RERI -0.064 -0.289 0.161 
S 1.058 0.844 1.325 S 0.895 0.597 1.341 
 
Exposure RR Lower CI Upper CI Exposure RR Lower CI Upper CI 
CKD 1.263 1.215 1.312 CKD 1.147 1.092 1.205 
COPD 1.525 1.427 1.629 COPD 1.292 1.177 1.419 
CKD*COPD 1.546 1.452 1.646 CKD*COPD 1.529 1.389 1.682 
Measure Estimate Lower CI Upper CI Measure Estimate Lower CI Upper CI 
RERI -0.241 -0.369 -0.113 RERI 0.089 -0.089 0.268 
S 0.694 0.573 0.840 S 1.204 0.828 1.750 
*interaction; CKD, Chronic kidney disease; COPD, chronic obstructive pulmonary disease. Red = significant biological 
interaction. 
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Figures  
Figure 11.1a Observed COPD and Age interaction for mortality                                      Figure 11.1b Predicted COPD and Age interaction for mortality 
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Figure 11.2a Observed CKD and Age interaction for mortality                                     Figure 11.2b Predicted CKD and Age interaction for mortality 
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Figure 11.3 Biological DM and CKD interaction for mortality 
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Figure 11.4 Biological DM and CKD interaction for hospital admission 
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Figure 11.5 Biological COPD and CKD interaction for mortality 
 
 
Figure 11.6   Biological COPD and CKD interaction for hospital admission 
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Figure 11.7 Biological comorbidity and age interaction for mortality and hospital admission 
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Figure 11.8   Biological CKD and gender interaction for hospital admission 
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Chapter 12 Model building: testing different comorbidity measures 
 
This chapter investigates and compares the contribution of the different comorbidity measures to pre-specified 
HF prognostic models for mortality and separately for hospital admission. The work was carried out in three 
stages: (i) building the core model, (ii) comparing the fit of a set of different models with each of the 
comorbidity status, severity and severity change measures added and replaced in turn (for DM, COPD, CKD 
separately) and (iii) comparing the fit of a set of models with comorbidity status, severity and severity change 
measures for all of the three comorbidities included together. 
 
12.1 Building the core model 
First the pre specified model was built for each outcome using all covariates in the adjusted models in 
Chapters 9 and 10 (termed core model).  The core model included age, gender, alcohol, smoking, systolic 
blood pressure, cholesterol, BMI, haemoglobin, HF medication and quadratic extensions where indicated 
previously. In addition, prior hospital admission was added to the core models for the hospital admission 
outcome. All continuous variables were centered about their means prior to their inclusion in the model to 
remove collinearity with their respective quadratic term. This also meant that the risk estimate generated by 
the model would be comparable to a patient with the reference category of each of the categorical variables 
and the average value of the continuous variable.  
 
12.2 Testing measures for each comorbidity 
The first approach was to investigate each of the comorbidities separately. A set of models for each of the 
three comorbidities were constructed. The set of models for COPD example would be: 
a) Core model* + COPD (status) 
b) Core model* + COPD (severity using drug definition) 
c)  Core model* + COPD (severity change using drug change definition) 
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*DM and CKD were added to the core model 
 
First, COPD was added to the core model by presence or absence status (model a). Second, the COPD 
status measure was exchanged for the COPD severity measure (drugs; model b1 or physiological measure; 
model b2). Lastly the COPD severity measure was exchanged for a severity change measure (drugs; model 
c1 or physiological measure; model c2). The remaining two comorbidities (DM, CKD) were added to each 
core model by their status measure only. An additional step was included for the CKD models. Given that all 
HF patients had an eGFR measure, severity and change measures could also be simultaneously included in 
the final step of the CKD model testing.  
 
Conditional logistic regression was performed for each model and tests of model fit were used to compare 
models. Tests included the receiver operating curve (ROC), log-likelihood, likelihood ratio test, Akaike and 
Bayesian information criterion (AIC and BIC) and McFadden’s R2 (Chapter 6.4.3).  Models were first created 
using the full data. Due to varying amounts of missing data in the comorbidity measures, in the second step, 
models were restricted to the data which had complete observations for all the models, so that they could be 
compared.  
 
12.3 Testing measures for all comorbidities 
In a final step, models were compared using different measures for all three comorbidities simultaneously 
included by (i) status, (ii) status exchanged for comorbidity severity measures and lastly (ii) severity measures 
exchanged for severity change measures. An example risk score was developed for the best fitting model for 
both outcomes. 
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12.4 HF comorbidity and mortality models 
 
12.4.1 Mortality models with comorbid DM 
Using the drug definitions of DM severity and change, there were incremental improvements of the diabetes 
HF mortality model when the DM status measure was exchanged by the DM severity measure and then the 
DM severity change measure (Table 12.1a). The most improvement was observed when the status measure 
was exchanged for the severity change measure (LR test p<0.001). There was some improvement in Pseudo 
R2, AIC, BIC and log likelihood when the severity measure was exchanged for the severity change measure 
and the LR test was non-significant for model improvement for the severity model compared to the change 
model. The same pattern of improvement was observed when the DM severity measures using the 
physiological definition of DM severity (HbA1c) were compared (Table 12.1b).  
 
When the reduced DM drug severity model was compared to the DM physiological severity model directly 
using the complete data, the drug measures of severity and change showed improved model fit across all 
measures compared to the physiological measures. 
 
12.4.2 Mortality model with comorbid COPD 
Using the drug definitions of COPD severity, there was improvement of the comorbid COPD mortality model 
with the replacement of the status measure for the severity measure and the change measure (Table 12.2a). 
When the status measure was exchanged for the severity measures the AIC and BIC improved by 189 and 
170 respectively. The improvement was more modest when the status measure was exchanged for the 
change measure but both models had a significantly better fit than the status model (p<0.001).  
 
When comparing the mortality models using physiological measures of COPD (FEV1), replacement of COPD 
status by measures of severity showed some improvement in AIC and BIC but this was less than the 
improvement observed using the drug measures.  Log likelihood, ROC and pseudo R2 also improved (LR test; 
p<0.001). The COPD measure using physiological change was no better than the COPD status model with 
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similar model fit (Table 12.2b) (LR test; p=0.271). When the reduced COPD drug severity model was 
compared to the COPD physiological severity model directly (same number of observations), the drug 
measures of severity and change showed slightly improved model fit across all measures compared to the 
physiological measures. 
 
12.4.3 Mortality model with comorbid CKD 
There was a substantial improvement in model fit when CKD status was replaced by CKD severity measure 
(eGFR) and the severity change measure (Table 12.3). AIC and BIC improved by 732 and 723 with the 
replacement of status by severity and by 330 and 312 respectively when the status measure was exchanged 
for the severity change measure. Pseudo R2, log likelihood and ROC favoured the severity model. However 
when baseline eGFR was added to the severity change model (model d) the model had the best overall fit and 
showed improvement from the severity model (model b) with an improvement of 269 in AIC and 336 in BIC. 
Following the addition of baseline eGFR into the change model there was incremental improvement from 
status to severity to change. The LR test for each stage of improvement was significant (p<0.001). 
 
12.5 Mortality model: all comorbidities 
A final model comparison was made between the core model with all three comorbidities added by status 
(status model), followed by severity measures (using drug measures for DM and COPD and eGFR for CKD) 
and finally severity change measures (using drug measures of change for DM and COPD and eGFR change 
for CKD) (Table 12.4). Baseline eGFR was then added to this final model. 
 
There was improvement in model fit from the status model to the severity model and from the status model to 
the change model. The most improvement was observed between the status and the severity model with an 
improvement of AIC of 937.5, BIC of 890, log likelihood of 474, pseudo R2 of 0.015 and ROC of 0.01. The 
severity model had the best model fit until baseline eGFR was added to the change model. This then 
improved significantly from the severity model (p<0.001).   
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12.5.1 Example HF comorbidity mortality model 
An example model was constructed using all covariates and the measures of best fit for each comorbidity that 
were observed in the previous investigations. These were: DM drug severity change, COPD drug severity, 
CKD severity and change. A linear predictor for the risk of mortality was generated by the model. A histogram 
of this linear predictor showed a range between -2 and 6 with most predictions between 0 and 2 (Figure 12.1). 
The risk of mortality for the different units of linear predictor are shown in Table 12.5. Taking the centering and 
quadratic extensions into account the linear predictor for an individual patient would be calculated as set out in 
Table 12.6. As the continuous predictors were centred at their means, the risk per unit can be interpreted as 
the risk difference from a HF patient with an average level of haemoglobin, eGFR, systolic BP, cholesterol and 
BMI and in the reference category of all other predictors. Due to the absence of an intercept, which is inherent 
in conditional logistic regression, the actual risk cannot be determined from the model. Risk groups are 
instead constructed based on proportion of risk above the baseline risk.  
 
The C-index for the ROC for the model was 74% (Figure 12.2). This can be interpreted as a 74% chance that 
in a randomly selected case and control, the case would be given a higher predicted risk than the 
control(463).  
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12.6 Heart failure comorbidity and first hospital admission models  
12.6.1 Hospital admission model with comorbid DM 
Model testing for the DM models was focused on the drug severity measures. This was due to these 
measures having better fit in the mortality models, the higher percentage of missing physiological data in the 
narrower measurement time-window for the HF-HA sub-sample and the non-stratified effects for categories of 
HbA1c change in the adjusted associations with hospital admission (Chapter 10).  Using the drug definitions 
of severity, there was improvement of the diabetes HF hospital admission model with the replacement of the 
status measure with the severity measure (Table 12.7) (LR test p<0.001) and across all measures of model fit 
(AIC, BIC, Pseudo R2 and log likelihood); AIC improved by 35 and BIC by 18. The improvement was less for 
the severity change measure which only had borderline significance for improvement from the status measure 
(p=0.05).   
 
12.6.2 Hospital admission model with comorbid COPD 
Using the drug definitions of COPD severity, there was improvement of the hospital admission model with the 
replacement of the status measure with the severity measure (Table 12.8) (LR test p<0.001). AIC improved by 
35 and BIC by 17. There was no improvement in model fit by exchanging the status measure for the severity 
change measure (LR test p=0.585) and all measures of model fit were similar. 
 
12.6.3 Hospital admission model with comorbid CKD 
There was a substantial improvement in model fit when CKD status was replaced by severity and the severity 
change measure (Table 12.9). AIC and BIC improved by 82 and 39 with the replacement of status by severity 
and by 61 and 45 respectively when the status measure was exchanged for the severity change measure. 
Pseudo R2, log likelihood and ROC favoured the severity model and this had significantly better fit than the 
change model (p<0.001). However, when baseline eGFR categories were added to the severity change 
model (model d) the model had the best overall fit and showed improvement from the severity model (model 
b) with further improvement of 48 in AIC and 23 in BIC. Following the addition of baseline eGFR into the 
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change model there was incremental improvement from status to severity to change. The LR test for each 
stage of improvement was significant (p<0.001). 
 
12.7 HF hospital admission model: all comorbidities 
A final model comparison was made between the core model with all three comorbidities added by status 
(status model), followed by severity measures (using drug measures for DM and COPD and categories for 
CKD) and finally severity change measures (using drug measures of change for DM and COPD and eGFR 
change for CKD) (Table 12.10). Baseline CKD categories were then added to this final model. 
 
There was improvement in model fit from the status model to the severity model and from the status model to 
the change model. The most improvement was observed between the status and the severity model with an 
improvement of AIC of 124, BIC of 48, log-likelihood of 71, pseudo R2 of 0.01 and ROC of 0.04. The severity 
model had the best model fit until baseline renal status was added to the change model. This then showed 
some improvement to the severity model (p=0.02).   
 
12.7.1 Example model 
An example model was constructed using all covariates and the measures of best fit for each comorbidity that 
were observed in the prior investigations. These were; DM drug severity, COPD drug severity, CKD severity 
and change. A linear predictor for the risk of first hospital admission was generated by the model. A histogram 
of this linear predictor showed a range between -1 and 5 with most predictions between 0 and 1.5 (Figure 
12.3). 
 
The risk of hospital admission for the different units of linear predictor are shown in Table 12.11. As the 
continuous predictors were centred at their means the risk per linear unit can be interpreted as the percentage 
risk above that of a HF patient with an average level of haemoglobin, eGFR, systolic BP, cholesterol and BMI 
and in the reference category of all other predictors. Due to the absence of intercept inherent in conditional 
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logistic regression the actual risk cannot be determined from the model. Risk groups are instead constructed 
based on proportion of risk above the baseline risk.  
 
C-index for the ROC for the model was 68% (Figure 12.4). This can be interpreted as a 68% chance that in a 
randomly selected case and control, the case would be given a higher predicted risk. Taking the centering and 
quadratic extensions into account the linear predictor for an individual patient would be calculated as set out in 
Table 12.13. 
 
12.8 Chapter summary  
There was significant improvement in model fit for both outcomes when comorbidity status measures were 
exchanged for severity measures defined by either physiological or drug measures with the latter providing 
the best overall fit. Comorbidity severity change measures improved mortality model fit when replacing status 
measures for all comorbidities. This was also true for hospital admission models when including DM drug 
severity change or eGFR change over their respective status measures. Comorbidity severity change 
measures improved mortality model fit over the severity measures for DM and CKD but this was only true for 
CKD in the hospital admission models.  The best fitting models used a combination of drug severity and 
change measures for comorbid DM and COPD and eGFR severity and change for CKD. The C-index for 
mortality (74%) was better than for hospital admission (68%). These results will be discussed in detail in the 
next Chapter 13.
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Tables 
Table 12.1a Mortality models with comorbid DM drug severity measures 
 
Comorbidity measure model 
*110505 observations 
df Pseudo R2 AIC BIC Log 
likelihood 
LR test ROC 
a Diabetes Status 18 0.1991 58201.80 58384.44 -29081.90  0.728 
b Diabetes Severity  20 0.1998 58154.34 58356.21 -29056.17 p<0.001ab 0.729 
c Diabetes Severity change  19 0.2001 58128.17 58320.43 -29044.08 p=1.0bc/p<0.001ac 0.729 
*102990 observations (in order to compare with diabetes physiological severity models) 
a Diabetes Status 18 0.2033 54309.56 54490.86 -27135.78  0.730 
b Diabetes Severity  20 0.2040 54254.89 54455.29 -27106.45 p<0.001ab 0.730 
c Diabetes Severity change  19 0.2042 54248.89 54439.74 -27104.45 p=1.0bc/ p<0.001ac 0.731 
All models adjusted for  age, gender, beta-blocker, ACEi or ARB, diuretics, systolic BP (systolic2), haemoglobin (Hb2), BMI (BMI2), cholesterol, 
smoking, alcohol, COPD, eGFR.  Diabetes status (clinical code or prescription), severity (drug categories in 4-month time-window prior to 
death; none, any oral, insulin only) and change by recent drug category change over prior 1 year (same or increase, decrease). ab; LR test of 
model a nested in b; ac; LR test of model a nested in c, bc; LR test of model c nested in b. 
Table 12.1b Mortality models with comorbid DM physiological severity measures 
 
Comorbidity measure model 
*102990 observations 
df Pseudo 
R2 
AIC BIC Log 
likelihood 
LR test  ROC 
a Diabetes Status 18 0.2033 54309.56 54490.86 -27135.78 p<0.001ac 0.730 
b Diabetes Severity  23 0.2035 54303.68 54532.71 -27127.84 p<0.01ab 0.730 
c Diabetes Severity change  20 0.2036 54293.51 54493.90 -27125.75 p=1.00cb 0.730 
All models adjusted for COPD, renal dysfunction (eGFR<60)  age, gender, beta-blocker, ACEi or ARB, diuretics, systolic BP (systolic2), 
haemoglobin (Hb2), BMI (BMI2), cholesterol, smoking, alcohol . Diabetes status (clinical code or prescription), severity (HbA1c 
categories; most recent within 3 years of death) and change by recent HbA1c change over 1 year prior to death.  ac; LR test of model a 
nested in c; ab; LR test of model a nested in b, cb; LR test of model c nested in b. 
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12.2a Mortality models with comorbid COPD drug severity measures 
 
Comorbidity measure model 
*110505 observations 
Df Pseudo R2 AIC BIC Log likelihood LR test ROC 
a COPD Status 18 0.199 58201.80 58384.43 -29081.90  0.7284 
b COPD Severity  20 0.201 58013.08 58214.95 -28985.54 p<0.001ab 0.7301 
c COPD Severity change  20 0.200 58083.63 58285.50 -29020.82 p<0.001ac 0.7297 
*90610 observations (in order to compare to COPD physiological severity models) 
a COPD Status 18 0.211 47965.17 48144.05 -23963.59  0.7331 
b COPD Severity  20 0.212 47928.35 48126.05 -23943.17 p<0.001ab 0.7337 
c COPD Severity change  20 0.212 47935.65 48133.35 -23946.83 p<0.001ac 0.7297 
All models adjusted for COPD, renal dysfunction (eGFR<60),  age, gender, beta-blocker, ACEi or ARB, diuretics, systolic BP (systolic2), 
haemoglobin (Hb2), BMI (BMI2), cholesterol, smoking, alcohol , COPD status (clinical code and prescription), severity (drug categories in 4-
month time-window prior to death; no oral steroids or oxygen, oral steroids but no oxygen, oxygen) and severity change by recent drug 
category change over 1-year (new onto oral steroids or oxygen) prior to death. ab; LR test of model a nested in b, ac; LR test of model a 
nested in c.  
Table 12.2b Mortality models with comorbid COPD physiological severity measures 
 
Comorbidity measure model 
 *90610 observations 
Df Pseudo R2 AIC BIC Log 
likelihood 
LR test ROC 
a COPD Status 18 0.211 47965.17 48144.05 -23963.59 p=0.271ac 0.7331 
b COPD Severity  21 0.212 47930.59 48137.71 -23943.30 p<0.001ab 0.7334 
c COPD Severity change  20 0.211 47966.56 48164.26 -23962.28 p<0.001cb 0.7332 
All models adjusted for COPD, renal dysfunction (eGFR<60),  age, gender, beta-blocker, ACEi or ARB, diuretics, systolic BP 
(systolic2), haemoglobin (Hb2), BMI (BMI2), cholesterol, smoking, alcohol. COPD status (clinical code and prescription), severity (FEV1 
categories; most recent within 3 years of death) and change by recent FEV1 change over 1 year prior to death. ac; LR test of model a 
nested in c. ab; LR test of model a nested in b, cb; LR test of model c nested in b. 
  
319 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12.3 Mortality models with comorbid CKD 
 
 
Comorbidity measure model 
*90643 observations 
df Pseudo 
R2 
AIC BIC Log 
likelihood 
LR test ROC 
a Renal Status 17 0.1957 48692.70 48862.17 -24328.35  0.724 
b Renal Severity  18 0.2078 47960.74 48139.62 -23961.37 p<0.001ab 0.733 
c Renal severity change 20 0.2012 48362.38 48550.67 -24161.19 p=1.0bc/<0.001ac 0.727 
d Model   b +c  21 0.2140 47691.71 47803.14 -23776.01 p<0.001bd/cd 0.734 
All models adjusted for recent age, gender, beta-blocker, ACEi or ARB, diuretics, systolic BP (systolic2), haemoglobin (Hb2), 
BMI (BMI2), cholesterol, smoking, alcohol, COPD, DM. Renal status (eGFR<60), severity (eGFR categories using most recent 
eGFR within maximum of 3 years prior to death) and change by categories of eGFR change over 1 year prior to death (same, 
increase, medium decrease, severe decrease). ab; LR test of model a nested in b, bc; LR test of model b nested in c. 
Table 12.4 Mortality models with comorbidities 
 
Comorbidity measure model 
*90643 observations 
df Pseudo 
R2 
AIC BIC Log 
likelihood 
LR test ROC 
a Status 18 0.196 48692.70 48862.17 -24328.35  0.724 
b Severity 23 0.211 47755.21 47971.75 -23854.60 p<0.001ab 0.733 
c  Severity change 24 0.204 48185.14 48411.09 -24068.57 p=1bc/<0.001ac 0.729 
d Model c + CKD severity  26 0.217 47431.28 47676.05 -23689.64 p<0.001bc/bd 0.736 
Status model: COPD (clinical code and prescription) Diabetes (Clinical code or prescription) Renal dysfunction (recent eGFR <60).  
Severity model (drugs):   Diabetes drug severity measures (none, any oral hypoglycaemic, insulin only) and COPD drug severity 
measures (no oral steroids or oxygen, oral steroids but no oxygen, oxygen) based on at least one prescription within a 4-month time 
window before death). Renal dysfunction based on most recent eGFR value within 3-years. 
Severity change model (drugs):  Diabetes and COPD based on drug severity measures (at least one prescription within a 4 month 
time window before death compared to at least one prescription in a 4-month time window up to 1-year prior to death). Renal 
dysfunction change measure based on eGFR (measured as most recent within 3-years and a previous measure between 6-months 
and 3-years prior to measure 1-year change). All models adjusted for age, gender, beta-blocker, ACEi or ARB, diuretics, systolic BP 
(systolic2), haemoglobin (Hb2), BMI (BMI2), cholesterol, smoking, alcohol. Severity change model further adjusted for recent eGFR. 
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Table 12.5 Linear predictor for HF comorbidity mortality model 
 
Linear predictor score No. observations No. cases Risk (% cases) 
≤-1 371 5 1 
>-1 to 0 7579 278 4 
>0 to 1 28531  2,815 10 
>1 to 2 32573 7,585 23 
>2 to 3 16558 7,200 43 
>3 to 4 4279 2,663 62 
>4 to 5 679 482 71 
>5 73 53 73 
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Table 12.6 Comorbidity HF mortality risk score 
 
 Score =  Centred value Increments of the 
continuous variable 
 Score 
 Age in years -77 ÷5 x 0.24 
+ Male    0.13 
+ COPD no steroids or prescribed oxygen    0.12 
+ COPD on oral steroids but no prescribed oxygen    0.60 
+ COPD on prescribed oxygen    1.13 
+ Diabetes and stable diabetes drugs over previous year    0.20 
+ Diabetes increase in drug stage over previous year    0.27 
+ Diabetes reduced drugs over previous year    0.82 
+ eGFR (any increase) over previous year    0.21 
+ eGFR (6mls to 15mls decrease) over previous year    0.16 
+ eGFR (>15mls decrease) over previous year    0.57 
- Current eGFR (ml/min/kg2) -58 ÷5 x 0.39 
+ Current eGFR (ml/min/kg2) -58 ÷5 x 0.01 
+ No beta- blocker    0.31 
+ No ACEi or ARB    0.59 
+ Diuretics    0.16 
- Systolic BP (mm/hg) -131 ÷5 X 0.08 
+ Systolic BP (mm/hg) -131 ÷5 X 0.01 
- Cholesterol (per mmol/L) -5  X 0.05 
- Haemoglobin -13  X 0.12 
+ Haemoglobin -13  x 0.23 
- BMI (per kg/m2) -28  x 0.03 
+ BMI (per kg/m2) -28  x 0.002 
+ Ex-smoker    0.05 
+ Current smoker    0.36 
- Alcohol – current drinker    0.05 
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Table 12.7  Hospital admission models with DM drug severity measure 
 
Comorbidity measure model 
*53159 observations 
df Pseudo R2 AIC BIC Log 
likelihood 
LR test ROC 
a Diabetes Status 18 0.1636 30801.77 30970.50 -15381.89  0.6796 
b Diabetes Severity  20 0.1647 30766.47 30952.98 -15362.24 p<0.001ab 0.6798 
c Diabetes Severity change  20 0.1638 30799.64 30986.15 -15378.82 p=0.05ac 0.6801 
All models adjusted for recent age, gender, COPD, renal dysfunction (eGFR<60), prior hospital admission, systolic bp (BP2), beta- 
blocker, ACEi or ARB, diuretics, haemoglobin (Hb2), BMI, cholesterol, smoking, alcohol. Diabetes status (clinical code or 
prescription), severity (drug categories in 4-month time-window prior to admission; none, any oral, insulin only) and change by recent 
drug category change over prior 6 months. ab; LR test of model a nested in b, ac; LR test of model a nested in c. 
Table 12.8 Hospital admission models with COPD drug severity measures 
 
Comorbidity measure model 
*53159 observations 
Df Pseudo 
R2 
AIC BIC Log 
likelihood 
LR test  ROC 
a COPD Status 18 0.1636 30801.77 30970.51 -15381.89 p=0.585ac 0.6796 
b COPD Severity  20 0.1647 30766.67 30953.17 -15362.33 p<0.001ab 0.6804 
c COPD Severity change  19 0.1636 30803.47 30981.09 -15381.74 p<0.001bc 0.6796 
All models adjusted for recent age, gender, diabetes, renal dysfunction (eGFR<60), prior hospital admission, systolic bp (BP2), 
beta- blocker, ACEi or ARB, diuretics, haemoglobin (Hb2), BMI, cholesterol, smoking, alcohol. . COPD status (clinical code and 
prescription), severity (drug categories in 4-month time-window prior to admission; no oral steroids or oxygen, oral steroids but no 
oxygen, oxygen) and severity change by recent drug category change over prior 6 months (new onto oral steroids or oxygen). ab; 
LR test of model a nested in b, ac; LR test of model a nested in c.  bc; LR test of model c nested in b 
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Table 12.9 Hospital admission models with comorbid CKD 
 
Comorbidity measure model 
*33907 observations 
df Pseudo 
R2 
AIC BIC Log 
likelihood 
LR test ROC 
a Renal Status 18 0.1633 19923.04 20083.23 -9942.52  0.676 
b Renal Severity  23 0.1671 19841.52 20043.87 -9896.76 p<0.001ab 0.678 
c  Renal Severity change 21 0.1660 19861.42 20038.48 -9909.71 p<0.001ac/bc 0.678 
d Model c +renal severity 26 0.1694 19793.34 20020.99 -9869.67 p<0.001bd 0.680 
All models adjusted for Age, gender, diabetes, COPD, prior hospital admission, beta-blocker, ACEi or ARB, diuretics, BP, 
haemoglobin, BMI, cholesterol, smoking, alcohol. Renal status (eGFR <60), severity by 7 eGFR categories and change by recent 
% change over prior 6 months. ab; LR test of model a nested in b, bc; LR test of model b nested in c. 
Table 12.10 Hospital admission model: comorbidities 
 
Comorbidity measure model 
*33907 observations 
df Pseudo R2 AIC BIC Log likelihood LR test ROC 
Status 18 0.163 19923.03 20083.23 -9942.52  0.676 
Severity  27 0.169 19798.92 20035.00 -9871.46 p<0.001ab 0.680 
Severity change 24 0.166 19863.02 20065.37 -9907.51 p<0.001ac/bc 0.677 
Model C + renal severity  29 0.170 19795.29 20048.23 -9867.65 p=0.02bd/p<0.001cd 0.680 
Status measures: COPD (clinical code) Diabetes (Clinical code or prescription) CKD (recent eGFR <60).  
Severity measures:   Diabetes and COPD based on drug severity measure (at least one prescription within a 4 month time window before 
admission). CKD based on eGFR within 6months. 
Severity change:  Diabetes and COPD based on drug severity measures (at least one prescription within a 4 month time window before 
admission compared to at least one prescription in a 4-month time window up to 6 months prior to admission). CKD based on eGFR 
(measured within 6months and a previous measure between 1-months and 1-year prior to measure 6 month change). 
All models adjusted for age, gender, prior hospital admission, beta-blocker, ACEi or ARB, diuretics, systolic BP (BP2), haemoglobin (Hb2), 
BMI, cholesterol, smoking, alcohol. Severity change model further adjusted for recent eGFR stage. 
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Table 12.11    Linear predictor for HF comorbidity hospital admission model 
 
Linear predictor score No. observations No. cases Risk (% cases) 
≤-0.5 798 121 15 
>-0.5 to 0 10646 2,109 20 
>0 to 0.5 10610 2,833 27 
>0.5 to 1 5413 1,980 37 
>1 to 1.5 2231 1,025 46 
>1.5 to 2 1325 794 60 
>2 to 2.5 1397 952 66 
>2.5 to 3 886 646 68 
>3 to 3.5 372 314 73 
>3.5 to 4 147 133 84 
>4 to 4.5 82 73 90 
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Table 12.12 Comorbidity HF hospital admission risk score 
 
 Score =  Centred value Increments of the 
continuous variable 
 Score 
 Age  -77 ÷5 x 0.03 
+ Male    0.16 
+ Prior admission in past 3 months    2.09 
+ Prior admission in past 3 months to 6 months    0.89 
+ Prior admission in past 6 months to 1 year    0.38 
+ COPD not on steroids or oxygen    0.21 
+ COPD on oral steroids but no oxygen    0.64 
+ COPD and on  oxygen    0.86 
- *Diabetes on no drugs    0.001 
+ Diabetes on any oral hypoglycaemic    0.25 
+ Diabetes on insulin only    0.32 
+ *eGFR >105    0.19 
+ *eGFR 90-105    0.10 
+ *eGFR 45-59    0.07 
+ *eGFR 30-44    0.06 
+ eGFR 15-29    -0.04 
+ eGFR <15     0.008 
+ eGFR (any % increase over past 6 months)     0.10 
+ eGFR (6-25% decrease over past 6 months)    0.12 
+ eGFR (>25% decrease over past 6 months)    0.34 
+ No beta-blocker    0.09 
+ No ACEi or ARB    0.35 
- *Diuretics    0.03 
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- Systolic BP (mm/hg) -136   0.02 
+ Systolic BP2 (mm/hg) -136  x 0.004 
- Cholesterol (mmol/L) -5  x -.04 
- Haemoglobin -13  x 0.13 
+ Haemoglobin2 -13  x 0.03 
- BMI (kg/m2) -28  x 0.008 
+ Current smoker    0.11 
- *Alcohol – current drinker    0.02 
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Figures 
Figure 12.1 Histogram of linear predictor from the comorbidity HF mortality model 
 
 
Figure 12.2 Receiver operator curve for HF comorbidity severity and change model. 
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Figure 12.3 Histogram of linear predictor from the comorbidity HF hospital admission model 
 
 
Figure 12.4 Receiver operator curve for HF comorbidity severity and change model. 
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Chapter 13 CPRD Discussion 
 
This discussion chapter will first summarise the findings from the six CPRD results chapters (Chapters 7 to 
12). Further discussion will then be organised via the research questions set out in the methods chapter 
(Chapter 6) and will finish with a comprehensive consideration of the strengths and limitations of the 
approaches used with a specific focus on chance, bias and confounding.  
 
13.1 Summary of findings 
In an unselected general population incident cohort of HF patients the comorbidities of DM, COPD and CKD 
were common and associated with the outcomes of mortality and hospital admission. Within these comorbid 
groups risk ranged by the severity of the comorbid disease during follow-up, which was defined by drug 
prescriptions or physiological indicators. For each comorbid disease, severity was worse in those 
experiencing hospital admission or death. Change in the severity of comorbid disease during the HF life 
course was also common, with a greater prevalence of this change occurring in the imminent time-period prior 
to the two outcomes.   
 
The strengths of association were similar across all comorbid diseases and for both outcomes with some 
evidence of stronger associations for COPD than CKD. There was evidence of weaker associations for 
incident diabetes (occurring after HF diagnosis) than for prevalent diabetes (occurring before HF diagnosis). 
This association was in the opposite direction for COPD but the difference between prevalent and incident 
COPD was not significant. For all comorbid diseases the risk associated with both outcomes was significantly 
differentiated by severity groups defined by drug prescriptions or physiological indicators. There was also 
significant differentiation in the associations between categories of severity change for each of the 
comorbidities and mortality. Whilst there was a trend of increasing risk with worsening DM and COPD severity 
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for hospital admission the categories of change were similar. There was however significant differentiation in 
the categories of change for CKD.  
 
There was a significant statistical and biological interaction between COPD and CKD with a lower than 
expected risk estimate for mortality when the two were experienced together. There was a biological 
interaction between DM and CKD in the opposite direction with a higher than expected combined risk estimate 
for mortality. When the HF group was stratified by younger and older age there were significant statistical 
interactions for all three comorbidities with mortality demonstrating a less than multiplicative relationship as a 
product of the lower relative risk in older age groups. Biological interaction was only present for COPD and 
age and CKD and age for mortality. There was a lower than expected risk associated with COPD in older age. 
The association of CKD in older age groups opposed the statistical interaction and demonstrated a higher 
than expected risk of mortality.  Other biological interaction was found for CKD and gender with males having 
a higher risk of hospital admission and death than females. Whilst there was some evidence of statistical 
interaction between male gender and DM for hospital admission and between male gender and COPD for 
mortality this was no evidence of biological interaction. 
 
When the contributions of the different comorbidity measures to prognostic models were tested, there were 
differences for mortality and hospital admission. For mortality the fit of the models improved when the status 
measures were exchanged for either the severity or the change measures. This improvement was similar for 
the comorbid DM severity or change measures by drug and physiological indicators and COPD by drug 
indicators. When defined by physiological indicators there was better model fit for the COPD severity than 
change measures which in turn were similar to the status measure. For admission all comorbidity drug 
severity measures were a better fit than status measures but the change measures did not improve model fit. 
The exception was CKD where there was an incremental improvement of model fit for both mortality and 
admission with the replacement of CKD status for severity measures and then the replacement of severity for 
change measures.  For DM and COPD the models using drug severity measures had better overall fit than 
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those using physiological measures. Overall discrimination was better for the mortality models than the 
hospital admission models.  
 
13.2 Prevalence of DM, COPD and CKD, severity and change 
The prevalence of the three comorbid diseases ranged from 14% for COPD to 24% for DM to 55% for CKD. 
The largest proportion of DM and COPD comorbidity developed prior to the onset of HF. The prevalence of 
COPD was lower than in prior studies, which in the systematic review ranged from 17-35% (mean 18%)(239). 
The review studies were mainly conducted in specialist settings which are more likely to have employed 
objective measures of detection for COPD such as spirometry, which in turn is known to yield higher 
prevalence(342). In this study COPD clinical codes were validated by prescriptions but this does not negate 
undiagnosed COPD in the community setting(343). The prevalence of DM and CKD which have more chance 
of detection using routinely collected physiological measures were comparable to the mid-range of the review 
studies (13-47% for DM and 39-79% for CKD). The review studies included mostly hospital patients which 
tended to have more severe HF patients with a higher prevalence of comorbidity compared to community 
settings(132).The prevalence of all comorbid diseases was slightly lower in the hospital admission linked sub-
sample that had a shorter average follow-up.   
 
In the total mortality cohort, of the COPD patients with FEV1 data (<50% of the HF-COPD sample), 41% were 
in the most severe two categories (FEV1 ≤49%). This was comparable to the 49% prevalence of severe 
COPD disease in a prior but smaller general population HF study(343). Drug severity was categorised for all 
COPD patients and the most severe groups (oral steroids or prescribed oxygen) had a prevalence of 30%. 
Most of the DM-HF group had a HbA1c measure (90%) and 19% of these were in the highest two HbA1c 
categories (HbA1c >8.5%) and 5% in the lowest (<5.5%). Of the DM group, 28% were on insulin which was 
lower than what has been found in hospital settings (39%)(293). From the 90% of the HF sample who had an 
eGFR measure, 8% had an eGFR in the lowest two categories (≤29 mls/min/m2) which was comparable to 
the 6% found in prior general population studies included in the systematic review(239). These prevalence 
rates were similar in the HF-HA sub sample. Approximately 15-20% of patients within each comorbid group 
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had experienced a worsening of the severity of the comorbid disease at a given time during follow-up (prior to 
their match date). Whilst previous evidence on comorbidity severity change in HF has focused on acute renal 
change in hospital settings the prevalence of this change was similar to that in the CPRD analyses 
(approximately 22%). This combined evidence shows that the CPRD sample used in this study is comparable 
to samples in previous studies and whilst the prevalence and severity of comorbidities may be less in the 
community setting of the general practice HF population than in hospital settings, the figures remain high with 
a large proportion of HF patients with severe and worsening comorbid disease.  
 
13.3   HF comorbidity associations with mortality and hospital admission 
13.3.1 Outcome risk 
In this general practice population of incident HF, 23% of patients died within one year of diagnosis and 46% 
within five years. Following the initial year after diagnosis, HF patients died at an average rate of 10% per 
year. A third of the HF-HA sub sample had a hospital admission within one month of HF diagnosis and 65% 
within a year. These figures are similar to other age matched general practice populations and demonstrate 
the high mortality and morbidity associated with incident HF in the general practice population.  Five year 
mortality in similar HF populations was previously 41% in Rotterdam(322) and 39% in Denmark(352).  A more 
recent study of prevalent European HF outpatients revealed an annual mortality rate of 6% which was less 
than the 10% found in the present study. The European study(131) had a younger profile with mean age 66 
years compared to the 78 years in this current study and included a lower percentage of incident HF patients. 
In an incident sample of non-selected HF in the outpatient setting in Olmsted County, 74% were hospitalised 
within a mean of 1.7 years(464) comparable to the 65% within 1 year found in this analysis.  
 
13.3.2 Comorbidity associations 
The three comorbidities investigated in this study were strongly and independently associated with all-cause 
mortality and first hospital admission following HF diagnosis. The adjusted strength of associations were 
similar across the three comorbidities and for both outcomes. The increase in risk in the comorbid groups 
relative to the non-comorbid groups ranged for mortality from 22% for CKD to 28% for DM to 35% for COPD 
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and for hospital admission from 15% for CKD to 25% for DM to 32% for COPD. These associations were 
comparable to those in the previous meta-analyses for DM (34%) and COPD (39%) for mortality(239). 
Relative risk increase for CKD was higher in the prior meta-analyses at 52%. The review studies were hospital 
focused with inclusion of more severe or acute renal disease during admission, which may in turn reflect HF 
severity status and account for some of this difference compared to the more chronic renal decline in the 
general HF population.  
 
The relative risk associated with an exposure is determined by the absolute risk generated by the exposure 
and the baseline risk of the non-exposed population to which it is compared. HF is a serious chronic disease 
which means that the baseline risk of death and hospital admission within the population is high. Mortality risk 
in hospital based HF samples has been found to be higher than in community HF samples(465) meaning that 
relative exposure effects may be smaller in the hospital setting. This has been found previously for individual 
comorbidities where their relative exposure effects have been found to be greater in community HF samples 
reflecting the lower baseline risk(132). The importance of the similarity of associations in this general practice 
population of incident HF compared to the systematic review findings, which were predominantly based in 
hospital settings, is that it demonstrates the higher baseline risk in an incident cohort of HF patients reflective 
of the mixed hospital and community based systematic review sample. The comorbid estimates in the present 
analyses were between those of a prevalent HF community sample and a post hospital admission sample 
previously reported(132).  
 
13.3.1 Comorbidity Life Course  
Previous evidence that uses baseline exposure to predict future outcomes usually includes prevalent 
comorbidity measures. This may be comorbidity that occurs prior to HF if an incident HF study is conducted or 
comorbidity that has occurred at any time prior to the study baseline in a prevalent HF study. This is the first 
study to investigate the relative effect of comorbidity that develops prior to HF compared to that which 
develops after HF onset for DM and COPD. This was conducted to understand the interrelations between 
chronic disease comorbidity and outcomes in HF.  
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Comorbidity may be a cause or a consequence of an index disease or unrelated and this may influence its 
association with outcomes. In this analysis, prevalent DM had a much stronger association than incident DM 
where the association was reduced for mortality and abolished for hospital admission. This is likely to be a 
result of prevalent DM being more severe with a longer duration, resulting in greater cardiovascular 
complications and more severe HF than incident DM(354,355,360). However, in the baseline descriptive 
studies, the difference in the prevalence of DM (occurring prior to HF) between survivors and non-survivors 
was minimal at one year follow-up (0.1%) and increased to 3.6% at >5years follow-up. This indicates that it 
might not just be the severity of the DM (whose onset may have been many years before HF), but the duration 
of the DM concurrent with HF. This infers possible interaction between the DM and HF severity which concurs 
with prior studies that have found DM to have stronger associations in those with coronary heart disease 
aetiology(294) and LVSD(295). Another potential explanation is that other competing factors driving mortality 
in the first year after HF diagnosis such as more severe HF disease at onset. The difference in the 
associations between the prevalent and incident comorbid COPD groups and outcomes were not significantly 
different, but were stronger for the incident COPD group occurring after HF. This difference for mortality was 
partly explained by worse deprivation in the COPD group.   
 
13.4 HF comorbidity severity and change associations with mortality and 
hospital admission 
13.4.1 DM drug severity and change 
The HF-DM group was stratified into a priori severity groups using drug indicators. These were then compared 
to the HF group without DM for the two outcomes. With the exception of the ‘no medications’ group for 
hospital admission, all severity categories were significantly and independently associated with both 
outcomes. For mortality there was no difference in risk between the oral hypoglycaemic group with or without 
added insulin, contrary to prior evidence from the general population with type 2 diabetes(430). Risk 
increased from this combined group, to the ‘no medications group’ to the highest risk in the insulin only group. 
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The increased risk in the insulin group has been found in prior hospital studies(179,293). The insulin group 
are likely to reflect longer duration of DM with more severe metabolic disturbances and increased severity of 
disease(149,430). These findings show that the insulin group are an important target for risk reduction within 
the general practice HF population.  
 
For the hospital admission outcome, there was no association with the ‘no medications’ group compared to 
the HF group without DM. Risk was significant and increased from the oral hypoglycaemic group to the insulin 
group. The difference in associations for the no medications group across both outcomes may be a reflection 
of the time-dependent measurement. No medications in the four months prior to death may be an indication of 
HF severity where drugs are discontinued in end stage disease(466). When measured earlier in the HF 
trajectory prior to admission, no medications are more likely to indicate less severe comorbid disease.   
 
This latter hypothesis is supported by the DM drug severity change measures. For both mortality and hospital 
admission the strongest associations were with the DM group with a recent reduction in drug category. This 
group carries the highest risk for both mortality and admission and constituted predominantly those with DM 
prescriptions recently discontinued (81%). The weaker strength of association for hospital admissions than 
mortality may be reflective of clinical intervention in response to the DM instability and admission avoidance.  
There was also significant and independent associations between the no drug change DM group and both 
outcomes and the increased DM drug category group with the latter having stronger associations.  
 
There was significant stratification of effects when the DM-HF group was categorised by drug severity and 
change measures and for hospital admission by severity. Whilst the drug change measures were not 
significantly stratified for admission there was a clear trend in increasing risk from the no change group to the 
increased group to the decreased category group. This is the first study to identify DM drug severity and 
recent change in routine clinical practice. Instability in diabetes disease indicated by drug category change 
(better or worse) is as important and feasible indicator of outcomes in the general population, given that these 
measures are automatically and electronically recorded.   
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13.4.2 DM physiological severity and change 
Despite the common co-existence of DM and HF, previous studies examining the association between HbA1c 
and outcomes in this population have been limited with only two small studies in the general practice 
population focused on mortality. The findings provide new evidence that categories of HbA1c severity in DM 
are independently and significantly associated with mortality and hospital admissions in the general practice 
HF population. There was a significant and linear trend of increasing risk relative to the non DM HF group 
from the lowest risk HbA1c category to the highest category of HbA1c for both outcomes. This reached a 
relative increase in risk of between 45 to 49% for the top two HbA1c categories (HbA1c >8.6%) for mortality 
and 64% in the top category for hospital admission (HbA1c >9.5%). These groups were significantly different 
from the lowest risk HbA1c category for mortality and lowest 3 risk categories for hospital admission.   
 
A U shape relationship was identified between HbA1c and mortality but not hospital admission. The lowest 
risk HbA1c category for mortality reflected the guideline driven target of 6.5-7.5%(418,419) but the lowest risk 
category for hospital admission was lower at 5.5-6.4%. There was an increase in risk below HbA1c 6.5-7.5% 
for the mortality outcome but there was no association with hospital admissions in the lowest category of 
HbA1c (<5.5%). This U shape relationship with mortality has been found in a smaller sample of mostly male 
veterans(288) that identified higher risk of mortality at levels of below 6.4% and above 9% similar to the 
present findings, but did not find a U shape relationship with hospital admissions and reported a non-
significant relationship of increasing risk between increasing HbA1c quintiles and hospital admission. The 
thesis findings add to this existing evidence and support a more complex relationship between HbA1c and 
outcomes in HF patients with diabetes. By studying a large sample of general practice HF population with 
diabetes, the findings demonstrate that patients in the lower and higher HbA1C categories have a higher 
mortality than patients with modest glycaemic control (6.5% < HbA1C ≤ 7.5%).   
 
The findings also show that the HbA1c category associated with the lowest risk was higher for mortality than 
for admissions. This reflects other studies which have found a shift to the right in the U curve in more 
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advanced disease demonstrating a lower threshold for hypoglycaemia(428). HbA1c in this analysis was the 
most recent measure prior to death. The higher threshold for low HbA1c for the hospital admission outcome 
may be in part due to less severe HF. A similar threshold to our study on hospital admissions was found in a 
less severe HF group undergoing cardiac revascularisation(429). This combined evidence implies that the 
target for HbA1c control in HF with diabetes needs to be guided by the severity of the HF population with 
higher targets in more severe disease and with more scope for intensive glucose lowering therapy in less 
severe HF.  
 
Short term changes in HbA1c have not previously been investigated in HF populations. In this general 
practice HF population, recent HbA1c change was independently and significantly associated with both 
outcomes. Importantly whilst the HF-DM group with an increase in HbA1c (>1%) yielded an increase in 
relative risk of approximately 27%, a decrease in HbA1c (>1%) indicated bigger increases in relative risk (49% 
for mortality and 34% for hospital admission). This decrease in HbA1c group had a significantly higher risk 
than the other two change groups for mortality and showed a trend of increased risk for admission. Both 
change groups were associated with a higher risk than the no change HF-DM group for both outcomes, 
compared to non-comorbid group. The higher risk in decreased HbA1c may result from a lower HbA1c end 
point (increasing the associated risk for mortality) or may reflect a higher baseline start HbA1c point (higher 
risk for both outcomes). Adjustment was not possible for baseline HbA1c which would have helped to further 
understand this association as HbA1c levels were only available for the DM group. However these findings 
were supported by a previous study on type 2 diabetes(431). The associations were again stronger in the 
decreased than the increased HbA1c group and independent of the diabetes reference group, but adjustment 
for HbA1c level was not possible due to small numbers with HbA1c change.  
 
 13.4.3 COPD drug severity and change 
This is the first study to use drug based measures of COPD severity to determine risk of poor outcomes in HF. 
Three different COPD drug severity frameworks were tested for their associations with mortality and hospital 
admission. The findings were that in the general practice population of incident HF that the level of guideline 
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driven ‘step-up’ of prescribed inhalers for COPD(410) was not associated with the risk of mortality. The risk 
estimates for all levels of inhaler therapy were small and only significant for triple therapy compared to no 
COPD HF. Inhaler therapy predominately is used for symptom control and the poor association with mortality 
likely reflects the lack of dose-response relationship between all classes of bronchodilators and FEV1(467-
469). However for both outcomes the prescription of oral steroids or oxygen therapy was strongly and 
independently associated with mortality and hospital admission.  
 
The prescription of oral steroids is known to increase mortality risk in COPD(470). One mechanism postulated 
relates to weakened muscle strength in prolonged therapy leading to poor pulmonary function(471). Oral 
steroid use in COPD has also been found to adversely affect the development and progression of other 
comorbidities including those with cardiovascular aetiologies such as hypertension and diabetes(472) which in 
HF could contribute to more severe disease. Drugs were measured in a four-month time window and so 
duration of prescribing could not be measured. However, short term prescribing is usually a result of acute 
exacerbations of COPD which are also a predictor of mortality(473). Oral steroids in this context are a likely 
pseudo-marker of more severe COPD disease.  
 
When the COPD group was stratified by a recent increase or decrease in at least one drug severity category 
both strata were significantly associated with mortality, but these associations were similar to the COPD group 
overall. This is likely to result from the multiple categories of inhaler therapy which had weak associations with 
mortality. Using the second drug severity change classification, there were significant, independent and 
stratified associations for COPD defined by the ‘no new steroids or oxygen’, new prescription of steroids or 
oxygen with mortality. The new on oral steroids or oxygen group are likely to indicate acute exacerbation in 
severe COPD or end-stage COPD.  
 
These associations differed for hospital admissions where ‘new oral steroids’ had similar association to the ‘no 
new steroids or oxygen’ group compared to the no COPD HF group. The prescription of oral steroids whilst 
indicating a COPD exacerbation may also serve to prevent some hospital admissions in this group. Newly 
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prescribed oxygen did show a stronger association with admission but this was non-significant and accounted 
only for a small number of observations (n=64, 0.5%).  Most hospital admissions occurred soon after the HF 
diagnosis. Increasing breathlessness is a shared symptom in patients with HF and COPD(374) and is likely to 
contribute to the reason for admission following HF diagnosis. This may deter the prescription of oxygen in 
this group prior to hospital assessment.  
 
13.4.4 COPD physiological severity and change 
GOLD guidelines recommend the use of forced expiration volume measured in 1 second (FEV1) to measure 
the severity of lung function in COPD(410). Whilst the recording of this measure in practice has historically 
been low it improved from 18% in 2003 to 62% in 2004 for COPD patients following guideline 
recommendations(411). The analyses spanned this timeframe and a 50% prevalence of COPD patients with 
at least one spirometry measure was shown. FEV1 could not be used for the smaller HF-HA sub sample. 
Narrower measurement time-windows and shorter average follow-up meant that minimal HF-COPD patients 
had this measure recorded. There was no previous evidence on the association between lung function in 
patients with a recorded diagnosis of COPD and mortality in unselected general practice HF populations. A 
key question for prognosis was whether the risk associated with COPD would differ according to lung function. 
One prior study in a hospital HF population found that severe COPD (FEV1<49%) was significantly 
associated with mortality, but the associations for moderate severity were non-significant(296).  
 
The key findings were that there were significant, stratified and independent associations between all COPD-
HF GOLD severity categories and higher mortality which increased from the mild group (GOLD stage 1; FEV1 
≥80% normal) to the severe group (GOLD stage 4; FEV1 <30%). Of note was the higher risk association in 
the mildest group than the overall COPD group meaning that the recording of FEV1 data was, in itself, 
associated with higher mortality risk. On further examination the FEV1 group compared to the non-FEV1 
COPD group had a much worse risk profile. They were older, more male (65% versus 58%), more deprived 
(3% more in most deprived quintile), with a higher prevalence of diabetes and a higher percentage on oral 
steroids (4%). They had lower mean cholesterol, BMI and haemoglobin albeit there were 3% fewer smokers in 
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this group. This profile suggests that these risk factors are driving some of the clinical decisions to request 
spirometry with a focus on higher risk HF-COPD patients. Whilst the associations compared to no COPD HF 
were adjusted for these risk factors, the higher prevalence and worse risk profile in the FEV1 COPD group is 
likely to indicate worse HF severity in this group and might partly explain the higher overall risk in this group 
compared to the group without FEV1 measure. 
 
This is the first study to investigate recent change in lung function and mortality in the general practice HF 
population. Worsening of a GOLD stage over a year yielded a 55% increase in relative risk from the COPD 
group with ‘no change or improved GOLD stage’, compared to the no COPD HF group. These two change 
group associations were independent and significant but not significantly different to each other. There was a 
trend of increasing risk from the COPD group with no FEV1 change to the COPD groups with 5% or 10% 
increase in FEV1 to the COPD groups with 5% or 10% decrease in FEV1. Whilst these change groups were 
not significantly different to each other and may again, in part, indicate worsening HF, they imply a potential 
important clinical indicator of increased risk. More consistent and routine monitoring with spirometry is 
required.  
 
13.4.5 CKD physiological severity and change 
Previous evidence in the general population of HF has determined that increased severity and change in renal 
function is an important predictor of HF outcomes. However there was only one study identified through the 
systematic review that included community patients or new onset HF and only one study that investigated 
hospital admissions(301). Investigation into change in renal function has so far been limited to the outcome of 
mortality in hospital populations (with one study including readmissions(474)). These studies have used acute 
change in creatinine which is susceptible to fluctuations due to patient factors. One prior study did suggest 
that change in creatinine in a more stable state, 6 months after discharge, was a better predictor of mortality 
than when measured during admission(156). The thesis findings adds important new evidence on renal 
function change in the general practice HF population for the outcomes of mortality and first hospital 
admission.  eGFR calculated via the modification in renal disease equation (MDRD) was used to measure this 
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change which adjusts for age, sex, race and body size and is a more accurate measure in stable 
populations(398,399).   
 
Two definitions of renal change were used; a relative and an absolute change measure. Previous studies 
have considered the use of eGFR change as being less dependent on baseline renal function than creatinine 
change(439). The latter has an exponential relationship with eGFR and for the same change in creatinine 
there will be a small or large change in eGFR depending on a lower or higher baseline eGFR respectively. 
This means that using creatinine change to define worsening renal function, those with lower baseline eGFR 
are more likely to experience this change. The CPRD analyses, showed that whilst lower baseline (start-point) 
eGFR (<60ml/min/m2) was significantly associated with severe renal decline using the percentage change 
measure, this switched to higher baseline eGFR using the absolute measure. This potentially reflects the 
linear rate of change of eGFR found at all baseline levels of eGFR(440). Those with higher baseline eGFR will 
have greater capacity for a severe absolute loss than those with poorer function and those at lower baseline 
eGFR are more likely to experience a given percentage loss given that this equates to less absolute loss than 
in higher baseline eGFR.  
 
A U shape relationship between eGFR and mortality but not hospital admission was shown. The lowest risk 
category of eGFR for both outcomes was 60-89ml/min/m2. Compared to this reference group there was an 
increase in risk of mortality, but not admissions above this category. This was most marked in the eGFR >105 
group. The increased risk of mortality in higher eGFR in the general population has been found 
previously(434) which, like in this study, starts to increase above 90ml/min/m2(437). This has been reported to 
reflect the inadequacies of the eGFR formula at low serum creatinine levels(437) or a false account of kidney 
function due to external causes such as loss of muscle mass in frailty or dilution of creatinine in severe 
HF(334). This may have been more marked in these analyses due to measurement of eGFR most recent to 
death in the case group and would also explain the lack of this association with earlier onset HF prior to 
admission. Risk also increased with every category below the reference group with clear stratification of risk 
estimates increasing to the highest level in the most severe group (<15ml/min/m2). Associations were similar 
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for falling eGFR from the reference category for hospital admissions also increased to the highest level in the 
most severe eGFR group. There was stratification of effects for the lowest two eGFR groups compared to all 
other eGFR categories. These associations were stronger than those in the prior meta-analysis for 
mortality(239) and for hospital admissions(475) and this may be indicative of the time-dependent 
measurement prior to an event having a stronger association with the event.  
 
Recent change in eGFR showed significant independent associations with both outcomes. For mortality, 
compared to the minimal change group, those with any increase or moderate decrease in eGFR had similar 
associations using both the absolute and percentage change measures (range OR 1.14-1.25). The risk of 
mortality associated with increasing eGFR has been previously reported in hospital HF populations(314) and 
is suggested to be either a pseudo effect of reduced creatinine levels in frailty or a marker of recent and 
imminent worsening function. The effect estimates for the most severe change in renal function was higher for 
the percentage change measure than the absolute change measure which was a function of the lower 
baseline start-point eGFR in the percentage change group. Following adjustment for this measure the effect 
estimates for both the absolute and relative change measures were the same. These estimates were 
diminished when adjusted for the end eGFR measure. This demonstrates that both the severity of the change 
and the resultant eGFR and are important components of risk in the HF-CKD population and can be used 
individually or better together, to identify patients with worse prognosis.  
 
eGFR change was also independently and significantly associated with first hospital admission following HF 
diagnosis. The associations were weaker than for mortality and non-significant for moderate decline or 
increasing eGFR using the absolute change measure. The two severe change groups had the strongest 
effects and these estimates were not reduced greatly by the adjustment of the start or end-point baseline 
eGFR or the end.  The weaker influence of adjustment may indicate different mechanisms associated with 
eGFR change before the two outcomes. Most first hospital admissions occurred soon after HF diagnosis. 
eGFR change prior to admission may indicate HF instability and more acute renal change than the eGFR 
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change that occurs chronically over time before death. This earlier more acute change and its indication of 
potential instability may be important for admission in both higher and lower eGFR states. 
 
These findings highlight the importance of the severity of CKD and change in the general practice HF 
population. Of particular note is the strong association between CKD change and first hospital admission 
following HF diagnosis that has not previously been investigated. It cannot be ruled out that the strength of 
associations with both outcomes might be, in part, related to the underlying haemodynamic status of the HF, 
particularly in the period of time following HF diagnosis and prior to admission or in deteriorating status prior to 
death(382). Adjustments could not be made for ejection fraction, NYHA or BNP, which are not routinely 
recorded in the CPRD. However, adjustment for a range of clinical and patient factors which are associated 
with more severe HF disease including diuretics and systolic blood pressure were made. The dose-response 
relationship found between categories of eGFR and outcomes in this study and the prior studies that have 
accounted for HF severity(156,475) all suggest an independent association between renal function and 
outcomes. eGFR is a well recorded routine measure in HF and can be easily used to target high risk groups in 
the general practice population for intervention. The difference in associations with CKD severity for both 
outcomes with a U shape identified for mortality, indicates the need to tailor this assessment according to the 
severity of the patient with caution given to the interpretation of higher eGFR levels in older frail patients with 
more severe disease.  
 
13.5 Comorbidity interactions 
13.5.1 Inter-relations 
There were biological interactions between two of the HF comorbidity disease pairs and mortality; DM-CKD 
and COPD-CKD.  The combination of DM and CKD had an association with mortality that yielded a higher 
than expected risk estimate. The synergy index, which measures the risk of two factors where there is 
interaction present as a proportion of the risk if there was no interaction present, was 29% additional risk 
relative to the pair without interaction. This finding is important for two reasons. Firstly, DM and CKD share 
pathophysiological pathways that may interact to intensify their progression(476) which increases the risk of 
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mortality. The intricate relationship between both diseases and HF is likely also to contribute to more severe 
HF disease. Secondly, this was the most prevalent disease combination in 10.3% of all HF patients, which 
indicates an important and high risk group for targeting with interventions.  
 
The combination of COPD and CKD had a significant statistical and biological interaction which was in the 
opposite direction to DM and CKD. When these comorbid diseases were experienced together in HF they 
exerted a less than expected risk of mortality with a synergy index equating to a 30% reduction in risk relative 
to if there was no interaction. As previously discussed, both COPD and CKD create a complex interplay of 
pathological interactions with cardiovascular mechanisms, coupled with responsive processes to 
haemodynamic compromise in HF. Congestion in COPD and poor cardiac output in CKD can lead to worse 
physiological measures such as FEV1 and eGFR which can blur the relationship between the comorbid 
severity and poor outcomes. The reduction in risk when the two comorbidities coexist supports the hypothesis 
that both diseases share an indication for HF severity. Prognosis assessment for patients with this comorbid 
disease combination would require close consideration of their HF disease severity.  
 
13.5.2 HF Severity 
Age was used in this study as a pseudo indicator of HF severity, an approach which has been used in prior 
HF studies and has indicated a differential relative effect of comorbidities across age groups through 
significant statistical interaction(139). Statistical interaction was found between all three comorbidities and 
older age which when considered together was less than multiplicative. However this was likely due to the 
lower baseline risk in the younger age group meaning that the relative risk associated with comorbidity was 
greater in these groups. When tested for biological interaction, only COPD and older age was significant in the 
same direction as the statistical interaction. There was also a significant interaction between CKD and age but 
this went in the opposite direction with a worse mortality risk from CKD in older age.  
 
The less than additive effect of COPD and older age indicates that there are less sufficient causes for 
mortality that include COPD and older age than expected(477). This may be due to competing risks of other 
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causes of mortality unrelated to COPD or because of the shared indication of worse HF severity in COPD and 
older age reducing their overall effect when experienced in tandem. The supra-additive biological interaction 
between CKD and older age is a likely consequence of a lower threshold for poor renal function in older age. 
These combined results also indicate the importance of measuring biological interaction to understand causal 
mechanisms. Statistical interaction considers the need for a product term in a statistical model but does not 
determine whether the absolute risk differs for any given factor(453). Relying on statistical interaction which is 
the focus of most previous evidence would not have identified the biological interaction between CKD and DM 
and would have suggested an opposite association for CKD and older age.  
 
13.5.3 Other factors 
There was a significant statistical and biological interaction between male gender and CKD for both outcomes. 
This might indicate more severe renal disease in men than women or a higher propensity for admission in 
men than women with renal disease and HF. Previous evidence points to a gender difference in terms of 
progression to end stage renal disease with women on average being 10 years older(478) and with a slower 
rate of decline(479). In patients with CKD there was only minimal difference in the prevalence of the most 
severe renal category (eGFR <15) between men (2.4%) and women (1.9%), but men did have a higher 
prevalence of severe renal decline (17%) than women (14.5%) and might account for some of the increased 
risk.  
 
13.6 Comorbidity models 
Risk prediction models can assist in identifying individuals at risk of adverse events and to target limited 
resources to those most at risk. The objective of this thesis was to firstly determine whether the measures of 
comorbidity severity and change proximal to poor outcomes would be associated with those outcomes. The 
second objective discussed here was to determine whether the comorbidity measures that had significant 
associations for mortality and hospital admission would contribute to the fit of a multivariable model for both 
outcomes. The hypothesis was that comorbidity measures that take account of severity and change over time 
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may provide better prediction of outcomes. The clinical importance in addition to better prediction for HF 
patients is that the severity of comorbidity is potentially amenable to modification and can act as a trigger for 
interventions to reduce risk.  
 
Severity: When the different comorbidity measures were tested in an overall core model including all other 
covariates there were some similarities and some differences across the two outcomes. For both mortality and 
hospital admission, for all three comorbidities defined by drug or physiological severity measures (where 
included) there were significant improvements in model fit when these measures replaced the comorbidity 
status measures of presence or absence. This is an important consideration for prognosis. Most current 
prognostic models include comorbidity by status which misses important information for individuals who vary 
in the severity of their comorbid disease. Inclusion of severity in prognosis would facilitate routine monitoring 
and targeted intervention to the most at risk groups. 
 
Severity change: With the exception of COPD severity change using physiological measures, comorbidity 
severity change measures were a significant improvement over status measures for mortality. The model fit 
however was similar to the models with the comorbidity severity measures. For the hospital admission 
outcome, with the exception of CKD change, the models with the severity change measures showed no 
improvement in model fit over the comorbidity status models.  
 
For CKD for both outcomes, the severity model showed the best fit compared to the severity change model 
but both were a significant improvement on the status model. When baseline renal status was added to the 
change model there was significant improvement in model fit and this resulted in incrementally better model fit 
from the renal status model to the renal severity model to the renal change model for both outcomes. This 
may have been a similar finding for DM and COPD, if it was possible to adjust for baseline comorbidity status 
in the mortality models and requires further investigation.  
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The difference in the contribution of the change measures to the hospital admission models compared to the 
mortality models also requires further investigation. It is possible that with the exception of CKD change, 
which has a clear indication for worsening HF severity prior to admission, that the high risk of cardiovascular 
compromise in new onset HF counteracts any additional risk associated with comorbidity change. This 
generates the hypothesis that comorbidity change in a more stable prevalent HF population may have yielded 
stronger and significant associations. A further consideration is that any noted change in comorbidity might 
trigger interventions aimed at hospital admission avoidance which reduces these associations. Where 
comorbidity change does improve the fit of a statistical model, as was the case in this study for all 
comorbidities and mortality and for admission with CKD, it provides an important clinical indicator of prognosis 
change during the life course of HF and comorbidity.  Like the comorbidity severity indicator, change that is 
routinely recorded is a feasible and clearly identifiable indicator of increased risk and a target for intervention. 
 
Overall comorbidity model: When all comorbidities were added by their different measures to the core model 
simultaneously, the comorbidity severity model had the best fit over the status or change model. Again adding 
baseline renal status to the change model improved its fit significantly and resulted in the change model 
having the best fit. The best fitting comorbidity models using mixed measures included DM by drug severity 
change for mortality and DM drug severity for hospital admissions, COPD by drug severity for both outcomes 
and CKD by baseline severity and severity change for both outcomes. Model discrimination was better for 
mortality (C-index 74%) than hospital admission (C-index 68%). Whilst the purpose of this thesis was to test 
the contribution of different comorbidity measures to a core HF model and not to produce a predictive model, 
the C-index for both outcomes was better than many prior models which in one meta-analysis showed a C-
index of 0.71 for mortality and 0.68 for hospital admission(186).  
 
The C-index has been demonstrated to have an upper limit that is determined by the distribution of risk in the 
sample. For an average risk of 10-50% with little spread then the upper limit of the C-statistic will be 0.62-
0.63(480). The lower C-index for first hospital admissions may be partly due to the narrow distribution of risk 
within the incident HF population with 33% of patients admitted within a month, 46% within 3 months and most 
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in a year. This might also explain previous low C-index in prior models to predict hospital admission and 
readmission(161,164) which is also a high risk outcome for hospitalised patients.   
 
The receiver operating characteristic (ROC) curve, or C-statistic has been criticised for its role in determining 
the accuracy of a prediction model, despite its constant use as a sole measure in the literature(458). Unlike 
calibration that determines, through statistics such as Hosmer-Lemeshow(481), how well the model 
predictions fit the observed data, the ROC merely ranks individuals into high and low risk. This does not 
indicate at all the range of individual risk within the groups. A model could predict all cases to have a risk of 
0.52 and all controls 0.51. This would be very poor at prediction but have perfect discrimination. For this 
reason other global measures of model fit that don’t rely on the ranking of cases have been recommended 
and were used in this thesis(482).   
 
ROC is also a poor statistic to use in order to choose the best variable from a set of variables to use in a 
model. A factor that has a strong and significant effect on an outcome may have little influence on the ROC if 
it doesn’t alter the ranking of higher and lower risk. However in terms of prediction it can have a big influence 
on an individual’s overall risk estimate(458). In our analyses the ROC had the least response to the addition of 
the different comorbidity measures but this does not rule out improved predictive accuracy which was clearly 
evidenced by the other measures of model fit. 
 
13.7 Strengths and limitations 
Strengths and limitations are now discussed focusing on (i) the use of routinely collected data and (ii) 
specific considerations when using CPRD. Particular attention will be given to chance, bias and 
confounding.  
 
13.7.1 Using routinely collected data 
Health care data that is routinely collected during healthcare activity is becoming increasingly 
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available and used for health research to answer innovative, efficient and cost-effective research 
questions(483). There are many advantages of using routinely collected data over other bespoke 
modes of data collection which include the potential for large representative population based 
samples, long follow-up, low attrition, low cost and generalisability to real world populations where 
care is delivered(484). However routinely collected data is for clinical and administration purposes 
and is not based on any a priori research questions(485). Unlike in a prospective study the data 
collection cannot be chosen to reduce bias(486). This can create a number of challenges which 
include the large sample size and spurious correlations(487), inconsistent coding and sampling bias, 
missing variables, missing data and measurement bias(488). These will now be discussed in turn. 
 
13.7.1.1 Large sample size 
One of the key advantages of using routinely collected data is the availability of large samples of 
observations.  All patients who attend routine clinical consultations are captured on electronic 
databases with drop-out usually only occurring when patients move to a new practice, transfer to a 
care institution or die which provides the potential for large captures of clinical information for use in 
research. Large samples mean that detailed analyses of exposures can be performed taking account 
of multiple confounders. The current investigation was conducted using a large sample from the UK 
general practice population which allowed detailed analyses of three HF comorbidities and 
adjustment for a range of covariates. It was possible to investigate exposure effects within sub-
groups and to investigate interactions between the exposures and other covariates.  
 
However, due to the high precision in big data, a small and clinically non-significant effect may be 
statistically significant with a low P value(489). In contrast a low P value in a smaller well designed 
study indicates a much larger effect size and may have more clinical importance(490). For this 
reason significance tests have to be viewed with caution when analysing large samples. In this study 
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the covariates in the multivariable models were pre-specified rather than relying on selection 
approaches that use statistical tests. Approaches such as stepwise selection when using large 
samples of observations can lead to the inclusion of clinically unimportant covariates(225). Observed 
effect sizes, confidence intervals and absolute differences were used where available rather than 
relying on the P value. Where statistical testing was used, a lower P value (<0.01) to indicate 
significance was selected. To improve computational efficiency for performing Lowess regression 
(data plots), a random sample of the data was used.  
 
13.7.1.2 Inconsistent coding and sampling bias 
Whilst using big data has the advantage of detailed analyses and generalisability of study findings, 
one of the key disadvantages is the inability to ascertain with any certainty the clinical status of the 
subjects included.   Routinely collected data includes codes applied by clinicians in practice to record 
their patient’s clinical information during consultations. These codes might relate to symptoms, 
diagnoses, medical history, treatments, care activity and referrals. Key challenges of using routinely 
collected data are that the codes applied to any specific disease group or clinical event might vary 
greatly amongst practitioners, be inaccurately applied or not applied.  Coding decisions can also be 
influenced by health systems that provide financial recompense according to the code applied such 
as those based on insurance claims(491). Using routinely collected data to identify disease or 
exposure groups can be biased where there is inconsistent or inaccurate clinical coding.   
 
The Quality and Outcomes framework (QoF) in the UK provides financial reward to GPs linked to the 
application of specific codes. In QoF diagnostic codes are often linked to appropriate tests and 
provision of evidence based therapies and so the focus is on more comprehensive and standardised 
coding, accuracy of diagnosis and improving quality care provision(93). The frequency of disease 
coding has improved since QoF and the accuracy of coding within the CPRD has been tested 
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against gold standards such as clinical verification and found to be valid for a range of 
morbidities(492, 493). However, whilst this increases specificity it is reliant on the selection of an 
appropriate code set and does not rule out accidental miscoding or negate that there may be 
subjects with a specific morbidity without a respective code applied. In this study Read codes were 
used for the selection of the HF sample and identification of the exposed groups(404) and careful 
consideration of the codes used was required to reduce the risk of misclassification. Any 
misclassification can lead to bias in the estimation of effects, the direction of which will depend on 
whether the misclassification is differential or non-differential across cases and controls(9) and will 
be explored in the following subsections.    
 
Heart failure cohort: When using routinely collected data it is important that the sample is 
representative of the population from which it is drawn. The CPRD, one of the largest validated 
sources of routinely collected general practice data globally(237, 492) is representative of the UK 
general population who are registered with a CPRD general practice(238) but sampling requires 
careful consideration. An accurate clinical code being applied to a patient’s record relies on the 
patient presenting to their general practice and the appropriate clinical code being applied. The 
decisions that underlie both factors may vary greatly across individuals(488). The HF cohort was 
selected from the CRPD on the basis of a first HF consultation code applied over a ten-year time 
window to March 2012. HF diagnosis relies on the presence of a combination of symptoms, signs 
and objective evidence of cardiac abnormality(93). HF symptoms in patient consultors are often non-
specific which can lead to delayed or inaccurate diagnosis. The use of echocardiogram to aid 
diagnosis only improved following inclusion in the Quality Outcomes Framework(QoF) for general 
practitioners in 2006(103) and so  the ESC diagnostic criteria for HF(93) could not be applied in this 
study due to the lack of routine recording of echocardiogram data. This means that the Read code 
for HF may have been inconsistently applied due to unconfirmed diagnosis and the accuracy of HF 
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codes may be a function of time. In this study the incident HF sample was selected using READ 
diagnostic codes for HF and excluding process codes that were indicative of prevalent HF. Whilst the 
potential for missed or inaccurate coding exists with routinely collected data, the accuracy of the HF 
diagnosis represented by clinical codes has been found to be 84% (406).  Patient data in the CPRD 
is subjected to stringent quality checks and this study included 3-years of up-to-standard clinical data 
prior to study entry to validate the HF index date. The clinical code set used was validated by HF 
specialists and used in previous CPRD studies (405).  
 
The code set used for identification of the HF subjects was based on Chapter G58 of the Read code 
which focuses on HF clinical diagnosis. A search was also performed for codes outside of chapter 
G58 that indicated a HF diagnosis. The search included cardiac terms that were combined with the 
term ‘failure’. The inclusion of the term ‘failure’ was chosen to increase the accuracy of the diagnosis 
which is a combination of signs, symptoms and impaired ventricular function rather than any 
individual component. Whilst two of the codes in chapter G58 refer to impaired ventricular function or 
pulmonary oedema rather than ‘failure’ per se, these were retained due to their inclusion in the heart 
failure chapter which means their application is more likely to be a descriptor of HF. Other similar 
codes and symptom codes outside of chapter G58 were excluded due to the higher potential for 
reduced precision. Whilst there may be variations in the precision of the HF diagnosis using routinely 
collected data, the sample reflects the real world of HF in the general practice population which is 
important for the application of prognosis. This is in contrast to the randomised controlled trials 
whose use of strict control of internal bias and careful selection of patients, means that 
generalisability outside of the study sample can be limited. Further validation of the study findings 
across different HF diagnosis groups would be required. 
 
Cases and controls: Both outcome measures related to objective events that are routinely recorded. 
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All-cause mortality cases were identified using a CPRD verified algorithm and where available cross 
checked with Office of National Statistics data. All-cause admission was identified by the first 
discharge date following the HF incidence date. A control sample should represent the population at 
risk of becoming a case and be selected independently of the exposure of interest. Controls should 
differ from cases only on the basis of their event status(494). Controls in the analyses were randomly 
sampled from risk sets defined by the cases after matching on calendar and follow-up time. Controls 
could be used more than once and later become a case. In this way the control sample reflected 
both the population at risk and the exposure time distribution in the entire denominator population. 
This design, consisting of a nested case-control approach within a well-defined cohort, virtually rules 
out the potential for selection bias and produces unbiased estimates of the exposure rate ratio(495).  
 
In the HF-HA sub-sample a high number of events occurred in close proximity to the HF index date. 
To ensure that the controls differed to the cases on event status, controls were used that did not 
experience the event in the next 3 months after their selection as a control. This is analogous to the 
wash-out period often employed in case-crossover studies where separation is created between the 
case and control windows within the same patient to allow for the investigation of exposures that are 
associated with more insidious case events(408). The aim of this separation of time windows in the 
case cross-over approach is to ensure that the exposure measurement in the control window is not 
associated with the comparator case event that is occurring in close proximity. In the thesis, 
comorbidity exposure status over the six months prior to the first hospital admission was 
investigated. Whilst, a six month wash-out period could have been used, the control sample would 
have been too limited in size due to the high event rate within the first six months. This does mean 
that the comorbidity exposure effects on hospital admission may have been reduced as a result of 
the controls having an event within the following six-months which creates an overlap between the 
exposure measurement windows. This creates the hypothesis that investigation of the association 
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between comorbidity severity and change prior to admission in a prevalent HF cohort (with fewer 
more widely distributed events) would yield stronger exposure effects.  
 
Exposures: Comorbidity exposure groups were identified using physiological measures (CKD) or a 
combination of clinical codes and drug measures (DM and COPD). These approaches were 
validated by clinical experts and prior evidence where available. All patients had 3 years of up to 
standard data prior to study entry so that prevalent DM or COPD comorbidity exposure occurring 
before to HF and incident comorbidity exposure occurring after could be identified.  
 
The prevalence of CKD identified by Read codes was very low prior to 2006 which then increased 
remarkably post 2006. This difference likely indicates the low coding of CKD prior to the Quality 
Outcomes Framework(QoF) in general practice. Early coding of CKD was reliant on specialist 
investigations and objective evidence of disease. The QoF introduced the eGFR as a standard 
diagnostic measure into general practice and encouraged the early diagnosis of CKD using this 
readily available approach. These factors are likely to have led to the increase of CKD codes beyond 
this point. Given the clear discrepancy in coding across the two time-points the decision was to use 
the eGFR measure which is routinely recorded in all HF patients in the analyses. Due to the variation 
of physiological measures over time, the eGFR measure could not be used to position the timing of 
the CKD onset.  
 
Whilst the clinical diagnosis of DM and CKD in general practice is based on an objective 
physiological measure, this is not often the case for COPD. Spirometry is under-utilised(411) and 
where it is used can be misinterpreted in the context of HF(415). A validated approach for 
identification of COPD using a combination of clinical codes and prescriptions was used, which has 
shown good precision in the CPRD(412,413). However within the COPD group, there was a 
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difference between those with and without an FEV1 measure recorded with the latter having a 
healthier risk profile and lower mortality risk. This could be due to misclassification of COPD in the 
absence of spirometry (i.e. the healthier non-FEV1 COPD group did not actually have COPD) or a 
propensity for using spirometry in more severe or symptomatic HF-COPD patients.  
 
Despite the high precision previously found for identification of COPD in the CPRD using combined 
clinical and prescription codes, the possibility of misclassification cannot be excluded. In situations 
where misclassification is non differential and the exposure is dichotomous then the exposure effect 
will be diluted and the resultant bias will be towards the null value(9). However given that the use of 
spirometry (with the assumption of improved diagnostic accuracy) appears to be associated with 
more severe HF-COPD patients it is likely that the misclassification would be differential on the event 
status with healthier controls subjected to more misclassification (due to the more infrequent 
spirometry leading to over or under-diagnosis).  
 
Finally, it cannot be ruled out that some of the higher risk in the more severe FEV1 group may also 
result from conflation of spirometry results in the context of severe HF(342,343) which would 
increase the relative estimates associated with the COPD status in this group(415). The higher 
relative risk of mortality in the FEV1 group with mild COPD (GOLD stage 1) than in the general 
COPD group (with or without FEV1) suggests that the increased risk in this group may in part relate 
to worse HF severity. However whilst routine use of spirometry including FEV1/FVC ratio is required 
to test and disentangle these associations(397), the dose-response relationship between reducing 
GOLD stages and increasing mortality risk does suggest a true association between COPD and 
mortality. 
 
Confounders: A wide range of routinely collected confounders relating to socio-demographic, risk 
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factors and drug data were used that were based on evidence in HF prognosis studies and were 
subjected to detailed investigation. For a specific physiological confounder, the measure was 
converted from any varied units of measurement to a standard unit and removal of implausible 
values was performed prior to selection.  To account for the time-varying nature of confounders, the 
most recent available measure to the match date was used. Key challenges for the measurement of 
confounding when using routinely collected data are measurement error, unmeasured confounding 
through missing variables and missing data.  The CPRD analyses used the most recent 
measurement of confounders prior to the match date in recognition of the dynamic status of 
confounders that change over time, but did not include duration of the confounder which may 
influence its confounding influence on the exposure association. Additionally, measurement error of 
the confounders in routine practice cannot be ruled out, albeit non-differential measurement error will 
introduce bias towards the null value(496). 
 
13.7.1.3 Missing variables 
Key advantages of prospective studies are the ability to collect all relevant data required to answer 
the research question and take account of confounding or to randomise the intervention exposure to 
reduce the bias caused by unmeasured confounding(486). This is not possible in retrospective 
studies using routine data and lack of information in relation to potential confounders is 
common(491). Bias will remain where there are unobserved or imperfectly measured factors that 
influence both exposure and outcomes and it is important to acknowledge the potential confounding 
caused by missing information in the interpretation of findings. 
 
In this study the covariates were selected using the prior review(239). However there was a key gap 
in the available data in relation to the research questions. Whilst severity measures were available 
for the comorbidity exposures these were absent for HF. Adjustments therefore could not be made 
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for ejection fraction, New York Heart Association (NYHA) class or brain natriuretic peptide (BNP), 
which are not routinely recorded in the CPRD. This is important because of the close relationship 
between HF severity and the physiological severity measures for both COPD and CKD. When age 
was used as a pseudo measure of HF severity there were biological interactions present for both 
comorbidities which emphasises their interrelationships. The lack of HF severity measures meant 
that it was not possible to distinguish between the independent influence of the comorbidities on the 
estimates of effects for the outcomes investigated. Lack of some known confounders in the CPRD 
such as HF severity means that unmeasured confounding was a possibility and this was 
acknowledged in the interpretation of the findings.  
 
13.7.1.4 Missing data 
An important consideration when using routinely collected data is the varying level of missing data 
inherent in some clinical variables. Provision of health care by different providers, inconsistency of 
clinical tests which are performed as needed rather than on a regular schedule and variation in 
coding of isolated events means that routine data provides only a partial picture of the patient(491). 
In this study the exposures were focused on chronic disease comorbidities which undergo routine 
monitoring and standard treatments guided by national policies, which reduces their risk of being 
missed. Three years of up to standard clinical data was also available prior to study inclusion for 
each subject reducing the risk of missed recording. The outcome measures were also objective, 
routinely recorded measures. Hospital admissions are identified through discharge codes which are 
applied by hospitals to seek financial recompense for the care they deliver and thus increases 
completeness. For the mortality outcome all deaths are recorded on registration by the Office of 
National Statistics and this was used, where linkage was available, to validate the CPRD mortality 
status. However there was varying levels of missing data in the covariates included in the analysis 
which can potentially lead to bias when associated with case status(9). 
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The level of missing data ranged from 0.5% (blood pressure) to 18% (cholesterol). Deprivation was 
available for only 59% of the overall cohort so was only included in a sensitivity analysis for the 
mortality outcome. Missing data was more prevalent in the case group than the control group. The 
differential nature of missing data can lead to selection bias(225). In this study, given that the 
comorbidities were associated with the case group, the differential missingness could have led to 
lower prevalence of comorbidity than would naturally be found in the denominator population by 
using complete case analysis.  
 
To minimise this bias, several approaches to handle missing data were considered. Full case 
analysis, missing indicator or overall mean imputation were not chosen as the missing data were not 
completely at random and, where this is the case, these approaches can lead to bias(497). Instead 
confounders were imputed using single chained equations followed by a validity check that the 
imputed data was not statistically significantly different than the available data. In single imputation, 
only one estimate is used. In multiple imputation, various estimates are used, reflecting the 
uncertainty in the estimation of this distribution. Single imputation has been found be better than the 
other approaches previously mentioned(449) and if the data are missing at random or missing 
completely at random will result in unbiased, similar direction and magnitude of regression 
coefficients to multiple imputation(449, 498). However one of the limitations of the single imputation 
approach used in this study is that by not accounting for the uncertainty in the missing data, it can 
lead to too small estimated standard errors and confidence intervals(499).  
 
13.7.1.5 Measurement bias; comorbidity severity and change 
A priori definitions of comorbidity severity and change based on current clinical 
guidelines(410,418,419,432) were used supported by available evidence. For DM there is no clear 
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physiological measure of severity. HbA1c as a salient indicator of glucose stability was used(420) 
based on evidence of association with cardiovascular outcomes(425) and routine measurement in 
clinical practice. FEV1 for COPD and eGFR for CKD are evidence based indicators of severity that 
are included in current guidelines. Whilst the level of missing data was acceptable for DM and CKD 
(approximately 10%), missing FEV1 data was 50% in the total COPD cohort and more in the hospital 
admission linked sub-sample which had more narrow measurement time-windows. In addition to the 
physiological measure, for COPD and DM, a drug severity indicator was used which was complete 
for the comorbid groups. Given the high level of missing FEV1 data in the hospital admission linked 
sub-sample, the analyses was restricted to the drug measures for the COPD group. 
 
In CKD, eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) formula. This 
equation adjusts for significant non-renal influences such as age, sex, race, and body size, is 
preferred to other equations such as the Cockcroft-Gault formula(399) and has been validated in the 
HF population(398). Whilst Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) is now 
the recommended formula for estimation given its higher accuracy in higher eGFR groups, the 
MDRD was chosen for comparability with prior evidence and preference in older age groups, lower 
eGFR groups(500) and in HF.  
 
For the severity change measure, two measures were used which were identified in maximum time-
windows for each patient and the absolute and relative change between the two measures was 
standardised over a specified time for each outcome. Other methods were considered such as fitting 
a regression line to change slopes to calculate the rate of decline for an individual but it was decided 
that using categories of change based on evidence guidelines was preferable as they are easily 
identifiable and clinically meaningful.   
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Adjustment was not possible for the DM or COPD change measures by baseline levels which may 
have diminished the strength of associations, particularly for DM and mortality where a U shape 
relationship was observed. The effect of an increase or decrease in HbA1c is likely to be influenced 
by the start and end HbA1c. Where there are opposing baseline and change effects this could lead 
to reduced or abolished effects where they are considered alone. This was clearly seen in CKD 
where adjustment for baseline eGFR status was possible. The adjustment made a clear difference to 
the associations of eGFR with both outcomes and significantly improved the fit of the multivariable 
models. Whilst the model fit for the DM and COPD models did not improve when the severity 
measures were exchanged for severity change measures this could be a product of the lack of 
adjustment of the severity change measure with severity. 
 
Time-dependent measurement of exposure: Previous studies have been criticised for not including 
long enough follow up periods to identify the power of individual factors contributing to risk(183) or 
not taking account of the time-varying nature of exposures. These criticisms were counteracted in 
two ways. Firstly, the CPRD was a longitudinal HF cohort with up to 12 years follow-up.  Secondly, 
with the recognition that comorbidity exposures and other factors change from disease onset over 
the course of the HF, severity and change were measured during follow-up and in specific time-
windows before an outcome. The time-windows for the physiological measurement of severity were 
longer for mortality (maximum of 3 years) than for hospital admission (maximum 6 months). This was 
to allow capture of routinely collected data and the hypothesis that change occurs more chronically 
and over a longer time prior to death than to hospital admission. That said most measures were 
recorded within 7 months of mortality.  
 
Future validation is required in a prospective study where exposure change is measured 
retrospectively at baseline in a prevalent cohort. The hypothesis generated by the CPRD analyses is 
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that this change should be associated with imminent outcomes (1 year mortality and 6 month 
hospital admission) in the prevalent general practice HF population. An incident cohort was used, so 
that comorbidity could be investigated within the life course of HF and associated outcomes. Using a 
matched analysis on time in follow-up meant that adjustment for the HF duration was possible whilst 
measuring comorbidity severity and change during follow-up. To test comorbidity severity and 
change within a prevalent cohort would mean that both these factors would require consideration in 
the model.  
 
13.7.2 Specific considerations when using CPRD 
13.7.2.1 Study design 
The purpose of this thesis was to ascertain the importance of recent comorbidity severity and change 
for hospital admission and death during the heart failure disease course. This was driven by the 
hypothesis that comorbidities would be more severe and change prior to these outcomes.  A nested 
case-control design using risk set sampling of controls was used for the analyses. The strength of 
this approach is that it allows the measurement of time-dependent exposures and yields similar 
estimates of effect to a Cox proportional hazards analysis but more efficiently (220) and has been 
employed in a number of prior studies(160,431). Increased efficiency was required in this study due 
to the long follow-up, use of biomarkers to measure severity which change frequently over time and 
the high number of events (see section 4.4.1).  
 
Using the risk-set sampling approach, the probability of the selection of a control is directly 
proportional to their person-time contribution to the denominator of the incidence rate. The control 
series is therefore sampled to represent the person-time distribution of exposure in the source 
population(9) which provides a valid estimate of the incidence rate ratio(219). The analysis of the 
nested case-control data was based on the conditional logistic likelihood which is a partial likelihood 
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similar to Cox's partial likelihood for survival data (501) and is a natural extension of the counting 
process formulation of Cox's proportional hazards model (section 4.4.1)(502).  
 
However the risk set sampling approach has some limitations. The most recent exposure 
measurement reflects the exposure time distribution in the source population up to the point of 
measurement.  This means that the comorbidity severity and change experienced by the source 
population since HF diagnosis and up to the point of analysis is included. The first limitation is that 
the time-dependent nature of measurement means that these measures could not be used directly 
for prognosis(221) as prediction can only be based on prior and not future knowledge. Second, the 
measure of risk generated by this approach compares the rates of event in the exposed and 
unexposed groups. The rate ratio, similar to a hazard ratio, provides a relative estimate of 
instantaneous risk over the study period and does not reflect a time-unit of the study or the time to an 
event.  The lack of an intercept using conditional logistic regression also means that absolute risk 
cannot calculated directly by the model(227) and so survival plots cannot be readily produced. That 
said, baseline hazard functions can be calculated for case-control studies which are nested within a 
known cohort and the number of individuals at risk at each failure time is known(503), but this was 
not done in this study. The focus of this thesis was to ascertain the importance of recent comorbidity 
severity and change during the course of HF for the outcomes of mortality and hospital admission 
and not to produce a prognostic model. The significant associations of these measures with both 
outcomes and the improvement  to statistical models following their addition demonstrates their 
potential importance for prognosis which can now be further tested in a prospective cohort using an 
non-matched design. The hypothesis is that a prognostic model including these measures should 
predict 6-month hospital admission and 1-year mortality within a prevalent general practice HF 
population. 
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13.7.2.2 Long follow-up 
The HF population in CPRD ranged from 2002 to 2012 which means there will be variation in the 
diagnosis and clinical management of the HF sample. The influence of clinical guidelines and 
inclusion of HF in the Quality and Outcomes Framework in 2006(103) means that HF management 
will have changed over this time period. The use of beta blockers and ACEi as the mainstay of HF 
pharmacological interventions was significantly higher in the HF sample after 2006 as was the 
prevalence of comorbidity. Use of devices which were not included in this study, have also increased 
in later years(93). However, matching on calendar time in the analyses means that these time-
varying factors were adjusted for with the cases being compared to controls at the same time point. 
Use of time-dependent measures also means that any developments in clinical or patient 
characteristics during follow-up will have been captured. In addition the mainline drug treatments 
were adjusted in the analyses.  
 
13.7.2.3 All-cause outcomes 
When selecting appropriate study outcomes, two options exist; disease specific outcomes and 
generic ‘all-cause’ outcomes. The choice will depend on the study hypotheses and the availability of 
data. Disease specific outcomes allow the investigation of the influence of various exposures on the 
pathophysiological progression of the index disease under study whereas generic outcomes 
investigate the influence of exposures on the progression of the patient. In this thesis all-cause 
hospital admissions and mortality were chosen for two main reasons. The life-course experience of 
people with HF has changed over recent decades. Whereas cardiovascular causes used to be the 
predominant cause of admission and death in HF, non-cardiovascular comorbid diseases now 
predominate(125). Given the relative severity of HF which is akin to most common cancers, the 
assumption might be that other less severe comorbid diseases would only influence these patient 
outcomes through moderation of the HF severity and would not impact directly. However research 
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has shown that non-CVD causes have now overtaken cardiovascular causes of both outcomes in the 
HF patient(159). This means that in terms of understanding the life course of the heart failure patient, 
these non-CVD comorbidities needed to be captured in the outcomes investigated. For patients this 
provides important information on how more likely their risk of hospital admission and death are 
given their multiple diseases compared to having HF alone. Investigation of interaction between the 
comorbidities also provides important information regarding the summation of risk across diseases.  
 
However, to understand the interaction between the comorbidities and the HF to determine how they 
influence the progression of the HF, disease specific outcomes would be required. This information 
is important to identify whether interventions should be targeted at the index disease, the comorbid 
disease or both and was a limitation of this study. A key challenge to using disease specific 
outcomes is their availability and accuracy. The CPRD makes available HES data which lists all ICD-
10 codes linked to the hospital discharge. These codes are not ordered and don’t provide information 
on the cause of admission. The principal code at discharge can be identified but this requires 
additional costs which were not available for this study.  In England and Wales, the legal requirement 
to register all deaths means that death registrations with the Office of National Statistics (ONS) 
provides the most complete data source for mortality statistics. However ONS data is only available 
under the CPRD linkage scheme which covered only 60% of the study cohort.   
 
An additional consideration when choosing outcomes is the accuracy of the available data. The 
ability to investigate disease progression by disease specific outcomes rests on the fundamental 
assumption that the cause of death can be determined accurately. The determination of the 
underlying cause of death is often ambiguous and the accuracy of death certificates has been found 
to be low in a number of prior studies(504, 505). Assignment of a specific cause is subject to error 
particularly when the patient has a number of underlying diseases or health factors. HF itself is 
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considered a mediator between disease and death and is therefore ill-defined as a cause of death. 
HF is often applied where the aetiology is not known but this is not consistent and underreporting of 
circulatory diseases on death certificates is common(506). For this reason coding recommendations 
from the International Classification of Diseases Tenth Revision (ICD-10) are to apply other plausible 
heart conditions in place of HF(507).  
 
All-cause mortality outcomes are now advocated in cancer screening trials where bias due to death 
coding errors has been found in a number of studies(508). The recognition that some cardiac 
interventions may cause non-cardiac deaths(509) has also seen all-cause mortality being used more 
in cardiac drug trials(510, 511). Conceptually, in considering an index disease as the cause of death, 
all deaths that are directly or indirectly caused by the index disease or its treatment should be 
included(508). An example would be a patient with HF who dies of renal failure secondary to the HF 
who is then coded with renal failure as the cause of death. Using all-cause mortality means that all 
indirect and direct deaths caused by HF are captured and there is no bias in the application of the 
cause of death.  
 
13.7.2.4 Model building  
To test the contribution of comorbidity measures to statistical models, a set of pre-specified covariates were 
used to build the core model. The selected covariates were based on prior evidence identified in the 
systematic review and through detailed consideration of the exposure associations with and without the 
covariate included. It has been argued that these approaches are preferable to stepwise selection which relies 
on statistical testing using arbitrary thresholds for exclusion that can lead to bias and overfitting(225,455-457). 
One of the limitations in the study and discussed previously, was the missing information on some of the 
potential predictors indicated by the prior evidence. A key missing variable that was not included in the models 
was HF severity. Whilst the analysis accounted for duration of HF, severity can vary widely depending on a 
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number of patient and treatment factors. A range of factors that are associated with HF severity including HF 
drugs, systolic blood pressure and renal function were included, but better adjustment would include more 
specific physiological measures of HF severity. Hospital admissions are also a known predictor of mortality in 
HF and were strongly associated with first hospital admission following HF diagnosis in this study. However 
the hospital admission data was only available for 60% of the total dataset and so was not included in the 
mortality analyses but should be considered for future model building. Inclusion of HF severity measures and 
hospital admissions in both the future testing of the comorbidity severity and change exposures and the 
development of HF comorbidity severity and change prediction models is required to better elucidate the 
independent exposure associations and potentially substantially improve prediction.   
 
13.8 Chapter Summary 
In the incident HF general practice population, a quarter of patients died within a year and a third had a 
hospital admission within a month of diagnosis. DM, COPD and CKD were common HF comorbidities and a 
high proportion of these groups had severe or worsening comorbid disease during their HF disease course. 
These dynamic severity and change measures of comorbidity were found to have significant and independent 
associations with both outcomes and improved statistical models in HF. This has important implications for HF 
management and prognosis which will be discussed in the final Chapter 14. 
 
  
367 
 
 
Chapter 14   Summary and implications  
 
This chapter summarises the key findings from the three thesis phases and within the context of the prior 
evidence from Chapters 1-4, sets out the implications of the findings for public health, healthcare services and 
education, nursing practice, clinical care and prognosis research.  Finally the future directions of the work are 
discussed. 
 
14.1 Overview 
In three phases, this thesis has synthesised the current evidence and developed new evidence on the 
influence of non-cardiovascular (CVD) comorbidities on outcomes in the general population of HF patients. In 
the first phase a systematic review identified 68 prior prognosis studies that focused on non-selected HF 
patients and included one or more non-CVD comorbidities, but there were important evidence gaps. Previous 
studies were based mainly in hospital settings and focused on mortality, where non-CVD comorbidities were 
found to have significant and independent associations. There was little evidence relating to community 
settings or other outcomes such as hospital admissions or quality of life. Chronic disease comorbidities 
change in severity as they progress during the life course of an index disease and this may alter their 
influence on patient outcomes. Whilst some evidence existed on the effects of renal dysfunction severity and 
change in hospital based HF patients, a key evidence gap was on how comorbidity severity or change 
influences patient outcomes in the general practice HF population. This information is important for the 
monitoring and management of comorbidities in the specialist or routine care of the index disease, to identify 
patients whose prognosis is changing, to target interventions at the highest risk HF groups and to tailor 
interventions to those with the most potential benefit. Phase two and three included a new set of studies to 
address these evidence gaps. 
In phase two and three, a national UK dataset of new HF patients from the general practice population was  
used to investigate the influence of dynamic indicators of non-CVD comorbidity severity and change on 
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mortality (phase 2) and hospital admissions (phase 3) over 12 years of follow-up. A new conceptual 
framework was developed for the inclusion of comorbidities in the prognosis of an index disease and 
measures of comorbidity severity and change were devised using routinely collected clinical data and 
underpinned by current evidence and clinical guidelines. Three comorbidities of DM, COPD and CKD were 
selected from the systematic review based on their higher prevalence in the HF population and the potential 
for measuring their severity and change using routinely collected data to test the study hypotheses. This set of 
studies found that the risk of hospital admission and mortality was high following HF diagnosis and there were 
similar significant and independent associations between all three comorbidities and both outcomes. An 
additional finding was that combinations of different comorbidities experienced together, yielded different risk 
estimates than expected from considering their independent effects.   
 
When each of the three comorbid groups were categorised by their severity measured during follow-up and 
prior to an event, there was significant differentiation of risk between the severity categories, with higher 
severity categories associated with the greatest risk for hospital admission and mortality. When comorbidity 
status measures (presence or absence) were replaced by their severity measures there was significant 
improvement in the fit of the prognostic models for both outcomes. Recent change in severity over a year was 
also significantly and independently associated with mortality and provided better model fit over status 
measures for all comorbidities and over status and severity measures for DM and CKD. Recent change in 
severity over 6-months using drug measures were significantly associated with first hospital admission but did 
not significantly improve the fit of the prognostic models. Using a physiological measure of change for CKD, 
recent severity and change measures incrementally improved model fit for hospital admission.  
 
14.2 General implications  
Public health: Chronic diseases such as HF are the predominant cause of death globally. Clinical 
epidemiology or prognosis seeks to understand the onset, progression, interventions and outcomes of people 
with a disease and is of key importance for public health policy and primary and secondary prevention. In an 
ageing society older people often experience more than one chronic disease at the same time and this 
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comorbidity can lead to poorer health and earlier death and has become a global health care priority requiring 
a radical redesign of health services, clinical care, education and research.  
 
Prognosis and subsequent public health policy has traditionally focused on the aetiology and risk factors 
relating to the index disease. In a national cohort of patients from the general practice population where most 
chronic diseases are routinely managed and recorded, this thesis found that other chronic disease 
comorbidities are highly prevalent, have significant importance for outcomes in patients with an index disease 
and require further consideration in prognosis. Understanding which of the most prevalent chronic disease 
comorbidities are associated with the highest risk in the general population of people with an index disease is 
of critical importance to public health focused on improving outcomes. Where multiple comorbidities coexist, 
specific combinations of diseases such as DM and CKD, carry a higher than expected risk for people with an 
index disease and provide a key target for health interventions aimed at prevention or optimisation of 
therapies.   
 
Healthcare services: Over the past two decades healthcare systems and delivery have been framed around 
the management of specific chronic diseases supported by national and international, standardised guidelines 
and disease-specific policy. This specialism has improved outcomes in patients with a specific disease but for 
many diseases such as HF, outcomes remain poor.  The findings in this thesis demonstrate the importance of 
other disease comorbidities for outcomes. A key finding was that the progression and increasing severity of 
chronic disease comorbidities over the course of an index disease is associated with significantly higher risk 
of poor outcomes. This is important because, whilst chronic disease comorbidities are incurable, increasing 
severity may itself be amenable to intervention and modification to reduce risk.  Better integration of chronic 
disease management and care is therefore required for the index disease and the comorbidities. Disease 
specific policy and care delivery needs to take account of other diseases, their routine monitoring and 
measurement and recommended interventions. Patients require integrated information to optimise their 
understanding of self-management where multiple diseases coexist and also their potential disease course 
within the context of their comorbid diseases.   
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Healthcare Education: In the same way that clinical care is organised around specialism, the review of 
individual conditions is most often the focus of healthcare education and particularly specialist nurse curricula. 
This means that specialists might lack knowledge about comorbidities, shared disease mechanisms or how to 
provide optimal management for the index disease and the comorbidities for a high percentage of patients 
who experience both. The high prevalence and importance of comorbidities for patient outcomes found in this 
thesis means that education curricula needs to be redesigned to better prepare clinicians to manage patients 
with multiple diseases(512). 
 
Nursing practice and heart failure specialisation: The nursing profession has developed over recent years 
through specialisation with nurses taking on advanced knowledge and skills in the management of a specific 
disease, condition or intervention. Specialist nurses use these skills to prevent and manage patients’ 
symptoms and to provide interventions in relation to a specific disease, to prevent deterioration. Whilst this 
specialisation has improved outcomes for patients, the current context of increasing numbers of people with 
comorbidities means that it can be at the expense of person-centred and holistic care.  
 
This thesis has demonstrated the high prevalence of chronic disease comorbidities in the general practice HF 
population which leads to earlier hospital admission and death for these patients. Whilst the reasons for this 
association might be multi-factorial including shared pathophysiological processes and risk factors or conflicts 
in management and care, it poses new and important challenges for specialist nursing.   In the HF example, 
comorbidity can cause conflicts in treatments, drug interactions and challenges for patient self-care that is 
managed through multiple different disease specific self-management plans. The inclusion of co-morbidities in 
HF management is then a key component of holistic nursing care.  
 
Whilst guidelines should help nurses to make decisions in their daily practice, much of the guidance that 
nurses’ provide patients on the key components of self-care behaviour such as lifestyle advice and symptom 
monitoring and management are not adequately included in guidelines. Comorbidity, which is an important 
  
371 
 
 
consideration, has only brief inclusion in this guidance and focuses on medical management.  Heart failure 
specialist nursing has demonstrated excellent advantages for patients through focused nursing care 
approaches on the management of aetiology, pathophysiology and symptoms, but this thesis indicates that 
there now needs to be a broader specialist approach which takes account of the growing number of patients 
with comorbidities. 
 
Prognosis research: Prognosis is important for the management of people with chronic diseases in order to 
target groups for treatments, assess the efficacy of interventions or differential responses to treatments, to 
assess different health care practices and to better inform patients for shared decision making. The clinical 
course of a chronic disease can be lengthy from new onset to more severe disease to death and so the 
accurate prediction of outcomes requires the simultaneous account of multiple and varied environment, host 
and disease factors. This thesis has shown that alongside disease specific factors that influence its severity 
and progression such as aetiology and risk factors related to the index disease, other chronic diseases 
present at the same time are an important consideration. 
 
Whilst there is growing recognition of the importance of comorbidities for patient outcomes, prognosis studies 
have so far been limited to the presence or absence of comorbid disease which ignores the dynamic nature of 
comorbidity that develops in severity and changes over time, often in tandem with the index disease.  This 
thesis has shown that individual risk stratification using comorbidity is a dynamic process that is improved by 
longitudinal information on the disease severity and its recent change over time. More specifically, recent 
severity and/or change is a useful indicator of patients whose prognosis is changing and who are at a higher 
risk of imminent hospital admission or death in the general practice population. This could act as an important 
trigger for targeting interventions to reduce the risk of poor outcomes.     
 
The comorbidity measures used in this thesis were based on routinely recorded clinical information 
underpinned by current evidence and clinical guidelines. This means that the measures can be easily applied 
in practice, are clinically useful in routine care and familiar to clinicians and patients. For some diseases, 
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routine monitoring using physiological measures is inconsistent and this thesis highlights the importance of 
regular monitoring of both the index and comorbid disease. The drug measures of comorbidity severity 
showed significant associations with both outcomes and are automatically and electronically recorded on all 
patients, providing a consistent disease severity measure. Recent change in drug severity improved prognosis 
for mortality but not hospital admission. This implies that different factors might be influencing admissions that 
require further consideration in prognosis. An additional implication for prognosis from this thesis relates to the 
interaction between comorbidities. Chronic disease comorbidities are currently included independently from 
one another in prognostic models. The thesis findings that relate to the importance of different combinations of 
comorbidities, means that they may need joint consideration for more accurate prediction.  
 
14.3 Heart Failure implications 
Public health: This thesis has shown that the prognosis of people in the general practice population with a 
new diagnosis of HF remains very poor despite optimisation of medical interventions over previous years. A 
quarter of all patients with HF died within a year of diagnosis and half within five years. Most patients also 
experienced at least one admission into hospital and a third of these were within a month of diagnosis. Non-
CVD comorbidities were highly prevalent with half of all HF patients having at least one of the three 
comorbidities (DM, COPD, CKD) investigated. Despite the high risk associated with a new diagnosis of heart 
failure, these prevalent comorbid diseases increased risk of admissions and mortality significantly. Current 
public health policy focuses on the primary and secondary prevention of cardiovascular disease. The 
increasing number of people with CVD and other comorbidities means that these approaches need to be 
extended to identify and target shared risk factors for the most common CVD and comorbidity combinations.  
Further improvements in the poor prognosis in end-stage CVD require a broader approach to prevention as 
well as diagnosis, investigations and interventions that take account of non-CVD comorbidities.  
 
Clinical care: The monitoring and management of non-CVD comorbidities needs to be included in routine HF 
care. Central to current HF clinical guidelines is the optimisation of drug therapies as well as assessment for 
interventions such as devices or surgery. The importance of the non-CVD comorbidities for patient outcomes 
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in this thesis implies that optimisation of treatments needs to include the comorbidity as well as the HF. The 
lack of guidance on comorbidities often inherent in disease specific guidelines means that better integration of 
specialist services may be required to deliver optimal care across diseases.  
 
HF Prognosis: The trajectory of HF is complicated with wide variation in the experience of patients following 
diagnosis. Current prognosis tools have limitations including their use of invasive and complex clinical data 
and biometrics, their focus on select populations and use of static or single prognostic indicators measured at 
baseline. Whilst some dynamic cardiovascular prognostic indicators are included in HF prognostic models 
such as BMI, ejection fraction and blood pressure these are all based on a single measure and do not include 
indicators of change. This thesis has shown that dynamic measures of the severity of non-CVD comorbidities 
and their recent change that occurs during the HF disease course has significant associations with both 
mortality and hospital admissions and improves prognostic models for both outcomes. These comorbidity 
factors based on routinely collected clinical data and clinical guidelines provide the potential for a simple and 
clinically useful prognostic model for identifying HF patients whose risk is changing and require more intensive 
support. This is turn has implications for HF interventions that so far, have largely been tested in randomised 
controlled trials that have excluded patients with comorbidity. Optimal pharmacotherapy for this patient group 
remains poorly defined and there is also limited evidence of the efficacy of interventions that are considered in 
higher risk HF groups such as the implantation of devices or heart transplant. 
 
14.4 Future developments 
14.4.1 HF comorbidity and prognosis  
Prognostic factors: This thesis demonstrated that dynamic measures of non-CVD comorbidities are important 
prognostic factors for hospital admission and mortality in an incident general practice HF population. There 
were interactions between some of the comorbidity pairs which indicate possible shared aetiology, risk factors 
or pathophysiological processes or a shared indication for an unmeasured factor. Further investigation is 
required to understand these mechanisms. The interaction between HF and the comorbidities is also 
important in order to inform the development of possible interventions which could be aimed at the HF, the 
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comorbidity or the combined diseases. Future work should consider these interactions which would require a 
general practice population with and without HF for the analyses. Other approaches within the HF cohort 
would include the investigation of CVD versus non-CVD outcomes or the interaction between the comorbidity 
severity and HF severity on outcomes. Age was used as a pseudo measure of severity and showed a 
significant biological interaction between CKD and older age in the opposite direction than expected when 
observing statistical interaction. The indication is that the effect of CKD is modified in more severe HF which is 
likely given the close pathophysiological pathways. These relationships require further detailed investigation 
using more refined HF severity measures.   
 
Prognostic models: This thesis has shown that prognostic models are significantly improved by the inclusion 
of dynamic and time-dependent measures of non-CVD comorbidities. The CPRD is a comprehensive national 
dataset that includes longitudinal and routinely recorded clinical data on chronic disease management. Whilst 
HF related drug data and risk factors are available, physiological or blood test data to measure HF severity is 
not yet included. This means that the final models focused on severity and change for the comorbidities but 
not the HF.  The final prognostic models using these comorbidity measures were comparable or better than 
prior HF models that included HF severity measures.  This thesis also used a nested case-control design with 
risk set sampling of controls which allowed the efficient measurement of time-dependent severity and change. 
Whilst this approach yields unbiased estimates of rate ratios, absolute risk cannot be calculated due to the 
lack of an intercept. Model development now requires the addition of dynamic and time-dependent measures 
of HF severity as well as the comorbidities and testing within a non-matched cohort. With the addition of a 
variable that indicates time since HF diagnosis, this model should predict 6-month hospital admission and 1-
year mortality within a prevalent general practice HF population. This model development will require the 
linkage of specialist and general practice data. 
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14.4.2 Interventions  
HF prognosis studies have included comorbidities but there is still no clear evidence of tailored therapeutic 
interventions to reduce the individual risk of HF patients with comorbidity. Further epidemiological enquiry is 
required to investigate the complex relationships between comorbidities and outcomes in HF so that big data 
studies can be translated to the development of interventions. Therapeutic trials need to be developed to 
investigate the efficacy and efficiency of HF interventions in patients with comorbidity so that optimal therapy 
can be tailored to the patient. Pharmacological treatments and optimal doses need to be investigated for any 
differential effect across comorbid groups and new drugs that target shared mechanisms may need to be 
developed. Stratified medicine prognosis approaches are also required so that interventions such as devices 
in HF can be targeted to those with the most potential benefit and least harm. Whilst these interventions are 
often targeted at the higher risk HF groups there is limited information on whether high risk that is due to 
comorbidity would be mitigated by these approaches. Health service interventions also require testing to 
investigate their effectiveness in improving the joint optimisation of treatment for combined diseases.  The 
integration of services and specialist care and of patient self-management approaches all require 
investigation. 
 
14.4.3 Outcomes   
A key gap identified in this thesis is the lack of prognosis studies that included patient centred outcomes such 
as health related quality of life (HR-QoL). This is an important gap given the poor HR-QoL found in HF 
populations which deteriorates as the disease progresses and which is itself associated with poor outcomes. 
The multi-factorial components of HR-QoL mean that is potentially amenable to modification through targeted 
interventions which makes it a clinically important outcome. The inclusion of patient important outcomes in 
prognosis is a key indication within international position statements and provides a mechanism to identify 
patients earlier whose prognosis is changing.  
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Given the high prevalence and importance of non-CVD comorbidities shown in this thesis, future work needs 
to investigate their association with HR-QoL. To that end, three linked studies have been conducted or 
planned to investigate the association between non-CVD comorbidities and HR-QoL: 
 
(i) Quality of life study 1: HF and osteoarthritis publication on HR-QoL.   In the first study the impact of non-
CVD comorbidity on cardiovascular symptom specific physical limitations was investigated(29) (see E-
Appendix E18). General practice patients with hypertension, ischaemic heart disease or HF with or without 
comorbid osteoarthritis (OA) were surveyed on their physical limitations related to their chest pain and 
shortness of breath. This survey data was linked to their clinical data and the comorbid CVD groups with OA 
were compared to those without, using linear regression. This study found that OA added to the CVD 
symptom related physical limitations and there was some evidence of interaction between the OA and HF 
observed for chest pain limitations. This study indicates the potential importance of non-CVD comorbidities for 
HR-QoL which includes symptoms as a component. The possible interaction provides further evidence that 
non-CVD comorbidities require including in HF specific management.  
 
(ii) Quality of life study 2: 2C-HF prospective hospital investigation.  In the second study, a new cohort of 180 
HF patients were recruited from specialist HF outpatients’ clinics and surveyed at baseline and at 1 month and 
3 months follow-up (see E-Appendix E19 for ethics committee protocol). These surveys included generic and 
HF specific health measures that were linked to their clinical HF and comorbidity data extracted at baseline. 
This data included the comorbidity severity and change measures used in the CPRD studies and will be used 
to test these measures for their association with HR-QoL and change in HR-QoL over three months. The 
opportunity with this cohort analysis will be the inclusion of HF severity measures into the prognostic model. 
 
(iii) Quality of life study 3: Swedish HF registry study.   A third study is planned (see E-Appendix E20 for 
protocol) using the Swedish HF register (S-HFR). Whilst there are local HF registers in the UK there is no 
national register or routinely collected measures of quality of life in administration data. In the Swedish 
healthcare system, the national quality registers are obliged to incorporate patient reported outcomes for 
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certification at a high level. This is a unique database which has prospectively collected patient-reported 
outcome measures and there is data on around 50,000 HF patients from the hospital and outpatient HF 
population in Sweden. The data includes information on different comorbidities and patient-centred 
questionnaires on physical health, symptoms and quality-of-life which have been repeated over time. The data 
for this study has already been obtained and will be used to explore the influence of comorbidities on quality 
of life with a specific focus on the factors that moderate or mediate these associations. This analysis will 
provide the basis for the development of nurse interventions to improve outcomes in this group. 
 
14.5 Conclusions 
Heart failure is a serious chronic disease where, in the general practice population, a third of patients are 
admitted into hospital within a month of diagnosis and a third die within a year. Non-CVD comorbidities are 
common in this population and are associated with higher risk of being admitted into hospital or dying earlier. 
As with HF, chronic disease comorbidities progress in severity from new onset to end stage disease. This 
thesis has shown that prognosis, which is the prediction of outcomes within a disease population, also 
changes as the HF and comorbidities progress and change overtime. The dynamic nature of comorbidities is 
significantly and independently associated with increasing risk of poor outcomes and provides the potential for 
using routinely collected and clinically meaningful information to identify patients whose risk is changing.  
This information is important for both public health and the clinical management of individual patients. 
Common non-CVD comorbidities experienced individually or in combination provide key targets for primary 
and secondary prevention. At a public policy level this information needs to be included in specialist disease 
management guidelines to improve outcomes in the HF population. For individual patient management this 
information is important so that interventions that optimise HF and comorbidity treatments can be targeted at 
the highest risk groups or so that treatments can be tailored to individuals that have the most potential benefit. 
More work needs to be done to elucidate the underlying mechanisms that explain the increased risk 
associated with non-CVD comorbidities so that interventions can be developed that target the index disease, 
the comorbidities, the disease combination or the patients’ management of their combined diseases.
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